<SEC-DOCUMENT>0001193125-19-129723.txt : 20190430
<SEC-HEADER>0001193125-19-129723.hdr.sgml : 20190430
<ACCEPTANCE-DATETIME>20190430171404
ACCESSION NUMBER:		0001193125-19-129723
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190626
FILED AS OF DATE:		20190430
DATE AS OF CHANGE:		20190430
EFFECTIVENESS DATE:		20190430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACADIA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001070494
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				061376651
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50768
		FILM NUMBER:		19783120

	BUSINESS ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-558-2871

	MAIL ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d664711ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Filed by the Registrant &#9746;&nbsp;&nbsp;&nbsp;&nbsp;Filed by a Party other than the Registrant &#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material Pursuant to &#167; <FONT STYLE="white-space:nowrap">240.14a-12</FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA Pharmaceuticals Inc. </B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified in
Its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy
Statement if Other Than the Registrant) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box) </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table below per Exchange Act Rules <FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT
STYLE="white-space:nowrap">0-11.</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Title of each class of securities to which transaction applies: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Aggregate number of securities to which transaction applies: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule <FONT
STYLE="white-space:nowrap">0-11</FONT> (Set forth the amount on which the filing fee is calculated and state how it was determined): </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Proposed maximum aggregate value of transaction: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Total fee paid: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Check box if any part of the fee is offset as provided by Exchange Act Rule
<FONT STYLE="white-space:nowrap">0-11(a)(2)</FONT> and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount Previously Paid: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Form, Schedule or Registration Statement No.: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filing Party: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Date Filed: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3611 Valley Centre Drive, Suite 300 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California 92130 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON JUNE&nbsp;26, 2019 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Dear Stockholder: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend the 2019 Annual Meeting of Stockholders of ACADIA Pharmaceuticals Inc., a Delaware corporation
(&#147;ACADIA&#148; or the &#147;Company&#148;). The meeting will be held on June&nbsp;26, 2018 at 8:00&nbsp;a.m. at the Hilton La Jolla Torrey Pines, 10950 North Torrey Pines Road, La Jolla, California 92037 for the following purposes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect two Class&nbsp;III directors named herein to hold office until the Company&#146;s 2022 Annual Meeting
of Stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve an amendment to the Company&#146;s 2010 Equity Incentive Plan, as amended, to, among other things,
increase the aggregate number of shares of common stock authorized for issuance under the plan by 8,300,000 shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve an amendment to the Company&#146;s 2004 Employee Stock Purchase Plan, as amended, to, among other
things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 600,000 shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve, on an advisory basis, the compensation of the Company&#146;s named executive officers, as disclosed
in this proxy statement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To ratify the selection of Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent registered public
accounting firm for the fiscal year ending December&nbsp;31, 2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To conduct any other business properly brought before the meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These items of business are more fully described in the proxy statement accompanying this notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The record date for the annual meeting is April&nbsp;29, 2019. Only stockholders of record at the close of business on that date may vote at
the meeting or any adjournment or postponement thereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#146; Meeting to be held </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>on June&nbsp;26, 2019 at 8:00 a.m. at the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Hilton La Jolla Torrey Pines, 10950 North Torrey Pines Road, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>La Jolla, California 92037 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The proxy statement and annual report to stockholders </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>are available at http://ir.acadia-pharm.com. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By Order of the Board of Directors</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g664711g16y78.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Austin D. Kim</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Vice President, General Counsel</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>and Secretary</I></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">San Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2019 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>You are cordially invited to attend the meeting in person. Whether or not you expect to attend the meeting, please complete, date, sign and
return the enclosed proxy, or vote over the telephone or the internet as described in these materials, as promptly as possible in order to ensure your representation at the meeting. Even if you have voted by proxy, you may still vote in person if
you attend the meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must obtain a proxy issued in your name from that record holder. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3611 Valley Centre Drive, Suite 300 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California 92130 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE
ANNUAL MEETING OF STOCKHOLDERS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD JUNE&nbsp;26, 2019 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why am I receiving these materials? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have sent you these proxy materials because the Board of Directors (sometimes referred to as the &#147;Board&#148;) of ACADIA is soliciting your proxy to vote at the 2019 Annual Meeting of Stockholders, including at any adjournments or postponements
of the meeting. You are invited to attend the annual meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the meeting to vote your shares. Instead, you may simply complete, sign and return the
enclosed proxy card, or follow the instructions below to submit your proxy over the telephone or through the internet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to mail
these proxy materials on or about May&nbsp;7, 2019 to all stockholders of record entitled to vote at the annual meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I attend the annual
meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The meeting will be held on Wednesday, June&nbsp;26, 2019, at 8:00 a.m. at the Hilton La Jolla Torrey Pines, 10950 North
Torrey Pines Road, La Jolla, California 92037. Information on how to vote in person at the annual meeting is discussed below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
directions to the annual meeting, please visit the following web address: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">https://www.google.com/maps/place/10950+N+Torrey+Pines+Rd,+La+Jolla,+CA+92037 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who can vote at the annual meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only
stockholders of record at the close of business on April&nbsp;29, 2019 will be entitled to vote at the annual meeting. On the record date, there were 144,165,923 shares of common stock outstanding and entitled to vote. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If on April&nbsp;29, 2019 your shares were registered directly in your name with ACADIA&#146;s transfer agent, Computershare, Inc., then you
are a stockholder of record. As a stockholder of record, you may vote in person at the meeting or vote by proxy. Whether or not you plan to attend the meeting, we urge you to fill out and return the proxy card that may be mailed to you, or vote by
proxy over the telephone or on the internet as instructed below, to ensure your vote is counted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered
in the Name of a Broker or Bank </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If on April&nbsp;29, 2019 your shares were held, not in your name, but rather in an account at a
brokerage firm, bank, dealer, or other similar organization, then you are the beneficial owner of shares held in &#147;street name&#148; and these proxy materials were forwarded to you by that organization. The organization holding your account is
considered to be the stockholder of record for purposes of voting at the annual meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. You are also invited to attend
the annual meeting. However, since you are not the stockholder of record, you may not vote your shares in person at the meeting unless you request and obtain a valid proxy from your broker or other agent. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What am I voting on? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are five matters scheduled for a vote: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Election of two Class&nbsp;III directors, Laura Brege and Stephen Davis, to hold office until our 2022 Annual
Meeting of Stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approval of an amendment to the Company&#146;s 2010 Equity Incentive Plan, as amended, to, among other things,
increase the aggregate number of shares of common stock authorized for issuance under the plan by 8,300,000 shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approval of an amendment to the Company&#146;s 2004 Employee Stock Purchase Plan, as amended, to, among other
things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 600,000 shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advisory approval of the compensation of the Company&#146;s named executive officers, as disclosed in this proxy
statement in accordance with SEC rules; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ratification of the selection of Ernst&nbsp;&amp; Young LLP as our independent registered public accounting firm
for the fiscal year ending December&nbsp;31, 2019. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if another matter is properly brought before the meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors knows of no other matters that will be presented for consideration at the 2019 Annual Meeting. If any other matters are
properly brought before the meeting, it is the intention of the persons named in the accompanying form of proxy to vote on those matters in accordance with their best judgment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I vote? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may either vote
&#147;For&#148; both the nominees to the Board of Directors or you may &#147;Withhold&#148; your vote for any nominee you specify. For each of the other matters to be voted on, you may vote &#147;For&#148; or &#147;Against&#148; or abstain from
voting. The procedures for voting are as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record, you may vote in person at the annual meeting, vote by proxy using the enclosed proxy card, vote by proxy
over the telephone, or vote by proxy through the internet. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote in person even if you have already voted
by proxy. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote in person, come to the annual meeting and we will give you a ballot when you arrive.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote using the proxy card, simply complete, sign and date the enclosed proxy card and return it promptly in
the envelope provided. If you return your signed proxy card to us before the annual meeting, we will vote your shares as you direct. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote over the telephone, dial toll-free <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-800-652-8683</FONT></FONT></FONT> using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and control number from the enclosed proxy. Your vote must be received by
11:59 p.m. Eastern Daylight Time on June&nbsp;25, 2019 to be counted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote through the internet, go to http://www.investorvote.com/ACAD to complete an electronic proxy card. You
will be asked to provide the company number and control number from the enclosed proxy card. Your vote must be received by 11:59 p.m. Eastern Daylight Time on June&nbsp;25, 2019 to be counted. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of Broker or Bank </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, on April&nbsp;29, 2019, your shares were held, not in your name, but rather in an account at a brokerage firm, bank or other similar
organization, then you should have received a voting instruction form with these proxy </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
materials from that organization rather than from ACADIA. Simply complete and mail the voting instruction form to ensure that your vote is counted. Alternatively, you may vote by telephone or
over the internet as instructed by your broker, bank or other agent. To vote in person at the annual meeting, you must obtain a valid proxy from your broker, bank, or other agent. Follow the instructions from your broker, bank or other agent
included with these proxy materials, or contact your broker, bank or other agent to request a proxy form. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1.00pt;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:2%; margin-right:2%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>We provide <FONT STYLE="white-space:nowrap">on-line</FONT> proxy voting to allow you to
vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from
internet access providers and telephone companies. </B></P></div> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes do I have? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On each matter to be voted upon, you have one vote for each share of common stock you owned as of the close of business on April&nbsp;29, 2019.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if I return a proxy card, or otherwise vote, but do not make specific choices? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you return a signed and dated proxy card, or otherwise vote, without marking voting selections, your shares will be voted &#147;For&#148;
the election of each of the two nominees for director, &#147;For&#148; approval of the amendment to the Company&#146;s 2010 Equity Incentive Plan, as amended, &#147;For&#148; approval of the amendment to the Company&#146;s 2004 Employee Stock
Purchase Plan, as amended, &#147;For&#148; the advisory approval of executive compensation, and &#147;For&#148; the ratification of the selection of Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent registered public accounting firm, as
applicable. If any other matter is properly brought before the meeting, one of the individuals named in the accompanying form of proxy will vote your shares using his or her best judgment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who is paying for this proxy solicitation? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees may also solicit
proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of
forwarding proxy materials to beneficial owners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What does it mean if I receive more than one set of proxy materials? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you receive more than one set of proxy materials, your shares are registered in more than one name or in different accounts. Please follow
the voting instructions on the proxy cards in the proxy materials to ensure that all of your shares are voted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Can I change my vote after submitting
my proxy? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yes. You can revoke your proxy at any time before the final vote at the meeting. If you are the record holder of your
shares, you may revoke your proxy in any one of the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may submit a properly completed proxy card with a later date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may grant a subsequent proxy by telephone or through the internet. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may send a timely written notice that you are revoking your proxy to ACADIA&#146;s Secretary at
3611&nbsp;Valley Centre Drive, Suite 300, San Diego, California 92130. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may attend the annual meeting and vote in person. Simply attending the meeting will not, by itself, revoke
your proxy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your most current proxy card or telephone or internet proxy is the one that is counted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held by your broker or bank as a nominee or agent, you should follow the
instructions provided by your broker or bank. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>When are stockholder proposals due for next year&#146;s annual meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be considered for inclusion in next year&#146;s proxy materials, your proposal must be submitted in writing by January&nbsp;8, 2020, to
ACADIA&#146;s Secretary at 3611 Valley Centre Drive, Suite 300, San Diego, California 92130. If you wish to submit a proposal that is not to be included in next year&#146;s proxy materials or nominate a director, your proposal generally must be
submitted in writing to the same address no later than March&nbsp;28, 2020 but no earlier than February&nbsp;27, 2020. Please review our bylaws, which contain additional requirements regarding advance notice of stockholder proposals and nominations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How are votes counted? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Votes will
be counted by the inspector of election appointed for the meeting, who will separately count, for the proposal to elect directors, votes &#147;For&#148;, &#147;Withhold&#148; and broker <FONT STYLE="white-space:nowrap">non-votes;</FONT> and, with
respect to other proposals, votes &#147;For&#148; and &#147;Against&#148;, abstentions and, if applicable, broker <FONT STYLE="white-space:nowrap">non-votes.</FONT> Abstentions will be counted towards the vote total for each of Proposals 2, 3, 4 and
5, and will have the same effect as &#147;Against&#148; votes. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will not be counted towards the vote total for any proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What are &#147;broker <FONT STYLE="white-space:nowrap">non-votes&#148;?</FONT></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> occur when a beneficial owner of shares held in &#147;street name&#148; does not give
instructions to the broker or nominee holding the shares as to how to vote on matters deemed <FONT STYLE="white-space:nowrap">&#147;non-routine.&#148;</FONT> Generally, if shares are held in street name, the beneficial owner of the shares is
entitled to give voting instructions to the broker or nominee holding the shares. If the beneficial owner does not provide voting instructions, the broker or nominee can still vote the shares with respect to matters that are considered to be
&#147;routine&#148;, but not with respect to <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters. Under the rules and interpretations of the New York Stock Exchange, <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT>
matters are matters that may substantially affect the rights or privileges of stockholders, such as mergers, stockholder proposals, elections of directors, advisory approval of executive compensation, or certain amendments to charter documents. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes are needed to approve each proposal? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the minimum vote needed to approve each proposal and the effect of abstentions and broker <FONT
STYLE="white-space:nowrap">non-votes.</FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposal Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vote Required for Approval</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Effect
of<BR>&nbsp;&nbsp;&nbsp;&nbsp;Abstentions&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Effect&nbsp;of&nbsp;Broker&nbsp;&nbsp;&nbsp;&nbsp;
<BR><FONT STYLE="white-space:nowrap">Non-Votes</FONT></B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Election of directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The two nominees receiving the most &#147;For&#148; votes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">None</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">None</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 8,300,000 shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;For&#148; votes from the holders of a majority of shares present in person or represented by proxy and entitled to vote on the matter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Against</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">None</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to 2004 Employee Stock Purchase Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 600,000 shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;For&#148; votes from the holders of a majority of shares present in person or represented by proxy and entitled to vote on the matter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Against</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">None</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Advisory approval of the compensation of the Company&#146;s named executive officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;For&#148; votes from the holders of a majority of shares present in person or represented by proxy and entitled to vote on the matter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Against</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">None</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ratification of the selection of Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;For&#148; votes from the holders of a majority of shares present in person or represented by proxy and entitled to vote on the matter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Against</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">None</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is the quorum requirement? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least a majority of the
outstanding shares entitled to vote are present at the meeting in person or represented by proxy. On the record date, there were 144,165,923 shares outstanding and entitled to vote. Thus, the holders of 72,082,962 shares must be present in person or
represented by proxy at the meeting to have a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your shares will be counted towards the quorum only if you submit a valid proxy (or
one is submitted on your behalf by your broker, bank or other nominee) or if you vote in person at the meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted towards the quorum requirement. If there is no
quorum, the holders of a majority of shares present at the meeting in person or represented by proxy may adjourn the meeting to another date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I find out the results of the voting at the annual meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preliminary voting results will be announced at the annual meeting. Final voting results will be reported in a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K,</FONT> which we plan to file within four business days after the date of the annual meeting. If final voting results are not available to us in time to file a Form <FONT STYLE="white-space:nowrap">8-K</FONT> within
four business days after the date of the meeting, we intend to file a Form <FONT STYLE="white-space:nowrap">8-K</FONT> to publish preliminary results and, within four business days after the final results are known to us, file an additional Form <FONT
STYLE="white-space:nowrap">8-K</FONT> to publish the final results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What proxy materials are available on the internet? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proxy statement and Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018 are available at <I><FONT
STYLE="white-space:nowrap">http://ir.acadia-pharm.com</FONT></I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>ROPOSAL</SMALL> 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>LECTION</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ACADIA&#146;s Board of Directors is divided into three classes. Each class consists of approximately
<FONT STYLE="white-space:nowrap">one-third</FONT> of the total number of directors, and each class has a three-year term. Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors. A director elected by
the Board to fill a vacancy in a class, including a vacancy created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director&#146;s successor is duly elected and qualified, or
until such director&#146;s earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors presently has seven members. There are currently
two directors in Class&nbsp;III, whose term of office expires in 2019. The two nominees for Class&nbsp;III directors are Laura Brege and Stephen Davis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Ms.&nbsp;Brege and Mr.&nbsp;Davis is currently a director of the Company who was previously elected by the Company&#146;s
stockholders. If elected at the annual meeting, each of these nominees would serve until the 2022 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or, if sooner, until the director&#146;s death,
resignation or removal. The terms of the directors in Classes I and II expire at our 2020 and 2021 Annual Meetings of Stockholders, respectively. It is the Company&#146;s policy to encourage directors and nominees for director to attend the Annual
Meeting. All of our directors except Julian C. Baker attended the 2018 Annual Meeting of Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors are elected by a
plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors. The two nominees receiving the highest number of affirmative votes will be elected. Shares represented by
executed proxies will be voted, if authority to do so is not withheld, for the election of the two nominees named below. If any nominee becomes unavailable for election as a result of an unexpected occurrence, your shares that would have been voted
for that nominee instead will be voted for the election of a substitute nominee proposed by the Board of Directors. Each person nominated for election has agreed to serve if elected. Our management has no reason to believe that any nominee will be
unable to serve. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><SMALL>A</SMALL> V<SMALL>OTE</SMALL> &#147;<SMALL>FOR</SMALL>&#148; E<SMALL>ACH</SMALL> N<SMALL>AMED</SMALL> N<SMALL>OMINEE</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information as of April&nbsp;30, 2019 for our directors and executive officers: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen R. Biggar, M.D., Ph.D.&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julian Baker&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura Brege&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Daly&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edmund Harrigan, M.D.&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Soland&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen R. Davis&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director and Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Srdjan R. Stankovic, M.D., M.S.P.H.&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Austin D. Kim&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, General Counsel, and Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elena H. Ridloff&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, Chief Financial Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael J. Yang&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, Chief Commercial Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee (the &#147;NCG Committee&#148;) seeks to assemble a Board
that, as a whole, possesses the appropriate balance of professional and industry knowledge, financial expertise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and high-level management experience necessary to oversee and direct the Company&#146;s business. The NCG and the Board also recognize the potential importance of diversity in board composition,
including diversity of experience, gender and ethnicity. To that end, the NCG Committee has identified and evaluated nominees in the broader context of the Board&#146;s overall composition, as well as the Company&#146;s current needs and future
needs, with the goal of having Board members who complement and strengthen the skills of each other through diversity and who also exhibit qualities that the NCG Committee views as critical to effective functioning of the Board, including sound
judgment, collegiality, and integrity. The following is a brief biography of each nominee and a discussion of the specific experience, qualifications, attributes or skills of each nominee that led the NCG Committee to recommend that person to
continue to serve on the Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominees for Election for a Three-year Term Expiring at the 2022 Annual Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Laura Brege </I>has served as a director of our company since May 2008. Currently, Ms.&nbsp;Brege is Managing Director of Cervantes Life
Science Partners, LLC., a health care advisory and consulting company. From September 2012 to July 2015, Ms.&nbsp;Brege served as President and the Chief Executive Officer of Nodality, Inc., a privately held biotechnology company focused on
innovative personalized medicine. Prior to joining Nodality in September 2012, Ms.&nbsp;Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., from June 2006 to December 2011, including Executive Vice President and Chief Operating
Officer. Before joining Onyx, Ms.&nbsp;Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early-stage financing for technology companies, since 1999. Prior to Red Rock, she was the Senior Vice
President and Chief Financial Officer at COR Therapeutics. Earlier in her career, Ms.&nbsp;Brege served as Vice President and Chief Financial Officer at Flextronics and Vice President and Treasurer of The Cooper Companies. Ms.&nbsp;Brege currently
serves on the boards of directors of HLS Therapeutics, Inc., Pacira BioSciences, Inc., Portola Pharmaceuticals, Inc. and Dynavax Technologies Corporation. During the past five years, Ms.&nbsp;Brege served on the boards of directors of Aratana
Therapeutics and Delcath Systems, Inc. The NCG Committee believes that Ms.&nbsp;Brege&#146;s industry background, including her extensive experience as an officer of public companies in the biotechnology industry, position her to make an effective
contribution to the Board and the Audit Committee. In addition, her past financial experience and current knowledge of financing trends are extremely valuable to the Board when considering financing strategies for the Company. Ms.&nbsp;Brege earned
her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stephen R. Davis</I> has served as our
Chief Executive Officer and as a director of our company since September 2015. Mr.&nbsp;Davis joined us in July 2014 as our Executive Vice President, Chief Financial Officer and Chief Business Officer and served as our Interim Chief Executive
Officer from March through August of 2015. Mr.&nbsp;Davis brings over 20 years of executive-level experience in the pharmaceutical industry. Prior to joining our company, he was Executive Vice President and Chief Operating Officer at Heron
Therapeutics, Inc., which he joined in 2013, and Executive Vice President and Chief Operating Officer at Ardea Biosciences, Inc. from 2010 to 2013. Prior to joining Ardea, Mr.&nbsp;Davis served in numerous executive roles at Neurogen Corporation
from 1994 to 2010, including Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer. Mr.&nbsp;Davis currently serves on the board of directors of Bellicum Pharmaceuticals, Inc. During the past five years, Mr.&nbsp;Davis served
on the boards of directors of Heron Therapeutics and Synageva BioPharma Corp. Earlier in his career, Mr.&nbsp;Davis practiced as a certified public accountant with a major accounting firm and as a corporate and securities attorney with a Wall Street
law firm. The NCG Committee believes that Mr.&nbsp;Davis&#146; deep experience as an executive officer enables him to bring critical company-specific and industrywide knowledge and leadership skills to the Board. Mr.&nbsp;Davis received his Bachelor
of Science degree in accounting from Southern Nazarene University and a Juris Doctorate from Vanderbilt University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a
brief biography, and a discussion of the specific experience, qualifications, attributes or skills of each director whose term will continue after the annual meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors Continuing in Office Until the 2020 Annual Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>James Daly </I>has served as a director of our company since January 2016. Mr.&nbsp;Daly served as Executive Vice President and Chief
Commercial Officer at Incyte Corporation from October 2012 to June 2015. Prior to joining Incyte, Mr.&nbsp;Daly worked for Amgen, Inc. for 10 years, holding multiple leadership positions. In his last role, Mr.&nbsp;Daly served as Senior Vice
President, North America Commercial Operations, Global Marketing and Commercial Development. Previously, he served as Vice President and General Manager of Amgen&#146;s Oncology Business Unit. His teams at Amgen were responsible for the successful
launch of many products, including Aranesp<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Neulasta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Vectibix<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Nplate<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Xgeva<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Prolia<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Previously, Mr.&nbsp;Daly spent over 16 years with Glaxo
Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. He currently serves on the boards of directors of argenx SE, Bellicum Pharmaceuticals, Chimerix Inc. and Halozyme Therapeutics. Mr.&nbsp;Daly earned his B.S. in pharmacy and M.B.A. from the
University at Buffalo, The State University of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Edmund P. Harrigan, M.D. </I>has served as a director of our company since
November 2015. Dr.&nbsp;Harrigan served as Senior Vice President of Worldwide Safety and Regulatory for Pfizer Inc. from 2012 to 2015, where he led a <FONT STYLE="white-space:nowrap">3,500-person</FONT> team in 80 countries that was responsible for
collecting, interpreting and reporting clinical safety data for more than 600 marketed products, and managed regulatory interactions with global health agencies. Dr.&nbsp;Harrigan&#146;s previous executive leadership roles at Pfizer included serving
as Senior Vice President, Head of Worldwide Business Development, Senior Vice President, Head of Worldwide Regulatory Affairs and Quality Assurance, and Vice President, Head of Neuroscience and Ophthalmology. Earlier in his career at Pfizer,
Dr.&nbsp;Harrigan served as Vice President of Clinical Development, Therapeutic Area Head, CNS and Pain. Before entering the pharmaceutical industry in 1990, Dr.&nbsp;Harrigan was a practicing neurologist for seven years. He currently serves on the
board of directors of Bellicum Pharmaceuticals and PhaseBio Pharmaceuticals, Inc. Dr.&nbsp;Harrigan earned his B.A. degree in chemistry from St. Anselm College and holds an M.D. from the University of Massachusetts at Worcester. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors Continuing in Office Until the 2021 Annual Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Julian C. Baker </I>has served as a director of our company since December 2015. Mr.&nbsp;Baker is a Managing Partner of Baker Bros.
Advisors LP, which he and his brother, Felix Baker, Ph.D., founded in 2000. Mr.&nbsp;Baker&#146;s career as a fund manager began in 1994 when he <FONT STYLE="white-space:nowrap">co-founded</FONT> a biotechnology investing partnership with the Tisch
family. Previously, Mr.&nbsp;Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston. Mr.&nbsp;Baker currently serves on the boards of directors of Genomic Health, Inc. and Incyte Corporation. During
the past five years, Mr. Baker served on the board of directors of Idera Pharmaceuticals, Inc. Mr.&nbsp;Baker holds an A.B. from Harvard University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stephen R. Biggar, M.D., Ph.D</I>. has served as a director of our company since January 2013. Dr.&nbsp;Biggar is a Partner at Baker Bros.
Advisors LP, a registered investment adviser focused on long-term investments in life-sciences companies. Dr.&nbsp;Biggar joined Baker Bros. Advisors LP in 2000. During the past five years, Dr.&nbsp;Biggar served on the board of directors of
Synageva BioPharma Corp. Dr.&nbsp;Biggar received an M.D. and a Ph.D. in immunology from Stanford University and received a B.S. in genetics from the University of Rochester. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Daniel Soland </I>has served as a director of our company since March 2015. Mr.&nbsp;Soland served as Chief Executive Officer of uniQure
N.V., a human gene therapy company, from December 2015 until September 2016. Mr.&nbsp;Soland previously served as Senior Vice President and Chief Operating Officer of ViroPharma, Inc. starting in 2008 until it was acquired in 2014, and as Vice
President and Chief Commercial Officer of ViroPharma from 2006 to 2008. During his tenure at ViroPharma, Mr.&nbsp;Soland managed the commercial, manufacturing and quality organizations, helped build the company&#146;s commercial infrastructure in
the United States, Europe, and Canada and led the launch of Cinryze<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, one of the most successful ultra-orphan drugs in the United States. Mr.&nbsp;Soland served as President, Chiron Vaccines,
of Chiron Corporation from 2005 to 2006 and led the growth of the vaccine business to over $1&nbsp;billion in sales. From 2002 through 2005, Mr.&nbsp;Soland served as President and Chief </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Executive Officer of Epigenesis Pharmaceuticals. Earlier in his career, Mr.&nbsp;Soland worked for GlaxoSmithKline in increasing roles of responsibility from 1993 to 2002, including as Vice
President and Director, Worldwide Marketing Operations, GSK Biologicals. He currently serves on the board of directors of DBV Technologies SA. Mr.&nbsp;Soland holds a B.S. in pharmacy from the University of Iowa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is biographical information for each of our executive officers other than Mr.&nbsp;Davis, whose biographical information is
set forth above: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Srdjan Stankovic, M.D., M.S.P.H. </I>has served as our President since November 2018. Dr.&nbsp;Stankovic previously
served as our Executive Vice President, Head of Research and Development and has been with our company since November 2015. With a background in clinical and academic psychiatry, Dr.&nbsp;Stankovic brings over 20 years of executive level experience
in drug development and clinical and medical affairs. Dr.&nbsp;Stankovic has built and led multidisciplinary teams for small molecules and biologics in therapeutic areas including neurology, psychiatry, oncology, cardiology and pain. He has led
teams to achieve approvals of KEPPRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, FENTORA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, TREANDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, NUVIGIL<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and ARISTADA<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>. Prior to joining our company, Dr.&nbsp;Stankovic served as Senior Vice President of Clinical Development and Medical
Affairs at Alkermes plc. from 2013 to 2015. Prior to Alkermes, he held the position of Senior Vice President and Head of Global Clinical Development for Teva Pharmaceuticals Ltd. He was appointed to this role following Teva&#146;s acquisition of
Cephalon, Inc. where he served as Senior Vice President, Worldwide Clinical Research. Dr.&nbsp;Stankovic also served as Senior Vice President, Medical Affairs and Clinical Development CNS at Forest Laboratories, Inc. and held executive positions in
research and development at Neurogen Corporation, Johnson and Johnson, and UCB. Dr.&nbsp;Stankovic received his M.D. from the University of Belgrade and holds a Master of Science in public health from the University of Alabama at Birmingham. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Austin D. Kim </I>is our Executive Vice President, General Counsel, and Secretary and has been with our company since July 2018. From 2006
until 2017, Mr.&nbsp;Kim held several senior legal positions at Teva Pharmaceuticals, a global specialty pharmaceutical company. At Teva, Mr.&nbsp;Kim was most recently Vice President and Deputy General Counsel, Corporate/M&amp;A, handling corporate
and securities law matters, acquisitions and corporate development, capital markets transactions and corporate governance matters. Before joining Teva, Mr.&nbsp;Kim was Deputy General Counsel at IVAX Corporation, a global generic pharmaceutical
company, which was acquired by Teva in 2006. Earlier in his career, Mr.&nbsp;Kim was a senior lawyer at Transamerica Corporation, practiced law at Pillsbury, Madison&nbsp;&amp; Sutro and clerked for Judge Vaughn Walker of the United States District
Court, Northern District of California. Mr.&nbsp;Kim received his J.D. from Columbia University School of Law and his A.B. in English literature and economics from Stanford University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Elena Ridloff, CFA</I> is our Executive Vice President, Chief Financial Officer. Ms. Ridloff was previously Senior Vice President, Investor
Relations and Interim Chief Financial Officer and has been with our company since April 2018. Ms.&nbsp;Ridloff joined us from Alexion Pharmaceuticals, Inc., where she served as Executive Director, Investor Relations from April 2014 to January 2016
and Vice President, Investor Relations from January 2016 to March 2018, and served as a member of Alexion&#146;s Operating Committee. While at Alexion, Ms.&nbsp;Ridloff was responsible for building and leading an investor relations function. Prior
to joining Alexion, Ms.&nbsp;Ridloff served as the Chief Executive Officer and Managing Member of BIOVISIO, an independent consulting firm providing strategic, financial and investor relations counsel to the life sciences industry, from January 2012
to April 2014. Ms.&nbsp;Ridloff also served as Managing Director at Maverick Capital, a hedge fund responsible for investments in the biotechnology, pharmaceutical, medical device and life science sectors, from July 2005 to January 2012.
Ms.&nbsp;Ridloff earned her B.A. in history and sociology of science from the University of Pennsylvania, and is a Chartered Financial Analyst. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Michael J. Yang </I>is our Executive Vice President, Chief Commercial Officer and has been with our company since March 2017. Mr.&nbsp;Yang
joined us from Janssen Pharmaceutical Companies of Johnson&nbsp;&amp; Johnson, where he served as President of Janssen Biotech Inc. and was responsible for building Janssen&#146;s U.S. Immunology business, generating more than $8&nbsp;billion in
annual revenues. Mr.&nbsp;Yang began his career at Johnson&nbsp;&amp; Johnson in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
1997 and held numerous senior commercial positions such as President, CNS where he was responsible for growing the anti-psychotic long-acting therapy portfolio. His broad background of
commercialization and general management experience also includes roles as the Worldwide General Manager of the Medical Device companies of Therakos, Inc and Veridex, LLC, where he launched new platforms, expanded global revenues and diversified the
product lines. Prior to that, Mr.&nbsp;Yang was Vice President of Sales and Marketing, Oncology at Ortho Biotech Inc. Mr.&nbsp;Yang earned his B.S. in business administration, marketing from San Diego State University. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Independence of the Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
required under the Nasdaq Stock Market (&#147;Nasdaq&#148;) listing standards, a majority of the members of a listed company&#146;s board of directors must qualify as &#147;independent&#148;, as affirmatively determined by the board of directors.
Our Board of Directors consults with the Company&#146;s counsel to ensure that the Board&#146;s determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#147;independent&#148;, including
those set forth in the applicable Nasdaq listing standards (including as independence is currently defined in Rule 5605(d)(2) of those listing standards). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with these considerations, after review of all identified relevant transactions or relationships between each director, or any of
his or her family members, and the Company, its senior management and its independent registered public accounting firm, the Board has affirmatively determined that all of our current directors are independent directors within the meaning of the
applicable Nasdaq listing standards except for Mr.&nbsp;Davis, our Chief Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our independent directors meet quarterly in
regularly scheduled executive sessions at which only <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are present and which are presided over by the Chairman of the Board. All of the committees of our Board of Directors are comprised
entirely of directors determined by the Board to be independent within the meaning of the applicable Nasdaq listing standards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership
Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors has an independent chair who has authority, among other things, to call and preside over Board
meetings, including meetings of the independent directors, to set meeting agendas and to determine materials to be distributed to the Board. Accordingly, the Board Chairman has substantial ability to shape the work of our Board. The Company believes
that separation of the positions of Board Chairman and Chief Executive Officer reinforces the independence of our Board in its oversight of the business and affairs of the Company. In addition, the Company believes that having an independent Board
Chairman creates an environment that is more conducive to objective evaluation and oversight of management&#146;s performance, increasing management accountability and improving the ability of our Board to monitor whether management&#146;s actions
are in the best interests of the Company and its stockholders. As a result, the Company believes that having an independent Board Chairman can enhance the effectiveness of our Board as a whole. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in Risk Oversight</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One
of the Board&#146;s functions is risk oversight for the Company. The Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through various Board
standing committees that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk
appropriate for the Company. Our Compensation Committee is responsible for overseeing the Company&#146;s executive compensation plans and arrangements and assessing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whether any of our compensation policies or procedures has the potential to encourage excessive risk-taking. The Audit Committee oversees management of financial risks. The Audit Committee also
monitors compliance with legal and regulatory requirements related to our finances. The NCG Committee manages risks associated with corporate governance, including the independence of the Board and potential conflicts of interest. Typically, the
applicable Board committees discuss the applicable risk oversight at least annually at one of the regularly scheduled meetings for that committee with the relevant employees. While each committee is responsible for evaluating certain risks and
overseeing the management of such risks, the entire Board of Directors is regularly informed through committee reports and reports from management about such risks. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Meetings of the Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Board of Directors met nine times during 2018, including five special telephonic meetings. All directors attended at least 75% of the aggregate number of meetings of the Board and of the committees on which they served, held during the portion of
the last fiscal year for which they were directors or committee members. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Regarding Committees of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides
membership and meeting information for 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Audit&nbsp;Committee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Compensation&nbsp;Committee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nominating&nbsp;and<BR>Corporate<BR>Governance<BR>Committee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julian Baker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Biggar, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura Brege</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Daly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Soland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Meetings in 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Committee Chair </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a description of the Audit Committee, Compensation Committee and NCG Committee of the Board of Directors. The Board of Directors has
determined that each member of such committees meets the applicable Nasdaq rules and regulations regarding &#147;independence&#148; and that each member is free of any relationship that would impair his or her individual exercise of independent
judgment with regard to the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee of the Board of Directors is composed of three directors, each of whom is independent, and was established by the Board in
accordance with Section&nbsp;3(a)(58)(A) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), to oversee the Company&#146;s corporate accounting and financial reporting processes and audits of its financial statements.
The Audit Committee operates pursuant to a written charter that is available on our website at <I>http://www.acadia-pharm.com.</I> The functions of the Audit Committee include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and <FONT STYLE="white-space:nowrap">pre-approving</FONT> the engagement of our independent registered
public accounting firm to perform audit services and any permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> services, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our annual and quarterly results, financial statements and reports and discussing the statements and
reports with our independent registered public accounting firm and management, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with our independent registered public accounting firm and management, as appropriate,
significant issues that arise regarding accounting principles and financial statement presentation, and matters concerning the scope, adequacy and effectiveness of our internal control over financial reporting, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for the receipt, retention and treatment of complaints received by us regarding
accounting, internal auditing controls or auditing matters, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for the confidential and anonymous submission by employees of concerns regarding
questionable accounting or auditing matters, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving any transaction with a related person that must be disclosed by us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors reviews the Nasdaq listing standards definition of independence for Audit Committee members on
an annual basis and has determined that all members of the Audit Committee are independent (as independence is currently defined in the applicable Nasdaq listing standards). Our Board of Directors has determined that Ms.&nbsp;Brege qualifies as an
&#147;audit committee financial expert&#148;, as defined in applicable SEC rules. The Board made a qualitative assessment of Ms.&nbsp;Brege&#146;s level of knowledge and experience based on a number of factors, including her formal education, prior
experience and business acumen. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Report of the Audit Committee of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The material in this report is not &#147;soliciting material&#148;, is not deemed &#147;filed&#148; with the SEC and is not to be
incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation
language in any such filing. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary purpose of the Audit Committee is to oversee our financial reporting processes on behalf of
our Board of Directors. The Audit Committee&#146;s functions are more fully described in its charter, which is available on our website at <I>http://www.acadia-pharm.com.</I> Management has the primary responsibility for our financial statements and
reporting processes, including our systems of internal controls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee has reviewed and discussed the audited financial
statements for the fiscal year ended December&nbsp;31, 2018 with our management. The Audit Committee has discussed with the independent registered public accounting firm the matters required to be discussed by the applicable requirements of the
Public Company Accounting Oversight Board (&#147;PCAOB&#148;) and the SEC. The Audit Committee has also received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the
PCAOB regarding the independent accountants&#146; communications with the audit committee concerning independence and has discussed with the independent registered public accounting firm the accounting firm&#146;s independence. Based on the
foregoing, the Audit Committee has recommended to the Board of Directors that the audited financial statements be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2018.
The Audit Committee also has engaged Ernst&nbsp;&amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2019 and is seeking ratification of such selection by the stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing report has been furnished by the Audit Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Laura Brege, Committee Chair </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">James Daly </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Daniel Soland </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation
Committee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee is composed of three directors and all members of the Compensation Committee are independent. The
Compensation Committee operates pursuant to a written charter that is available </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on our website at <I>http://www.acadia-pharm.com</I>. The functions of the Compensation Committee include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our Board of Directors the compensation and other terms of employment of our
executive officers and reviewing and suggesting corporate performance goals and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">objectives relevant to such compensation, which shall support and reinforce our long-term strategic goals,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to our Board of Directors the type and amount of compensation to be paid or awarded to <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors for their service on our Board of Directors and its committees, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating and recommending to our Board of Directors the equity incentive plans, compensation plans and similar
programs advisable for us, as well as modification, administration or termination of existing plans and programs, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies with respect to equity compensation arrangements, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the terms of any employment agreements, severance arrangements, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">change-in-control</FONT></FONT> protections and any other compensatory arrangements for our executive officers and approving any such agreements for all officers prior to approval by the Board of Directors, and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering and responding to votes by the Company&#146;s stockholders to approve executive compensation as
required by Section&nbsp;14A of the Exchange Act and determining the Company&#146;s recommendations regarding the frequency of advisory votes on executive compensation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each year, the Compensation Committee reviews with management the Company&#146;s Compensation Discussion and Analysis and considers whether to
recommend that it be included in proxy statements and other filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee Processes and Procedures.</I> Typically,
the Compensation Committee meets quarterly and with greater frequency if necessary. The agenda for each meeting is usually developed by the chair of the Compensation Committee, in consultation with management. The Compensation Committee meets
regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, provide financial or other
background information or advice or otherwise participate in Compensation Committee meetings. The Chief Executive Officer does not participate in, and is not present during, any deliberations or determinations of the Compensation Committee regarding
his compensation or his individual performance. The charter of the Compensation Committee grants the Compensation Committee full access to all books, records, facilities and personnel of the Company, as well as authority to obtain, at the expense of
the Company, advice and assistance from internal and external legal, accounting or other advisors and consultants and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. The
Compensation Committee has direct responsibility for the oversight of the work of any advisers engaged for the purpose of advising the Committee. In particular, the Compensation Committee has authority to retain compensation consultants to assist in
its evaluation of executive and director compensation, including the authority to approve the consultant&#146;s reasonable fees and other retention terms. Under the committee&#146;s charter, the Compensation Committee may select, or receive advice
from, a compensation consultant, legal counsel or other adviser to the Compensation Committee, other than <FONT STYLE="white-space:nowrap">in-house</FONT> legal counsel and certain other types of advisers, only after taking into consideration six
factors, prescribed by the SEC and Nasdaq, that bear upon the adviser&#146;s independence; however, there is no requirement that any adviser be independent. For fiscal 2018, after taking into consideration the six factors prescribed by the SEC and
Nasdaq, the Compensation Committee engaged Frederic W. Cook&nbsp;&amp; Co., Inc. (&#147;FW Cook&#148;) as a compensation consultant to assist with Board and executive compensation. The Compensation Committee requested that FW Cook: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluate the efficacy of the Company&#146;s existing executive compensation strategy and practices in supporting
and reinforcing the Company&#146;s long-term strategic goals; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assist in refining the Company&#146;s compensation strategy and in developing and implementing an executive
compensation program to execute that strategy, including developing performance-based options designed focused on long-term incentives for executive officers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of its engagement, FW Cook was requested by the Compensation Committee to review and update, as necessary, the comparator group of
companies used for fiscal 2017 compensation discussions and to perform analyses of competitive performance and compensation levels for that group. At the request of the Compensation Committee, FW Cook also conducted interviews with certain members
of the Compensation Committee and senior management to learn more about the Company&#146;s business operations and strategy, key performance metrics and strategic goals, as well as the labor markets in which the Company competes. Following an active
dialogue with FW Cook and our President and Chief Executive Officer, the Compensation Committee recommended that the Board of Directors approve the recommendations discussed in the Compensation Discussion and Analysis section of this proxy
statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under its charter, the Compensation Committee may form, and delegate authority to, subcommittees, as appropriate. In addition,
in 1998, the Board of Directors formed a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Stock Option Committee to which it delegated authority to grant, without any further action required by the Compensation Committee, stock options to
employees who are not executive officers of the Company. In July 2018, the Board of Directors delegated the authority to grant options under the 2010 Equity Incentive Plan, as amended, to Mr.&nbsp;Davis and Mr.&nbsp;Kim, acting together. The purpose
of this delegation of authority is to enhance the flexibility of option administration within the Company and to facilitate the timely grant of options to <FONT STYLE="white-space:nowrap">non-management</FONT> employees, particularly new employees,
within specified limits approved by the Board of Directors. The authority of the <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Stock Option Committee is specified at least once every quarter, but, generally, it may not grant options in excess
of 100,000 shares to any one employee. Typically, as part of its oversight function, the Compensation Committee will review on a quarterly basis the list of grants made by the committee. During fiscal 2018, the subcommittee exercised its authority
to grant options to purchase an aggregate of 3,634,351 shares to <FONT STYLE="white-space:nowrap">non-officer</FONT> employees, including an aggregate of 2,031,351 biannual refresher options grants delegated by the Compensation Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, the Compensation Committee has met at one or more meetings held during the first quarter of the year to discuss and make
recommendations to the Board of Directors for annual compensation adjustments, annual bonuses, annual equity awards, and new performance objectives. However, the Compensation Committee also considers matters related to individual compensation, such
as compensation for new executive hires, as well as high-level strategic issues, such as the effectiveness of the Company&#146;s compensation strategy, potential modifications to that strategy and new trends, plans or approaches to compensation, at
various meetings throughout the year. Generally, the Compensation Committee&#146;s process comprises two related elements: the determination of compensation levels and the establishment of performance objectives for the current year. For executives
other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations submitted to it by the Chief Executive Officer. In the case of the Chief Executive Officer, the evaluation of his performance
is conducted by the Compensation Committee, which recommends to the Board of Directors any adjustments to his compensation as well as awards to be granted. For all executives, as part of its deliberations, the Compensation Committee may review and
consider, as appropriate, materials such as financial reports and projections, operational data, executive stock ownership information, company stock performance data, analyses of historical executive compensation levels and current company-wide
compensation levels, compensation surveys, and recommendations of compensation consultants, if applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specific determinations of
the Compensation Committee with respect to executive compensation for fiscal 2018 are described in greater detail in the Compensation Discussion and Analysis section of this proxy statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominating and Corporate Governance Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The NCG Committee of the Board of Directors currently is composed of three independent directors and operates pursuant to a written charter
that is available on our website at <I>http://www.acadia-pharm.com.</I> The functions of the NCG Committee include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interviewing, evaluating, nominating and recommending individuals for membership on our Board of Directors,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating nominations by stockholders of candidates for election to our Board of Directors,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating performance of our Board of Directors and applicable committees of the Board and determining whether
continued service on the Board is appropriate, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing, reviewing and amending a set of corporate governance policies and principles, including our Code of
Business Conduct and Ethics, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering questions of possible conflicts of interest of officers and directors as such questions arise, and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing and reviewing the processes and procedures we use to provide information to the Board of Directors and
its committees. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Candidates for director nominees are reviewed in the context of the current composition of our Board of
Directors, our operating requirements and the long-term interests of our stockholders. In conducting this assessment, the NCG Committee considers skills, diversity, age, and such other factors as it deems appropriate given the current needs of the
Board of Directors and ACADIA, to maintain a balance of knowledge, experience and capability. The NCG Committee does not have a formal policy regarding diversity, but does recognize the potential importance of diversity in board composition,
including diversity of experience, gender and ethnicity, and believes that directors should represent a diversity of viewpoints. To these ends, the NCG Committee has identified and evaluated nominees in the broader context of the Board&#146;s
overall composition, as well as the Company&#146;s current needs and future needs, with the goal of having Board members who complement and strengthen the skills of each other through diversity and who also exhibit qualities that the NCG Committee
views as critical to effective functioning of the Board of Directors, including sound judgment, collegiality, and integrity. In the case of incumbent directors whose terms of office are set to expire, the NCG Committee reviews such directors&#146;
experience, qualifications, attributes, overall service to us during their term, including the number of meetings attended, level of participation, quality of performance, and any other relevant considerations. In the case of new director
candidates, the NCG Committee also determines whether the nominee would be independent under applicable Nasdaq listing standards, and SEC rules and regulations with the advice of counsel, if necessary. The NCG Committee uses its network of contacts
to compile a list of potential candidates, but has also engaged, when it deemed appropriate, a professional search firm. The NCG Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible
candidates after considering the function and needs of our Board of Directors. The NCG Committee meets to discuss and consider candidates&#146; qualifications and selects candidates for recommendation to the Board by majority vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The NCG Committee will consider director candidates recommended by stockholders. The NCG Committee does not intend to alter the manner in
which it evaluates candidates, based on whether the candidate was recommended by a stockholder. Stockholders who wish to recommend individuals for consideration by the NCG Committee must do so by delivering a written recommendation to the NCG
Committee at the following address: 3611 Valley Centre Drive, Suite 300, San Diego, California 92130. Each submission must set forth: the name and address of the stockholder on whose behalf the submission is made; the number of our shares that are
owned beneficially by such stockholder as of the date of the submission; the full name of the proposed candidate; a description of the proposed candidate&#146;s business experience for at least the previous five years; complete biographical
information for the proposed candidate; and a description of the proposed candidate&#146;s qualifications as a director. For the proposed candidate to be considered for nomination for the 2020 Annual Meeting of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stockholders, the written communication must be received no earlier than February&nbsp;27, 2020 and no later than by March&nbsp;28, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Communications With the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors has adopted a formal process by which stockholders may communicate with the Board of Directors or any of its directors.
Stockholders who wish to communicate with the Board of Directors may do so by sending written communications addressed to the Company&#146;s General Counsel at 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130. All communications will be
compiled by the General Counsel and submitted to the Board or the individual directors on a periodic basis. These communications will be reviewed by the General Counsel, who will determine whether they should be presented to the Board. The purpose
of this screening is to allow the Board of Directors to avoid having to consider irrelevant or inappropriate communications (such as advertisements, solicitations and hostile communications). All communications directed to the Audit Committee in
accordance with the Company&#146;s Open Door Policy for Reporting Complaints Regarding Accounting and Auditing Matters, discussed below, will be treated in accordance with that policy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted the
ACADIA Pharmaceuticals Inc. Code of Business Conduct and Ethics that applies to all officers, directors and employees. The Code of Business Conduct and Ethics is available on our website at <I>http://www.acadia-pharm.com. </I>If we make any
substantive amendments to this Code of Business Conduct and Ethics or grant any waiver from a provision of the Code to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Open Door Policy for Reporting Accounting and Auditing Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted an Open Door Policy for Reporting Complaints Regarding Accounting and Auditing Matters to facilitate the receipt, retention and
treatment of complaints regarding accounting, internal accounting controls or auditing matters, as well as the confidential, anonymous submission by our employees of concerns regarding these matters. The Open Door Policy is available on our website
at <I>http://www.acadia-pharm.com.</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;16(a) Beneficial Ownership Reporting Compliance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16(a) of the Exchange Act requires our directors and executive officers, and persons who own more than ten percent of a registered
class of our equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. Officers, directors and greater than ten percent stockholders are required by SEC
regulation to furnish us with copies of all Section&nbsp;16(a) forms they file. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To our knowledge, based solely on a review of the copies
of such reports furnished to us and written representations that no other reports were required, during the fiscal year ended December&nbsp;31, 2018, all Section&nbsp;16(a) filing requirements applicable to our officers, directors and greater than
ten percent beneficial owners were complied with, except that one report in October 2018 for each of Messrs. Davis, Stankovic, Yang and Young were filed late. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>ROPOSAL</SMALL> 2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVAL</SMALL> O<SMALL>F</SMALL> A<SMALL>N</SMALL> A<SMALL>MENDMENT</SMALL> T<SMALL>O</SMALL> T<SMALL>HE</SMALL> 2010
E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 27, 2019, our Board of Directors amended the ACADIA Pharmaceuticals Inc. 2010 Equity Incentive Plan, as amended (the &#147;2010
Plan&#148;), subject to stockholder approval, to among other things, increase the number of shares of common stock authorized for issuance under the 2010 Plan by 8,300,000 shares. We refer to the 2010 Plan, as so amended, as the &#147;Amended 2010
Plan&#148; throughout this proxy statement. References in this proposal to our Board of Directors include the Compensation Committee of the Board where applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of the material terms of the Amended 2010 Plan are summarized below. The key difference between the terms of the 2010 Plan and
the Amended 2010 Plan is as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Amended 2010 Plan provides that an additional 8,300,000 shares may be issued pursuant to stock awards granted
under the Amended 2010 Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this Proposal 2, our Board of Directors is requesting stockholder approval of the
Amended 2010 Plan, including the increase to the number of shares of common stock authorized for issuance under the Amended 2010 Plan by 8,300,000 shares. As of December&nbsp;31, 2018, approximately 6,700,000 shares were authorized for issuance
under the 2010 Plan. If stockholder approval of this Proposal 2 is obtained, therefore, an aggregate of approximately 15,000,000 shares will be authorized for issuance under the Amended 2010 Plan, less the number of shares underlying equity awards
(1)&nbsp;that have been granted since December&nbsp;31, 2018 (after applying the share counting provisions described herein) and (2)&nbsp;that are intended to be granted prior to the date of the 2019 Annual Meeting. The Board of Directors believes
that the Amended 2010 Plan is an integral part of our long-term compensation philosophy and the Amended 2010 Plan is necessary to continue providing the appropriate levels and types of equity compensation for our employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Awards Are an Integral Component of Our Compensation Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equity awards have been historically and, we believe, will continue to be an integral component of our overall compensation program for our
employees and directors. Approval of the Amended 2010 Plan will allow us to continue to grant stock options and other equity awards at levels we determine to be appropriate in order to attract new employees and directors, retain our existing
employees and to provide incentives for such persons to exert maximum efforts for the Company&#146;s success and ultimately increase stockholder value. The Amended 2010 Plan allows the Company to utilize a broad array of equity incentives with
flexibility in designing such incentives, including traditional option grants, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance stock awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2018, stock awards covering an aggregate of 19,868,781 shares were outstanding under our 2004 Equity Incentive Plan (the
&#147;2004 Plan&#148;) and the 2010 Plan, collectively. In addition, 6,676,769 shares remained available for future grant under the 2010 Plan as of such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides certain additional information regarding our equity incentive
program as of December&nbsp;31, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock subject to outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,868,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average exercise price of outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining term of outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock subject to outstanding full value awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock available for grant under the 2010 plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,676,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock available for grant under other equity incentive
plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,853,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Per-share</FONT> closing price of common stock as reported on
Nasdaq Global Select Market</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Size of Our Share Reserve Increase Request Is Reasonable </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our request to increase the share reserve of the Amended 2010 Plan by 8,300,000 shares is approved, we will have approximately 10,800,000
shares authorized for issuance after the Annual Meeting, after taking into account grants made after December&nbsp;31, 2018 and those anticipated to be made through the date of our Annual Meeting. We believe that such number of shares will be
sufficient to attract, retain and motivate employees for the next year. We anticipate seeking approval from our stockholders in 2020 of an additional increase to the share reserve under the Amended 2010 Plan. The size of our request is also
reasonable in light of the equity granted to our employees and directors over the last three years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We Manage Our Equity Incentive Award Use
Carefully, and Dilution Is Reasonable </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continue to believe that equity awards such as stock options and other types of stock awards
are a vital part of our overall compensation program. Our compensation philosophy reflects broad-based eligibility for equity incentive awards, and we grant awards to substantially all of our employees. However, we recognize that equity awards
dilute existing stockholders, and, therefore, we must responsibly manage the growth of our equity compensation program. We are committed to effectively monitoring our equity compensation share reserve, including our &#147;burn rate,&#148; to ensure
that we maximize stockholders&#146; value by granting the appropriate number of equity incentive awards necessary to attract, reward, and retain employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows our historical dilution and burn rate percentages for fiscal years 2018, 2017 and 2016.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>As of December&nbsp;31</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Full Dilution(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross Burn Rate(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Full dilution is calculated as (shares available for grant + shares subject to outstanding equity incentive
awards)/(common stock outstanding + shares available for grant + shares subject to outstanding equity incentive awards). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Gross Burn Rate is calculated as (shares subject to options granted + shares subject to other equity incentive
awards granted)/weighted average common shares outstanding. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Burn Rate </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides detailed information regarding the activity related to our equity incentive plans for fiscal years 2018, 2017 and
2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Fiscal Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock subject to stock options granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,273,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,867,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,721,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock subject to full value awards granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares of common stock outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,583,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,858,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Burn Rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The approval of the Amended 2010 Plan will allow us to continue to grant stock options, and would allow us to
grant other awards described below, at levels determined appropriate by our Board of Directors or its delegate. The Amended 2010 Plan will continue to provide us with flexibility in designing equity incentives in an environment where a number of
companies have moved from traditional option grants to other stock-based awards, including stock appreciation rights, restricted stock awards, restricted stock unit awards, and performance stock awards. The Amended 2010 Plan allows us to utilize
multiple types of equity incentives in order to secure and retain the services of our employees, consultants and directors, and to provide long-term incentives that align the interests of our employees, consultants and directors with the interests
of our stockholders. We generally do not make awards to consultants and have no current plans to make any awards to consultants under the Amended 2010 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Aspects of Our Amended 2010 Plan Designed to Protect Our Stockholders&#146; Interests </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended 2010 Plan includes certain provisions that are designed to protect our stockholders&#146; interests and to reflect corporate
governance best practices including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stockholder approval is required for additional shares. </I>The Amended 2010 Plan does not contain an annual
&#147;evergreen&#148; provision. Thus, stockholder approval is required each time we need to increase the share reserve allowing our stockholders the ability to have a say on our equity compensation programs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Repricing is not allowed. </I>The Amended 2010 Plan prohibits the repricing of outstanding equity awards and
the cancelation of any outstanding equity awards that have an exercise price or strike price greater than the current fair market value of our common stock in exchange for cash or other stock awards under the Amended 2010 Plan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Share counting provisions. </I>The share reserve under the Amended 2010 Plan is reduced one share for each
share of common stock issued pursuant to an option, stock appreciation right and or other stock award with an exercise price that is at least 100% of the fair market value of our common stock on the date of grant (an &#147;Appreciation Award&#148;)
granted under the Amended 2010 Plan and 1.42 shares for each share of common stock issued pursuant to a stock award that is not an Appreciation Award (a &#147;Full Value Award&#148;) under the Amended 2010 Plan. This helps to ensure that management
and our Board of Directors and Compensation Committee is using the share reserve effectively and with regard to the value of each type of equity award. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Minimum vesting requirements</I>. The Amended 2010 Plan provides that, except as may be provided in connection
with a corporate transaction or a change in control (and excluding for substitute awards, awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors that vest on the earlier of the <FONT STYLE="white-space:nowrap">one-year</FONT>
anniversary of the date of grant or the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year&#146;s annual meeting), no stock award granted on or after June&nbsp;13, 2017 may vest until at least
12&nbsp;months following the date of grant of such award, except that up to 5% of the share reserve of the Amended 2010 Plan may be subject to awards granted on or after June&nbsp;13, 2017 that do not meet such vesting requirements.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Submission of amendments to Amended 2010 Plan to stockholders. </I>The Amended 2010 Plan requires stockholder
approval for material amendments to the Amended 2010 Plan, including as noted above, any increase in the number of shares reserved for issuance under the Amended 2010 Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Flexibility in designing equity compensation scheme. </I>The Amended 2010 Plan allows us to provide a broad
array of equity incentives, including traditional option grants, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, and other stock awards. By providing this flexibility we can quickly and
effectively react to trends in compensation practices and continue to offer competitive compensation arrangements to attract and retain the talent necessary for the success of our business. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Broad-based eligibility for equity awards. </I>We grant equity awards to the vast majority of our employees.
By doing so, we tie our employees&#146; interests with stockholder interests and motivate our employees to act as owners of the business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Restrictions on dividends</I>. The Amended 2010 Plan provides that (i)&nbsp;no dividends or dividend
equivalents may be paid with respect to any shares of our common stock subject to an award before the date such shares have vested, (ii)&nbsp;any dividends or dividend equivalents that are credited with respect to any such shares will be subject to
all of the terms and conditions applicable to such shares under the terms of the applicable award agreement (including any vesting conditions), (iii) any dividends or dividend equivalents that are credited with respect to any such shares will be
forfeited to us on the date such shares are forfeited to or repurchased by us due to a failure to vest, and (iv)&nbsp;in no event shall dividends be paid or credited with respect to an Appreciation Award. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Amended 2010 Plan contains a limit on the total annual compensation that may be paid or granted to any <FONT
STYLE="white-space:nowrap">non-employee</FONT> director for service as a director. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General 2010 Plan Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2010 Plan was adopted by the Board of Directors on March&nbsp;12, 2010 and approved by our stockholders on June&nbsp;11, 2010. The 2010
Plan was the successor to and continuation of the 2004 Plan. All outstanding stock awards granted under the 2004 Plan continue to be subject to the terms and conditions as set forth in the agreements evidencing such stock awards and the terms of the
2004 Plan; provided, however, that any shares subject to outstanding stock options granted under the 2004 Plan that expire or terminate for any reason prior to exercise become available for issuance pursuant to stock awards granted under the Amended
2010 Plan. Following June&nbsp;11, 2010, the effective date of the 2010 Plan, no additional stock awards have been granted under the 2004 Plan. As of June&nbsp;11, 2010, 802,809 shares remaining available for issuance as new stock awards under the
2004 Plan became available for issuance pursuant to stock awards granted under the 2010 Plan. In March 2013, our Board of Directors adopted, and in June 2013, our stockholders approved, an amendment to the 2010 Plan to increase the number of shares
reserved for issuance under the 2010 Plan by 7,500,000 shares. In April 2015, our Board of Directors adopted, and in June 2015, our stockholders approved, an amendment to the 2010 Plan to increase the number of shares reserved for issuance under the
2010 Plan by 5,000,000 shares. In April 2016, our Board of Directors adopted, and in June 2016, our stockholders approved, an amendment to the 2010 Plan to increase the number of shares reserved for issuance under the 2010 Plan by 3,000,000 shares.
In April 2017, our Board of Directors adopted, and in June 2017, our stockholders approved, an amendment to the 2010 Plan to increase the number of shares reserved for issuance under the 2010 Plan by 5,500,000 shares. In April 2018, our Board of
Directors adopted, and in June 2018, our stockholders approved, an amendment to the 2010 Plan to increase the number of shares reserved for issuance under the 2010 Plan by 6,700,000 shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this Proposal 2, stockholders are requested to approve the Amended 2010 Plan. The affirmative vote of the holders of a majority of the
shares present in person or represented by proxy and entitled to vote on this matter at the Annual Meeting will be required to approve the adoption of the Amended 2010 Plan. Abstentions will be counted toward the tabulation of votes cast on Proposal
2 and will have the same effect as negative votes. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted toward a quorum, but are not counted for any purpose in determining whether this matter has been approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL>
R<SMALL>ECOMMENDS</SMALL> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> P<SMALL>ROPOSAL</SMALL> 2.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of the Amended 2010 Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material features of the Amended 2010 Plan are outlined below. This summary is qualified in its entirety by reference to the complete text
of the Amended 2010 Plan. Stockholders are urged to read the actual text of the Amended 2010 Plan in its entirety, which is appended to this proxy statement as <B>Appendix A</B> and may be accessed from the SEC&#146;s website at <I>www.sec.gov</I>.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Background </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the Amended
2010 Plan provide for the grant of both nonstatutory stock options (&#147;NSOs&#148;) and incentive stock options (&#147;ISOs&#148;), restricted stock, restricted stock units, stock appreciation rights, other stock-related awards, and performance
awards that may be settled in cash, stock, or other property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shares Available for Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Proposal 2 is approved, the total number of shares of our common stock reserved for issuance under the Amended 2010 Plan will consist
of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares that are subject to stock awards outstanding under the 2004 Plan and the 2010 Plan, as of
December&nbsp;31, 2018, that subsequently expire or terminate for any reason prior to exercise or settlement or are forfeited because of the failure to meet a contingency or condition required to vest vesting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares previously reserved for issuance under the 2010 Plan, of which 6,676,768 remained available
for future grant as of December&nbsp;31, 2018; plus </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">8,300,000 shares being added under this Proposal 2; less </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares subject to awards granted after December&nbsp;31, 2018 and prior to the Annual Meeting.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We call this aggregate number the &#147;Share Reserve.&#148; The number of shares available for issuance under the
Amended 2010 Plan is reduced by (i)&nbsp;one share for each share of common stock issued pursuant to a Stock Appreciation Right, (ii) 1.47 shares for each share issued pursuant to a Full Value Award granted under the Amended 2010 Plan between
June&nbsp;6, 2018 and June&nbsp;26, 2019 and (iii) 1.42 shares for each share issued pursuant to a Full Value Award granted under the Amended 2010 Plan on or after June&nbsp;26, 2019. The Share Reserve under the Amended 2010 Plan may be exceeded so
long as the number of shares of common stock actually issued upon the vesting or exercise of equity awards made under the Amended 2010 Plan does not exceed the Share Reserve. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, there were 6,676,769 shares of common stock (plus any shares that might thereafter be returned to the plan as a
result of cancellation or expiration of options) available for future grant under the 2010 Plan. In addition, as of such date, stock awards covering an aggregate of 19,868,781 shares, collectively, were outstanding under the 2004 Plan and the 2010
Plan, and no other awards were outstanding. The weighted average exercise price of all options outstanding as of December&nbsp;31, 2018 was approximately $28.04 and the weighted average remaining term of such options was approximately 7.6 years. A
total of 143,853,597 shares of our common stock were outstanding as of December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue common stock pursuant to a
stock award and the common stock is later forfeited, then the forfeited shares will become available for issuance under the Amended 2010 Plan. To the extent that a Full Value Award again becomes available for issuance under the Amended 2010 Plan,
then the number of shares of common stock available for issuance under the Amended 2010 Plan will increase by 1.47 shares for Full Value </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Awards granted between June&nbsp;6, 2018 and June&nbsp;26, 2019, and by 1.42 shares for Full Value Award granted after June&nbsp;26, 2019. Any shares we reacquire pursuant to our withholding
obligations and any shares we reacquire as consideration for the exercise of an option or stock appreciation right, however, do not become available for issuance under the Amended 2010 Plan. In addition, if the exercise price of any award is
satisfied by the tender of shares of common stock to us (whether by actual delivery or attestation), the tendered shares do not become available for issuance under the Amended 2010 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our approximately 465
employees and all of our six <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are eligible to participate in the Amended 2010 Plan and may receive all types of awards; provided that incentive stock options may be granted under the
Amended 2010 Plan only to our employees in the United States. Our consultants are also eligible to participate in the Amended 2010 Plan, but we generally do not make awards to consultants and have no current plans to make any awards to consultants
under the Amended 2010 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limit on <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Amended 2010 Plan, the following limit on compensation will apply to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors.
The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director with respect to any period commencing on the date of the Company&#146;s Annual
Meeting of Stockholders for a particular year and ending on the day immediately prior to the date of the Company&#146;s Annual Meeting of Stockholders for the next subsequent year, including awards granted and cash fees paid by the Company to such <FONT
STYLE="white-space:nowrap">non-employee</FONT> director, will not exceed (i) $1,500,000 in total value or (ii)&nbsp;in the event such <FONT STYLE="white-space:nowrap">non-employee</FONT> director is first appointed or elected to the Board during
such period, $2,000,000 in total value, in each case calculating the value of any awards based on the grant date fair value of such awards for financial reporting purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended 2010 Plan is
administered by our Board of Directors, which may in turn delegate authority to administer the plan to a committee. Our Board of Directors has delegated administration of the Amended 2010 Plan to our Compensation Committee and an additional <FONT
STYLE="white-space:nowrap">Non-Officer</FONT> Stock Option Committee created by the Board that has separate but concurrent jurisdiction with the Compensation Committee to make certain discretionary equity awards under the Amended 2010 Plan to all
eligible employees other than executive management. Subject to the terms of the Amended 2010 Plan, our Compensation Committee may determine the recipients, numbers and types of stock awards to be granted, and terms and conditions of the stock
awards, including the period of their exercisability and vesting. Subject to the terms of the Amended 2010 Plan and limitations on the size of individual and aggregate grants that are set quarterly by our Board of Directors, our <FONT
STYLE="white-space:nowrap">Non-Officer</FONT> Stock Option Committee may determine the recipients and numbers of stock options to be granted, provided that the terms and conditions of the option awards conform to
<FONT STYLE="white-space:nowrap">pre-approved</FONT> standards regarding the period of their exercisability and vesting. The fair market value applicable to a stock award and the exercise price of options granted under the Amended 2010 Plan is
determined in accordance with the terms of the Amended 2010 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the discretion of our Board of Directors, the Compensation Committee
may consist solely of two or more <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> of the Exchange Act. Our Compensation Committee has the authority
to delegate certain administrative powers to a subcommittee of one or more members. As used herein, except as explicitly stated otherwise, with respect to the Amended 2010 Plan, the &#147;Board&#148; refers to any committee the Board of Directors
appoints (including the Compensation Committee and the <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Stock Option Committee) or, if applicable, any subcommittee, as well as to the Board of Directors itself. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Repricing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Amended 2010 Plan, the Board does not have the authority to reprice any outstanding stock options or stock appreciation rights by
reducing the exercise price of the stock award or cancelling any outstanding stock awards in exchange for cash or other stock awards under the plan without the approval of our stockholders (which approval must be obtained within 12 months prior to
the repricing event). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Minimum Vesting Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Amended 2010 Plan, except as may be provided in connection with a corporate transaction or a change in control, no stock award
granted on or after June&nbsp;13, 2017 may vest until at least 12 months following the date of grant of such stock award, except that up to 5% of the share reserve of the Amended 2010 Plan may be subject to stock awards granted on or after
June&nbsp;13, 2017 that do not meet such vesting requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends and Dividend Equivalents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended 2010 Plan provides that dividends or dividend equivalents may be paid or credited with respect to any shares of our common stock
subject to an award, as determined by the Board and contained in the applicable award agreement; provided, however, that (i)&nbsp;no dividends or dividend equivalents may be paid with respect to any such shares before the date such shares have
vested, (ii)&nbsp;any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of the applicable award agreement (including any
vesting conditions), and (iii)&nbsp;any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to us on the date such shares are forfeited to or repurchased by us due to a failure to vest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Options </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options may be granted under the
Amended 2010 Plan pursuant to stock option agreements. The Amended 2010 Plan permits the grant of options that qualify as incentive stock options, or ISOs, and nonstatutory stock options, or NSOs. Individual stock option agreements may be more
restrictive as to any or all of the permissible terms described in this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price of NSOs may not be less than 100% of
the fair market value of the common stock subject to the option on the date of grant. The exercise price of ISOs may not be less than 100% of the fair market value of the common stock subject to the option on the date of grant and, in some cases
(see &#147;Limitations&#148; below), may not be less than 110% of such fair market value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of stock options granted under the
Amended 2010 Plan may not exceed ten years. Unless the terms of an optionholder&#146;s stock option agreement provide for earlier or later termination, if an optionholder&#146;s service relationship with us, or any affiliate of ours, ceases due to
(i)&nbsp;disability, the optionholder may exercise any vested options for up to 12 months after the date the service relationship ends or (ii)&nbsp;death, the optionholder&#146;s beneficiary, may exercise any vested options for up to 18 months after
the date the service relationship ends. Except as explicitly provided otherwise in an optionholder&#146;s award agreement, if an optionholder&#146;s service relationship with us is terminated for &#147;cause&#148; as defined in the Amended 2010
Plan, all options terminate upon the service termination date, and the optionholder is prohibited from exercising any option from the time of such termination. If an optionholder&#146;s service relationship with us ceases for any reason other than
for cause or upon disability or death, the optionholder may exercise any vested options for up to three months after the date the service relationship ends, unless the terms of the stock option agreement provide for a longer or shorter period to
exercise the option. For example, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors have three years from the end of their service on the Board to exercise options that have vested as of their service termination date. In no event may
an option be exercised after its expiration date. Under the Amended 2010 Plan, the option term may be extended in the event that exercise of the option following termination of service is prohibited by applicable securities laws or if the sale of
stock received upon exercise of an option would violate our insider trading policy. In no event, however, may any option be exercised beyond the expiration of its term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acceptable forms of consideration for the purchase of our common stock issued under the
Amended 2010 Plan will be determined by our Board and may include cash, check, bank draft or money order made payable to us, common stock previously owned by the optionholder, payment through a broker assisted exercise or, for NSOs only, a net
exercise feature, or other legal consideration approved by our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options granted under the Amended 2010 Plan may become exercisable
in cumulative increments, or &#147;vest&#148;, as determined by our Board at the rate specified in the option agreement (subject to the limitations described in &#147;Minimum Vesting Requirements&#148; above). Shares covered by different options
granted under the Amended 2010 Plan may be subject to different vesting schedules as our Board may determine. Vesting can be time-based or performance-based or can be a hybrid of performance- and time-based vesting. Our Board also has flexibility to
provide for accelerated vesting of equity awards in certain events. Our Board and Compensation Committee intend to continue to grant stock options to our officers with accelerated vesting, subject to additional conditions, in the event of a change
of control of the Company as defined in the Amended 2010 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, an optionholder may not transfer a stock option other than by
will or the laws of descent and distribution or a domestic relations order. However, an optionholder may designate a beneficiary who may exercise the option following the optionholder&#146;s death. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate fair market
value, determined at the time of grant, of shares of our common stock with respect to ISOs that are exercisable for the first time by a participant during any calendar year under all of our stock plans may not exceed $100,000. The options or
portions of options that exceed this limit are treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any affiliate
unless the following conditions are satisfied: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the option exercise price must be at least 110% of the fair market value of the stock subject to the option on
the date of grant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the term of any ISO must not exceed five years from the date of grant. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate maximum number of shares of common stock that may be issued pursuant to the exercise of ISOs will be 28&nbsp;million under the
Amended 2010 Plan. In addition, no employee may be granted options, stock appreciation rights, or other stock awards under the Amended 2010 Plan covering more than two million shares of our common stock in any calendar year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock
awards may be granted pursuant to restricted stock award agreements. A restricted stock award may be granted in consideration for cash, check, bank draft or money order payable to us, the recipient&#146;s past or future services performed for us or
an affiliate of ours, or any other form of legal consideration acceptable to the Board. Shares of our common stock acquired under a restricted stock award may be subject to forfeiture to us in accordance with a vesting schedule to be determined by
our Board (subject to the limitations described in &#147;Minimum Vesting Requirements&#148; above). Rights to acquire shares of our common stock under a restricted stock award may be transferred only upon such terms and conditions as are set forth
in the restricted stock award agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Unit Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock unit awards may be granted pursuant to restricted stock unit award agreements. Payment of any purchase price may be made in
any legal form acceptable to the Board. We will settle a payment due to a recipient of a restricted stock unit award by delivery of shares of our common stock, by cash, by a combination </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of cash and stock as deemed appropriate by our Board, or in any other form of consideration determined by our Board and set forth in the restricted stock unit award agreement. Dividend
equivalents may be credited in respect of shares of our common stock covered by a restricted stock unit award. Restricted stock unit awards may be subject to vesting in accordance with a vesting schedule to be determined by our Board (subject to the
limitations described in &#147;Minimum Vesting Requirements&#148; above). Except as otherwise provided in the applicable restricted stock unit award agreement, restricted stock units that have not vested will be forfeited upon the participant&#146;s
termination of continuous service for any reason. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock appreciation rights may be granted pursuant to a stock appreciation right agreement. Each stock appreciation right is denominated in
common stock share equivalents. The strike price of each stock appreciation right will be determined by our Board, but shall in no event be less than 100% of the fair market value of the stock subject to the stock appreciation right at the time of
grant. Our Board may also impose restrictions or conditions upon the vesting of stock appreciation rights that it deems appropriate (subject to the limitations described in &#147;Minimum Vesting Requirements&#148; above). Stock appreciation rights
may be paid in our common stock, in cash, in any combination of the two, or any other form of legal consideration approved by our Board and contained in the stock appreciation right agreement. Stock appreciation rights shall be subject to the same
conditions upon termination and restrictions on transfer as stock options under the Amended 2010 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Stock Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended 2010 Plan provides for the grant of performance stock awards. Performance awards may be granted, may vest or may be exercised based
upon the attainment during a certain period of time of certain performance goals (subject to the limitations described in &#147;Minimum Vesting Requirements&#148; above). The length of any performance period, the performance goals to be achieved
during the performance period, and the measure of whether and to what degree such performance goals have been attained shall be determined by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Performance goals under the Amended 2010 Plan shall be determined by the Board or a committee of the Board, based on any one or more of the
following performance criteria: (i)&nbsp;the attainment of certain target levels of, or a specified percentage increase in, revenues, earnings, income before taxes and extraordinary items, net income, operating income, earnings before income tax,
earnings before interest, taxes, depreciation and amortization or a combination of any or all of the foregoing; (ii)&nbsp;the attainment of certain target levels of, or a percentage increase in, <FONT STYLE="white-space:nowrap">after-tax</FONT> or <FONT
STYLE="white-space:nowrap">pre-tax</FONT> profits including, without limitation, that attributable to continuing and/or other operations; (iii)&nbsp;the attainment of certain target levels of, or a specified increase in, operational cash flow;
(iv)&nbsp;the achievement of a certain level of, reduction of, or other specified objectives with regard to limiting the level of increase in, all or a portion of, the Company&#146;s bank debt or other long-term or short-term public or private debt
or other similar financial obligations of the Company, which may be calculated net of such cash balances and/or other offsets and adjustments as may be established by the Committee; (v)&nbsp;earnings per share or the attainment of a specified
percentage increase in earnings per share or earnings per share from continuing operations; (vi)&nbsp;the attainment of certain target levels of, or a specified increase in return on capital employed or return on invested capital; (vii)&nbsp;the
attainment of certain target levels of, or a percentage increase in, <FONT STYLE="white-space:nowrap">after-tax</FONT> or <FONT STYLE="white-space:nowrap">pre-tax</FONT> return on stockholders&#146; equity; (viii)&nbsp;the attainment of certain
target levels of, or a specified increase in, economic value added targets based on a cash flow return on investment formula; (ix)&nbsp;the attainment of certain target levels in, or specified increases in, the fair market value of the shares of the
Company&#146;s common stock; (x)&nbsp;the growth in the value of an investment in the Company&#146;s common stock; (xi)&nbsp;the attainment of a certain level of, reduction of, or other specified objectives with regard to limiting the level in or
increase in, all or a portion of controllable expenses or costs or other expenses or costs; (xii)&nbsp;gross or net sales, revenue and growth of sales revenue (either before or after cost of goods, selling and general administrative expenses,
research and development expenses and any other expenses or interest); (xiii) total stockholder return; (xiv)&nbsp;return on assets or net assets; (xv)&nbsp;return on sales; (xvi)&nbsp;operating profit or net operating profit; (xvii)&nbsp;operating
margin; (xviii)&nbsp;gross or net profit margin; (xix)&nbsp;cost reductions or savings; (xx)&nbsp;productivity; (xxi) operating efficiency; (xxii)&nbsp;working </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital; or (xxiii)&nbsp;market share; (xxiv)&nbsp;customer satisfaction; (xxv)&nbsp;workforce diversity;(xxvi) results of clinical trials; (xxvii)&nbsp;acceptance of a new drug application by a
regulatory body; (xxviii)&nbsp;regulatory body approval for commercialization of a product; (xxix)&nbsp;regulatory body approval of additional indications or improved labeling for an already- approved product; (xxx)&nbsp;launch of a new drug;
(xxxi)&nbsp;completion of <FONT STYLE="white-space:nowrap">out-licensing,</FONT> <FONT STYLE="white-space:nowrap">in-licensing</FONT> or disposition of product candidates or other acquisition or disposition projects; (xxxii)&nbsp;successful
completion of a financing; (xxxiii)&nbsp;maintenance and enhancement of investor base; and (xxxiv)&nbsp;other measures of performance selected by our Board. These performance criteria can be calculated under generally accepted accounting principles
(&#147;GAAP&#148;) or can be calculated using <FONT STYLE="white-space:nowrap">non-GAAP</FONT> results as predetermined when establishing the performance goals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Stock Awards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other forms of stock
awards valued in whole or in part with reference to our common stock may be granted either alone or in addition to other stock awards under the Amended 2010 Plan. Our Board will have sole and complete authority to determine the persons to whom and
the time or times at which such other stock awards will be granted, the number of shares of our common stock to be granted and all other conditions of such other stock awards. Other forms of stock awards may be subject to vesting in accordance with
a vesting schedule to be determined by our Board (subject to the limitations described in &#147;Minimum Vesting Requirements&#148; above). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes to
Capital Structure </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that there is a specified type of change in our capital structure not involving the receipt of
consideration by us, such as a stock split or stock dividend, the class and number of shares reserved under the Amended 2010 Plan (including share limits) and the class and number of shares and exercise price or strike price, if applicable, of all
outstanding stock awards will be appropriately adjusted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of certain significant corporate transactions, our Board has the discretion to take one or more of the following actions with
respect to outstanding stock awards under the Amended 2010 Plan: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for assumption, continuation, or substitution of a stock award by a surviving or acquiring entity (or its
parent company); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the assignment of any reacquisition or repurchase rights applicable to any shares of our common stock
issued pursuant to a stock award to the surviving or acquiring corporation (or its parent company); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accelerate the vesting and exercisability of a stock award followed by the termination of the stock award;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the lapse of any reacquisition or repurchase rights applicable to any shares of our common stock
issued pursuant to a stock award; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cancel or arrange for the cancellation of a stock award, to the extent not vested or not exercised prior to the
effective date of the corporate transaction, in exchange for cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the surrender of a stock award in exchange for a payment equal to the excess of (a)&nbsp;the value of
the property the holder of the stock award would have received upon the exercise of the stock award, over (b)&nbsp;any exercise price payable by such holder in connection with such exercise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board need not take the same action for each stock award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the Amended 2010 Plan, a corporate transaction will be deemed to occur in the event of the consummation of (i)&nbsp;a sale of
all or substantially all of our consolidated assets, (ii)&nbsp;a sale of at least 50% of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding securities, (iii)&nbsp;a merger or consolidation in which we are not the surviving corporation, or (iv)&nbsp;a merger or consolidation in which we are the surviving corporation but
shares of our outstanding common stock are converted into other property by virtue of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A stock award may be subject to
additional acceleration of vesting and exercisability upon or after a change in control, as provided in the stock award agreement or in any other written agreement between us and the participant, but in the absence of such provision, no acceleration
shall occur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Amendments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Board will continue to have the authority to amend or terminate the Amended 2010 Plan. However, no amendment, including the one put forth in this Proposal 2, or termination of the plan will adversely affect any rights under awards already granted to
a participant unless agreed to by the affected participant. We will obtain stockholder approval of any amendment to the Amended 2010 Plan as required by applicable law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>U.S. Federal Income Tax Consequences </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
information set forth below is a summary only and does not purport to be complete. The information is based upon current federal income tax rules and therefore is subject to change when those rules change. Because the tax consequences to any
recipient may depend on his or her particular situation, each recipient should consult the recipient&#146;s tax adviser regarding the federal, state, local, and other tax consequences of the grant or exercise of an award or the disposition of stock
acquired as a result of an award. The Amended 2010 Plan is not qualified under the provisions of Section&nbsp;401(a) of the Code, and is not subject to any of the provisions of the Employee Retirement Income Security Act of 1974. Our ability to
realize the benefit of any tax deductions described below depends on our generation of taxable income as well as the requirement of reasonableness, the provisions of Section&nbsp;162(m) of the Code, and the satisfaction of our tax reporting
obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nonstatutory Stock Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, there is no taxation upon the grant of an NSO where the option is granted with an exercise price equal to the fair market value of
the underlying stock on the grant date. On exercise, an optionholder will recognize ordinary income equal to the excess, if any, of the fair market value on the date of exercise of the stock over the exercise price. If the optionholder is employed
by us, that income will be subject to withholding tax. The optionholder&#146;s tax basis in those shares will be equal to their fair market value on the date of exercise of the option, and the optionholder&#146;s capital gain holding period for
those shares will begin on that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m) of the Code and
the satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the optionholder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Incentive Stock Options </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended 2010
Plan provides for the grant of stock options that qualify as &#147;incentive stock options&#148;, as defined in Section&nbsp;422 of the Code. Under the Code, an optionholder generally is not subject to ordinary income tax upon the grant or exercise
of an ISO, subject to alternative minimum tax obligations upon exercise of an ISO. If the optionholder holds a share received on exercise of an ISO for more than two years from the date the stock option was granted and more than one year from the
date the stock option was exercised, which is referred to as the required holding period, the difference, if any, between the amount realized on a sale or other taxable disposition of that share and the holder&#146;s tax basis in that share will be
long-term capital gain or loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, however, an optionholder disposes of a share acquired on exercise of an ISO before the end of the
required holding period, which is referred to as a disqualifying disposition, the optionholder generally will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognize ordinary income in the year of the disqualifying disposition equal to the excess, if any, of the fair market value of the share on the date the ISO was exercised over the exercise
price. However, if the sales proceeds are less than the fair market value of the share on the date of exercise of the stock option, the amount of ordinary income recognized by the optionholder will not exceed the gain, if any, realized on the sale.
If the amount realized on a disqualifying disposition exceeds the fair market value of the share on the date of exercise of the stock option, that excess will be short-term or long-term capital gain, depending on whether the holding period for the
share exceeds one year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the alternative minimum tax, the amount by which the fair market value of a share of stock
acquired on exercise of an ISO exceeds the exercise price of that stock option generally will be an adjustment included in the optionholder&#146;s alternative minimum taxable income for the year in which the stock option is exercised. If, however,
there is a disqualifying disposition of the share in the year in which the stock option is exercised, there will be no adjustment for alternative minimum tax purposes with respect to that share. In computing alternative minimum taxable income, the
tax basis of a share acquired on exercise of an ISO is increased by the amount of the adjustment taken into account with respect to that share for alternative minimum tax purposes in the year the stock option is exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not allowed an income tax deduction with respect to the grant or exercise of an ISO or the disposition of a share acquired on exercise
of an ISO after the required holding period. If there is a disqualifying disposition of a share, however, we are allowed a deduction in an amount equal to the ordinary income includible in income by the optionholder, subject to Section&nbsp;162(m)
of the Code and provided that amount constitutes an ordinary and necessary business expense for us and is reasonable in amount, and either the employee includes that amount in income or we timely satisfy our reporting requirements with respect to
that amount. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, the recipient of a restricted stock award will recognize ordinary compensation income at the time the stock is received equal to the
excess, if any, of the fair market value of the stock received over any amount paid by the recipient in exchange for the stock. If, however, the stock is not vested when it is received (for example, if the employee is required to work for a period
of time in order to have the right to sell the stock), the recipient generally will not recognize income until the stock becomes vested, at which time the recipient will recognize ordinary compensation income equal to the excess, if any, of the fair
market value of the stock on the date it becomes vested over any amount paid by the recipient in exchange for the stock. A recipient may, however, file an election with the Internal Revenue Service, within 30 days of his or her receipt of the stock
award, to recognize ordinary compensation income, as of the date the recipient receives the award, equal to the excess, if any, of the fair market value of the stock on the date the award is granted over any amount paid by the recipient in exchange
for the stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The recipient&#146;s tax basis for the determination of gain or loss upon the subsequent disposition of shares acquired
from stock awards will be the amount paid for such shares plus any ordinary income recognized either when the stock is received or when the stock becomes vested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m) of the Code and the satisfaction of a tax reporting
obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the stock award. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock
Appreciation Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may grant under the Amended 2010 Plan stock appreciation rights separate from any other award or in tandem with
other awards under the Amended 2010 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the rights are granted with a strike price equal to the fair market value of the
underlying stock on the grant date and where the recipient may only receive the appreciation inherent in the stock appreciation rights in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of our common stock, the recipient will recognize ordinary compensation income equal to the fair market value of the stock received upon such exercise. If the recipient may receive the
appreciation inherent in the stock appreciation rights in cash or other property and the stock appreciation right has been structured to conform to the requirements of Section&nbsp;409A of the Code, then the cash will be taxable as ordinary
compensation income to the recipient at the time that the cash is received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the requirement of reasonableness, the provisions
of Section&nbsp;162(m) of the Code, and the satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the stock appreciation right. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, the
recipient of a stock unit structured to conform to the requirements of Section&nbsp;409A of the Code or an exception to Section&nbsp;409A of the Code will recognize ordinary compensation income at the time the stock is delivered equal to the excess,
if any, of the fair market value of the shares of our common stock received over any amount paid by the recipient in exchange for the shares of our common stock. To conform to the requirements of Section&nbsp;409A of the Code, the shares of our
common stock subject to a stock unit award may generally only be delivered upon one of the following events: a fixed calendar date (or dates), separation from service, death, disability or a change in control. If delivery occurs on another date,
unless the stock units otherwise comply with or qualify for an exception to the requirements of Section&nbsp;409A of the Code, in addition to the tax treatment described above, the recipient will owe an additional 20% federal tax and interest on any
taxes owed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The recipient&#146;s tax basis for the determination of gain or loss upon the subsequent disposition of shares acquired from
stock units will be the amount paid for such shares plus any ordinary income recognized when the stock is delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the
requirement of reasonableness, the provisions of Section&nbsp;162(m) of the Code and the satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of
the stock award. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;162 Limitations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation of persons who are &#147;covered employees&#148; of the Company is subject to the tax deduction limits of Section&nbsp;162(m) of
the Code. The exemption from Section&nbsp;162(m)&#146;s deduction limit for performance-based compensation has been repealed, effective for taxable years beginning after December&nbsp;31, 2017, such that compensation paid to our covered employees in
excess of $1&nbsp;million will not be deductible unless it qualifies for transition relief applicable to certain arrangements in place as of November&nbsp;2, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest of Certain Persons in the Amended 2010 Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders should understand that our directors, executive officers and other employees may be considered as having an interest in the
approval of the Amended 2010 Plan because they may, in the future, receive awards under it. If approved, the annual grants made to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in connection with our Annual Meeting, beginning
with the 2019 Annual Meeting of Stockholders, would be issued under the Amended 2010 Plan. This would include an option for 15,000 shares for each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. The Board believes that it is important
to our growth and long-term success to be able to continue to offer these incentives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Plan Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No awards that may be made under the Amended 2010 Plan to any of the Named Executive Officers are currently determinable, as there are no
guaranteed or contractually required awards. Future grants to the Named </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Executive Officers are subject to approval of our Board or the applicable committee. Awards covering up to 135,000 shares may be made to all current
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors as a group, including one nominee for <FONT STYLE="white-space:nowrap">re-election</FONT> at the Annual Meeting. As described in the preceding paragraph, this amount reflects the NSO
grants to be made pursuant to our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation plan at the Annual Meeting as described under &#147;Director Compensation&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plan Information </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides certain information, as of December&nbsp;31, 2018, with respect to all of our equity compensation plans in effect
on that date: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of&nbsp;securities&nbsp;to&nbsp;be<BR>issued upon exercise of<BR>outstanding options,<BR>warrants and rights<BR></B></P>
<P ALIGN="center" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><B>(a)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise price of<BR>outstanding&nbsp;options,<BR>warrants and rights<BR></B></P>
<P ALIGN="center" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><B>(b)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;securities<BR>remaining&nbsp;available&nbsp;for<BR>issuance under equity<BR>compensation
plans<BR>(excluding&nbsp;securities&nbsp;reflected&nbsp;in<BR>column (a))<BR>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by stockholders(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,330,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,742,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by stockholders(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,330,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,742,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes the 2004 Plan, the 2010 Plan and our 2004 Employee Stock Purchase Plan (the &#147;ESPP&#148;). 65,967
shares under column (c)&nbsp;are attributable to our ESPP. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2018, we did not have any equity compensation plans that were not approved by our
stockholders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>ROPOSAL</SMALL> 3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVAL</SMALL> <SMALL>OF</SMALL> <SMALL>AN</SMALL> A<SMALL>MENDMENT</SMALL> T<SMALL>O</SMALL> T<SMALL>HE</SMALL> 2004
E<SMALL>MPLOYEE</SMALL> S<SMALL>TOCK</SMALL> P<SMALL>URCHASE</SMALL> P<SMALL>LAN</SMALL></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 27, 2019, our Board of Directors amended the ACADIA Pharmaceuticals Inc. 2004 Employee Stock Purchase Plan, as amended (the
&#147;Purchase Plan&#148;), subject to stockholder approval, to, among other things, increase the number of shares of common stock authorized for issuance under the Purchase Plan by 600,000 shares. We refer to the Purchase Plan, as so amended, as
the &#147;Amended Purchase Plan&#148; throughout this proxy statement. References in this proposal to our Board of Directors include the Compensation Committee of the Board, where applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of the material terms of the Amended Purchase Plan are summarized below. The key differences between the terms of the Purchase
Plan and the Amended Purchase Plan are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Amended Purchase Plan provides that an additional 600,000 shares of our common stock may be issued pursuant
to purchase rights granted under the Amended Purchase Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Amended Purchase Plan provides that offerings under the Amended Purchase Plan may provide that shares of our
common stock purchased pursuant to purchase rights granted under the Amended Purchase Plan may be subject to a minimum holding period. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this Proposal 3, our Board of Directors is requesting stockholder approval of the Amended Purchase Plan, including the increase to the
number of shares of common stock authorized for issuance under the Purchase Plan by 600,000 shares. The Board of Directors believes that the Amended Purchase Plan is an integral part of our long-term compensation philosophy and the Amended Purchase
Plan is necessary to continue providing the appropriate levels and types of equity compensation for our employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why We Are Asking Our Stockholders
to Approve the Amended Purchase Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, 154,291 shares were available for future issuance under the
Purchase Plan without giving effect to the approval of the Amended Purchase Plan. Without replenishment, we believe such amount may be insufficient to meet our anticipated employee recruiting and retention needs beyond the second quarter of 2019.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Aspects of Our Purchase Plan Designed to Protect Our Stockholders&#146; Interests </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Purchase Plan includes certain provisions that are designed to protect our stockholders&#146; interests and to reflect corporate
governance best practices including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stockholder approval is required for additional shares.</I> The Amended Purchase Plan does not contain an
annual &#147;evergreen&#148; provision. Thus, stockholder approval is required each time we need to increase the share reserve allowing our stockholders the ability to have a say on our equity compensation programs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Submission of amendments to the Amended Purchase Plan to stockholders.</I> The Amended Purchase Plan requires
stockholder approval for material amendments to the Amended Purchase Plan, including as noted above, any increase in the number of shares reserved for issuance under the Amended Purchase Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Broad-based eligibility for equity awards.</I> The vast majority of our employees are eligible to participate
in the Amended Purchase Plan. By doing so, we tie our employee&#146;s interests with stockholder interests and motivate our employees to act as owners of the business. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Amended Purchase Plan Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2004, the Board of Directors originally adopted, and in May 2004, the stockholders subsequently approved, the Purchase Plan. There
were 125,000 shares of ACADIA common stock initially reserved for issuance under the Purchase Plan. In addition, the Purchase Plan contained an evergreen provision providing for an annual increase in the shares available for purchase under the
Purchase Plan equal to the lesser of 1% of the outstanding shares of common stock on the record date for each Annual Meeting of Stockholders; 150,000 shares; or a number determined by the Board of Directors, as of the date of each annual meeting of
stockholders beginning with annual meeting of stockholders in 2005. Pursuant to the evergreen provision, an additional 1,400,000 shares of ACADIA common stock were made available for purchase under the Purchase Plan between 2005 and 2014. The
evergreen provision terminated after the annual increase in 2014. In April 2016, the Board of Directors adopted, and in June 2016, the stockholders subsequently approved, an amendment to the Purchase Plan, pursuant to which, among other things, an
additional 400,000 shares of common stock were reserved for issuance under the Purchase Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, an aggregate
of 1,770,709 shares of ACADIA common stock had been purchased under the Purchase Plan and 154,291 shares of common stock (plus any shares that might in the future be returned to the Purchase Plan as a result of cancellations or expiration of
purchase rights) remained available for future purchase under the Purchase Plan. A total of 143,853,597 shares of ACADIA common stock were outstanding as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this Proposal 3, stockholders are requested to approve the Amended Purchase Plan. The affirmative vote of the holders of a majority of the
shares present in person or represented by proxy and entitled to vote at the Annual Meeting will be required to approve the adoption of the Amended Purchase Plan. Abstentions will be counted toward the tabulation of votes cast on Proposal 3 and will
have the same effect as negative votes. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted toward a quorum, but are not counted for any purpose in determining whether this matter has been approved. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> P<SMALL>ROPOSAL</SMALL> 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of the Amended Purchase Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material features of the Amended Purchase Plan are outlined below. This summary is qualified in its entirety by reference to the complete
text of the Amended Purchase Plan. Stockholders are urged to read the actual text of the Amended Purchase Plan in its entirety, which is appended to this proxy statement as <B>Appendix&nbsp;B</B> and may be accessed from the SEC&#146;s website at
www.sec.gov. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of
the Amended Purchase Plan is to provide a means by which employees of ACADIA (and any related corporations designated by the Board of Directors to participate in the Amended Purchase Plan) may be given an opportunity to purchase ACADIA common stock
through payroll deductions, to assist ACADIA in retaining the services of its employees, in recruiting new employees and to provide incentives for such persons to exert maximum efforts for the Company&#146;s success. As of April&nbsp;29, 2019,
approximately 465 employees were eligible to participate in the Amended Purchase Plan.. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights to purchase common stock granted under
the Amended Purchase Plan are intended to qualify as options issued under an &#147;employee stock purchase plan&#148; as that term is defined in Section&nbsp;423(b) of the Code. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors
administers the Amended Purchase Plan and has the final power to construe and interpret both the Amended Purchase Plan and the rights granted under it. The Board of Directors has the power </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to delegate administration of the Amended Purchase Plan to a committee composed of not fewer than two members of the Board. The Board of Directors has delegated administration of the Amended
Purchase Plan to the Compensation Committee. The Compensation Committee has the power, subject to the provisions of the Amended Purchase Plan, to determine when and how rights to purchase ACADIA common stock will be granted and the provisions of
each offering of such rights (which need not be identical). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Subject to Amended Purchase Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Amended Purchase Plan had 154,291 shares of ACADIA common stock available for future purchase under the
Amended Purchase Plan. Subject to this Proposal 3, an additional 600,000 shares of ACADIA common stock will be made available for future purchases under the Amended Purchase Plan beginning with the next offering period that commences on or after
June&nbsp;26, 2019. If purchase rights granted under the Amended Purchase Plan expire, lapse or otherwise terminate without being exercised, the shares of ACADIA common stock not purchased under such rights again become available for issuance under
the Amended Purchase Plan. A total of 143,853,597 shares of ACADIA common stock were outstanding as of December&nbsp;31, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Offerings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Purchase Plan is implemented by offerings of purchase rights to all eligible employees from time to time by the Compensation
Committee. The maximum length for an offering under the Amended Purchase Plan is 27 months. Currently, under the Amended Purchase Plan, each offering is 24 months long and is divided into four shorter &#147;purchase periods&#148; approximately six
months long. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
person, other than a part-time or seasonal employee, who is customarily employed at least 20 hours per week and 5 months per calendar year by ACADIA (or by any parent or subsidiary of ACADIA designated by the Board of Directors) on the first day of
an offering is eligible to participate in that offering, provided such employee has been continuously employed by ACADIA or the designated parent or subsidiary for such period preceding the grant as our Board of Directors or the Compensation
Committee may require, but in no event will the required period of continuous employment be greater than two years. We exclude from participation those of our employees who are employed in jurisdictions outside of the United States if, as of the
offering date of the offering, the grant of such purchase rights would not be in compliance with the applicable laws of any jurisdiction in which the employee resides or is employed. Officers of ACADIA who are &#147;highly compensated&#148; as
defined in the Code may be eligible to participate in the offerings, unless our Board of Directors or the Compensation Committee provides otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No employee is eligible to participate in the Amended Purchase Plan if, immediately after the grant of purchase rights, the employee would
own, directly or indirectly, stock possessing 5% or more of the total combined voting power or value of all classes of stock of ACADIA or of any parent or subsidiary of ACADIA (including any stock which such employee may purchase under all
outstanding rights and options). In addition, no employee may accrue the right to purchase more than $25,000 worth of ACADIA common stock (determined at the fair market value of the shares at the time such rights are granted) under all employee
stock purchase plans of ACADIA and any parent and subsidiaries in any calendar year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Participation in the Amended Purchase Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Eligible employees enroll in the Amended Purchase Plan by delivering to ACADIA, prior to the date selected by our Board of Directors or the
Compensation Committee as the offering date for the offering, an agreement authorizing payroll deductions of up to 15% of such employees&#146; total compensation during the offering. Our Board of Directors may provide that each person who, during
the course of an offering, first </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
becomes eligible to participate in the Amended Purchase Plan will, on a date or dates specified in the offering which coincides with the day on which such person becomes eligible to participate
or which occurs thereafter, receive a purchase right under that offering. Our Board of Directors may provide that each person who, during the course of an offering, first becomes eligible to participate in the Amended Purchase Plan will, on a date
or dates specified in the offering which coincides with the day on which such person becomes eligible to participate or which occurs thereafter, receive a purchase right under that offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase Price </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price per
share at which shares of common stock are sold in an offering under the Amended Purchase Plan is the lower of (i) 85% of the fair market value of a share of common stock on first day of the offering or (ii) 85% of the fair market value of a share of
common stock on the purchase date, as set by our Board of Directors or the Compensation Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Payment of Purchase Price; Payroll Deductions
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price of the shares is accumulated by payroll deductions over the offering. At any time during the offering, a
participant may reduce or terminate his or her payroll deductions as our Board of Directors provides in the offering. A participant may increase or begin such payroll deductions after the beginning of the offering only as provided for in the
offering. All payroll deductions made for a participant are credited to his or her account under the Amended Purchase Plan and deposited with the general funds of ACADIA. A participant may make additional payments into such account only if
specifically provided for in the offering and only if the participant has not had the maximum amount withheld during the offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase of Stock
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By executing an agreement to participate in the Amended Purchase Plan, the employee is entitled to purchase shares under the Amended
Purchase Plan. In connection with offerings made under the Amended Purchase Plan, our Board of Directors or the Compensation Committee specifies a maximum number of shares of common stock an employee may be granted the right to purchase and the
maximum aggregate number of shares of ACADIA common stock that may be purchased pursuant to such offering by all participants. If the aggregate number of shares to be purchased upon exercise of purchase rights granted in the offering would exceed
the maximum aggregate number of shares of ACADIA common stock available, our Board of Directors or the Compensation Committee would make a pro rata allocation of available shares in a uniform and equitable manner. Unless the employee&#146;s
participation is discontinued, his or her right to purchase shares is exercised automatically on the purchase date, as set by our Board of Directors, at the applicable price. See &#147;Withdrawal&#148; below. In addition, unless otherwise
specifically provided in the offering, the amount, if any, of accumulated payroll deductions remaining in any participant&#146;s account after the purchase of shares on the final purchase date of an offering will be distributed in full to the
participant at the end of such offering, without interest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Withdrawal </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While each participant in the Amended Purchase Plan is required to sign an agreement authorizing payroll deductions, the participant may
withdraw from a given offering by terminating his or her payroll deductions and by delivering to ACADIA a notice of withdrawal from the Amended Purchase Plan. Such withdrawal may be elected at any time during the offering except as provided by our
Board of Directors in the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon any withdrawal from an offering by the employee, ACADIA will distribute to the employee his or
her accumulated payroll deductions without interest, less any accumulated deductions previously applied to the purchase of shares of common stock on the employee&#146;s behalf during such offering, and such employee&#146;s interest in the offering
will be automatically terminated. The employee is not entitled to again participate in that offering. However, an employee&#146;s withdrawal from an offering will not have any effect upon such employee&#146;s eligibility to participate in subsequent
offerings under the Amended Purchase Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of Employment </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchase rights granted pursuant to any offering under the Amended Purchase Plan terminate immediately upon cessation of an employee&#146;s
employment for any reason, and ACADIA will distribute to such employee all of his or her accumulated payroll deductions, without interest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restrictions on Transfer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchase rights
granted under the Amended Purchase Plan are not transferable and may be exercised only by the person to whom such rights are granted. A participant may designate a beneficiary who is to receive any shares and cash, if any, from the
participant&#146;s account under the Amended Purchase Plan in the event of such participant&#146;s death after the offering but prior to delivery to the participant of the shares and cash, or who is to receive the cash from the participant&#146;s
account in the event of such participant&#146;s death during an offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Holding Period; Sales Restrictions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As proposed by this Proposal 3, beginning with offerings commencing after the Annual Meeting, offerings may contain a provision that requires
participants to hold the stock they purchase under the Amended Purchase Plan for a minimum period of time not exceeding six&nbsp;months from the date of purchase. Specifically, by executing an agreement to participate in future offerings under the
Amended Purchase Plan, the employee is agreeing that he or she will not (1)&nbsp;offer for sale, sell, pledge, or otherwise dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition
by any person at any time in the future of) any shares of our common stock purchased by him or her in such offering, or (2)&nbsp;enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic
benefits or risks of ownership of such shares, in each case before the passage of the relevant holding period. We may impose stop-transfer instructions with respect to the shares of Common Stock subject to the foregoing restriction until the end of
the applicable holding period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Adjustment Provisions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transactions not involving receipt of consideration by ACADIA, such as a reincorporation, combination, reclassification, stock dividend or
stock split, may change the type, class and number of shares of common stock subject to the Amended Purchase Plan and to outstanding purchase rights. In that event, the Amended Purchase Plan will be appropriately adjusted in the type, class and
maximum number of shares subject to the Amended Purchase Plan and the outstanding purchase rights granted under the Amended Purchase Plan will be appropriately adjusted in the type, class, number of shares and purchase limits of such purchase
rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Effect of Certain Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of (i)&nbsp;a dissolution, liquidation or sale of all or substantially all of the securities or assets of ACADIA, (ii)&nbsp;a
merger or consolidation in which ACADIA is not the surviving corporation, (iii)&nbsp;a reverse merger in which ACADIA is the surviving corporation but the shares of common stock outstanding immediately preceding the merger are converted by virtue of
the merger into other property, whether in the form of securities, cash or otherwise, or (iv)&nbsp;a sale or other disposition of at least 50% of the outstanding securities of the Company, any surviving corporation may continue or assume purchase
rights outstanding under the Amended Purchase Plan or may substitute similar rights. If any surviving corporation does not assume such rights or substitute similar rights, then the participants&#146; accumulated payroll deductions will be used to
purchase shares of common stock immediately prior to such transaction under the ongoing offering and the participants&#146; rights under such ongoing offering will terminate immediately after such purchase. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Duration, Amendment and Termination </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Board of Directors or the Compensation Committee may suspend or terminate the Amended Purchase Plan at any time. Unless terminated earlier, the Amended Purchase Plan will terminate at the time that all of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of common stock reserved for issuance under the Amended Purchase Plan have been issued under the terms of the Amended Purchase Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors or the Compensation Committee may amend the Amended Purchase Plan at any time. Any amendment of the Amended Purchase
Plan must be approved by the stockholders within 12 months of its adoption by the Board of Directors or the Compensation Committee if the amendment would (i)&nbsp;increase the number of shares of common stock reserved for issuance under the Amended
Purchase Plan, (ii)&nbsp;modify the requirements relating to eligibility for participation in the Amended Purchase Plan (to the extent such modification requires stockholder approval in order for the Amended Purchase Plan to obtain employee stock
purchase plan treatment under Section&nbsp;423 of the Code or to comply with the requirements of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act, or &#147;Rule
<FONT STYLE="white-space:nowrap">16b-3&#148;);</FONT> or (iii)&nbsp;modify the Amended Purchase Plan in any other way if such modification requires stockholder approval in order for the Amended Purchase Plan to obtain employee stock purchase plan
treatment under Section&nbsp;423 of the Code or to comply with the requirements of Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchase rights granted before amendment or termination of the Amended Purchase Plan will not be altered or impaired by any amendment or
termination of the Amended Purchase Plan without consent of the employee to whom such rights were granted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Information
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchase rights granted under the Amended Purchase Plan are intended to qualify for favorable federal income tax treatment associated
with rights granted under an employee stock purchase plan which qualifies under provisions of Section&nbsp;423 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant
will be taxed on amounts withheld for the purchase of shares of common stock as if such amounts were actually received. Otherwise, no income will be taxable to a participant until disposition of the acquired shares, and the method of taxation will
depend upon the holding period of the acquired shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the stock is disposed of more than two years after the beginning of the
offering period and more than one year after the stock is transferred to the participant, then the lesser of (i)&nbsp;the excess of the fair market value of the stock at the time of such disposition over the purchase price or (ii)&nbsp;the excess of
the fair market value of the stock as of the beginning of the offering period over the purchase price (determined as of the beginning of the offering period) will be treated as ordinary income. Any further gain or any loss will be taxed as a
long-term capital gain or loss. At present, such capital gains generally are subject to lower tax rates than ordinary income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the
stock is sold or disposed of before the expiration of either of the holding periods described above, then the excess of the fair market value of the stock on the purchase date over the purchase price will be treated as ordinary income at the time of
such disposition. The balance of any gain will be treated as capital gain. Even if the stock is later disposed of for less than its fair market value on the exercise date, the same amount of ordinary income is attributed to the participant, and a
capital loss is recognized equal to the difference between the sales price and the fair market value of the stock on such purchase date. Any capital gain or loss will be short-term or long-term, depending on how long the stock has been held. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no federal income tax consequences to ACADIA by reason of the grant or exercise of purchase rights under the Purchase Plan. ACADIA
is entitled to a deduction to the extent amounts are taxed as ordinary income to a participant (subject to the requirement of reasonableness and the satisfaction of tax reporting obligations). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Plan Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participation in the
Amended Purchase Plan is voluntary and each eligible employee will make his or her own decision whether and to what extent to participate in the plan. It is therefore not possible to determine the benefits or amounts that will be received in the
future by individual employees or groups of employees under the Amended Purchase Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>ROPOSAL</SMALL> 4 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DVISORY</SMALL> V<SMALL>OTE</SMALL> <SMALL>ON</SMALL> E<SMALL>XECUTIVE</SMALL> C<SMALL>OMPENSATION</SMALL></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our 2018 Annual Meeting of Stockholders, the stockholders indicated their preference that the Company solicit a <FONT
STYLE="white-space:nowrap">non-binding</FONT> advisory vote on the compensation of the named executive officers, commonly referred to as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay</FONT></FONT> vote,&#148;
every year. Consistent with that preference, our Board of Directors is soliciting an advisory vote at the 2019 Annual Meeting of Stockholders and intends to do so each year until the stockholders indicate a different preference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This vote is not intended to address any specific item of compensation, but rather the overall compensation of the Company&#146;s named
executive officers and the compensation philosophy, policies and practices described in this proxy statement. The compensation of the Company&#146;s named executive officers subject to the vote is disclosed in the Compensation Discussion and
Analysis, the compensation tables, and the related narrative disclosure contained in this proxy statement. As discussed in those disclosures, the Company believes that its compensation policies and decisions are designed to align executive
compensation with the Company&#146;s business objectives and corporate performance, to be consistent with current market practices, and to enable the Company to attract and retain talented and experienced executives to lead the Company successfully
in a competitive environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, our Board of Directors is asking the stockholders to indicate their support for the
compensation of the Company&#146;s named executive officers as described in this proxy statement by casting a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote &#147;for&#148; the following resolution: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, that the compensation paid to the Company&#146;s named executive officers, as disclosed pursuant to Item 402 of Regulation <FONT
STYLE="white-space:nowrap">S-K,</FONT> including the Compensation Discussion and Analysis, compensation tables and narrative discussion, is hereby APPROVED.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the vote is advisory, it is not binding on our Board of Directors or the Company. Nevertheless, the views expressed by stockholders,
whether through this vote or otherwise, are important to management and the Board of Directors and, accordingly, the Board of Directors and the Compensation Committee intend to consider the results of this vote in making determinations in the future
regarding executive compensation arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of this proposal requires the vote of the holders of a majority of the shares
present in person or represented by proxy and entitled to vote on this matter at the Annual Meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted toward a quorum for Proposal 4, and abstentions will have
the same effect as &#147;Against&#148; votes. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>
R<SMALL>ECOMMENDS</SMALL> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><SMALL>A</SMALL> V<SMALL>OTE</SMALL> &#147;<SMALL>FOR</SMALL>&#148; P<SMALL>ROPOSAL</SMALL> 4 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>ROPOSAL</SMALL> 5 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ATIFICATION</SMALL> <SMALL>OF</SMALL> S<SMALL>ELECTION</SMALL> <SMALL>OF</SMALL> I<SMALL>NDEPENDENT</SMALL> R<SMALL>EGISTERED</SMALL>
P<SMALL>UBLIC</SMALL> A<SMALL>CCOUNTING</SMALL> F<SMALL>IRM</SMALL></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee of our Board of Directors has engaged
Ernst&nbsp;&amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2019 and is seeking ratification of such selection by our stockholders at the annual meeting. Ernst&nbsp;&amp; Young LLP was
selected by the Audit Committee as our independent registered public accounting firm in March 2015. Representatives of Ernst&nbsp;&amp; Young LLP are expected to be present at the annual meeting. They will have an opportunity to make a statement if
they so desire and will be available to respond to appropriate questions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither our bylaws nor other governing documents or law require
stockholder ratification of the selection of Ernst&nbsp;&amp; Young LLP as our independent registered public accounting firm. However, the Audit Committee is submitting the selection of Ernst&nbsp;&amp; Young LLP to our stockholders for ratification
as a matter of good corporate practice. If our stockholders fail to ratify the selection, the Audit Committee will reconsider whether to retain Ernst&nbsp;&amp; Young LLP. Even if the selection is ratified, the Audit Committee in its discretion may
direct the appointment of a different independent registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of ACADIA and our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be approved, the ratification of the selection of Ernst&nbsp;&amp; Young LLP as our independent registered public accounting firm must
receive a &#147;For&#148; vote from the majority of shares present in person or represented by proxy and entitled to vote on this matter at the annual meeting. Abstentions will have the same effect as &#147;Against&#148; votes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principal Accountant Fees and Services </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides information regarding the fees billed to us by Ernst&nbsp;&amp; Young LLP for the fiscal years ended
December&nbsp;31, 2018 and 2017: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">905,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">847,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax fees(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,027,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,005,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents fees for services rendered for the audit and reviews of our financial statements, including fees
related to auditing work for our compliance with Section&nbsp;404 of the Sarbanes-Oxley Act. Audit fees also include fees for services associated with periodic reports and other documents filed with the SEC, such as fees related to our <FONT
STYLE="white-space:nowrap">S-8</FONT> registration statements filed in each of 2018 and 2017, including documents issued in connection with those filings such as consents. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents fees for preparation of federal, state and foreign income taxes and related schedules and
calculations </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Policies and Procedures. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee has <FONT STYLE="white-space:nowrap">pre-approval</FONT> policies and procedures in place, pursuant to which services
proposed to be performed by our independent registered public accounting firm are <FONT STYLE="white-space:nowrap">pre-approved</FONT> by the Audit Committee. The policies generally provide for <FONT STYLE="white-space:nowrap">pre-approval</FONT> of
specified services in the defined categories of audit services, audit-related services, and tax services up to specified amounts. <FONT STYLE="white-space:nowrap">Pre-approval</FONT> may also be given as part of the Audit Committee&#146;s approval
of the scope of the engagement of the independent registered public accounting firm or on an individual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">service-by-service</FONT></FONT> basis. The
<FONT STYLE="white-space:nowrap">pre-approval</FONT> of <FONT STYLE="white-space:nowrap">non-audit</FONT> services also has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been delegated to the Chair of the Audit Committee, but each <FONT STYLE="white-space:nowrap">pre-approval</FONT> decision is reported to the full Audit Committee at its next scheduled meeting.
All of the fees listed under the captions &#147;Tax fees&#148; and &#147;All other fees&#148; incurred in 2018 and 2017 were approved in accordance with our <FONT STYLE="white-space:nowrap">pre-approval</FONT> policies and procedures. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><SMALL>A</SMALL> V<SMALL>OTE</SMALL> &#147;<SMALL>FOR</SMALL>&#148; P<SMALL>ROPOSAL</SMALL> 5 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>THER</SMALL> M<SMALL>ATTERS</SMALL></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We know of no other matters that will be presented for consideration at the annual meeting. If any other matters properly come before the
annual meeting, it is the intention of the persons named in the accompanying form of proxy to vote the shares they represent as the Board of Directors may recommend. By submitting your proxy, you grant discretionary authority with respect to such
other matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>ECURITY</SMALL> O<SMALL>WNERSHIP</SMALL> <SMALL>OF</SMALL> C<SMALL>ERTAIN</SMALL>
B<SMALL>ENEFICIAL</SMALL> O<SMALL>WNERS</SMALL> <SMALL>AND</SMALL> M<SMALL>ANAGEMENT</SMALL></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides information
regarding the beneficial ownership of our common stock as of February&nbsp;8, 2019 by: (i)&nbsp;each of our directors, (ii)&nbsp;each of our Named Executive Officers (as defined below), (iii) all of our current directors and executive officers as a
group, and (iv)&nbsp;each person, or group of affiliated persons, known by us to beneficially own more than five percent of our common stock. The table is based upon information supplied by our officers, directors and principal stockholders and/or a
review of Schedules 13D and 13G, if any, and other documents filed with the SEC. Unless otherwise indicated in the footnotes to the table and subject to community property laws where applicable, we believe that each of the stockholders named in the
table has sole voting and investment power with respect to the shares indicated as beneficially owned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable percentages are based
on 143,907,981 shares outstanding on February&nbsp;8, 2019, adjusted as required by rules promulgated by the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment
power with respect to those securities. In addition, the rules include shares of common stock issuable pursuant to the exercise of stock options or warrants that are either immediately exercisable or exercisable on or before April&nbsp;9, 2019,
which is 60 days after February&nbsp;8, 2019. These shares are deemed to be outstanding and beneficially owned by the person holding those options or warrants for the purpose of computing the percentage ownership of that person, but they are not
treated as outstanding for the purpose of computing the percentage ownership of any other person. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Shares&nbsp;Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage of<BR>Shares&nbsp;Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baker Bros. Advisors LP(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,860,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FMR LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,543,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Vanguard Group(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,162,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blackrock Inc.(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,133,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen R. Davis(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,417,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Srdjan R. Stankovic, M.D., M.S.P.H.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elena H. Ridloff(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Austin D. Kim(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Yang(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Todd S. Young(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen R. Biggar, M.D., Ph.D.(12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,860,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julian C. Baker(13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,860,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Soland(14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura Brege(15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edmund P. Harrigan, M.D.(16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Daly(17)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current directors and executive officers as a group (11 persons)(18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,287,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise noted below, the address for each person or entity listed in the table is c/o ACADIA
Pharmaceuticals Inc., 3611 Valley Centre Drive, #300, San Diego, California 92130. Unless otherwise indicated below, the persons and entities named in the table above have sole voting and sole investment power with respect to all shares beneficially
owned, subject to community property laws where applicable. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock reported to us as beneficially owned by Baker Bros. Advisors LP (&#147;BBA&#148;)
includes 35,976,940 shares owned by Baker Brothers Life Sciences, L.P. (&#147;BBLS&#148;), 3,736,902 shares owned by 667, L.P., and 92,750 shares issuable to Dr.&nbsp;Biggar upon the exercise of stock options and 53,750 shares issuable to
Mr.&nbsp;Baker upon the exercise of stock options. Pursuant to an agreement between Dr.&nbsp;Biggar and Baker Bros. Advisors LP, Dr.&nbsp;Biggar disclaims voting, dispositive power and pecuniary interest in stock options granted to him for services
he performs as an employee of BBA. Mr.&nbsp;Baker has </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
voting and investment power over the shares held by each of 667, BBLS and 14159, as a principals of <FONT STYLE="white-space:nowrap">BBA-GP.</FONT> Mr.&nbsp;Baker disclaims beneficial ownership
of all shares held by 667, BBLS and 14159, except to the extent of his indirect pecuniary interest therein. Does not include an aggregate of 489,269 shares issuable under warrants held by the Baker Brothers Funds, which are subject to a 19.99%
ownership limitation that restricts exercise. BBA is the management company and investment adviser to 667, BBLS and 14159 and may be deemed to beneficially own all shares held by 667, BBLS, 14159, Mr.&nbsp;Baker and Dr.&nbsp;Biggar. Baker Bros.
Advisors (GP) LLC, or <FONT STYLE="white-space:nowrap">BBA-GP,</FONT> is the sole general partner of BBA. Julian C. Baker and Felix J. Baker have voting and investment power over the shares held by each of 667, BBLS and 14159, as principals of <FONT
STYLE="white-space:nowrap">BBA-GP.</FONT> Julian C. Baker, Felix J. Baker, BBA and <FONT STYLE="white-space:nowrap">BBA-GP</FONT> disclaim beneficial ownership of all shares held by 667, BBLS and 14159, except to the extent of their indirect
pecuniary interest therein. The address for the Baker Brothers Funds is 860 Washington Street, 3rd&nbsp;Floor, New York, New York 10014. This information is based on the most recent Schedule 13D filed on behalf of Baker Bros. Advisors LP, subsequent
filings, and our records relating to current outstanding stock options </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address for FMR LLC is 245 Summer Street, Boston, Massachusetts 02210. This information is based on its
most recently filed Schedule 13G. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address for The Vanguard Group is 100 Vanguard Boulevard, Malvern, Pennsylvania 19355. This information is
based on its most recently filed Schedule 13G. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address for Blackrock Inc. is 55 East 52<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Street, New
York, NY 10055. This information is based on its most recently filed Schedule 13G. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 2,316 shares owned by Mr.&nbsp;Davis and 1,414,997 shares issuable to Mr.&nbsp;Davis upon the exercise
of stock options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 421,612 shares issuable to Dr.&nbsp;Stankovic upon the exercise of stock options.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms. Ridloff joined the Company in April 2018 and at February 8, 2019 did not have any vested equity awards.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Kim joined the Company in July 2018 and his option grants do not begin vesting until July 2019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 876 shares owned by Mr.&nbsp;Yang and 237,108 shares issuable to Mr.&nbsp;Yang upon the exercise of
stock options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Young left the Company in October 2018 and therefore his equity awards were cancelled.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 35,976,940 shares owned by BBLS, 3,736,902 shares owned by 667, L.P., and 92,750 shares issuable to
Dr.&nbsp;Biggar upon the exercise of stock options, and 53,750 shares issuable to Mr.&nbsp;Baker upon the exercise of stock options. Dr.&nbsp;Biggar is an employee at BBA but disclaims beneficial ownership of any securities held by the Baker
Brothers funds. Additionally, pursuant to an agreement between Dr.&nbsp;Biggar and BBA, Dr.&nbsp;Biggar disclaims beneficial ownership of any stock options granted to him for services he performs as an employee of BBA. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 35,976,940 shares owned by BBLS, 3,736,902 shares owned by 667, L.P., and 92,750 shares issuable to
Dr.&nbsp;Biggar upon the exercise of stock options, and 53,750 shares issuable to Mr.&nbsp;Baker upon the exercise of stock options. Mr.&nbsp;Baker has voting and investment power over the shares held by each of 667, BBLS and 14159, as a principal
of <FONT STYLE="white-space:nowrap">BBA-GP.</FONT> Mr.&nbsp;Baker disclaims beneficial ownership of all shares held by 667, BBLS and 14159, except to the extent of his indirect pecuniary interest therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 10,000 shares owned by Mr.&nbsp;Soland and 92,500 shares issuable to Mr.&nbsp;Soland upon the exercise
of stock options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 86,250 shares issuable to Ms.&nbsp;Brege upon the exercise of stock options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 1,000 shares owned by Dr.&nbsp;Harrigan and 80,000 shares issuable to Dr.&nbsp;Harrigan upon the
exercise of stock options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 80,000 shares issuable to Mr.&nbsp;Daly upon the exercise of stock options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 2,558,967 shares issuable upon the exercise of stock options. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>XECUTIVE</SMALL> C<SMALL>OMPENSATION</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>C<SMALL>OMPENSATION</SMALL> D<SMALL>ISCUSSION</SMALL> <SMALL>AND</SMALL> A<SMALL>NALYSIS</SMALL></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Summary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation
Committee of the Board of Directors, which consists entirely of independent directors, administers the Company&#146;s executive compensation program. The role of the Compensation Committee is to oversee compensation and benefit plans and policies,
to administer stock plans, and to review and recommend to the full Board of Directors for approval all compensation decisions relating to executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Compensation Objectives and Philosophy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s executive compensation policies are designed to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">align executive compensation with business objectives and corporate performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract and retain executive officers who contribute to the Company&#146;s long-term success;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reward and motivate executive officers who contribute to operating and financial performance; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">link executive officer compensation and stockholder interests through the grant of long-term incentives.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee believes that compensation programs should include short-term and long-term components,
including cash and equity-based compensation, and should encourage and reward performance as measured against established goals. The Compensation Committee evaluates both performance and compensation to make sure that compensation provided to
executives of the Company remains competitive relative to compensation paid by companies of similar size and stage of development operating in the biotechnology and pharmaceutical industry, taking into account the Company&#146;s relative performance
and strategic goals. The Compensation Committee considers the total current and potential long-term compensation of each executive officers in establishing each element of compensation, but views each element as related but distinct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee&#146;s philosophy is anchored by its strong
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> orientation and alignment with stockholder interests, based on the following beliefs. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I><FONT STYLE="white-space:nowrap">&#147;At-risk&#148;</FONT> compensation focuses executives on achievement
of short- and long-term goals.</I></B> The Company&#146;s executive compensation program is primarily performance-based, for both short-term incentives (annual cash bonuses) and long-term incentives (equity awards). In 2018, a large majority (81.2%
and 77.5%, respectively) of the primary compensation (base salary, regular annual cash incentives at target and the grant date fair market value of equity awards) of the Chief Executive Officer and of the other named executive officers who served
throughout 2018 was variable, based on performance and/or stock price. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Short-term cash incentives should be based on objective, measurable goals to drive the achievement of
strong annual performance. </I></B>For 2018, under the regular annual cash incentive program, executives were eligible for target bonuses ranging from 45% to 70% of base salary. Under this program, if the threshold (minimum) performance level is not
achieved, there is 0% payout. 75% of the target bonus is payable if the threshold level is achieved with respect to a performance goal, and a maximum of 150% of the target bonus is payable for achieving an outperform (highest) level with respect to
such goal. As discussed in further detail below, in response to unique and unanticipated challenges that arose during 2018 with respect to NUPLAZID commercialization, the Compensation Committee implemented a
<FONT STYLE="white-space:nowrap">one-time,</FONT> special incentive bonus designed to achieve two specific NUPLAZID market adoption goals in the fourth quarter of 2018. The special incentive bonus provided an opportunity that would be paid out at
21%, 28% and 35% of executives&#146; base salary at threshold, target and outperform levels of performance and were eligible to be earned based on Company performance against two equally-weighted,
<FONT STYLE="white-space:nowrap">pre-established,</FONT> quantifiable NUPLAZID commercialization metrics in the quarter. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Stock options are inherently performance-based, as executives realize value only if there is stock price
appreciation and such appreciation is maintained through the applicable vesting and exercise dates.</I></B> In addition to time-based option grants, equity grants to senior management, including the named executive officers, continue to include
performance-based option grants (25% of the total), which become vested only upon the achievement of specific and difficult to attain commercial, clinical and regulatory long-term objectives. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Restricted stock units are part of a balanced portfolio of equity awards.</I></B> With the support of
stockholders (as discussed in further detail below), for the second half of 2018, the Compensation Committee determined to include RSUs in the mix of equity awards granted to both senior management and all employees in the Fall of 2018. The RSU
grants, which represented 25% of senior management&#146;s total Fall grant, were added to bring the Company&#146;s equity award approach in line with industry and peer practices. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Consistency in compensation decisions from year to year and balancing the dilutive impact of equity grants
with the competitiveness of our compensation program are key objectives.</I></B> Historically, in determining equity awards to senior management, the primary focus has been on the number of shares underlying option awards relative to the number of
basic shares of common stock outstanding, rather than the Black-Scholes grant date fair value of the award. The Compensation Committee believes that this ownership- and dilution-based approach to awarding stock options provided a better measure of
the potential increases in stockholder value and allowed for consistent evaluation regardless of fluctuations in share price. For example, focusing on the number of shares and the incremental sharing rate of potential future upside (rather than
targeting a specific Black-Scholes grant date fair value) avoided rewarding executives with larger, more dilutive grants following a decline in the stock price. As the Company has recently incorporated full-value awards into the equity mix, however,
the Company is considering an additional shift toward dollar-denominated equity grants, pursuant to which actual grant numbers will be determined by dividing the grant date fair value of awards into the approved dollar values. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pay for Performance in 2018 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2018
was in certain respects a challenging year for the Company. Strong commercial execution was achieved in the first quarter, including NUPLAZID volume growth and net sales. However, the publication in April 2018 by CNN of a negative article on the
Company and NUPLAZID resulted in a significant slowing of commercial momentum throughout the remainder of the year. Nevertheless, key objectives were achieved during the year, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The number of health care professionals treating five or more patients with NUPLAZID increased by 50%;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enrollment targets were met in clinical trials for dementia-related psychosis, major depressive disorder and
schizophrenia (both inadequate response and negative symptoms); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA approval was obtained for the 34 mg capsule and 10 mg tablet dosage forms; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company executed its first business development transaction with the exclusive North American license to
trofinetide, thereby taking a critical step toward diversification. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, despite the negative media attention,
in September 2018 the FDA favorably concluded its tracked safety issue review of NUPLAZID with the issuance of a rare public statement reaffirming the positive benefit-risk profile of NUPLAZID for patients with hallucinations and delusions
associated with Parkinson&#146;s disease psychosis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with the Company&#146;s <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> philosophy, executive pay in 2018 was in line with the Company&#146;s performance during the year: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>CEO pay decreased 57% compared to 2017.</I></B><B> </B>The primary compensation (base salary, earned cash
incentives and the grant date fair market value of equity awards) of the Chief Executive Officer for 2018 decreased by 57% relative to 2017. This change was driven by significantly lower equity grant values and below-target short-term cash incentive
payouts (including the special incentive bonus program). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Cash incentives paid out below target.</I></B> As discussed in further detail below, the regular annual
cash incentive bonuses were earned at only 77% of target, while the special fourth-quarter incentive bonuses were earned at the threshold (minimum) level, equal to 75% of target. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Realizable equity values are low. </I></B>The realizable value of executives&#146; 2018 equity compensation
was dramatically lower than the grant date fair values (which, in the case of options, are Black-Scholes driven) included in the Summary Compensation Table. At December&nbsp;31, 2018, options granted to executives in 2018 were all underwater. For
further information, see the &#147;2018 Realizable Total Compensation&#148; table on page 52. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Say-on-Pay</FONT></FONT> and Stockholder Engagement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the Compensation Committee&#146;s annual
review of the executive compensation program, it considers the outcome of the annual advisory vote of stockholders. At the 2018 Annual Meeting, approximately 60% of the &#147;say on pay&#148; votes cast were in favor of the compensation of the
Company&#146;s named executive officers in 2017. While the vote was favorable, as it has been every year since 2013, the first time an advisory vote was held, the approval percentage dropped significantly from 2017, and marked the third straight
decline in the percentage of favorable votes. The Compensation Committee believes that the low favorable vote at the 2018 annual meeting was influenced by the high grant date Black-Scholes values of equity awards, which reflected a near three-year
high in the price of the Company&#146;s common stock at the time of grant. Notwithstanding this belief, the Compensation Committee determined that prompt responsive action was advisable. Accordingly, at the direction of the Compensation Committee,
senior management of the Company augmented its Spring investor engagement by conducting a Fall outreach program, seeking, among other things, interim feedback on the Company&#146;s executive compensation program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the Fall outreach to stockholders, the Chairman of the Board of Directors and the Company&#146;s Senior Vice President, Investor Relations
and then-interim Chief Financial Officer contacted stockholders representing approximately 39% of the then-outstanding shares of the Company, and conducted an active dialogue with the Company&#146;s largest long-term institutional investors,
collectively representing approximately 29% of the then-outstanding shares. Together with the ownership of the entities affiliated with the Chairman, discussions were held with stockholders representing over 50% of the Company&#146;s
then-outstanding shares. In addition, during 2018 and 2019 to date, senior management of the Company presented at 13 investor conferences, hosted 81 investors on visits to the Company, and held approximately 400 meetings and calls with investors on
an individual basis. The Company believes these discussions help further align the Company&#146;s interests with the best interests of its stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the executive compensation feedback the Company received
during the Fall outreach, and the actions taken in response. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stockholder Feedback</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Company Actions</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;Concern over historic option burn rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;Burn rate for 2018 reduced 33% from 2017, reflecting decrease in 2018
annual grant budget, with executive awards reduced accordingly</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;RSUs, which have less volatility than stock options, and have retentive value,
could be added to the mix of equity awards as a part of a balanced portfolio</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;RSUs were included for the first time in the Fall equity awards for
2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;RSUs, if used, should comprise a relatively smaller proportion of the equity
mix than stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;RSUs comprised 25% of the equity mix for the Fall 2018 grants</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;Performance RSUs should be considered as a part of the equity mix, potentially
in place of performance-based options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;The Company is considering the inclusion of performance RSUs in place of
performance-based options</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;Unique bonus programs may be warranted; but should be performance-based and
disclosed clearly to stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;The special fourth-quarter 2018 incentive bonus was based on objective goals.
The Company has provided detailed disclosure below regarding these incentives.</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Positive Pay Practices </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s executive compensation program reflects several positive pay governance practices, as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>What We Do</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>What We Don&#146;t Do</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;&#8201;Grant compensation that is primarily <FONT STYLE="white-space:nowrap">at-risk</FONT>
and tied to performance</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;&#8201;Subject short- and long- term incentive compensation to measurable and rigorous goals</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;&#8201;Use an independent compensation
consultant</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;&#8201;Cap annual cash
incentive payments at 150% of target and performance-based stock options at 200% of target</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;&#8201;Structure compensation to avoid excessive risk taking</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;&#8201;Provide competitive compensation
that is benchmarked against an industry peer group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&times;&#8201;&#8201;Allow hedging of Company equity</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&times;&#8201;&#8201;Reprice stock options</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&times;&#8201;&#8201;Provide excessive
perquisites</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&times;&#8201;&#8201;Provide
supplemental executive retirement plans</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&times;&#8201;&#8201;Pay tax <FONT STYLE="white-space:nowrap">gross-ups</FONT> on a change in control</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&times;&#8201;&#8201;Provide &#147;single
trigger&#148; change in control payments</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&times;&#8201;&#8201;Provide excessive severance benefits</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Determining Executive Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Peer Group and Benchmarking </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>General</I>. The Compensation Committee uses peer group benchmarks developed in coordination with an independent compensation consulting
firm to assist it in understanding market factors, including the range of base salary, target annual incentive compensation, and equity grant levels offered for comparable roles at comparable companies. While benchmarking may not always be
appropriate as a stand-alone tool for setting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compensation due to variations in the businesses and strategic objectives of the peer group, the Compensation Committee believes that using this information as a reference point is an important
part of the compensation-related decision-making process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>2018 Peer Groups.</I> The Compensation Committee engaged an independent
compensation consulting firm, Frederic W. Cook&nbsp;&amp; Co. (&#147;FW Cook&#148;), to assist it with the development of a peer group to reference for compensation decisions for the year ended December&nbsp;31, 2018. As part of its engagement, FW
Cook was requested by the Compensation Committee to review and update, as necessary, the comparator group of companies that FW Cook had developed with the Compensation Committee for fiscal 2017 compensation decisions. At the request of the
Compensation Committee, FW Cook also conducted interviews with members of the Compensation Committee and senior management to learn more about the Company&#146;s business operations and strategy, key performance metrics and strategic goals, as well
as the labor markets in which the Company competes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In establishing the peer groups for 2018, the Compensation Committee considered
potential peer companies&#146; stage of development and size (especially market capitalization) relative to ACADIA. During 2018, two peer groups were used. For the decisions made early in 2018, including the Spring equity grants and the setting of
annual incentive bonuses, the Company used the peer group shown immediately below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Acorda Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Alkermes plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><STRIKE>Alnylam
Pharmaceuticals Inc.</STRIKE> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">bluebird bio </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Clovis Oncology, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><STRIKE>Exelixis, Inc.</STRIKE> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Halozyme Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Intercept Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Intra-Cellular Therapies, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Ironwood Pharmaceuticals, Inc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><STRIKE>Jazz Pharmaceuticals plc</STRIKE> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Nektar Therapeutics </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Neurocrine
Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pacira Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Portola Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Puma Biotechnology, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Sage
Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><STRIKE>Seattle Genetics, Inc.</STRIKE> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><STRIKE>Tesaro, Inc.</STRIKE> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Medicines Company </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following
an active dialogue with FW Cook, in the summer of 2018 the Compensation Committee approved modifications to the peer group to remove five larger companies and create an updated group for reference with respect to compensation decisions in the Fall
of 2018. The five companies marked above were removed from the peer group, and the companies in bold below were added to the peer group. The resulting peer group consists of: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Acorda Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Alder BioPharma </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Alkermes
plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Amarin </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Arena
Pharmaceuticals </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Array BioPharma </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">bluebird bio </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Clovis Oncology, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Corcept
Therapeutics </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>GW Pharma </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Halozyme Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Insmed </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Intercept
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Intra-Cellular Therapies, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Ironwood Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Nektar Therapeutics </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Neurocrine
Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pacira Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Portola Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Puma Biotechnology, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Sage
Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Supernus Pharmaceuticals </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Medicines Company </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When the
updated 2018 peer group was selected, ACADIA&#146;s market capitalization of approximately $2.179&nbsp;billion was 17% lower than the median peer market capitalization of $2.649&nbsp;billion (as of July&nbsp;15, 2018). ACADIA&#146;s slightly smaller
size was considered by the Compensation Committee when it evaluated the peer market data. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance Evaluation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, the Chief Executive Officer has evaluated the performance of the other executive officers on an annual basis and made
recommendations to the Compensation Committee with respect to salary adjustments, bonuses and equity awards. For 2018, Mr.&nbsp;Davis provided guidance to the Compensation Committee on the Company&#146;s achievement of corporate goals, based on his
discussions with senior management. The Compensation Committee exercises its discretion in determining recommendations to the Board for salary adjustments and discretionary cash and equity awards for executive officers. Mr.&nbsp;Davis did not
participate in, and was not present during, any deliberations or determinations of the Compensation Committee regarding his compensation or his performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Elements of Executive Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation for executives consists of four principal components: base salary, potential annual incentive bonus, long-term incentives, and
post-employment compensation. Changes to these components have been generally determined and made or paid, as appropriate, in the Spring of each year. In 2018, as described below under &#147;Special Incentive Bonus,&#148; another element of
compensation was implemented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Base Salary</I><I>.</I> As a general matter, the base salary for each executive is initially established
through <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiation at the time of hire, taking into account such officer&#146;s qualifications, experience, prior salary (if available), and competitive market salary information for similar
positions in the biotechnology industry. Base salaries of executives are reviewed annually and any adjustment is determined by an assessment of corporate performance, the performance of each executive officer against his or her individual job and
functional area&#146;s responsibilities including, where appropriate, the impact of such performance on the Company&#146;s business results, the financial position of the Company, competitive market conditions for executive compensation for similar
positions, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-of-living</FONT></FONT> considerations. The Compensation Committee generally seeks to set executive salaries around the 50<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> percentile of the applicable comparator group. For 2018, base salaries were increased by approximately 3% for each named executive officer (other than newly-hired executives), reflecting standard,
annual cost of living and merit adjustments. The percentage increase was the same for non-executives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Annual Incentive Bonuses</I><I>.</I> The Compensation Committee believes that
performance-based cash bonuses play an important role in providing incentives to executives to achieve defined annual corporate goals. At the beginning of each year, the Compensation Committee reviews a detailed set of overall corporate performance
goals for the current year prepared by management that are intended to apply to the executives&#146; annual incentive awards. If those goals are achieved in full, 75% of the executives&#146; annual target incentive awards would be earned. In early
2018, the Compensation Committee reserved the ability to approve an additional set of corporate performance goals at <FONT STYLE="white-space:nowrap">mid-year</FONT> that would result, if achieved in full, in the remaining 25% of the
executives&#146; annual target incentive awards being earned. The performance metrics against which executive officers are measured are <FONT STYLE="white-space:nowrap">pre-established,</FONT> clearly communicated, measurable, and consistently
applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The target annual incentive bonuses, as a percentage of base salary, for the executive officers in 2018 were 70% for
Mr.&nbsp;Davis, 45% for Mr.&nbsp;Young, 65% for Dr.&nbsp;Stankovic, 50% for Mr.&nbsp;Yang and 45% for Mr.&nbsp;Kim. These bonus targets were unchanged from 2017, with the exception of Dr.&nbsp;Stankovic, whose bonus target was increased <FONT
STYLE="white-space:nowrap">mid-year</FONT> in connection with his promotion and related increase in responsibilities, and Mr.&nbsp;Kim, whose bonus target was established in connection with the start of his employment. These percentages were
generally set around the 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile of the applicable peer group. Actual bonuses range from 0 to 150% of the applicable target percentage based on the Compensation Committee&#146;s
quantifiable assessment of total corporate goal achievement to align delivered pay with actual performance. Mr. Young left the Company in October 2018 and therefore was not paid an annual incentive bonus for 2018. Mr. Kim joined the Company in July
2018 and therefore his annual incentive bonus was pro-rated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For 2018, the Board of Directors established corporate goals related to the
following categories: </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>2018 Corporate Annual Cash Incentive Plan Goals</I></B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>1.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NUPLAZID(45%)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;Achievement of full-year 2018 sales forecast</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;Achievement of fourth quarter 2018 sales forecast</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;Improvement in revenue-centric actions and metrics (reduction in hub
cancellations; increase in HCPs with a minimum number of patients; achievement of targeted bottle sales level)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>2.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Research&amp; Development (35%)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;Achievement of site initiation and patient enrollment targets for
dementia-related psychosis study;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;Completion of major depressive disorder study enrollment by <FONT
STYLE="white-space:nowrap">mid-year;</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;Achievement of site initiation and patient enrollment targets for
schizophrenia studies (inadequate response and negative symptoms)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;Obtain FDA approvals of 34 mg capsule and 10 mg tablet</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>3.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Corporate/BusinessDevelopment (20%)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.60em; text-indent:-1.60em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8201;Execution of a definitive agreement to add a product or product
candidate</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Actual payout is determined by the Compensation Committee based on achievement of the <FONT
STYLE="white-space:nowrap">pre-established</FONT> goals, which have individual weightings and criteria for determination of payout above and below target levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the sustained commercial disruption caused by the media articles mentioned in &#147;Pay for Performance in 2018&#148; above, a
significant portion of the NUPLAZID-related objectives described above were not met, and the Compensation Committee determined that the percentage achieved was 14%. This was offset in part by achievement at an outperform level in certain Research
and Development objectives, with the Compensation Committee determining that the percentage achieved was 43%. The Corporate/Business Development objective was met at the target level, and accordingly the Compensation Committee determined that the
percentage achieved was 20%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The annual cash incentive percentage, therefore, was only 77% of target for each executive. The resulting individual bonus percentages were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018&nbsp;Annual<BR>Bonus<BR>Achieved (as<BR>%&nbsp;of&nbsp;Target)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018&nbsp;Target<BR>Bonus&nbsp;(as&nbsp;%&nbsp;of<BR>Base Salary)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual&nbsp;Bonus<BR>for&nbsp;2018&nbsp;(as&nbsp;%<BR>of&nbsp;Base&nbsp;Salary)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Davis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Todd Young(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Srdjan Stankovic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Austin Kim(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Yang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Young left the Company in October 2018 and therefore was not paid an annual incentive bonus for 2018.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Kim joined the Company in July 2018 and therefore his annual incentive bonus was <FONT
STYLE="white-space:nowrap">pro-rated.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Special Fourth-Quarter Cash Incentive.</I> Beginning in late Spring
2018, the Company faced unforeseen commercial challenges with respect to NUPLAZID as a result of unwarranted negative media attention, specifically CNN&#146;s publication on April&nbsp;9, 2018 of an article focusing on adverse events experienced by
patients who were taking NUPLAZID. The article was largely anecdotal and did not establish any causal connection between NUPLAZID and the adverse events. Apparently in response to the April&nbsp;9 article, the FDA commenced a &#147;tracked safety
issue&#148; review of post-marketing patient mortality data. On April&nbsp;25, 2018 CNN published another article regarding the FDA&#146;s review and repeated many of the negative insinuations from its initial article. In summer 2018, it became
apparent that the negative publicity was causing PDP patients and their caregivers to be reluctant to commence or continue treatment with NUPLAZID. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In response to these unique and unanticipated challenges, the Compensation Committee believed it was of critical importance to focus
management on specific objectives designed to stabilize NUPLAZID&#146;s commercial base in the fourth quarter of 2018, which would be critically important to returning NUPLAZID to its long-term growth potential. Therefore, in the Fall of 2018, the
Compensation Committee implemented a <FONT STYLE="white-space:nowrap">one-time,</FONT> special incentive bonus program with a separate set of commercial goals specific to the fourth quarter of 2018, the achievement of which was expected to position
the Company for commercial recovery in 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The goals and weightings for the special incentive program were: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">improvement in average daily new patient referrals in the fourth quarter, compared to a baseline established
during the Spring-Summer timeframe, which was the period of greatest impact from the CNN articles (weighted at 50%) and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">improvement in average weekly bottles prescribed, compared to the same baseline period (weighted at 50%)
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Threshold (minimum), target and outperform (highest) levels were set for each of these equally-weighted goals, the
achievement of which would result in the payment of 21%, 28% or 35% of base salary at the threshold, target and outperform levels, respectively. The specific performance metrics were <FONT STYLE="white-space:nowrap">pre-established,</FONT> clearly
communicated, measurable, and consistently applied. The Compensation Committee determined that the objectives set in the Fall were achieved at the threshold (minimum) level, thereby resulting in a special fourth quarter cash incentive payment to
each executive of 21% of base salary in the aggregate. Given that the target </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
special bonus was set 28% of base salary, the threshold level of achievement resulted in awards representing only 75% of the target special bonus, as shown in the table below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent&nbsp;of&nbsp;Q4<BR>Special&nbsp;Bonus<BR>Achieved</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Special&nbsp;Bonus<BR>Target</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Overall<BR>Special&nbsp;Bonus<BR>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Davis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Todd Young(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Srdjan Stankovic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Austin Kim(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Yang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Young left the Company in October 2018 and therefore was not paid a special bonus for the fourth
quarter. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Kim joined the Company in July 2018 and therefore his special bonus for the fourth quarter was <FONT
STYLE="white-space:nowrap">pro-rated.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Long-Term Incentives</I><I>.</I> In 2018, annual equity awards for all
employees were split into Spring and Fall grants. In 2017, the Board decided to split the annual grant into two biannual grants for all employees in an effort to mitigate the impact of potential significant stock price fluctuations during the year.
In 2018, ordinary course grants were made in April and in October, with the following equity mixes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">April awards: 75% time-based stock options and 25% performance-based stock options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">September awards: 50% time-based stock options; 25% performance-based stock options; 25% time-based RSUs
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Time-Based Stock Options</I>. Options are granted based on the belief that they naturally align executives with the
creation of stockholder value and are the best long-term incentive vehicle to retain and promote the Company&#146;s entrepreneurial culture. Time-based options vest 25% after one year and in equal monthly installments over the next three years, and
have a <FONT STYLE="white-space:nowrap">ten-year</FONT> term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee believes that stock options are inherently
performance-based, incentivize employees to make decisions that ensure long-term success, and are appropriate and advantageous for the following additional reasons: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Value is only realized if the stock price increases, thereby aligning the interests of executives with those of
stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stock options have greater downside risk than full-value awards, as they do not provide any value to the holder
if the stock price declines below the exercise price (determined as of the date of grant). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <FONT STYLE="white-space:nowrap">ten-year</FONT> term of options gives executives the opportunity to realize
value over a long period of time, which promotes long-term thinking and value creation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stock options are well understood, and help attract and retain employees who contribute to the Company&#146;s
entrepreneurial culture. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Performance-Based Stock Options</I>. Performance-based options provide the benefits
described above and also provide additional alignment with the Company&#146;s long-term strategic goals. Performance-based options are earned only if the Company achieves rigorous long-term goals related to NUPLAZID revenue, pimavanserin
development, and other research and development efforts (as discussed in further detail below). The goals may be achieved between 2019 and 2023, with a decreasing number points (or no points) earned for achievement in later years. Up to 44 possible
points may be earned, and achieving certain point thresholds results in options being earned. The goals represent diversified business and development strategies, not all of which are expected to come to fruition. As such, we consider achievement of
all goals to be highly unlikely and the achievement of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the points required to earn target and maximum level payouts to represent very strong and truly outstanding performance, respectively. There is a minimum vesting period of two years on all earned
awards. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="89%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Performance Option Earn Out Schedule</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Points<BR>Earned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Awards&nbsp;Earned<BR>(% Target)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>&lt;4</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>4</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>8</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>75</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>12</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>15</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>125</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>18</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>150</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>21</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>175</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B></B><B></B><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B></B>&#9744;<B></B><B>24</B></TD>
<TD NOWRAP VALIGN="top"><B></B><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>200</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The performance option goals are <FONT STYLE="white-space:nowrap">pre-established,</FONT> clearly
communicated, measurable, and consistently applied. They focus on long-term performance, unlike our annual cash incentive program, which focuses on short-term performance. The categories of goals, performance periods and weightings are as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Goal Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Performance&nbsp;Period*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighting</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NUPLAZID revenue achievement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">2019-2023</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">29%&nbsp;of&nbsp;available&nbsp;points</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FDA approval of additional uses of pimavanserin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020-2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">52% of available points</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development and approval of <FONT STYLE="white-space:nowrap">non-pimavanserin</FONT>
compound(s)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021-2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">19% of available points</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A decreasing number of points, or zero points, would be earned for achievement in later years.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Time-Based Restricted Stock Units</I>. The Company added RSUs as a part of the October grants. The Company believes
that RSUs are a stable equity vehicle that has significant retentive value. The RSUs vest in four annual installments beginning on the first anniversary of the grant date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of equity awards granted is based on the executive&#146;s position, the executive&#146;s performance in the prior year, the
Company&#146;s overall performance, the executive&#146;s potential for continued sustained contributions to the Company&#146;s success, and competitive market information. Based on market data provided by FW Cook, the Compensation Committee
considers the equity grant levels of the peer group, including awards granted as a percentage of outstanding shares when recommending equity awards for executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The disclosed Black-Scholes grant date fair value of our CEO&#146;s 2018 equity awards decreased 62.1% compared to the value of equity awards
in 2017. The decrease in grant value resulted primarily from a decrease in the Company&#146;s share price at the time the awards were granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The performance-based nature of the Company&#146;s compensation program is evident in the realizable value of executives&#146; 2018 equity
compensation, which is dramatically lower than the grant date fair values (Black-Scholes driven, in the case of options) included in the Summary Compensation Table. See the table below. Moreover, at December&nbsp;31, 2018, all options granted to
executives in 2018 were underwater. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="42" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018 Realizable Total Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018 Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Difference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>+</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual<BR>Annual<BR>Incentive</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>+</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Special<BR>Q4<BR>Bonus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>+</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Realizable<BR>Award<BR>Value(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>+</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>=</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>-</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Compensation<BR>Disclosed</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>=</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stephen Davis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">719,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">387,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">105,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">384,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,597,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,508,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,910,356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-75.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Todd Young<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">473,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,486,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,012,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-68.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Srdjan Stankovic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">524,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">596,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,455,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,678,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,223,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-74.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Austin Kim<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">518,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,126,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,607,569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-75.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Michael Yang</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,036,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,182,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,146,069</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-67.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1.</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount reflects the value of outstanding RSUs as of December&nbsp;31, 2018. At such date, all of the
options granted to executives in 2018 were underwater. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2.</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Young left the Company in October 2018 and therefore his cash and equity awards were cancelled.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3.</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Kim joined the Company in July 2018 and therefore his annual incentive and special fourth-quarter
bonuses were <FONT STYLE="white-space:nowrap">pro-rated</FONT> accordingly. &#147;All Other Compensation&#148; for Mr. Kim includes a sign-on bonus of $200,000, which is subject to a two-year clawback, as follows: (i) if Mr. Kim voluntarily leaves
the Company on or before the first anniversary of his hire date, 100% of such bonus must be repaid, and (ii) if Mr. Kim voluntarily leaves the Company after the first anniversary of his hire date but on or before the second anniversary of his hire
date, 100% less a percentage equal to x/12 of such bonus (where x is the number of months or partial months that Mr. Kim was employed after the first year of his employment) must be repaid. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executives&#146; stock options are granted with an exercise price based on the fair market value, which has been deemed to be the closing
price on the date of grant. Stock option grants to executives currently are made pursuant to our 2010 Plan. We do not coordinate the grant of stock options to the timing of releases of material <FONT STYLE="white-space:nowrap">non-public</FONT>
information. New hire equity grants, which are made to all employees (including executives) at the time of hire, consist solely of time-based options. The number of options is established through arm&#146;s-length negotiation at the time of hire,
taking into account the executive&#146;s qualifications, experience and competitive market information for similar positions in the biotechnology industry, as well as the current compensation approach of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For fiscal 2018, please see the Grants of Plan-Based Awards table included below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restrictions on Equity.</I> Pursuant to the terms of the Company&#146;s Amended and Restated Policy for Stock Trading by Officers,
Directors and Certain Other Employees, executive officers are prohibited from engaging in speculative trading with respect to securities of the Company, including any hedging transactions. In addition, pursuant to that policy, executive officers may
not pledge or otherwise transfer any beneficially owned Company securities without prior notification and approval by the Chief Executive Officer or Chief Financial Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Post-employment Compensation.</I> The named executive officers are entitled to certain severance and change in control benefits, the terms
of which are described below under &#147;&#151;Potential Payments upon Termination or Change of Control.&#148; These severance and change in control benefits are an essential element of the overall executive compensation package, and assist the
Company in recruiting and retaining talented individuals and aligning the executive&#146;s interests with the best interests of the stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Other Benefits</I>. The Company provides certain additional benefits to executive officers that are also generally available to employees,
including medical, dental, vision and life insurance coverage, 401(k) matching contributions, an employee stock purchase plan and, for new hires who are relocating, certain relocation benefits (including, among other things, certain moving expenses
and reimbursement of certain costs incurred in connection with the sale of an existing home and purchase of a new home); however, the Compensation Committee in its discretion may revise, amend or add to these benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee Interlocks and Insider Participation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As indicated above, the Compensation Committee currently consists of Dr.&nbsp;Biggar and Messrs. Baker and Daly. No member of the Compensation
Committee has ever been an officer or employee of the Company. None of the executive officers currently serves, or has served during the last completed fiscal year, on the compensation committee or board of directors of any other entity that has one
or more executive officers serving as a member of the Board of Directors or Compensation Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Risk Assessment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although a portion of the compensation provided to our executive officers and other employees is performance-based, the executive compensation
program does not encourage excessive or unnecessary risk </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
taking. This is primarily due to the fact that the compensation programs are designed to encourage executive officers and other employees to remain focused on both short-term and long-term
strategic goals within the context of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> compensation philosophy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Report </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The
material in this report is not &#147;soliciting material&#148;, is not deemed &#147;filed&#148; with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or
after the date hereof and irrespective of any general incorporation language in any such filing. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee has
reviewed and discussed with management the Compensation Discussion and Analysis contained in this proxy statement. Based on this review and discussion, the Compensation Committee has recommended to the Board of Directors that the Compensation
Discussion and Analysis be included in this proxy statement and incorporated into the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing report has been furnished by the Compensation Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Stephen Biggar, Committee Chair </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Julian Baker </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">James Daly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows for the fiscal years ended December&nbsp;31, 2018, 2017, and 2016, compensation awarded to or paid to, or earned by,
the Company&#146;s Chief Executive Officer, former Chief Financial Officer, and its three other executive officers as of December&nbsp;31, 2018 (the &#147;Named Executive Officers&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Compensation Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>Year</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;<BR></B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>Salary<BR>($)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;<BR>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;<BR></B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>Bonus<BR>($)(1)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;<BR>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;<BR><BR></B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>Stock<BR>Awards<BR>($)(2)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;<BR>&nbsp;<BR>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;<BR><BR></B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>Option<BR>Awards<BR>($)(3)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;<BR>&nbsp;<BR>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;<BR><BR><BR></B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)(4)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;<BR><BR></B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;<BR>&nbsp;<BR>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>Total ($)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stephen&nbsp;Davis(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief&nbsp;Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">2018<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">2017</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">2016</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">719,833<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">700,000</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">675,992</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">&#151;&nbsp;&nbsp;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">437,705</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">505,400<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">&#151;&nbsp;&nbsp;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">&#151;&nbsp;&nbsp;</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">4,771,631<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">13,905,418</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">8,133,720</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">493,806<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">535,938</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">&#151;&nbsp;&nbsp;</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">17,362<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">16,790</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">14,030</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">6,002,632<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">15,158,146</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">9,261,447</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Todd Young(6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Former Executive Vice President, Chief Financial Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">2018<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">2017</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">2016</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">350,568<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">409,542</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">147,462</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">&#151;&nbsp;&nbsp;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">61,381</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">99,761<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">&#151;&nbsp;&nbsp;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">&#151;&nbsp;&nbsp;</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">973,878<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">2,675,273</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">4,287,440</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">201,572</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">&#151;&nbsp;&nbsp;</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">61,887<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">15,232</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">200,260</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">1,386,333<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">3,301,619</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">4,696,543</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Srdjan Stankovic(7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">2018<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">2017</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">2016</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">524,785<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">489,844</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">475,000</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">&#151;&nbsp;&nbsp;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">219,688</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">705,700<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">&#151;&nbsp;&nbsp;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">&#151;&nbsp;&nbsp;</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">4,094,313<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">6,420,193</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">2,033,430</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">334,289<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">267,883</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">&#151;&nbsp;&nbsp;</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">19,294<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">18,549</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">15,100</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">4,972,681<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">7,196,469</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">2,743,218</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Austin Kim(8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive&nbsp;Vice President, General Counsel, and Secretary</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">195,704</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,597,106</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">86,306</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">47,096</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,126,212</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Michael Yang(9)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Vice President, Chief Commercial&nbsp;Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">2018<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">2017</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">485,250<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">361,731</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">&#151;&nbsp;&nbsp;</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">212,800<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">&#151;&nbsp;&nbsp;</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">2,077,607<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">11,460,367</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">237,773<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">197,822</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">169,480<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">84,028</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" ALIGN="right">2,970,110<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right">12,103,948</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts for Messrs. Davis, Stankovic and Young represent cash bonuses awarded for 2016 based the Company&#146;s
achievement of corporate performance goals. Amount for Mr. Kim represents a sign-on bonus of $200,000, which is subject to a two-year clawback, as follows: (i) if Mr. Kim voluntarily leaves the Company on or before the first anniversary of his hire
date, 100% of such bonus must be repaid, and (ii) if Mr. Kim voluntarily leaves the Company after the first anniversary of his hire date but on or before the second anniversary of his hire date, 100% less a percentage equal to x/12 of such bonus
(where x is the number of months or partial months that Mr. Kim was employed after the first year of his employment) must be repaid. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents value of RSUs granted in Fall 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts shown do not reflect compensation actually received by the named individual. &#147;Option Awards&#148;
includes the grant date fair value of option awards granted in the year indicated as computed in accordance with authoritative accounting guidance. See Note 2 to the consolidated financial statements in the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018, filed February&nbsp;27, 2019 with the SEC, for the assumptions used to determine the valuation of stock option awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts in 2017 are annual incentive bonuses. Amounts in 2018 are the aggregate of the annual incentive bonuses
and the special fourth-quarter bonuses. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For 2018, 2017 and 2016, &#147;All Other Compensation&#148; includes $13,750, $13,500 and $13,250 in employer
401(k) matching and $3,612, $3,290 and $780 of supplemental life insurance premium payments, respectively. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Young joined the Company in August 2016 and left the Company in October 2018. &#147;All Other
Compensation&#148; in 2018 includes $13,750 in employer 401(k) matching, $1,050 in supplemental life insurance premium payments, and $47,087 in accrued vacation. &#147;All Other Compensation&#148; in 2017 includes $13,500 in employer 401(k)
matching, $1,147 in supplemental life insurance premium payments and $585 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
in tax <FONT STYLE="white-space:nowrap">gross-ups</FONT> for relocation. &#147;All Other Compensation&#148; in 2016 includes $260 in supplemental life insurance premium payments and $200,000 in
relocation expenses, including $66,319 in tax <FONT STYLE="white-space:nowrap">gross-ups</FONT> for relocation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;All Other Compensation&#148; includes $13,750, $13,500 and $13,250 in employer 401(k) matching and
$5,544, $5,049 and $780 in supplemental life insurance premium payments for 2018, 2017 and 2016, respectively. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Yang joined the Company in February 2017. For 2018, &#147;All Other Compensation&#148; includes
$13,750 in employer 401(k) matching, $3,612 of supplemental life insurance premium payments, and $152,118 in relocation expenses, including $52,235 in tax <FONT STYLE="white-space:nowrap">gross-ups</FONT> for relocation. For 2017, &#147;All Other
Compensation&#148; includes $2,709 in supplemental life insurance premium payments and $81,319 in relocation expenses, including $28,917 in tax <FONT STYLE="white-space:nowrap">gross-ups</FONT> for relocation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Kim joined the Company in July 2018. For 2018, &#147;All Other Compensation&#148; includes $8,958 in
employer 401(k) matching, $1,505 of supplemental life insurance premium payments and $36,633 in relocation expenses, including $11,338 in tax <FONT STYLE="white-space:nowrap">gross-ups</FONT> for relocation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Grants of Plan-Based Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows certain information regarding grants of plan-based awards to the Named Executive Officers for the fiscal year ended
December&nbsp;31, 2018: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Grants of Plan-Based Awards in Fiscal 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated Future Payouts</B><br><B>Under <FONT STYLE="white-space:nowrap">Non-Equity</FONT></B><br><B>Incentive Plan Awards(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated Future Payouts</B><br><B>Under Equity</B><br><B>Incentive Plan Awards(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Equity</B><br><B>Awards:</B><br><B>Number of</B><br><B>Securities</B><br><B>Underlying</B><br><B>RSUs</B><br><B>(#)(3)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other</B><br><B>Option</B><br><B>Awards:</B><br><B>Number
of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Options</B><br><B>(#)(4)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise&nbsp;or</B><br><B>Base&nbsp;Price</B><br><B>of Option</B><br><B>Awards</B><br><B>($)(5)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date</B><br><B>Fair Value</B><br><B>of Option</B><br><B>Awards</B><br><B>($)(6)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Threshold</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Threshold</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stephen Davis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">503,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">755,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,170,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,758,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,210,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">505,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">633,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Todd Young</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Srdjan Stankovic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">341,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">511,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">617,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">927,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">605,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/19/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,627,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/19/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">453,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Michael Yang</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">520,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">781,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">509,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Austin Kim(7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,597,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reported represent the potential short-term incentive compensation amounts payable for our 2018 fiscal
year under our annual cash incentive program. The amounts reported represent each NEO&#146;s target and maximum possible payments for 2018. Because actual payments to the NEOs could range from 0% to 150% of their target bonus, no threshold payment
amount has been established for the NEOs. The actual short-term incentive bonus amount earned by each NEO for 2018 is reported in the <FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation column in the Summary Compensation
Table above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reported represent performance-based option awards which are subject to both performance and time-based
vesting conditions. Vesting of performance-based option awards is described above in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Compensation Discussion and Analysis in the Elements of Executive Compensation&#151;Long-Term Incentives section </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reported represent service-based restricted stock units which vest in four equal annual installments.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reported represent service-based option awards which are subject to a
<FONT STYLE="white-space:nowrap">pro-rata</FONT> <FONT STYLE="white-space:nowrap">one-year</FONT> cliff vest and 36 monthly installments thereafter. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In accordance with the terms of the 2010 Plan, the exercise price of each option was set at the market closing
price of our common stock on the date of grant. Similar to 2017, 2018 options were granted biannually and included performance-based grants. Performance-based and time-based vesting awards are expected to be made at the same time.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note 2 to the consolidated financial statements in the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018, filed February&nbsp;27, 2019 with the SEC, for the stock compensation expense assumptions used to determine the valuation and expensing of stock option awards. The
values recognized in the &#147;Grant Date Fair Value of Option Awards&#148; column above do not reflect estimated forfeitures. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Kim joined the Company in July&nbsp;2018 and the grant included in the table is his initial option
award. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows certain information regarding outstanding equity awards at December&nbsp;31, 2018 for the Named Executive Officers:
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Outstanding Equity Awards at December&nbsp;31, 2018 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options</B><br><B>Exercisable(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Securities<BR></B><br><B>Underlying</B><br><B>Unexercised<BR>Options</B><br><B>Unexercisable(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting</B><br><B>Commencement</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Exercise</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;That<BR>Have&nbsp;Not<BR>Vested(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting</B><br><B>Commencement</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value of<BR>Shares&nbsp;That<BR>Have Not<BR>Vested</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stephen Davis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/15/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/14/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/20/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/19/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/1/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/31/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/15/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/14/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/8/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/7/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/3/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/2/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/7/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/6/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/7/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/6/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/17/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/17/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/14/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/14/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">384,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,304,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">778,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">510,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">384,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Todd Young</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/22/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/21/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/8/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/7/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/7/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/6/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Srdjan Stankovic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/25/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/24/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/15/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/14/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/8/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/7/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/3/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/2/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/7/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/6/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/7/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/6/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/17/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/17/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/14/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/14/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/19/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/18/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/19/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">377,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">515,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">596,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Michael Yang</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/29/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/28/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/7/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/6/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/7/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/6/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/17/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/17/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/14/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/14/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">389,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">161,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Austin Kim</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/17/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Time-based options granted to our Named Executive Officers vest over four years with 25% of the total number of
shares subject to an option vesting after the first year and 1/48th per month thereafter. Awards are time-based unless indicated as performance-based awards. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Performance-based award. Vesting of performance-based option awards is described above in Compensation
Discussion and Analysis in the Elements of Executive Compensation&#151;Long-Term Incentives section. Performance-based options cannot be exercised prior to two years after the vesting commencement date (even if the vesting goals have been met) and
reflect the target shares issuable pursuant to such options. If appropriate performance criteria are met, the maximum possible shares issuable is twice the target amount of each grant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Time-based restricted stock units granted to our Named Executive Officers vest in four equal annual
installments. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option Exercises and Stock Vested </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the Named Executive Officers exercised any options in fiscal 2018. The Company made restricted stock awards for the first time in
October&nbsp;2018, and none of those awards vested in 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nonqualified Deferred Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our Named Executive Officers participates in or has account balances in nonqualified defined contribution plans or other nonqualified
deferred compensation plans maintained by us. Our Compensation Committee may elect to provide our officers and other employees with <FONT STYLE="white-space:nowrap">non-qualified</FONT> defined contribution or other nonqualified deferred
compensation benefits in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Payments Upon Termination or Change in Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts of compensation payable to each Named Executive Officer upon termination of the employment of the executive are described below.
Our Compensation Committee may in its discretion recommend revisions, amendments or additions to these benefits for the approval of the Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Payments due upon termination </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regardless
of the manner in which a Named Executive Officer&#146;s employment terminates, the Named Executive Officer is entitled to receive amounts earned during his term of employment, including accrued and unpaid salary and payment in lieu of unused
vacation days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;10, 2015, the Compensation Committee of the Board of Directors, acting pursuant to authority delegated to
it by our Board of Directors, adopted the ACADIA Pharmaceuticals Inc. Management Severance Benefit Plan (the &#147;Severance Plan&#148;) and the ACADIA Pharmaceuticals Inc. Amended and Restated Change in Control Severance Benefit Plan (the &#147;CIC
Plan&#148;, and together with the Severance Plan, the &#147;Plans&#148;). The CIC Plan amends and restates ACADIA&#146;s Change in Control Severance Benefit Plan that was effective as of March&nbsp;11, 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential payments under Management Severance Benefit Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Severance Plan entitles our current Named Executive Officers and other members of management to certain severance payments and benefits in
the event of a qualifying termination of employment, other than in connection with certain change in control events that are covered by the CIC Plan. In reviewing the terms of the Severance Plan, the Compensation Committee and the Board of Directors
reviewed information about the practices of other companies in the health care industry. In adopting the Severance Plan, the Board of Directors considered the benefit to the Company and its stockholders in providing stability for key employees. The
Severance Plan will be used for new members of management and the Compensation Committee believes that it will assist with recruiting in this regard. A qualifying termination is a termination by us for any reason other than cause, or, in certain
cases, by the employee for Good Reason (as defined below). For purposes of the Severance Plan, &#147;cause&#148; means (i)&nbsp;such employee&#146;s attempted commission of, or participation in, a fraud or act of dishonesty against the Company;
(ii)&nbsp;such employee&#146;s intentional, material violation of any contract or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement between the employee and the Company or of any statutory duty owed to the Company; (iii)&nbsp;such employee&#146;s unauthorized use or intentional unauthorized disclosure of the
Company&#146;s confidential information or trade secrets; (iv)&nbsp;such employee&#146;s gross negligence or gross misconduct; (v)&nbsp;such employee&#146;s material failure to competently perform his/her assigned duties for the Company;
(vi)&nbsp;sustained poor performance of any material aspect of the employee&#146;s duties or obligations including refusal to follow lawful instructions from the employee&#146;s manager or the then-current board of directors; or
(vii)&nbsp;employee&#146;s conviction of, or the entry of a pleading of guilty or nolo contendere by such employee to, any crime involving moral turpitude or any <FONT STYLE="white-space:nowrap">non-vehicular</FONT> felony; provided, in the case of
clauses (v)&nbsp;and (vi), such behavior shall be deemed cause only if such failure or poor performance has not been substantially cured to the satisfaction of the Board of Directors within 30 days after written notice of such failure or poor
performance has been given by the Company to the employee. The determination of whether a termination is for cause shall be made by the Board of Directors in its sole and exclusive judgment and discretion. &#147;Good Reason&#148; means (i)&nbsp;the
assignment to an employee of any duties or responsibilities that results in a material diminution in the employee&#146;s authorities, duties or responsibilities as in effect immediately prior to such reduction; provided, however, that a change
solely in the employee&#146;s title or reporting relationships shall not provide the basis for a termination with Good Reason; (ii)&nbsp;a material reduction by the Company in the employee&#146;s annual base salary, as in effect prior to such
reduction; (iii)&nbsp;a relocation of the employee&#146;s principal business office to a location that increases the employee&#146;s <FONT STYLE="white-space:nowrap">one-way</FONT> driving distance by 30&nbsp;miles or more, except for required
travel by the employee on the Company&#146;s business consistent with such employee&#146;s business travel obligations as in effect on the effective date; or (iv)&nbsp;a material breach by the Company of any provision of the Severance Plan or any
other material agreement between the employee and the Company concerning the terms and conditions of the employee&#146;s employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
amount of payments and the type of benefits provided under the Severance Plan vary based on the employee&#146;s position and include cash severance payments based on base salary and target bonus, accelerated vesting of equity awards, and payment for
continued coverage under group health plans. Specifically, each Named Executive Officer is entitled to (i)&nbsp;a base compensation severance benefit that is equal to the individual&#146;s base salary plus the individual&#146;s target bonus payment
for the year and (ii)&nbsp;a target bonus severance amount that is equal to the <FONT STYLE="white-space:nowrap">pro-rata</FONT> portion of the individual&#146;s target bonus payment for the year. In the case of Mr.&nbsp;Davis, the base compensation
severance benefit amount is multiplied by 1.5. In addition, the Named Executive Officers are also eligible to receive a <FONT STYLE="white-space:nowrap">pro-rated</FONT> portion of the target bonus for the year in which the termination occurs.
Mr.&nbsp;Davis would be eligible to receive 12 months of accelerated vesting of any outstanding stock awards in the event of a qualifying termination. If a qualifying termination had occurred, effective as of December&nbsp;31, 2018, and 12 months of
Mr.&nbsp;Davis&#146;s outstanding stock awards were deemed vested, the value of the accelerated awards to Mr.&nbsp;Davis would have been: $0.1&nbsp;million in addition to cash compensation of approximately $2.4&nbsp;million, for a total of
approximately $2.5&nbsp;million. The value of accelerated awards is calculated as the sum of the products of the (i)&nbsp;the difference between the exercise price of each option deemed accelerated and the fair market value of our common stock on
December&nbsp;31, 2018 multiplied by (ii)&nbsp;the number of shares deemed accelerated under the applicable option plus the value of accelarated RSUs. If a qualifying termination had occurred, effective as of December&nbsp;31, 2018, with respect to
each of Dr.&nbsp;Stankovic and Messrs. Kim and Yang, they would have received payments of approximately $1.6 million, $817,000 and $975,000, respectively. The payments and benefits provided under the Severance Plan replaced any severance or similar
payments or benefits under an employment agreement or other arrangement with us and are subject to the employee&#146;s compliance with the other terms and conditions of the Severance Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to receive any benefits under the Severance Plan, employees must sign a general release and waiver of all claims against the Company.
Benefits are payable within 10 days of an effective release. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential payments under Amended and Restated Change in Control Severance Benefit Plan
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2013, the Compensation Committee of our Board of Directors, acting pursuant to authority delegated to it by our Board of Directors,
adopted the ACADIA Pharmaceuticals Inc. Change in Control Severance Benefit Plan. The CIC Plan adopted in December 2015 amends and restates the Change in Control Severance Benefit Plan that was effective as of March&nbsp;11, 2013. In adopting the
plan, the Board considered the benefit to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company and its stockholders in providing incentives for management continuity in the event of a merger for the Company (as described above under&#151;Effect of change in control on stock option
awards). In reviewing the terms of the CIC Plan, the Compensation Committee and the Board reviewed information about the practices of other companies in the health care industry. The CIC Plan will also be used for new members of management and the
Compensation Committee believes that it will assist with recruiting in this regard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CIC Plan entitles our Named Executive Officers
and other key employees to certain severance payments and benefits in the event of a qualifying termination of employment up to one month prior to or within 18 months following certain change in control events. The CIC Plan thus requires a
&#147;double trigger&#148; before any benefits are received by the Named Executive Officers. A qualifying termination is a termination by us for any reason other than cause, or by the employee for good reason. For purposes of the CIC Plan,
&#147;cause&#148; means (i)&nbsp;such employee&#146;s attempted commission of, or participation in, a fraud against the Company; (ii)&nbsp;such employee&#146;s intentional, material violation of any contract or agreement between the employee and the
Company or of any statutory duty owed to the Company; (iii)&nbsp;such employee&#146;s unauthorized use or intentional unauthorized disclosure of the Company&#146;s confidential information or trade secrets; (iv)&nbsp;such employee&#146;s gross
negligence or gross misconduct with respect to such employee&#146;s job duties; (v)&nbsp;sustained poor performance of any material aspect of the employee&#146;s duties or obligations including refusal to follow lawful instructions from the
employee&#146;s manager or the then-current board of directors; or (vi)&nbsp;employee&#146;s conviction of, or the entry of a pleading of guilty or nolo contendere by such employee to, any crime involving moral turpitude or any <FONT
STYLE="white-space:nowrap">non-vehicular</FONT> felony; provided, in the case of clause (v), such behavior shall be deemed cause only if such failure or poor performance has not been substantially cured within 30 days after written notice of such
failure or poor performance has been given by the Company to the employee. &#147;Good reason&#148; means (i)&nbsp;the assignment to an employee of any duties or responsibilities that results in a material diminution in the employee&#146;s
authorities, duties or responsibilities as in effect immediately prior to such reduction; (ii)&nbsp;a material reduction by the Company in the employee&#146;s annual base salary, as in effect prior to such reduction; (iii)&nbsp;a relocation of the
employee&#146;s principal business office to a location that increases the employee&#146;s <FONT STYLE="white-space:nowrap">one-way</FONT> driving distance by 30&nbsp;miles or more, except for required travel by the employee on the Company&#146;s
business consistent with such employee&#146;s business travel obligations as in effect on the Effective Date; or (iv)&nbsp;a material breach by the Company of any provision of the CIC Plan or any other agreement between the employee and the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of payments and the type of benefits provided under the CIC Plan vary based on the employee&#146;s position and include cash
severance payments based on base salary and bonus, accelerated vesting of equity awards, and payment for continued coverage under group health plans. Specifically, each Named Executive Officer is entitled to a base compensation severance benefit
that is equal to the individual&#146;s base salary plus the individual&#146;s target bonus payment for the year, which amount is then multiplied by 2 for Mr.&nbsp;Davis and 1.5 for Dr.&nbsp;Stankovic and Messrs. Kim and Yang. In addition, the Named
Executive Officers are also eligible to receive a <FONT STYLE="white-space:nowrap">pro-rated</FONT> portion of the target bonus for the year in which the change in control occurs. Under the CIC Plan, any equity awards held by a Named Executive
Officer that are outstanding but unvested and that are not assumed by the acquiring company will vest. In addition, following a merger in which the options have been assumed, if a Named Executive Officer&#146;s employment is involuntarily terminated
or terminated by such officer for Good Reason, then any unvested options held by the Named Executive Officer will vest. Thus, this type of option acceleration would require a &#147;double trigger&#148; for the applicable Named Executive Officer, as
noted above. If a merger had occurred effective as of December&nbsp;31, 2018 and all performance awards were deemed vested, none of the Named Executive Officers would have realized any value because the stock price as of such date was below the
exercise price for the performance awards. In addition, the cash payout under the CIC Plan at December&nbsp;31, 2018 would have been approximately $3 million, $2.1 million, $1.1 million and $1.3 million, respectively. Mr.&nbsp;Davis,
Dr.&nbsp;Stankovic, Mr.&nbsp;Kim and Mr.&nbsp;Yang, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The payments and benefits provided under the CIC Plan replace any
severance or similar payments or benefits under an employment agreement or other arrangement with us, including the Severance Plan, and are subject to the employee&#146;s compliance with the other terms and conditions of the CIC Plan. In order to
receive any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
benefits under the CIC Plan, employees must sign a general release and waiver of all claims against the Company. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CEO Pay Ratio Disclosure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required by
Section&nbsp;953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(u) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> we are providing the following information about the relationship of the annual total
compensation of our principal executive officer (&#147;PEO&#148;) to the annual total compensation of our median employee. Stephen R. Davis, our President and Chief Executive Officer is our PEO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Item 402(u) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> we identified the median employee by estimating the
annual total compensation of each active employee, excluding Mr.&nbsp;Davis, as of December&nbsp;31, 2018, by (i)&nbsp;aggregating (A) the annual base salary (or hourly rate multiplied by expected annual work schedule, for hourly employees), (B) the
target bonus for 2018, and (C)&nbsp;the estimated accounting value of any equity awards granted during 2018 and (ii)&nbsp;ranking this compensation measure for our employees from lowest to highest. If such median employee&#146;s actual annual
compensation was not comparable to the CEO compensation, for example, because such median employee was hired during the year and thus did not receive a full year&#146;s salary or did not receive a full annual bonus, we used the next lower employee
who was comparable as the median employee. Once identified, we calculated the annual total compensation of our median compensated employee in a manner consistent with that used to calculate the annual total compensation of Mr.&nbsp;Davis and
disclosed in the Summary Compensation Table above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ratio of Mr.&nbsp;Davis&#146;s annual total compensation for 2018 of $6,002,632,
as reported in the Summary Compensation Table, to the annual total compensation for our median employee of $207,731, results in a pay ratio of approximately 29:1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pay ratio reported above is a reasonable estimate calculated in a manner consistent with SEC rules based on our internal records and the
methodology described above. The SEC rules for identifying the median compensated employee and calculating the pay ratio based on that employee&#146;s annual total compensation allow companies to adopt a variety of methodologies, to apply certain
exclusions, and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. Therefore, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other
companies have different employee populations and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2017, the
Board approved an update to the compensation program for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors that went into effect in June 2017. This change was made following a review of materials provided by FW Cook regarding
compensation of the same comparable group of companies that was used to evaluate executive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the updated director compensation plan, we provide each of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors with cash compensation solely in the form of annual retainers, as set forth in the table that follows this paragraph. We also reimburse our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors for their reasonable expenses incurred in attending meetings of our Board of Directors and committees of the Board and other Board activities. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Retainer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Retainer for Board Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Retainer for Audit Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Retainer for Audit Member <FONT STYLE="white-space:nowrap">(non-Chair)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Retainer for Compensation Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Retainer for Compensation Member
<FONT STYLE="white-space:nowrap">(non-Chair)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Retainer for Nominating and Corporate Governance Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Retainer for Nominating and Corporate Governance Member
<FONT STYLE="white-space:nowrap">(non-Chair)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the updated director compensation plan, each of our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors also receives an annual stock option grant under the 2010 Plan for 15,000 shares. Options granted to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are intended by us not to qualify as incentive stock options under the
Internal Revenue Code of 1986, as amended. These option grants are <FONT STYLE="white-space:nowrap">non-discretionary.</FONT> In addition, any person who joins the Board of Directors as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director
will receive an option to purchase 15,000 shares of common stock upon his or her election. The annual retainer amount and option grant could be <FONT STYLE="white-space:nowrap">pro-rated</FONT> for a director that joined the Board other than at the
first meeting of the Board following the annual meeting of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initial grants (i.e., those made upon a <FONT
STYLE="white-space:nowrap">non-employee</FONT> director&#146;s election to our Board of Directors) vest over two years following the date of grant, and annual grants vest at the rate of 1/4th each three months after the Annual Meeting of
Stockholders. The exercise price for option grants is equal to the closing price for the Company&#146;s common stock on the option grant date. In general, the term of stock options granted under the 2010 Plan may not exceed ten years. In addition,
in July 2017, the Board created two new committees: a Commercial Committee and a Scientific Committee. The 2018 compensation for the members of these committees was an option grant of 15,000 shares that vest at the rate of 1/4th each three months
after the Annual Meeting of Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the terms of a <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s
stock option agreement provide for earlier or later termination, if an optionholder&#146;s service relationship with us, or any affiliate of ours, ceases for any reason, the optionholder may exercise any vested options up to three years from
cessation of service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows, for the fiscal year ended December&nbsp;31, 2018, certain information with respect to
the compensation of all persons who served as directors of the Company during 2018, other than Mr.&nbsp;Davis, who is a director and our President and Chief Executive Officer, and did not receive additional compensation for his services as a
director. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or<BR>Paid&nbsp;in&nbsp;Cash(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen R. Biggar, M.D., Ph.D.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">105,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">171,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">276,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julian C. Baker(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura Brege(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">547,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">793,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Daly(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">342,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edmund P. Harrigan, M.D.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">342,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Soland(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">342,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Fees Earned or Paid in Cash&#148; includes the annual Board of Directors retainer and any applicable
additional retainers if the Director was a member or Chair of a committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Option Awards&#148; includes the grant date fair value of option awards granted as computed in accordance
with authoritative accounting guidance. See Note 2 to the consolidated financial statements in the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018, filed February&nbsp;27, 2019 with the SEC, for the assumptions used to
determine the valuation of stock option awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Fees Earned or Paid in Cash&#148; includes Annual Retainer of $50,000, Additional Retainer for Board
Chair of $30,000, Additional Retainer for Compensation Chair of $20,000, Additional Retainer for Nominating&nbsp;&amp; Corporate Governance Member <FONT STYLE="white-space:nowrap">(non-Chair)</FONT> of $5,000. &#147;Option Awards&#148; includes the
fair value of 15,000 stock options granted June&nbsp;6, 2018 with an exercise price of $17.52. As of December&nbsp;31, 2018, an aggregate of 96,500 stock options that had been granted to Dr.&nbsp;Biggar were outstanding. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Fees Earned or Paid in Cash&#148; includes Annual Retainer of $50,000, Additional Retainer for
Compensation Member <FONT STYLE="white-space:nowrap">(non-Chair)</FONT> of $10,000. &#147;Option Awards&#148; includes the fair value of 15,000 stock options granted June&nbsp;6, 2018 with an exercise price of $17.52. As of December&nbsp;31, 2018,
an aggregate of 57,500 stock options that had been granted to Mr.&nbsp;Baker were outstanding. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Fees Earned or Paid in Cash&#148; includes Annual Retainer of $50,000, Additional Retainer for Audit
Chair of $20,000 and Additional Retainer for Nominating&nbsp;&amp; Corporate Governance Member <FONT STYLE="white-space:nowrap">(non-Chair)</FONT> of $5,000. &#147;Option Awards&#148; includes the fair value of 15,000 stock options granted
June&nbsp;6, 2018 with an exercise price of $17.52. As of December&nbsp;31, 2018, an aggregate of 100,000 stock options that had been granted to Ms.&nbsp;Brege were outstanding. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Fees Earned or Paid in Cash&#148; includes Annual Retainer of $50,000, Additional Retainer for Audit
Member <FONT STYLE="white-space:nowrap">(non-Chair)</FONT> of $10,000, Additional Retainer for Compensation Member <FONT STYLE="white-space:nowrap">(non-Chair)</FONT> of $10,000. &#147;Option Awards&#148; includes the fair value of 30,000 stock
options granted on June&nbsp;6, 2018 with an exercise price of $17.52, which includes 15,000 stock options for being a member of the Commercial Committee. As of December&nbsp;31, 2018, an aggregate of 87,500 stock options that had been granted to
Mr.&nbsp;Daly were outstanding. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Fees Earned or Paid in Cash&#148; includes Annual Retainer of $50,000. &#147;Option Awards&#148; includes
the fair value of 30,000 stock options granted June&nbsp;6, 2018 with an exercise price of $17.52, which includes 15,000 stock options for being a member of the Scientific Committee. As of December&nbsp;31, 2018, an aggregate of 87,500 stock options
that had been granted to Dr.&nbsp;Harrigan were outstanding </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Fees Earned or Paid in Cash&#148; includes Annual Retainer of $50,000, Additional Retainer for Audit
Member <FONT STYLE="white-space:nowrap">(non-Chair)</FONT> of $10,000, Additional Retainer for Nominating and Corporate Governance Chair of $10,000. &#147;Option Awards&#148; includes the fair value of 30,000 stock options granted June&nbsp;6, 2018
with an exercise price of $17.12, which includes 15,000 stock options for being a member of the Commercial Committee. As of December&nbsp;31, 2018, an aggregate of 100,000 stock options that had been granted to Mr.&nbsp;Soland were outstanding.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>RANSACTIONS</SMALL> W<SMALL>ITH</SMALL> R<SMALL>ELATED</SMALL>
P<SMALL>ERSONS</SMALL></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related-Person Transactions Policy and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The charter of the Audit Committee states that it will review, consider and approve or ratify any &#147;related-persons transactions.&#148; A
&#147;related-person transaction&#148; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which the Company and any &#147;related person&#148; are participants involving an amount
that exceeds $120,000. Transactions involving compensation for services provided to the Company as an employee, director, consultant or similar capacity by a related person are not covered. A related person is any executive officer, director, or
more than 5% stockholder of the Company, including any of their immediate family members, and any entity owned or controlled by such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where a transaction has been identified as a related-person transaction, management must present information regarding the proposed
related-person transaction to the Audit Committee (or, where Audit Committee approval would be inappropriate, to another independent body of the Board) for consideration and approval or ratification. The presentation must include a description of,
among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to the Company of the transaction and whether any alternative transactions were available. To identify related-person transactions in
advance, the Company relies on information supplied by its executive officers and directors. In considering related-person transactions, the Audit Committee takes into account the relevant available facts and circumstances including, but not limited
to (a)&nbsp;the risks, costs and benefits to the Company, (b)&nbsp;the impact on a director&#146;s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated,
(c)&nbsp;the terms of the transaction, (d)&nbsp;the availability of other sources for comparable services or products and (e)&nbsp;the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. In the
event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval. In determining whether to approve, ratify or reject a related-person transaction, the Audit Committee will
look at, in light of known circumstances, whether the transaction is in, or is not inconsistent with, the best interests of the Company and its stockholders, as the Audit Committee determines in the good faith exercise of its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We describe below transactions and series of related transactions, since January&nbsp;1, 2018, with respect to which we were a party, will be
a party, or otherwise benefited, in which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts involved exceeded or will exceed $120,000; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a director, executive officer, beneficial owner of more than 5% of our common stock or any member of their
immediate family or any entity owned or controlled by such persons who had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Related-Person Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
bylaws provide that we will indemnify our directors and executive officers, and may indemnify other officers, employees and other agents, to the fullest extent permitted by law. Our bylaws also permit us to secure insurance on behalf of any officer,
director, employee or other agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our amended and restated bylaws permit such indemnification. We have obtained a policy of
directors&#146; and officers&#146; liability insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered, and intend to continue to enter, into indemnification agreements
with our directors and executive officers, in addition to the indemnification provided for in our bylaws. These agreements, among other things, require us to indemnify our directors and executive officers for certain expenses, including
attorneys&#146; fees, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of our directors or executive officers, or any of our subsidiaries or any
other company or enterprise to which the person provides services at our request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information regarding director independence is included under &#147;<I>Proposal 1&#151;Election of Directors</I>&#148; above and is
incorporated by reference herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>H<SMALL>OUSEHOLDING</SMALL> <SMALL>OF</SMALL> P<SMALL>ROXY</SMALL>
M<SMALL>ATERIALS</SMALL></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery
requirements for Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single set of Annual Meeting materials addressed to those stockholders. This process, which is commonly referred to as
&#147;householding&#148;, potentially means extra convenience for stockholders and cost savings for companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This year, a number of
brokers with account holders who are stockholders of ACADIA Pharmaceuticals Inc. will be householding our Annual Meeting materials. A single set of Annual Meeting materials will be delivered to multiple stockholders sharing an address unless
contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be householding communications to your address, householding will continue until you are notified otherwise or
until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate set of Annual Meeting materials, please notify your broker or ACADIA Pharmaceuticals Inc. Direct your written
request to ACADIA Pharmaceuticals Inc., 3611 Valley Centre Drive, Suite 300, San Diego, California 92130, Attn: Investor Relations, or contact Investor Relations at (858) <FONT STYLE="white-space:nowrap">558-2871</FONT> and we will undertake to
promptly deliver a separate copy of the Annual Meeting materials to you. Stockholders who currently receive multiple copies of the Annual Meeting materials at their addresses and would like to request householding of their communications should
contact their brokers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>THER</SMALL> M<SMALL>ATTERS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors knows of no other matters that will be presented for consideration at the 2019 Annual Meeting of Stockholders. If any
other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying form of proxy to vote on such matters in accordance with their best judgment. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By Order of the Board of Directors</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g664711g16y78.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin D. Kim</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Vice President, General Counsel</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>and Secretary</I></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">San Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A COPY OF
OUR ANNUAL REPORT TO THE SECURITIES AND EXCHANGE COMMISSION ON FORM <FONT STYLE="white-space:nowrap">10-K</FONT> FOR THE FISCAL YEAR ENDED DECEMBER&nbsp;31, 2018 IS AVAILABLE WITHOUT CHARGE UPON WRITTEN REQUEST TO: SECRETARY, ACADIA PHARMACEUTICALS
INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO, CA 92130. WE WILL FURNISH A COPY OF ANY EXHIBIT TO SUCH REPORT UPON WRITTEN REQUEST AND PAYMENT OF REASONABLE EXPENSES IN FURNISHING SUCH EXHIBIT. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69. </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Appendix A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA P<SMALL>HARMACEUTICALS</SMALL> I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2010 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
M<SMALL>ARCH</SMALL>&nbsp;12, 2010 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>:
J<SMALL>UNE</SMALL>&nbsp;11, 2010 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL>
D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL>&nbsp;17, 2013 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL>
S<SMALL>TOCKHOLDERS</SMALL>: J<SMALL>UNE</SMALL>&nbsp;7, 2013 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL>
B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL>&nbsp;17, 2015 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL>
<SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: J<SMALL>UNE</SMALL>&nbsp;15, 2015 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL>
<SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL>&nbsp;29, 2016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: J<SMALL>UNE</SMALL>&nbsp;10, 2016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
A<SMALL>PRIL</SMALL>&nbsp;19, 2017 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>:
J<SMALL>UNE</SMALL>&nbsp;13, 2017 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL>
D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL>&nbsp;30, 2018 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL>
S<SMALL>TOCKHOLDERS</SMALL>: J<SMALL>UNE</SMALL>&nbsp;6, 2018 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL>
B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL>&nbsp;27, 2019 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL>
<SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: [J<SMALL>UNE</SMALL>] [</B><FONT STYLE="font-family:SYMBOL; font-size:10pt" COLOR="#000000">&#183;</FONT><FONT STYLE="font-family:Times New Roman"><B></B><B>], 2019 </B></FONT></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>G<SMALL>ENERAL</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Successor to and Continuation of Prior Plan</B>. The Plan is intended as the successor to and continuation of the ACADIA
Pharmaceuticals Inc. 2004 Equity Incentive Plan, as amended (the &#147;<B><I>Prior Plan</I></B>&#148;). Following the Effective Date, no additional stock awards shall be granted under the Prior Plan. Any shares remaining available for grant as new
awards under the Prior Plan as of the Effective Date (the &#147;<B><I>Prior Plan&#146;s Available Reserve</I></B>&#148;) shall become available for issuance pursuant to Stock Awards granted hereunder. From and after the Effective Date, all
outstanding stock awards granted under the Prior Plan shall remain subject to the terms of the Prior Plan; provided, however, any shares underlying outstanding stock awards granted under the Prior Plan that expire or terminate for any reason prior
to exercise or settlement or are forfeited because of the failure to meet a contingency or condition required to vest such shares (the &#147;<B><I>Returning Shares</I></B>&#148;) shall become available for issuance pursuant to Awards granted
hereunder. All Awards granted on or after the Effective Date of this Plan shall be subject to the terms of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
<B>Eligible Award Recipients</B>. The persons eligible to receive Awards are Employees, Directors and Consultants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B>Available Awards</B>. The Plan provides for the grant of the following Awards: (i)&nbsp;Incentive Stock Options, (ii)&nbsp;Nonstatutory Stock Options, (iii)&nbsp;Stock Appreciation Rights (iv)&nbsp;Restricted Stock Awards, (v)&nbsp;Restricted
Stock Unit Awards, (vi)&nbsp;Performance Stock Awards, and (vii)&nbsp;Other Stock Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Purpose</B>. The Company, by
means of the Plan, seeks to secure and retain the services of the group of persons eligible to receive Awards as set forth in Section&nbsp;1(b), to provide incentives for such persons to exert maximum efforts for the success of the Company and any
Affiliate and to provide a means by which such eligible recipients may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>A<SMALL>DMINISTRATION</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Administration by Board</B>. The Board shall administer the Plan unless and until the Board delegates administration of the Plan
to a Committee or Committees, as provided in Section&nbsp;2(c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Powers of Board</B>. The Board shall have the power, subject to, and within
the limitations of, the express provisions of the Plan: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine from time to time (A)&nbsp;which of the persons eligible
under the Plan shall be granted Awards; (B)&nbsp;when and how each Award shall be granted; (C)&nbsp;what type or combination of types of Award shall be granted; (D)&nbsp;the provisions of each Award granted (which need not be identical), including
the time or times when a person shall be permitted to receive cash or Common Stock pursuant to a Stock Award; (E)&nbsp;the number of shares of Common Stock with respect to which a Stock Award shall be granted to each such person; and (F)&nbsp;the
Fair Market Value applicable to a Stock Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> To construe and interpret the Plan and Awards granted under it, and to
establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it shall
deem necessary or expedient to make the Plan or Award fully effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To settle all controversies regarding the Plan and
Awards granted under it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> To accelerate the time at which an Award may first be exercised or the time during which an Award or
any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Award stating the time at which it may first be exercised or the time during which it will vest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> To suspend or terminate the Plan at any time. Suspension or termination of the Plan shall not impair rights and obligations under
any Award granted while the Plan is in effect except with the written consent of the affected Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> To amend the Plan
in any respect the Board deems necessary or advisable. However, except as provided in Section&nbsp;9(a) relating to Capitalization Adjustments, to the extent required by applicable law or listing requirements, stockholder approval shall be required
for any amendment of the Plan that either (A)&nbsp;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&nbsp;materially expands the class of individuals eligible to receive Awards under the Plan,
(C)&nbsp;materially increases the benefits accruing to Participants under the Plan or materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, or (D)&nbsp;expands the types of Awards available for
issuance under the Plan. Except as provided above, rights under any Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan unless (1)&nbsp;the Company requests the consent of the affected Participant, and
(2)&nbsp;such Participant consents in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> To submit any amendment to the Plan for stockholder approval, including, but
not limited to, amendments to the Plan intended to satisfy the requirements of (A)&nbsp;Section 422 of the Code regarding incentive stock options or (B)&nbsp;Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not
limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided, however, that except with
respect to amendments that disqualify or impair the status of an Incentive Stock Option, a Participant&#146;s rights under any Award shall not be impaired by any such amendment unless (A)&nbsp;the Company requests the consent of the affected
Participant, and (B)&nbsp;such Participant consents in writing. Notwithstanding the foregoing, subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant&#146;s
consent if necessary to maintain the qualified status of the Award as an Incentive Stock Option or to bring the Award into compliance with Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ix)</B> Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best
interests of the Company and that are not in conflict with the provisions of the Plan or Awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> To adopt such procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as
are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Delegation to Committee</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>General</I></B>. The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If
administration of the Plan is delegated to a Committee, the Committee shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board shall thereafter be to the Committee or subcommittee), subject, however, to such
resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee. The
Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> Compliance</I></B>. A Committee may consist solely of two or more <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors, in accordance with Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Delegation to an Officer</B>. The Board may delegate to one or more Officers of the Company the authority to do one or both of
the following (i)&nbsp;designate Officers and Employees of the Company or any of its Subsidiaries to be recipients of Stock Awards and (ii)&nbsp;determine the number of shares of Common Stock to be subject to such Stock Awards granted to such
Officers and Employees of the Company; provided, however, that the Board resolutions regarding such delegation shall specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such
Officer may not grant a Stock Award to himself or herself. Notwithstanding anything to the contrary in this Section&nbsp;2(d), the Board may not delegate to an Officer authority to determine the Fair Market Value of the Common Stock pursuant to
Section&nbsp;13(w)(ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) Effect of Board&#146;s Decision</B>. All determinations, interpretations and constructions made by the
Board in good faith shall not be subject to review by any person and shall be final, binding and conclusive on all persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>
<B>Repricing; Cancellation and <FONT STYLE="white-space:nowrap">Re-Grant</FONT> of Stock Awards</B>. Neither the Board nor any Committee shall have the authority to: (i)&nbsp;reduce the exercise price of any outstanding Options or Stock Appreciation
Rights under the Plan, or (ii)&nbsp;cancel any outstanding Options or Stock Appreciation Rights that have an exercise price or strike price greater than the current Fair Market Value of the Common Stock in exchange for cash or other Stock Awards
under the Plan, unless the stockholders of the Company have approved such an action within 12 months prior to such an event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>
<B>Minimum Vesting Requirements.</B> Except as provided in Section&nbsp;9 (and (excluding, for this purpose, any (i)&nbsp;substitute awards, and (ii)&nbsp;awards to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors that vest on the
earlier of the one year anniversary of the date of grant or the next annual meeting of stockholders which&nbsp;is at least 50 weeks after the immediately preceding year&#146;s annual meeting), no Stock Award granted on or after June&nbsp;13, 2017
may vest (or, if applicable, be exercisable) until at least twelve (12)&nbsp;months following the date of grant of the Stock Award; <I>provided, however</I>, that up to 5% of the Share Reserve (as defined in Section&nbsp;3(a)(i)) may be subject to
Stock Awards granted on or after June&nbsp;13, 2017 that do not meet such vesting (and, if applicable, exercisability) requirements and, <I>provided further</I>, for the avoidance of doubt, that the foregoing restriction does not apply to the
Board&#146;s discretion to provide for accelerated exercisability or vesting of any Award, including in cases of retirement, death, disability or a change in control, in the terms of the Award or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Dividends and Dividend Equivalents.</B> Dividends or dividend equivalents may be paid or credited, as applicable, with respect
to any shares of Common Stock subject to an Award, as determined by the Board and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contained in the applicable Award Agreement; <I>provided, however</I>, that (i)&nbsp;no dividends or dividend equivalents may be paid with respect to any such shares before the date such shares
have vested under the terms of such Award Agreement, (ii)&nbsp;any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of
such Award Agreement (including, but not limited to, any vesting conditions), (iii) any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to the Company on the date, if any, such shares are
forfeited to or repurchased by the Company due to a failure to meet any vesting conditions under the terms of such Award Agreement and (iv)&nbsp;in no event shall dividends or dividend equivalents be paid or credited with respect to an Appreciation
Award. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Share Reserve</B>. Subject to Section&nbsp;9(a) relating to Capitalization Adjustments, the aggregate
number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date shall not exceed 44,314,234 shares (the &#147;<B><I>Share Reserve</I></B>&#148;), which number is the sum of (i)&nbsp;the number of shares
subject to the Prior Plan&#146;s Available Reserve, (ii)&nbsp;an additional 3,250,000 shares approved by the Board in March 2010 and subsequently approved by the Company&#146;s stockholders, (iii)&nbsp;an additional 7,500,000 shares approved by the
Board in April 2013 and subsequently approved by the Company&#146;s stockholders, (iv)&nbsp;an additional 5,000,000 shares approved by the Board in April 2015 and subsequently approved by the Company&#146;s stockholders, (v)&nbsp;an additional
3,000,000 shares approved by the Board in April 2016 and subsequently approved by the Company&#146;s stockholders, (vi)&nbsp;an additional 5,500,000 shares approved by the Board in April 2017 and subsequently approved by the Company&#146;s
stockholders, (vii)&nbsp;an additional 6,700,000 shares approved by the Board in April 2018 and subsequently approved by the Company&#146;s stockholders, (viii)&nbsp;an additional 8,300,000 shares approved by the Board in April 2019 and subsequently
approved by the Company&#146;s stockholders, plus (ix)&nbsp;an additional number of shares in an amount not to exceed 4,261,425 shares (which number consists of the Returning Shares, if any, as such shares become available from time to time). For
clarity, the Share Reserve in this Section&nbsp;3(a) is a limitation on the number of shares of the Common Stock that may be issued pursuant to the Plan and does not limit the granting of Stock Awards except as provided in Section&nbsp;7(a). Shares
may be issued in connection with a merger or acquisition as permitted by NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section&nbsp;303A.08, AMEX Company Guide Section&nbsp;711 or other applicable rule, and such issuance
shall not reduce the number of shares available for issuance under the Plan. Furthermore, if a Stock Award or any portion thereof (i)&nbsp;expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or
(ii)&nbsp;is settled in cash (i.e., the Participant receives cash rather than stock), such expiration, termination or settlement shall not reduce (or otherwise offset) the number of shares of Common Stock that may be available for issuance under the
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Subject to Section&nbsp;3(c), the number of shares available for issuance under the Plan shall be reduced by:
(i)&nbsp;one share for each share of stock issued pursuant to an Appreciation Award; (ii) 1.36 shares for each share of Common Stock issued pursuant to a Full Value Award granted before June&nbsp;6, 2018; (iii) 1.47 shares for each share of Common
Stock issued pursuant to a Full Value Award granted on or after June&nbsp;6, 2018 but before June&nbsp;26, 2019; and (iv) 1.42 shares for each share of Common Stock issued pursuant to a Full Value Award granted on or after June&nbsp;26, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Reversion of Shares to the Share Reserve</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Shares Available for Subsequent Issuance</I></B>. If any shares of common stock issued pursuant to a Stock Award are
forfeited back to the Company because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited shall revert to and again become available for issuance under the Plan. To
the extent (A)&nbsp;there is issued a share of Common Stock pursuant to a Full Value Award , or (B)&nbsp;any Returning Shares granted under the Plan pursuant to an award other than an option or stock appreciation right, and, pursuant to
Section&nbsp;1(a), Section&nbsp;3(a) or this Section&nbsp;3(c)(i), such share of Common Stock becomes available for issuance under the Plan (x)&nbsp;on or after June&nbsp;15, 2015, but prior to June&nbsp;6,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2018, then the number of shares of Common Stock available for issuance under the Plan shall increase by 1.36 shares, (y)&nbsp;on or after June&nbsp;6, 2018, but prior to June&nbsp;26, 2019, then
the number of shares of Common Stock available for issuance under the Plan shall increase by 1.47 shares and (y) on or after June&nbsp;26, 2019, then the number of shares of Common Stock available for issuance shall increase by 1.42 shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B><I>Shares Not Available for Subsequent Issuance</I></B>. If any shares subject to a Stock Award are not delivered to a
Participant because the Stock Award is exercised through a reduction of shares subject to the Stock Award (i.e., &#147;<B><I>net exercised</I></B>&#148;), the number of shares that are not delivered to the Participant shall no longer be available
for issuance under the Plan. Also, any shares subject to a Stock Award reacquired by the Company pursuant to Section&nbsp;8(g) and any shares reacquired by the Company as consideration for the exercise of an Option or Stock Appreciation Right shall
no longer be available for issuance under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Incentive Stock Option Limit</B>. Notwithstanding anything to the
contrary in this Section&nbsp;3 and, subject to the provisions of Section&nbsp;9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options
shall be 28,000,000 shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Aggregate
Compensation Limit. </B>The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director with respect to any period commencing on the date of the
Company&#146;s Annual Meeting of Stockholders for a particular year and ending on the day immediately prior to the date of the Company&#146;s Annual Meeting of Stockholders for the next subsequent year, including Awards granted and cash fees paid by
the Company to such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, will not exceed (i) $1,500,000 in total value or (ii)&nbsp;in the event such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director is first appointed or
elected to the Board during such period, $2,000,000 in total value, in each case calculating the value of any Awards based on the grant date fair value of such Awards for financial reporting purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Source of Shares</B>. The stock issuable under the Plan shall be shares of authorized but unissued or reacquired Common Stock,
including shares repurchased by the Company on the open market or otherwise. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>LIGIBILITY</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Eligibility for Specific Stock Awards</B>. Incentive Stock Options may be granted only to employees of the Company or a
&#147;<B><I>parent corporation</I></B>&#148; or &#147;<B><I>subsidiary corporation</I></B>&#148; thereof (as such terms are defined in Sections 424(e) and (f)&nbsp;of the Code). Stock Awards other than Incentive Stock Options may be granted to
Employees, Directors and Consultants; provided, however, Nonstatutory Stock Options and SARs may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#147;<B><I>parent</I></B>&#148; of the Company,
as such term is defined in Rule 405 promulgated under the Securities Act, unless the stock underlying such Stock Awards is treated as &#147;<B><I>service recipient stock</I></B>&#148; under Section&nbsp;409A of the Code because the Stock Awards are
granted pursuant to a corporate transaction (such as a spin off transaction) or unless such Stock Awards comply with the distribution requirements of Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Ten Percent Stockholders</B>. A Ten Percent Stockholder shall not be granted an Incentive Stock Option unless the exercise price
of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>P<SMALL>ROVISIONS</SMALL> R<SMALL>ELATING</SMALL> <SMALL>TO</SMALL> O<SMALL>PTIONS</SMALL>
<SMALL>AND</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Option or SAR shall
be in such form and shall contain such terms and conditions as the Board shall deem appropriate. All Options shall be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued,
a separate certificate or certificates shall be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, then the Option shall be a Nonstatutory Stock
Option. The provisions of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
separate Options or SARs need not be identical; provided, however, that each Option Agreement or Stock Appreciation Right Agreement shall conform to (through incorporation of provisions hereof by
reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Term</B>.
Subject to the provisions of Section&nbsp;4(b) regarding Ten Percent Stockholders, no Option or SAR shall be exercisable after the expiration of 10 years from the date of its grant or such shorter period specified in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Exercise Price</B>. Subject to the provisions of Section&nbsp;4(b) regarding Ten Percent Stockholders, the exercise price (or
strike price) of each Option or SAR shall be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Option or SAR is granted. Notwithstanding the foregoing, an Option or SAR may be granted with
an exercise price (or strike price) lower than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR if such Option or SAR is granted pursuant to an assumption of or substitution for another option or stock appreciation
right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of the Code. Each SAR will be denominated in shares of Common Stock equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Purchase Price for Options</B>. The purchase price of Common Stock acquired pursuant to the exercise of an Option shall be paid,
to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board shall have the authority to grant Options that do not permit all of the
following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The permitted methods of payment are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> by cash, check, bank draft or money order payable to the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the
stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> if the option is a Nonstatutory Stock Option, by a &#147;<B><I>net exercise</I></B>&#148; arrangement pursuant to which the
Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; provided, however, that the Company shall accept a cash
or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued; provided further, that shares of Common Stock will no longer be
subject to an Option and will not be exercisable thereafter to the extent that (A)&nbsp;shares issuable upon exercise are reduced to pay the exercise price pursuant to the &#147;net exercise,&#148; (B)&nbsp;shares are delivered to the Participant as
a result of such exercise, and (C)&nbsp;shares are withheld to satisfy tax withholding obligations; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> in any other form of
legal consideration that may be acceptable to the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Exercise and Payment of a SAR</B>. To exercise any outstanding
Stock Appreciation Right, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such Stock Appreciation Right. The appreciation distribution
payable on the exercise of a Stock Appreciation Right will be not greater than an amount equal to the excess of (A)&nbsp;the aggregate Fair Market Value (on the date of the exercise of the Stock Appreciation Right) of a number of shares of Common
Stock equal to the number of Common Stock equivalents in which the Participant is vested under such Stock Appreciation Right, and with respect to which the Participant is exercising the Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Appreciation Right on such date, over (B)&nbsp;the strike price that will be determined by the Board at the time of grant of the Stock Appreciation Right. The appreciation distribution in respect
to a Stock Appreciation Right may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Stock Appreciation Right Agreement evidencing such Stock
Appreciation Right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Transferability of Options and SARs</B>. The Board may, in its sole discretion, impose such limitations
on the transferability of Options and SARs as the Board shall determine. In the absence of such a determination by the Board to the contrary, the restrictions set forth in this Section&nbsp;5(e) on the transferability of Options and SARs shall apply
will apply. Notwithstanding the foregoing or anything in the Plan or a Stock Award Agreement to the contrary, no Option or SAR may be transferred to any financial institution without prior stockholder approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Restrictions on Transfer</I></B>. An Option or SAR shall not be transferable except by will or by the laws of descent and
distribution and shall be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may, in its sole discretion, permit transfer of the Option or SAR in a manner that is not prohibited by
applicable tax and securities laws upon the Participant&#146;s request. Except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B><I>Domestic Relations Orders</I></B>. Notwithstanding the foregoing, an Option or SAR may be transferred pursuant to a domestic
relations order; provided, however, that if an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B><I>Beneficiary Designation</I></B>. Notwithstanding the foregoing, the Participant may, by delivering written notice to the
Company, in a form provided by or otherwise satisfactory to the Company and any broker designated by the Company to effect Option exercises, designate a third party who, in the event of the death of the Participant, shall thereafter be entitled to
exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, the executor or administrator of the Participant&#146;s estate shall be entitled to exercise the
Option or SAR and receive the Common Stock or other consideration resulting from such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Vesting Generally</B>.
Subject to Section&nbsp;2(g), the total number of shares of Common Stock subject to an Option or SAR may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other
terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may
vary. The provisions of this Section&nbsp;5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Termination of Continuous Service</B>. Except as otherwise provided in the applicable Award Agreement or other agreement between
the Participant and the Company, if a Participant&#146;s Continuous Service terminates (other than for Cause or upon the Participant&#146;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the
Participant was entitled to exercise such Award as of the date of termination of Continuous Service) but only within such period of time ending on the earlier of (i)&nbsp;the date 3 months following the termination of the Participant&#146;s
Continuous Service (or such longer or shorter period specified in the applicable Award Agreement), or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the
Participant does not exercise his or her Option or SAR within the time specified herein or in the Award Agreement (as applicable), the Option or SAR shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Extension of Termination Date</B>. If the exercise of an Option or SAR following the termination of the Participant&#146;s
Continuous Service (other than for Cause or upon the Participant&#146;s death or Disability) would be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR shall terminate on the
earlier of (i)&nbsp;the expiration of a total period of 3 months (that need not be consecutive) after the termination of the Participant&#146;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such
registration requirements, or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement. In addition, unless otherwise provided in a Participant&#146;s Award Agreement, if the sale of any Common Stock
received upon exercise of an Option or SAR following the termination of the Participant&#146;s Continuous Service (other than for Cause) would violate the Company&#146;s insider trading policy, then the Option or SAR shall terminate on the earlier
of (i)&nbsp;the expiration of a period equal to the applicable post-termination exercise period after the termination of the Participant&#146;s Continuous Service during which the Sale of any Common Stock issuable upon exercise of the Option or SAR
would not be in violation of the Company&#146;s insider trading policy, or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Disability of Participant</B>. Except as otherwise provided in the applicable Award Agreement or other agreement between the
Participant and the Company, if a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise
such Option or SAR as of such date of termination of Continuous Service), but only within such period of time ending on the earlier of (i)&nbsp;the date 12 months following such termination of Continuous Service (or such longer or shorter period
specified in the Award Agreement), or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the
time specified herein or in the Award Agreement (as applicable), the Option or SAR (as applicable) shall terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B>Death
of Participant</B>. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if (i)&nbsp;a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s
death, or (ii)&nbsp;the Participant dies within the period, if any, specified in the Award Agreement for exercisability after the termination of the Participant&#146;s Continuous Service (for a reason other than death), then the Option or SAR may be
exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#146;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person
designated to exercise the Option or SAR upon the Participant&#146;s death, but only within the period ending on the earlier of (i)&nbsp;the date 18 months following the date of death (or such longer or shorter period specified in the Award
Agreement), or (ii)&nbsp;the expiration of the term of such Option or SAR as set forth in the Award Agreement. If, after the Participant&#146;s death, the Option or SAR is not exercised within the time specified herein or in the Award Agreement (as
applicable), the Option or SAR shall terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B>Termination for Cause</B>. Except as explicitly provided otherwise in a
Participant&#146;s Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant&#146;s Continuous Service is terminated for Cause, the Option or SAR shall terminate immediately upon
such Participant&#146;s termination of Continuous Service, and the Participant shall be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees</B>. No Option or SAR, whether or not vested, granted to an
Employee who is a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee for purposes of the Fair Labor Standards Act of 1938, as amended, shall be first exercisable for any shares of Common Stock until at least six months following the date of
grant of the Option or SAR. Notwithstanding the foregoing, consistent with the provisions of the Worker Economic Opportunity Act, (i)&nbsp;in the event of the Participant&#146;s death or Disability, (ii)&nbsp;upon a Corporate Transaction in which
such Option or SAR is not assumed, continued, or substituted, (iii)&nbsp;upon a Change in Control, or (iv)&nbsp;upon the Participant&#146;s retirement (as such term may be defined in the Participant&#146;s Award Agreement or in another applicable
agreement or in accordance with the Company&#146;s then current employment policies and guidelines), any such vested Options and SARs may be exercised earlier than six months following the date of grant. The foregoing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provision is intended to operate so that any income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise or vesting of an Option or SAR will be
exempt from his or her regular rate of pay. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>P<SMALL>ROVISIONS</SMALL> <SMALL>OF</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>WARDS</SMALL> O<SMALL>THER</SMALL>
T<SMALL>HAN</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> SARS. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Restricted Stock Awards</B>. Each
Restricted Stock Award Agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. To the extent consistent with the Company&#146;s Bylaws, at the Board&#146;s election, shares of Common Stock may
be (i)&nbsp;held in book entry form subject to the Company&#146;s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii)&nbsp;evidenced by a certificate, which certificate shall be held in such form and manner as
determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical; provided, however, that each
Restricted Stock Award Agreement shall conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Consideration</I></B>. A Restricted Stock Award may be awarded in consideration for (A)&nbsp;cash, check, bank draft or money
order payable to the Company, (B)&nbsp;past services to the Company or an Affiliate, or (C)&nbsp;any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under
applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B><I>Vesting</I></B>. Subject to Section&nbsp;2(g), shares of Common Stock awarded under the Restricted
Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B><I>Termination of Participant&#146;s Continuous Service</I></B>. If a Participant&#146;s Continuous Service terminates, the
Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant that have not vested as of the date of termination of Continuous Service under the terms of the Restricted
Stock Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B><I>Transferability</I></B>. Rights to acquire shares of Common Stock under the Restricted Stock
Award Agreement shall be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board shall determine in its sole discretion, so long as Common Stock awarded under the
Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement. Notwithstanding the foregoing or anything in the Plan or a Restricted Stock Award Agreement to the contrary, no Restricted Stock Award may be
transferred to any financial institution without prior stockholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Restricted Stock Unit Awards</B>. Each
Restricted Stock Unit Award Agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the
terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical; provided, however, that each Restricted Stock Unit Award Agreement shall conform to (through incorporation of the provisions hereof by reference in the
Agreement or otherwise) the substance of each of the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Consideration</I></B>. At the time of grant
of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid, if any, by the
Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B><I>Vesting</I></B>. Subject to Section&nbsp;2(g), at the time of the grant of a Restricted Stock Unit Award, the Board may
impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B><I>Payment</I></B>. A Restricted Stock Unit Award may be settled by the
delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B><I>Additional Restrictions</I></B>. At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems
appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B><I>Termination of Participant&#146;s Continuous Service</I></B>. Except as otherwise provided in the applicable Restricted Stock
Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#146;s termination of Continuous Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Performance Awards</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Performance Stock Awards</I></B>. A Performance Stock Award is a Stock Award that may vest or be exercised contingent upon
the attainment during a Performance Period of certain Performance Goals. A Performance Stock Award may, but need not, require the completion of a specified period of Continuous Service. Subject to Section&nbsp;2(g), the length of any Performance
Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained shall be conclusively determined by the Committee, in its sole discretion. The Board
may provide for or, subject to such terms and conditions as the Board may specify, may permit a Participant to elect for, the payment of any Performance Stock Award to be deferred to a specified date or event. In addition, to the extent permitted by
applicable law and the applicable Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B><I>Discretion</I></B>. The Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon
the attainment of any Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a Performance Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Other Stock Awards</B>. Subject to Sections 2(g) and 2(h), other forms of Stock Awards valued in whole or in part by reference
to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be
granted either alone or in addition to Stock Awards provided for under Section&nbsp;5 and the preceding provisions of this Section&nbsp;6. Subject to the provisions of the Plan, the Board shall have sole and complete authority to determine the
persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of
such Other Stock Awards. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Availability of Shares</B>. During the terms of the Stock Awards, the Company shall keep available at
all times the number of shares of Common Stock reasonably required to satisfy such Stock Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Securities Law
Compliance</B>. The Company shall seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the
Stock Awards; provided, however, that this undertaking shall not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable
efforts, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company shall be relieved from any
liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such authority is obtained. A Participant shall not be eligible for the grant of a Stock Award or the subsequent issuance of Common Stock pursuant to the Stock Award if such grant or issuance
would be in violation of any applicable securities law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>No Obligation to Notify or Minimize Taxes</B>. The Company shall
have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the Company shall have no duty or obligation to warn or otherwise advise such holder of a pending termination
or expiration of a Stock Award or a possible period in which the Stock Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>M<SMALL>ISCELLANEOUS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Use of Proceeds from Sales of Common Stock</B>. Proceeds from the sale of shares of Common Stock pursuant to Stock Awards shall
constitute general funds of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Corporate Action Constituting Grant of Stock Awards</B>. Corporate action
constituting a grant by the Company of a Stock Award to any Participant shall be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing
the Stock Award is communicated to, or actually received or accepted by, the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Stockholder Rights</B>. No
Participant shall be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Stock Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise
of the Stock Award pursuant to its terms, if applicable, and (ii)&nbsp;the issuance of the Common Stock subject to such Stock Award has been entered into the books and records of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>No Employment or Other Service Rights</B>. Nothing in the Plan, any Stock Award Agreement or any other instrument executed
thereunder or in connection with any Award granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or shall affect the
right of the Company or an Affiliate to terminate (i)&nbsp;the employment of an Employee with or without notice and with or without cause, (ii)&nbsp;the service of a Consultant pursuant to the terms of such Consultant&#146;s agreement with the
Company or an Affiliate, or (iii)&nbsp;the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the
case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Incentive Stock Option $100,000 Limitation</B>. To the extent that the aggregate Fair Market Value (determined
at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000, the Options or
portions thereof that exceed such limit (according to the order in which they were granted) shall be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Investment Assurances</B>. The Company may require a Participant, as a condition of exercising or acquiring Common Stock under
any Stock Award, (i)&nbsp;to give written assurances satisfactory to the Company as to the Participant&#146;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the
Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii)&nbsp;to
give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant&#146;s own account and not with any present intention of selling or otherwise distributing the
Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, shall be inoperative if (A)&nbsp;the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registered under a then currently effective registration statement under the Securities Act, or (B)&nbsp;as to any particular requirement, a determination is made by counsel for the Company that
such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or
appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Withholding Obligations</B>. Unless prohibited by the terms of a Stock Award Agreement, the Company may, in its sole discretion,
satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i)&nbsp;causing the Participant to tender a cash payment; (ii)&nbsp;withholding shares of Common
Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; provided, however, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be
withheld by law (or such lesser amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii)&nbsp;withholding cash from an Award settled in cash; (iv)&nbsp;withholding payment from
any amounts otherwise payable to the Participant; or (v)&nbsp;by such other method as may be set forth in the Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>
<B>Electronic Delivery</B>. Any reference herein to a &#147;<B><I>written</I></B>&#148; agreement or document shall include any agreement or document delivered electronically or posted on the Company&#146;s intranet (or other shared electronic
medium controlled by the Company to which the Participant has access). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Deferrals</B>. To the extent permitted by applicable
law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for
deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section&nbsp;409A of the Code. Consistent with Section&nbsp;409A of the Code, the Board may provide for distributions while a Participant is
still an employee or otherwise providing services to the Company. The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the
Participant&#146;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B>Compliance With Section</B><B></B><B>&nbsp;409A</B>. To the extent that the Board determines that any Award granted hereunder is
subject to Section&nbsp;409A of the Code, the Award Agreement evidencing such Award shall incorporate the terms and conditions necessary to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code. To the extent applicable, the Plan
and Award Agreements shall be interpreted in accordance with Section&nbsp;409A of the Code. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the Shares are publicly traded and
a Participant holding an Award that constitutes &#147;<B><I>deferred compensation</I></B>&#148; under Section&nbsp;409A of the Code is a &#147;<B><I>specified employee</I></B>&#148; for purposes of Section&nbsp;409A of the Code, to the extent
necessary to avoid the imposition of taxes under Section&nbsp;409A of the Code, no distribution or payment of any amount shall be made upon a &#147;<B><I>separation from service</I></B>&#148; before a date that is six months following the date of
such Participant&#146;s &#147;<B><I>separation from service</I></B>&#148; (as defined in Section&nbsp;409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant&#146;s death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B>Clawback/Recovery. </B>All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy
that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#146;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and
Consumer Protection Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a
reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of an event related to a Participant that would be categorized as Cause. No recovery of compensation under such a clawback
policy will be an event giving rise to a right to voluntary terminate employment upon a &#147;resignation for good reason,&#148; or for a &#147;constructive termination&#148; or any similar term under any plan of or agreement with the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DJUSTMENTS</SMALL> U<SMALL>PON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL>
C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; O<SMALL>THER</SMALL> C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Capitalization Adjustments</B>. In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately
adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a), (ii)&nbsp;the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options
pursuant to Section&nbsp;3(d), (iii)&nbsp;the class(es) and maximum number of securities that may be awarded to any person pursuant to Sections 3(e) and 6(c)(i) , and (iv)&nbsp;the class(es) and number of securities and price per share of stock
subject to outstanding Stock Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Dissolution or Liquidation</B>. Except as otherwise provided in the Stock Award Agreement, in the event of a dissolution or
liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#146;s right of repurchase) shall terminate
immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#146;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company
notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, provided, however, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject
to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Corporate Transaction</B>. The following provisions shall apply to Stock Awards in the event of a Corporate Transaction unless
otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of a Stock Award. In the
event of a Corporate Transaction, then, notwithstanding any other provision of the Plan, the Board shall take one or more of the following actions with respect to Stock Awards, contingent upon the closing or completion of the Corporate Transaction:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent
company) to assume or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an award to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate
Transaction); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> arrange for the assignment of any reacquisition or repurchase rights held by the Company in respect of Common
Stock issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent company); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> accelerate the vesting of the Stock Award (and, if applicable, the time at which the Stock Award may be exercised) to a date
prior to the effective time of such Corporate Transaction as the Board shall determine (or, if the Board shall not determine such a date, to the date that is 5 days prior to the effective date of the Corporate Transaction), with such Stock Award
terminating if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> arrange for the
lapse of any reacquisition or repurchase rights held by the Company with respect to the Stock Award; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> cancel or arrange for the
cancellation of the Stock Award, to the extent not vested or not exercised prior to the effective time of the Corporate Transaction, in exchange for such cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; or
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> make a payment, in such form as may be determined by the Board equal to the excess, if any, of (A)&nbsp;the value of the
property the Participant would have received upon the exercise of the Stock Award, over (B)&nbsp;any exercise price payable by such holder in connection with such exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board need not take the same action or actions with respect to all Stock Awards or
portions thereof or with respect to all Participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Change in Control</B>. A Stock Award may be subject to additional
acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the
Participant, but in the absence of such provision, no such acceleration shall occur. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
P<SMALL>LAN</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Plan Term</B>. The Board may suspend or terminate the Plan at any time. No
Incentive Stock Option will be granted after the 10th anniversary of the earlier of (i)&nbsp;the date the Plan, as most recently amended is adopted by the Board, or (ii)&nbsp;the date the Plan, as most recently amended is approved by the
stockholders of the Company. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
<B>No Impairment of Rights</B>. Suspension or termination of the Plan shall not impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan became effective on the Effective Date. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>C<SMALL>HOICE</SMALL> <SMALL>OF</SMALL> L<SMALL>AW</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of the State of California shall govern all questions concerning the construction, validity and interpretation of this Plan, without
regard to that state&#146;s conflict of laws rules. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>EFINITIONS</SMALL></B><SMALL></SMALL>. As used in the Plan, the following definitions shall apply to
the capitalized terms indicated below: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#147;<B><I>Affiliate</I></B>&#148; means, at the time of
determination, any &#147;<B><I>parent</I></B>&#148; or &#147;<B><I>subsidiary</I></B>&#148; of the Company as such terms are defined in Rule 405 of the Securities Act. The Board shall have the authority to determine the time or times at which
&#147;<B><I>parent</I></B>&#148; or &#147;<B><I>subsidiary</I></B>&#148; status is determined within the foregoing definition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
&#147;<B><I>Appreciation Award</I></B>&#148; means (i)&nbsp;a stock option or stock appreciation right granted under the Prior Plan or (ii)&nbsp;an Option or Stock Appreciation Right, or Other Stock Award, in each case with respect to which the
exercise or strike price is at least one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the stock option or stock appreciation right, or Option, Stock Appreciation Right, or Other Stock Award, as applicable, on the
date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#147;<B><I>Award</I></B>&#148; means a Stock Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> &#147;<B><I>Award Agreement</I></B>&#148; means a written agreement between the Company and a Participant evidencing the terms and
conditions of an Award. Each Award Agreement shall be subject to the terms and conditions of the Plan. The term &#147;<B><I>Award Agreement</I></B>&#148; shall have the same meaning as &#147;<B><I>Stock Award Agreement</I></B>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur with respect to,
the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend,
dividend in property other than cash, large nonrecurring cash dividend, stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of
Financial Accounting Standards No.&nbsp;123 (revised). Notwithstanding the foregoing, the conversion of any convertible securities of the Company shall not be treated as a Capitalization Adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#147;<B><I>Cause</I></B>&#148; shall have the meaning ascribed to such term in any written agreement between the Participant and
the Company defining such term and, in the absence of such an agreement, such term shall mean, with respect to a Participant, the occurrence of any of the following events: (i)&nbsp;such Participant&#146;s attempted commission of, or participation
in, a fraud or act of dishonesty against the Company; (ii)&nbsp;such Participant&#146;s intentional, material violation of any contract or agreement between the Participant and the Company or of any statutory duty owed to the Company;
(iii)&nbsp;such Participant&#146;s unauthorized use or disclosure of the Company&#146;s confidential information or trade secrets; (iv)&nbsp;such Participant&#146;s gross negligence or gross misconduct; (v)&nbsp;such Participant&#146;s material
failure to competently perform his/her assigned duties for the Company; (vi)&nbsp;sustained poor performance of any material aspect of the Participant&#146;s duties or obligations; or (viii)&nbsp;Participant&#146;s conviction of, or the entry of a
pleading of guilty or nolo contendere by Participant to, any crime involving moral turpitude or any felony. The determination that a termination of the Participant&#146;s Continuous Service is either for Cause or without Cause shall be made by the
Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant shall have no effect upon any
determination of the rights or obligations of the Company or such Participant for any other purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#147;<B><I>Change in
Control</I></B>&#148; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the
combined voting power of the Company&#146;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A)&nbsp;on account of
the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#146;s securities in a transaction or series of related transactions the primary purpose of which is to
obtain financing for the Company through the issuance of equity securities or (B)&nbsp;solely because the level of Ownership held by any Exchange Act Person (the &#147;<B><I>Subject Person</I></B>&#148;) exceeds the designated percentage threshold
of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this
sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not
occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and,
immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A)&nbsp;outstanding voting securities representing more
than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B)&nbsp;more than 50% of the combined outstanding voting power of the parent of the surviving Entity in such merger,
consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a
complete dissolution or liquidation of the Company shall otherwise occur; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> there is consummated a sale, lease, exclusive and
worldwide license, or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of
which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> individuals who, on the date this Plan is adopted by the Board, are members of the Board (the &#147;<B><I>Incumbent
Board</I></B>&#148;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a
majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the term Change in Control shall not include a sale of assets,
merger or other transaction effected exclusively for the purpose of changing the domicile of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>
&#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> &#147;<B><I>Committee</I></B>&#148; means a committee of one or more Directors to whom authority has been delegated by the Board in
accordance with Section&nbsp;2(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> &#147;<B><I>Company</I></B>&#148; means ACADIA Pharmaceuticals Inc., a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#147;<B><I>Consultant</I></B>&#148; means any person, including an advisor, who is (i)&nbsp;engaged by the Company or an Affiliate
to render consulting or advisory services and is compensated for such services, or (ii)&nbsp;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a
fee for such service, shall not cause a Director to be considered a &#147;<B><I>Consultant</I></B>&#148; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form <FONT
STYLE="white-space:nowrap">S-8</FONT> Registration Statement under the Securities Act is available to register the sale of the Company&#146;s securities to such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#147;<B><I>Continuous Service</I></B>&#148; means that the Participant&#146;s service with the Company or an Affiliate, whether as
an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the
Participant renders such service, provided that there is no interruption or termination of the Participant&#146;s service with the Company or an Affiliate, shall not terminate a Participant&#146;s Continuous Service; provided, however, if the Entity
for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#146;s Continuous Service shall be considered to have terminated on the date such Entity ceases to
qualify as an Affiliate. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#146;s sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of
(i)&nbsp;any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii)&nbsp;transfers between the Company, an Affiliate, or their successors. Notwithstanding the
foregoing, a leave of absence shall be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#146;s leave of absence policy, in the written terms of any leave of absence
agreement or policy applicable to the Participant, or as otherwise required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> &#147;<B><I>Corporate
Transaction</I></B>&#148; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> a sale or other disposition of all or substantially all, as determined by the Board in its discretion, of the consolidated assets
of the Company and its Subsidiaries; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> a sale or other disposition of at least 50% of the outstanding securities of the
Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of
Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> &#147;<B><I>Director</I></B>&#148; means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#147;<B><I>Disability</I></B>&#148; means, with respect to a Participant, the inability of such Participant to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as
provided in Sections 22(e)&nbsp;(3) and 409A(a)(2)(c)(i) of the Code, and shall be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#147;<B><I>Effective Date</I></B>&#148; means June&nbsp;11, 2010, which is the date the Company&#146;s stockholders first approved
the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> &#147;<B><I>Employee</I></B>&#148; means any person employed by the Company or an Affiliate. However, service solely
as a Director, or payment of a fee for such services, shall not cause a Director to be considered an &#147;<B><I>Employee</I></B>&#148; for purposes of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> &#147;<B><I>Entity</I></B>&#148; means a corporation, partnership, limited liability company or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> &#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> &#147;<B><I>Exchange Act Person</I></B>&#148; means any natural person, Entity or &#147;group&#148;
(within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#147;Exchange Act Person&#148; shall not include (i)&nbsp;the Company or any Subsidiary of the Company, (ii)&nbsp;any employee benefit plan of the Company or any
Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding securities pursuant to a registered public
offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v)&nbsp;any natural person, Entity or
&#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of
the Company&#146;s then outstanding securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value
of the Common Stock determined as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Common Stock is listed on any established stock exchange or traded on any
established market, the Fair Market Value of a share of Common Stock shall be the closing sales price for such stock as quoted on such exchange or market on the date of determination, or the next market trading day if such date of determination is
not a market trading day, as reported in The Wall Street Journal or such other source the Board deems reliable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> In the
absence of such markets for the Common Stock, the Fair Market Value shall be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> &#147;<B><I>Full Value Award</I></B>&#148; means (i)&nbsp;a stock award granted
under the Prior Plan or (ii)&nbsp;a Stock Award, in each case, that is not an Appreciation Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> &#147;<B><I>Incentive Stock
Option</I></B>&#148; means an option granted pursuant to Section&nbsp;5 of the Plan that is intended to be, and qualifies as, an &#147;incentive stock option&#148; within the meaning of Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#148; means a Director who either (i)&nbsp;is not
a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except
for an amount as to which disclosure would not be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated pursuant to the Securities Act (&#147;<B><I>Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT></I></B>&#148;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> and is not engaged
in a business relationship for which disclosure would be required pursuant to Item 404(b) of Regulation <FONT STYLE="white-space:nowrap">S-K;</FONT> or (ii)&nbsp;is otherwise considered a
&#147;<B><I><FONT STYLE="white-space:nowrap">non-employee</FONT> director</I></B>&#148; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> &#147;<B><I>Nonstatutory Stock Option</I></B>&#148; means any option granted pursuant to Section&nbsp;5 of the Plan that does not
qualify as an Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> &#147;<B><I>Officer</I></B>&#148; means a person who is an officer of the Company
within the meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> &#147;<B><I>Option</I></B>&#148; means an Incentive Stock Option
or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> &#147;<B><I>Option
Agreement</I></B>&#148; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement shall be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> &#147;<B><I>Optionholder</I></B>&#148; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> &#147;<B><I>Other Stock Award</I></B>&#148; means an award based in whole or in
part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;6(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B>
&#147;<B><I>Other Stock Award Agreement</I></B>&#148; means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement shall be
subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> &#147;<B><I>Own,</I></B>&#148; &#147;<B><I>Owned,</I></B>&#148;
&#147;<B><I>Owner,</I></B>&#148; &#147;<B><I>Ownership</I></B>&#148; A person or Entity shall be deemed to &#147;<B><I>Own,</I></B>&#148; to have &#147;<B><I>Owned,</I></B>&#148; to be the &#147;<B><I>Owner</I></B>&#148; of, or to have acquired
&#147;<B><I>Ownership</I></B>&#148; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to
direct the voting, with respect to such securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><I>Participant</I></B>&#148; means a person to whom an Award is
granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B>
&#147;<B><I>Performance Criteria</I></B>&#148; means the one or more criteria that the Board shall select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that shall be used to establish such
Performance Goals may be based on any one of, or combination of, the following as determined by the Board: (i)&nbsp;the attainment of certain target levels of, or a specified percentage increase in, revenues, earnings, income before taxes and
extraordinary items, net income, operating income, earnings before income tax, earnings before interest, taxes, depreciation and amortization or a combination of any or all of the foregoing; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ii)&nbsp;the attainment of certain target levels of, or a percentage increase in, <FONT STYLE="white-space:nowrap">after-tax</FONT> or <FONT STYLE="white-space:nowrap">pre-tax</FONT> profits
including, without limitation, that attributable to continuing and/or other operations; (iii)&nbsp;the attainment of certain target levels of, or a specified increase in, operational cash flow; (iv)&nbsp;the achievement of a certain level of,
reduction of, or other specified objectives with regard to limiting the level of increase in, all or a portion of, the Company&#146;s bank debt or other long-term or short-term public or private debt or other similar financial obligations of the
Company, which may be calculated net of such cash balances and/or other offsets and adjustments as may be established by a Committee comprised solely of Outside Directors; (v)&nbsp;earnings per share or the attainment of a specified percentage
increase in earnings per share or earnings per share from continuing operations; (vi)&nbsp;the attainment of certain target levels of, or a specified increase in return on capital employed or return on invested capital; (vii)&nbsp;the attainment of
certain target levels of, or a percentage increase in, <FONT STYLE="white-space:nowrap">after-tax</FONT> or <FONT STYLE="white-space:nowrap">pre-tax</FONT> return on stockholders&#146; equity; (viii)&nbsp;the attainment of certain target levels of,
or a specified increase in, economic value added targets based on a cash flow return on investment formula; (ix)&nbsp;the attainment of certain target levels in, or specified increases in, the fair market value of the shares of the Company&#146;s
common stock; (x)&nbsp;the growth in the value of an investment in the Company&#146;s common stock; (xi)&nbsp;the attainment of a certain level of, reduction of, or other specified objectives with regard to limiting the level in or increase in, all
or a portion of controllable expenses or costs or other expenses or costs; (xii)&nbsp;gross or net sales, revenue and growth of sales revenue (either before or after cost of goods, selling and general administrative expenses, research and
development expenses and any other expenses or interest); (xiii)&nbsp;total stockholder return; (xiv)&nbsp;return on assets or net assets; (xv)&nbsp;return on sales; (xvi)&nbsp;operating profit or net operating profit; (xvii)&nbsp;operating margin;
(xviii)&nbsp;gross or net profit margin; (xix)&nbsp;cost reductions or savings; (xx)&nbsp;productivity; (xxi)&nbsp;operating efficiency; (xxii)&nbsp;working capital; or (xxiii)&nbsp;market share; (xxiv)&nbsp;customer satisfaction;
(xxv)&nbsp;workforce diversity; (xxvi)&nbsp;results of clinical trials; (xxvii)&nbsp;acceptance of a new drug application by a regulatory body; (xxviii)&nbsp;regulatory body approval for commercialization of a product; (xxix)&nbsp;regulatory body
approval of additional indications or improved labeling for an already-approved product; (xxx)&nbsp;launch of a new drug; (xxxi)&nbsp;completion of <FONT STYLE="white-space:nowrap">out-licensing,</FONT>
<FONT STYLE="white-space:nowrap">in-licensing</FONT> or disposition of product candidates or other acquisition or disposition projects; (xxxii)&nbsp;successful completion of a financing; (xxxiii)&nbsp;maintenance and enhancement of investor base;
and (xxxiv)&nbsp;other measures of performance selected by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B> &#147;<B><I>Performance Goals</I></B>&#148; means, for
a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions,
Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board (i)&nbsp;in the Award
Agreement at the time the Award is granted or (ii)&nbsp;in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board shall appropriately make adjustments in the method of calculating the
attainment of Performance Goals for a Performance Period as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects, as applicable, for <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
dollar denominated Performance Goals; (3)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; and (5)&nbsp;to exclude the effects of
any items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles. In addition, the Board retains the discretion to reduce or eliminate the compensation or economic
benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period. Partial achievement of the specified criteria may result in the payment or vesting
corresponding to the degree of achievement as specified in the Stock Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B> &#147;<B><I>Performance
Period</I></B>&#148; means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#146;s right to and the payment of a Stock Award.
Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B> &#147;<B><I>Performance
Stock Award</I></B>&#148; means a Stock Award granted under the terms and conditions of Section&nbsp;6(c)(i). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B> &#147;<B><I>Plan</I></B>&#148; means this ACADIA Pharmaceuticals Inc. 2010
Equity Incentive Plan, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B> &#147;<B><I>Restricted Stock Award</I></B>&#148; means an award of shares of Common Stock
which is granted pursuant to the terms and conditions of Section&nbsp;6(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp)</B> &#147;<B><I>Restricted Stock Award
Agreement</I></B>&#148; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement shall be subject to the terms
and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B> &#147;<B><I>Restricted Stock Unit Award</I></B>&#148; means a right to receive shares of Common
Stock which is granted pursuant to the terms and conditions of Section&nbsp;6(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr)</B> &#147;<B><I>Restricted Stock Unit Award
Agreement</I></B>&#148; means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement shall be
subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss)</B> &#147;<B><I>Returning Shares</I></B>&#148; shall have the meaning set forth
in Section&nbsp;1(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt)</B> &#147;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu)</B> &#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv)</B> &#147;<B><I>Stock Appreciation Right</I></B>&#148; or &#147;<B><I>SAR</I></B>&#148; means a right to receive the appreciation on
Common Stock that is granted pursuant to the terms and conditions of Section&nbsp;5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ww)</B> &#147;<B><I>Stock Appreciation Right
Agreement</I></B>&#148; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement shall be subject to the
terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xx)</B> &#147;<B><I>Stock Award</I></B>&#148; means any right to receive Common Stock granted under
the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right, a Performance Stock Award or any Other Stock Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(yy)</B> &#147;<B><I>Stock Award Agreement</I></B>&#148; means a written agreement between the Company and a Participant evidencing the
terms and conditions of a Stock Award grant. Each Stock Award Agreement shall be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(zz)</B> &#147;<B><I>Subsidiary</I></B>&#148; means, with respect to the Company, (i)&nbsp;any corporation of which more than 50% of the
outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation shall have or might have voting
power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct or indirect interest
(whether in the form of voting or participation in profits or capital contribution) of more than 50%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aaa)</B> &#147;<B><I>Ten
Percent Stockholder</I></B>&#148; means a person who Owns (or is deemed to Own pursuant to Section&nbsp;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Appendix B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA P<SMALL>HARMACEUTICALS</SMALL> I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2004 E<SMALL>MPLOYEE</SMALL> S<SMALL>TOCK</SMALL> P<SMALL>URCHASE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>
<SMALL>ON</SMALL> F<SMALL>EBRUARY</SMALL>&nbsp;25, 2004 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>STOCKHOLDERS</SMALL>
<SMALL>ON</SMALL> M<SMALL>AY</SMALL>&nbsp;5, 2004 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL>
<SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL> <SMALL>ON</SMALL> A<SMALL>PRIL</SMALL>&nbsp;29, 2016 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL>
<SMALL>BY</SMALL> <SMALL>STOCKHOLDERS</SMALL> <SMALL>ON</SMALL> J<SMALL>UNE</SMALL>&nbsp;10, 2016 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL>
<SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL>&nbsp;27, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: [J<SMALL>UNE</SMALL>] [</B><FONT
STYLE="font-family:SYMBOL; font-size:10pt" COLOR="#000000">&#183;</FONT><FONT STYLE="font-family:Times New Roman"><B></B><B>], 2019 </B></FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>P<SMALL>URPOSE</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The purpose of the Plan is to provide a means by which Employees of the Company and certain designated Related Corporations may be
given an opportunity to purchase shares of the Common Stock of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Company, by means of the Plan, seeks to retain
the services of such Employees, to secure and retain the services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Company intends that the Purchase Rights be considered options issued under an Employee Stock Purchase Plan. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>EFINITIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in the Plan and any Offering, unless otherwise specified, the following terms have the meanings set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>&#147;Annual Meeting&#148; </I></B>means the annual meeting of the stockholders of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>&#147;Board&#148;</I></B><I> </I>means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>&#147;Code&#148;</I></B><I> </I>means the Internal Revenue Code of 1986, as amended<I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>&#147;Committee&#148;</I></B><I> </I>means a committee appointed by the Board in accordance with Section&nbsp;3(c) of the
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>&#147;Common Stock&#148;</I></B> means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>&#147;Company&#148;</I></B> means ACADIA Pharmaceuticals Inc., a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><I>&#147;Contributions&#148;</I></B> means the payroll deductions and other additional payments that a Participant contributes
to fund the exercise of a Purchase Right. A Participant may make payments not through payroll deductions only if specifically provided for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld
through payroll deductions during the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>&#147;Corporate Transaction&#148;</I></B> means the occurrence, in a
single transaction or in a series of related transactions, of any one or more of the following events: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> a sale, exchange,
lease, license or other disposition of all or substantially all of the consolidated assets of the Company; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> a sale, exchange or other disposition of more than fifty percent (50%) of the
outstanding securities of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> a merger, consolidation or similar transaction following which the Company is not the
surviving corporation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> a merger, consolidation or similar transaction following which the Company is the surviving
corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in
the form of securities, cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>&#147;Director&#148;</I></B><I> </I>means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>&#147;Eligible Employee&#148;</I></B><I> </I>means an Employee who meets the requirements set forth in the Offering for
eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>&#147;Employee&#148;</I></B><I> </I>means any person, including Officers and Directors, who is employed for purposes of
Section&nbsp;423(b)(4) of the Code by the Company or a Related Corporation. Neither service as a Director nor payment of a director&#146;s fee shall be sufficient to make an individual an Employee of the Company or a Related Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><I>&#147;Employee Stock Purchase Plan&#148;</I></B><I> </I>means a plan that grants Purchase Rights intended to be options
issued under an &#147;employee stock purchase plan,&#148; as that term is defined in Section&nbsp;423(b) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B>
<B><I>&#147;Exchange Act&#148;</I></B><I> </I>means the Securities Exchange Act of 1934, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B><I>&#147;Fair Market
Value&#148;</I></B><I> </I>means the value of a security, as determined in good faith by the Board. If the security is listed on any established stock exchange or traded on the Nasdaq National Market or the Nasdaq SmallCap Market, the Fair Market
Value of the security, unless otherwise determined by the Board,<I> </I>shall be the closing sales price (rounded up where necessary to the nearest whole cent) for such security (or the closing bid, if no sales were reported) as quoted on such
exchange or market (or the exchange or market with the greatest volume of trading in the relevant security of the Company) on the Trading Day prior to the relevant determination date, as reported in <I>The Wall Street Journal</I> or such other
source as the Board deems reliable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B><I>&#147;IPO Date&#148;</I></B> means the effective date of the initial public offering
of the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> <B><I>&#147;Offering&#148;</I></B><I> </I>means the grant of Purchase Rights to purchase shares of Common
Stock under the Plan to Eligible Employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> <B><I>&#147;Offering Date&#148;</I></B> means a date selected by the Board for an
Offering to commence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r) &#147;</B><B><I>Officer</I></B><B>&#148; </B>means<B> </B>a person who is an officer of the Company within
the meaning of Section&nbsp;16 of the Exchange Act and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B>
<B><I>&#147;Participant&#148;</I></B><I> </I>means an Eligible Employee who holds an outstanding Purchase Right granted pursuant to the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> <B><I>&#147;Plan&#148;</I></B><I> </I>means this ACADIA Pharmaceuticals Inc. 2004 Employee Stock Purchase Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> <B><I>&#147;Purchase Date&#148;</I></B><I> </I>means one or more dates during an Offering established by the Board on which
Purchase Rights shall be exercised and as of which purchases of shares of Common Stock shall be carried out in accordance with such Offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B><I>&#147;Purchase Period&#148;</I></B> means a period of time specified within
an Offering beginning on the Offering Date or on the next day following a Purchase Date within an Offering and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> <B><I>&#147;Purchase Right&#148;</I></B><I> </I>means an option to purchase shares of Common Stock granted pursuant to the Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> <B><I>&#147;Related Corporation&#148;</I></B><I> </I>means any parent corporation or subsidiary corporation, whether now or
hereafter existing, as those terms are defined in Sections 424(e) and (f), respectively, of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> <B><I>&#147;Securities
Act&#148;</I></B><I> </I>means the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z) &#147;</B><B><I>Trading Day</I></B><B>&#148; </B>means any
day on which the exchange(s) or market(s) on which shares of Common Stock are listed, whether it be an established stock exchange, the Nasdaq National Market, the Nasdaq SmallCap Market or otherwise, is open for trading. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DMINISTRATION</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board shall administer the Plan unless and until the Board delegates administration to a Committee, as provided in
Section&nbsp;3(c). Whether or not the Board has delegated administration, the Board shall have the final power to determine all questions of policy and expediency that may arise in the administration of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board (or the Committee) shall have the power, subject to, and within the limitations of, the express provisions of the Plan:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine when and how Purchase Rights to purchase shares of Common Stock shall be granted and the provisions of each
Offering of such Purchase Rights (which need not be identical). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> To designate from time to time which Related Corporations of
the Company shall be eligible to participate in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To construe and interpret the Plan and Purchase Rights, and to
establish, amend and revoke rules and regulations for the administration of the Plan. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it shall deem necessary or
expedient to make the Plan fully effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> To amend the Plan as provided in Section&nbsp;15. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of the
Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B>
To adopt such procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit participation in the Plan by Employees who are foreign nationals or employed outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Board may delegate administration of the Plan to a Committee of the Board composed of one (1)&nbsp;or more members of the
Board. If administration is delegated to a Committee, the Committee shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Board, subject, however, to such resolutions, not inconsistent with the
provisions of the Plan, as may be adopted from time to time by the Board. The Board may abolish the Committee at any time and revest in the Board the administration of the Plan. If administration is delegated to a Committee, references to the Board
in this Plan and in the Offering document shall thereafter be deemed to be to the Board or the Committee, as the case may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> All determinations, interpretations and constructions made by the Board in good
faith shall not be subject to review by any person and shall be final, binding and conclusive on all persons. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>S<SMALL>HARES</SMALL> <SMALL>OF</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL> S<SMALL>UBJECT</SMALL>
<SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Subject to the provisions of Section&nbsp;14
relating to adjustments upon changes in stock after the IPO Date, the shares of Common Stock that may be sold pursuant to Purchase Rights shall not exceed in the aggregate 2,525,000 shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The shares of Common Stock subject to the Plan may be unissued shares or shares that have been bought on the open market at
prevailing market prices or otherwise. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>G<SMALL>RANT</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>;
O<SMALL>FFERING</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board may from time to time grant or provide for the grant of Purchase
Rights to purchase shares of Common Stock under the Plan to Eligible Employees in an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering shall be in such form and shall
contain such terms and conditions as the Board shall deem appropriate, which shall comply with the requirement of Section&nbsp;423(b)(5) of the Code that all Employees granted Purchase Rights shall have the same rights and privileges. The terms and
conditions of an Offering shall be incorporated by reference into the Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering shall include (through incorporation of the provisions of this
Plan by reference in the document comprising the Offering or otherwise) the period during which the Offering shall be effective, which period shall not exceed twenty-seven (27)&nbsp;months beginning with the Offering Date, and the substance of the
provisions contained in Sections 6 through 9, inclusive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If a Participant has more than one Purchase Right outstanding under
the Plan, unless he or she otherwise indicates in agreements or notices delivered hereunder: (i)&nbsp;each agreement or notice delivered by that Participant shall be deemed to apply to all of his or her Purchase Rights under the Plan, and
(ii)&nbsp;a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have identical exercise prices) shall be exercised to the fullest possible extent before a Purchase Right with a higher
exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) shall be exercised. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>LIGIBILITY</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Purchase Rights may be granted only to Employees of the Company or, as the Board may designate as provided in Section&nbsp;3(b), to
Employees of a Related Corporation. Except as provided in Section&nbsp;6(b), an Employee shall not be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such Employee has been in the employ of the Company or the
Related Corporation, as the case may be, for such continuous period preceding such Offering Date as the Board may require, but in no event shall the required period of continuous employment be greater than two (2)&nbsp;years. In addition, the Board
may provide that no Employee shall be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such Employee&#146;s customary employment with the Company or the Related Corporation is more than twenty (20)&nbsp;hours per
week and more than five (5)&nbsp;months per calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board may provide that each person who, during the course of an
Offering, first becomes an Eligible Employee shall, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under that Offering,
which Purchase Right shall thereafter be deemed to be a part of that Offering. Such Purchase Right shall have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the date on which such Purchase Right is granted shall be the &#147;Offering Date&#148; of such Purchase Right for all purposes,
including determination of the exercise price of such Purchase Right; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the period of the Offering with respect to such Purchase Right shall begin on
its Offering Date and end coincident with the end of such Offering; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Board may provide that if such person first
becomes an Eligible Employee within a specified period of time before the end of the Offering, he or she shall not receive any Purchase Right under that Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> No Employee shall be eligible for the grant of any Purchase Rights under the Plan if, immediately after any such Purchase Rights
are granted, such Employee owns stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or of any Related Corporation. For purposes of this Section&nbsp;6(c), the rules of
Section&nbsp;424(d) of the Code shall apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase Rights and options shall be treated as stock owned by such Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> As specified by Section&nbsp;423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights under the Plan only if such
Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee&#146;s rights to purchase stock of the Company or any Related
Corporation to accrue at a rate which exceeds twenty five thousand dollars ($25,000) of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, shall be determined as of their respective
Offering Dates) for each calendar year in which such rights are outstanding at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Officers of the Company and any
designated Related Corporation, if they are otherwise Eligible Employees, shall be eligible to participate in Offerings under the Plan. Notwithstanding the foregoing, the Board may provide in an Offering that Employees who are highly compensated
Employees within the meaning of Section&nbsp;423(b)(4)(D) of the Code shall not be eligible to participate. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>; P<SMALL>URCHASE</SMALL> P<SMALL>RICE</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, shall be
granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board, but in either case not exceeding fifteen percent (15%), of such
Employee&#146;s Earnings (as defined by the Board in each Offering) during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date
shall be no later than the end of the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board shall establish one (1)&nbsp;or more Purchase Dates during an
Offering as of which Purchase Rights granted pursuant to that Offering shall be exercised and purchases of shares of Common Stock shall be carried out in accordance with such Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> In connection with each Offering made under the Plan, the Board may specify a maximum number of shares of Common Stock that may be
purchased by any Participant on any Purchase Date during such Offering. In connection with each Offering made under the Plan, the Board may specify a maximum aggregate number of shares of Common Stock that may be purchased by all Participants
pursuant to such Offering. In addition, in connection with each Offering that contains more than one Purchase Date, the Board may specify a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase
Date under the Offering. If the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a
pro rata allocation of the shares of Common Stock available shall be made in as nearly a uniform manner as shall be practicable and equitable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The purchase price of shares of Common Stock acquired pursuant to Purchase Rights
shall be not less than the lesser of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> an amount equal to eighty-five percent (85%) of the Fair Market Value of the shares of
Common Stock on the Offering Date; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> an amount equal to eighty-five percent (85%) of the Fair Market Value of the shares of
Common Stock on the applicable Purchase Date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>P<SMALL>ARTICIPATION</SMALL>; W<SMALL>ITHDRAWAL</SMALL>; T<SMALL>ERMINATION</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> A Participant may elect to authorize payroll deductions pursuant to an Offering under the Plan by
completing and delivering to the Company, within the time specified in the Offering, an enrollment form (in such form as the Company may provide). Each such enrollment form shall authorize an amount of Contributions expressed as a percentage of the
submitting Participant&#146;s Earnings (as defined in each Offering) during the Offering (not to exceed the maximum percentage specified by the Board). Each Participant&#146;s Contributions shall remain the property of the Participant at all times
prior to the purchase of Common Stock, but such Contributions may be commingled with the assets of the Company and used for general corporate purposes except where applicable law requires that Contributions be deposited with an independent third
party. To the extent provided in the Offering, a Participant may begin making Contributions after the beginning of the Offering. To the extent provided in the Offering, a Participant may thereafter reduce (including to zero) or increase his or her
Contributions. To the extent specifically provided in the Offering, in addition to making Contributions by payroll deductions, a Participant may make Contributions through the payment by cash or check prior to each Purchase Date of the Offering.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company a
notice of withdrawal in such form as the Company may provide. Such withdrawal may be elected at any time prior to the end of the Offering, except as provided otherwise in the Offering. Upon such withdrawal from the Offering by a Participant, the
Company shall distribute to such Participant all of his or her accumulated Contributions (reduced to the extent, if any, such Contributions have been used to acquire shares of Common Stock for the Participant) under the Offering, and such
Participant&#146;s Purchase Right in that Offering shall thereupon terminate. A Participant&#146;s withdrawal from an Offering shall have no effect upon such Participant&#146;s eligibility to participate in any other Offerings under the Plan, but
such Participant shall be required to deliver a new enrollment form in order to participate in subsequent Offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Purchase
Rights granted pursuant to any Offering under the Plan shall terminate immediately upon a Participant ceasing to be an Employee for any reason or for no reason (subject to any post-employment participation period required by law) or other lack of
eligibility. The Company shall distribute to such terminated or otherwise ineligible Employee all of his or her accumulated Contributions (reduced to the extent, if any, such Contributions have been used to acquire shares of Common Stock for the
terminated or otherwise ineligible Employee) under the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Purchase Rights shall not be transferable by a Participant
otherwise than by will, the laws of descent and distribution, or a beneficiary designation as provided in Section&nbsp;13. During a Participant&#146;s lifetime, Purchase Rights shall be exercisable only by such Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Unless otherwise specified in an Offering, the Company shall have no obligation to pay interest on Contributions, including, but
not limited to, any amounts distributed to Participants pursuant to Sections 8(b), 8(c) and 9(b) hereof. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>XERCISE</SMALL>; H<SMALL>OLDING</SMALL> R<SMALL>ESTRICTIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> On each Purchase Date during an Offering, each Participant&#146;s accumulated Contributions shall be applied to the purchase of
shares of Common Stock up to the maximum number of shares of Common Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permitted pursuant to the terms of the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares shall be issued upon the exercise of Purchase Rights
unless specifically provided for in the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If any amount of accumulated Contributions remains in a Participant&#146;s
account after the purchase of shares of Common Stock and such remaining amount is less than the amount required to purchase one share of Common Stock on the final Purchase Date of an Offering, then such remaining amount shall be held in such
Participant&#146;s account for the purchase of shares of Common Stock under the next Offering under the Plan, unless such Participant withdraws from such next Offering, as provided in Section&nbsp;8(b), or is not eligible to participate in such
Offering, as provided in Section&nbsp;6, in which case such amount shall be distributed to such Participant after the final Purchase Date, without interest. If the amount of Contributions remaining in a Participant&#146;s account after the purchase
of shares of Common Stock is at least equal to the amount required to purchase one (1)&nbsp;whole share of Common Stock on the final Purchase Date of the Offering, then such remaining amount shall be distributed in full to such Participant at the
end of the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> No Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued upon
such exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all laws applicable to the Plan. If on a Purchase Date during any Offering hereunder the
shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights or any Offering shall be exercised on such Purchase Date, and the Purchase Date shall be delayed until the shares of Common Stock are subject to
such an effective registration statement and the Plan is in such compliance, except that the Purchase Date shall not be delayed more than twelve (12)&nbsp;months and the Purchase Date shall in no event be more than twenty-seven (27)&nbsp;months from
the Offering Date. If, on the Purchase Date under any Offering hereunder, as delayed to the maximum extent permissible, the shares of Common Stock are not registered and the Plan is not in such compliance, no Purchase Rights or any Offering shall be
exercised and all Contributions accumulated during the Offering (reduced to the extent, if any, such Contributions have been used to acquire shares of Common Stock) shall be distributed to the Participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> With respect to any Common Stock of the Company purchased under any Offering, as a condition to participating in, and purchasing
shares of Common Stock under this Plan, the Board may require prior to the beginning of such Offering that each Participant must irrevocably agree that, without the prior written consent of the Company, such Participant will not, directly or
indirectly, (1)&nbsp;offer for sale, sell, pledge, or otherwise dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the future of) any shares of
Common Stock of the Company (the &#147;Held Shares&#148;) purchased by such Participant in such Offering, or (2)&nbsp;enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits
or risks of ownership of the Held Shares, in each case before the passage of a holding period determined by the Board which commences on the date the Participant purchased the applicable Held Shares (the &#147;Holding Period&#148;). The Company may
impose stop-transfer instructions with respect to the shares of Common Stock subject to the foregoing restriction until the end of the applicable Holding Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Each Participant understands and agrees that on any certificates evidencing&nbsp;the shares of Common Stock purchased under the
Plan, the Company may place a legend, substantially in the form of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SHARES EVIDENCED BY THIS CERTIFICATE CANNOT BE SOLD
UNTIL [INSERT DATE THAT IS EQUAL TO THE HOLDING PERIOD AFTER THE DATE OF PURCHASE]. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall seek to obtain from each federal, state, foreign or other regulatory commission or agency having
jurisdiction over the Plan such authority as may be required to issue and sell shares of Common Stock upon exercise of the Purchase Rights. If, after commercially reasonable efforts, the Company is unable to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of shares of Common Stock under the Plan, the
Company shall be relieved from any liability for failure to issue and sell shares of Common Stock upon exercise of such Purchase Rights unless and until such authority is obtained. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>U<SMALL>SE</SMALL> <SMALL>OF</SMALL> P<SMALL>ROCEEDS</SMALL> <SMALL>FROM</SMALL> S<SMALL>HARES</SMALL>
<SMALL>OF</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proceeds from the sale of shares of Common Stock
pursuant to Purchase Rights shall constitute general funds of the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>R<SMALL>IGHTS</SMALL> <SMALL>AS</SMALL> <SMALL>A</SMALL> <SMALL>STOCKHOLDER</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Participant shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to,
shares of Common Stock subject to Purchase Rights unless and until the Participant&#146;s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>ESIGNATION</SMALL> <SMALL>OF</SMALL> B<SMALL>ENEFICIARY</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> A Participant may file a written designation of a beneficiary who is to receive any shares of Common Stock and/or cash, if any, from
the Participant&#146;s account under the Plan in the event of such Participant&#146;s death subsequent to the end of an Offering but prior to delivery to the Participant of such shares of Common Stock or cash. In addition, a Participant may file a
written designation of a beneficiary who is to receive any cash from the Participant&#146;s account under the Plan in the event of such Participant&#146;s death during an Offering. Any such designation shall be on a form provided by or otherwise
acceptable to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Participant may change such designation of beneficiary at any time by written notice to the
Company. In the event of the death of a Participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such Participant&#146;s death, the Company shall deliver such shares of Common Stock and/or cash
to the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common Stock and/or cash
to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL>
S<SMALL>ECURITIES</SMALL>; C<SMALL>ORPORATE</SMALL> T<SMALL>RANSACTIONS</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> If, after the IPO Date,
any change is made in the shares of Common Stock, subject to the Plan, or subject to any Purchase Right, without the receipt of consideration by the Company (through merger, consolidation, reorganization, recapitalization, reincorporation, stock
dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other transaction not involving the receipt of consideration by the Company), the Plan
shall be appropriately adjusted in the type(s), class(es) and maximum number of shares of Common Stock subject to the Plan pursuant to Section&nbsp;4(a), and the outstanding Purchase Rights shall be appropriately adjusted in the type(s), class(es),
number of shares and purchase limits of such outstanding Purchase Rights. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. (The conversion of any convertible securities of the Company shall not be
treated as a &#147;transaction not involving the receipt of consideration by the Company.&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> In the event of a Corporate
Transaction, then: (i)&nbsp;any surviving or acquiring corporation may continue or assume Purchase Rights outstanding under the Plan or may substitute similar rights (including a right to acquire the same consideration paid to stockholders in the
Corporate Transaction) for those outstanding under the Plan, or (ii)&nbsp;if any surviving or acquiring corporation does not continue or assume such Purchase Rights or does not substitute similar rights for Purchase Rights outstanding under the
Plan, then, the Participants&#146; accumulated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Contributions shall be used to purchase shares of Common Stock within ten (10)&nbsp;business days prior to the Corporate Transaction under the ongoing Offering, and the Participants&#146;
Purchase Rights under the ongoing Offering shall terminate immediately after such purchase. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>MENDMENT</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board at any time, and from time to time, may amend the Plan. However, except as provided in
Section&nbsp;14 relating to adjustments upon changes in securities and except as to amendments solely to benefit the administration of the Plan, to take account of a change in legislation or to obtain or maintain favorable tax, exchange control or
regulatory treatment for Participants or the Company or any Related Corporation, no amendment shall be effective unless approved by the stockholders of the Company to the extent stockholder approval is necessary for the Plan to satisfy the
requirements of Section&nbsp;423 of the Code or other applicable laws or regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> It is expressly contemplated that the
Board may amend the Plan in any respect the Board deems necessary or advisable to provide Employees with the maximum benefits provided or to be provided under the provisions of the Code and the regulations promulgated thereunder relating to Employee
Stock Purchase Plans or to bring the Plan and/or Purchase Rights into compliance therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The rights and obligations under
any Purchase Rights granted before amendment of the Plan shall not be impaired by any amendment of the Plan except: (i)&nbsp;with the consent of the person to whom such Purchase Rights were granted, or (ii)&nbsp;as necessary to comply with any laws
or governmental regulations (including, without limitation, the provisions of the Code and the regulations promulgated thereunder relating to Employee Stock Purchase Plans). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
P<SMALL>LAN</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board in its discretion may suspend or terminate the Plan at any time. Unless
sooner terminated, the Plan shall terminate at the time that all of the shares of Common Stock reserved for issuance under the Plan, as increased and/or adjusted from time to time, have been issued under the terms of the Plan. No Purchase Rights may
be granted under the Plan while the Plan is suspended or after it is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Any benefits, privileges, entitlements and
obligations under any Purchase Rights while the Plan is in effect shall not be impaired by suspension or termination of the Plan except (i)&nbsp;as expressly provided in the Plan or with the consent of the person to whom such Purchase Rights were
granted, (ii)&nbsp;as necessary to comply with any laws, regulations, or listing requirements, or (iii)&nbsp;as necessary to ensure that the Plan and/or Purchase Rights comply with the requirements of Section&nbsp;423 of the Code. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan shall become effective as determined by the Board, but no Purchase Rights shall be exercised unless and
until the Plan has been approved by the stockholders of the Company within twelve (12)&nbsp;months before or after the date the Plan is adopted by the Board. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>M<SMALL>ISCELLANEOUS</SMALL> P<SMALL>ROVISIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering shall in any way alter the at
will nature of a Participant&#146;s employment or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation, or on the part of the Company or a Related
Corporation to continue the employment of a Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The provisions of the Plan shall be governed by the laws of the State
of California<B> </B>without resort to that state&#146;s conflicts of laws rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g664711dsp001.jpg" ALT="LOGO">
 </P> <P ALIGN="justify" STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">ACADIA Pharmaceuticals Inc. MMMMMMMMMMMMMM C123456789 000000000.000000 ext 000000000.000000 ext 000004 000000000.000000
ext 000000000.000000 ext ENDORSEMENT_LINE______________ SACKPACK_____________ 000000000.000000 ext 000000000.000000 ext Your vote matters &#150; here&#146;s how to vote! MR A SAMPLE You may vote online or by phone instead of mailing this card.
DESIGNATION (IF ANY) Votes submitted electronically must be ADD 1 ADD 2 received by 11:59 p.m., Eastern Time, on ADD 3 June&nbsp;25, 2019. ADD 4 ADD 5 Online ADD 6 Go to www.investorvote.com/ACAD or scan the QR code &#151; login details are located
in the shaded bar below. Phone Call toll free <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-652-VOTE</FONT></FONT></FONT> (8683)&nbsp;within the USA, US territories and Canada Save paper,
time and money! Using a black ink pen, mark your votes with an X as shown in this example. Sign up for electronic delivery at Please do not write outside the designated areas. www.investorvote.com/ACAD Annual Meeting Proxy Card 1234 5678 9012 345
qIF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q A Proposals &#151; THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE ELECTION OF EACH NOMINEE NAMED BELOW AND FOR PROPOSALS 2, 3, 4 AND 5. + 1. To elect two
Class&nbsp;III directors named herein to hold office until our 2022 Annual Meeting of Stockholders. 01&#151;Laura Brege 02&#151;Stephen Davis Mark here to vote Mark here to WITHHOLD For All EXCEPT&#151;To withhold authority to vote for any
nominee(s), FOR all nominees vote from all nominees write the name(s) of such nominee(s) below. For Against Abstain For Against Abstain 2. To approve an amendment to our 2010 Equity Incentive Plan, as 3. To approve an amendment to our 2004 Employee
Stock amended, to, among other things, increase the aggregate Purchase Plan, as amended, to, among other things, increase number of shares of common stock authorized for issuance the aggregate number of shares of common stock authorized under the
plan by 8,300,000 shares. for issuance under the plan by 600,000 shares. 4. To approve, on an advisory basis, the compensation of our 5. To ratify the selection of Ernst&nbsp;&amp; Young LLP as our independent named executive officers, as disclosed
in the proxy statement registered public accounting firm for the fiscal year ending for the annual meeting December&nbsp;31, 2019. B Authorized Signatures &#151; This section must be completed for your vote to be counted. &#151; Date and Sign Below
NOTE: Please sign as name appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, trustee or guardian, please give full title as such. Date (mm/dd/yyyy) &#151; Please print date below. Signature 1 &#151;
Please keep signature within the box. Signature 2 &#151; Please keep signature within the box. C 1234567890&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;J N T MR A SAMPLE (THIS AREA IS SET UP TO
ACCOMMODATE 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MMMMMM 1UPX 419225 MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND + </FONT></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g664711dsp002.jpg" ALT="LOGO">
 </P> <P ALIGN="justify" STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Important notice regarding the Internet availability of proxy materials for the Annual Meeting of Stockholders. The
Proxy Statement, Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the Year Ended December&nbsp;31, 2018 and Annual Report to Stockholders are available at http://ir.acadia-pharm.com. Small steps make an impact. Help the environment by
consenting to receive electronic delivery, sign up at www.investorvote.com/ACAD qIF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q Proxy &#151; ACADIA Pharmaceuticals Inc. + 3611 Valley Centre Drive, Suite 300
San Diego, California 92130 PROXY SOLICITED BY THE BOARD OF DIRECTORS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE&nbsp;26, 2019 The undersigned hereby appoints Stephen R. Davis, Austin D. Kim and Elena Ridloff, and each of them, as
attorneys and proxies of the undersigned, with full power of substitution, to vote all of the shares of stock of ACADIA Pharmaceuticals Inc. which the undersigned may be entitled to vote at the 2019 Annual Meeting of Stockholders of ACADIA
Pharmaceuticals Inc. to be held on June&nbsp;26, 2019 at 8:00 a.m. local time at the Hilton La Jolla Torrey Pines, 10950 North Torrey Pines Road, La Jolla, CA 92037, and at any and all postponements, continuations and adjournments thereof, with all
power that the undersigned would possess if personally present, upon and in respect of the following matters and in accordance with the following instructions, with discretionary authority as to any and all other matters that may properly come
before the meeting. The undersigned hereby revokes all previously submitted proxies for the Annual Meeting of Stockholders to be held on June&nbsp;26, 2019. UNLESS A CONTRARY DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED FOR EACH NOMINEE LISTED
IN PROPOSAL 1 AND FOR PROPOSALS 2, 3, 4 AND 5, EACH AS DESCRIBED IN THE ACCOMPANYING PROXY STATEMENT. IF SPECIFIC INSTRUCTIONS ARE INDICATED, THIS PROXY WILL BE VOTED IN ACCORDANCE THEREWITH. (Continued and to be marked, dated and signed, on the
other side) C <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Items Change of Address &#151; Please print new address below. Comments &#151; Please print your comments below. +&nbsp;&nbsp;&nbsp;&nbsp; </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g664711dsp001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g664711dsp001.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_[0 L4&AO=&]S:&]P(#,N,  X0DE-!"4      !
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M4\1PX\.-'[IWJ-)F<3@Q=8CS>8S=OBX3UIM+;BXER,3'2'R]1$'8R<N<T.<
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M>X;;W)87N:XC221X9'Q'F!^5&XCV4^ >.>IOICG_ $JS<6!W%+:RWDT4TC3
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M_/2N#_>21;_9(E_-#B_Y MOYK=^[,7G/IQ_N]X#_ &27/^DMJME=/]!VW?\
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MZ:@H"$+[+O.T:^IRNVM4WH7.=V=+V&#1!O6.JH")L2K9%)5[:TI5#@L,"42
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MK?M/=MF.D+MZMJ4C57T;B]2H4#4HU^K29&C:DBED1,P43;$YW-2#3BV@6?3
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M9%*W$H<>=9_D\'N<A5@LQP\>/)P/KCA10]RY.@[W4)F<<[F J?8:/DMA:(S
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MC+E_\-W+^;W(?RW-_"H?_P"6KV/??]L.4_K)B?P>GZL1L?\ U@EO?[S#1?\
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MIF",**L[;.R&F\(;"7V/3A1<+R;K2],4@EV**&VH!LBB,F3*Q7,Z2>=X_6)
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M=]:QZQ5CA(7M<6,>X1IL5V[]M9^V-B>*URV.!R;M]:<40< R=PE%@-H5'><
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MB>S#6-A+HI7&1SY@R5OS_B=U2,46-->IZ><V*U*V5J!R<C [B/5V#FVC,6D
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M!1PT_IAT^C];Q\7U=6U&DU)=\\ZE ]?-[4LF.M\6Z*&,LN6FW=3*M=8G%_\
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M&,XSC*/%82>>WNV0S,L9,?<7#HNK4ET!F  DZ8(#NF"?"2.-%2Q]-?1_-YG
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M8&1/'1.\*(F7)3STN N28*@S 0F] XXAQ.$O9K&YBAFBM)X;I[X^KJ-;=CW
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M;)32^0JW1)<29-O4NFQESG9&.W$PZPB"Q3D?#BU<Z(2+VXIHBRJ6FZ*%HEX
M( 2DO9[W<XETX%.HPF6F(Y+AJ;" -_C"6P&A3%XPWFC *\;9],)<#U) SSM1
MQT^5J.K4<*LUN.K\L%Q\87.LX\\^#&R3Q2F_O66HWD7L)>;8[=UL.5+FZF!U
MOYFX>9Z%UZTS/)NF-</:4HB(G"* 4KVP2:4/!0-Z0*G$O*/+D'<:-M#.GM\)
MZCR$11JH][:L@<, +'&0')Q=6XH(0P6S].2@-6-_>5!QIY-Q/2X<>'3=X?\
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M<-.F5@(A5OA5D.<[KV57/5"I(M*?;O,>4*[7^1[#L21]47HW*4Z^+*V5T)S
M4$G9VX3DS.R@!V?=AY7C $9(P9V3[JR9:S08VX!;I@TD3MMW%H@/!P(^L+7'
M2]HIX@>-"O1+K<.T;/;&5PGI]G&/MW6V($3V9N#!S.A;AY&N9<MEC/G7V\L@
MM[JVC+/WPQ^EQ;(URZCF6U510E0#;,KXH2$WR%H3)G' "1G^8,GR56!.6,IS
M?-+$'PCZ9\0<X^KC/.BC'WYI2";CR\#N/P<%\7LV-O9X8YF'RI;(W4REI.=0
MH#5OU?B%"#45%""O 5O5. 7@'9]=@'Y(%'A%-8T$7IS"@'%G^'+GC/DF$F!&
M$7['(18SC/3/)^SL@>4$W_$=^PK#8>^'#4W#94MU%O\ DEQ\X$@M_1\P001S
M!!'->0+;JDP2< +-KT8U>,B2 !,XX(2H.##"<B3APY9R=C!Q(P=0]?A!SCZN
M,\?9]^*DP34'/P.X?(H=L7>S0]SL/E0V/YQ-I<>'@#XOJ^' @\>P@]J\/E@J
M7R@G_*C77D"-R2$[X[1KRA'! $P103/>?@R:$ PYR'KUQC.,_J\?9V0K3H35
M_O'?L*WZA;YUF/[%RW4 K3R=Q6E2*TZ=:5!%>505_<V]4^ G#S:%=X F& I0
M+,UC7A(,,R,("SA>\^A0QB+%C&!=,YR'/ZV>/L[(<!T)N/YCOV%'ZA[XJUOV
M-EM3P2T>4N/$!2I'U?$"HJ1WCO0=O5.6+(!VA78!A* H$$<UC018(-+ <4=D
M.7/&<%&%&A$$7U,A%C.,],XX^SL@>(@F_P"([]A&[#WPX:FX;+%I<6U%I<?.
M!((_1\P001S!!'8O,-MU4,1  6;7PQJ@9,2@#,XX(2DL(S2\C(#ARSDX&#"1
MASD/7'B +'U<9X^S[\5)@FH.?@=^PH.Q=[-:YSL/E0UAHX^4N*-- :.^KX&A
M!X]A![0O5\L-2>4$_P"5*N?(&8(D!WQWC/E". $L8R@F>\_ (P #0YR'&>N,
M"QG]7''V=D*TZ$U?[QW["M^H6^M9B^Q<MU  2/)W%0"2 :=.M"00#W@]RJ!M
MO$7I]L:LI&PP22SMR:6HHJ-(LPMRF$&7.QTTCKB:G3S&+/K))]?9VD+0)U*6
M8",RU&(<'$*0'!)P2/L6W[B**SFAFE9$QSO$=88\#0X?,<US9V&I!B^=JH6T
MK4>\^A>>QV,VGF,3D\E9XVSGG)N'^;CM;QD0M)XPYUK<PS6^;LW%[XY,6&BY
M;-TY(71F3J-C!_B&Q:I^OJ1GPA\-BU^IW908UQ]Y?<R\,;IZPH^T,\87,ZE"
MSM\&=;6H3#NG2X2+SLK%PB@G&)SAAYSX;C#-BM(1*SKVA JX-T:IHW$N!!)>
M(I]!-6BC:T! 7<\7GO2>#&;8Q$>1MAFMKNB:))XH?*^8REC/++<,E:^5]Y%C
M<UY5\AE@;TH0\QLEC:5ZIY6TFD)+*JH&HIE752M!%R.LPK1P8'R%*K@B>7#7
MQ>_5Y#F!2X,ZRE_E2#'G=*C+,1I,N!J%6+)))#J<J$M+V"'4W+7$<V0=T0R0
M.:\0NI<!LCW $3=+4PFA.D.:*DQAJOMG=V&Q4EQ#ZH9['Y;?,[L5':Y!DT-V
MW%W.C.,AOKJ=K)6Y;[.Z]K)*YLLH@;- T22264< ^1YU]M1:^W-:<08&EBD,
MCLN4QR )2X6_1F?/D;M.&Q2M"%\[GI3NM&FJ: MSVK>P-Y;%DY$M9B!A%DQ/
MDHZT67L&Q6UC</<^%D#72'6UT;71/=(0QE!660M#-6NCFO(Y&HS8_P!4]E6^
M-V_LO/74]SBK3#VT]ZXW<-Q90W&.N[G(.99V1B9JR=[)#%:&=UYHEANY&N&F
M77'[R8))FUDB$8OBCIQ9L:K2"V94D%B\,22":I4\I:I2U'UC)62393,[FW+W
MNJS6UN;YLL*;?<KDV./FJD0SO$;#KN!\LD^*NHH)YY8I7N?I8=):1*US>((;
M+J<Z%I=K:YE&NIPI)N7#WF1O\SZ9[DQN&R^8R6/R=Y<7;H+1SK:2VE;D+>:W
MU2QR,AR0N)Y\1$ZX\W!<6FB&X;'1DGU5'9[ +SED]M]&H%7;S(;B*KIU<<&M
MK128S),2[.B^3N"YT&WO)-PMYV H7\TM/A !I+;B\!PX"$?P;^:TN\5':8XC
MSC60]0#B9O#0!H J.B?G1@G5K+S\SATW>V6VSNCTWL=L[#D8-UV]IBC?QQTD
MERX%N8HV6\;(P^(XIXK-9-<\S&Y?=O)\J!'<P%MU28),$NS:]&);GPHP@F<<
M$)6+S1$=$V,.6<GY\\.0?!Z_#QG'U>=;^S[\5K!-PY^!W#Y%\^NV+O9@>YV'
MRH$?SZVEQX>%?%]7X>''C3AQY+U8N*HLAP/%IUQD&1^7@>)Q&?#D?3 O!@7O
M3ID?ASC/3ZO3D_9V0_YB;_B._85_U WV#I^Q,OJI6GD[CEW_ */DO:.VZI!E
M3@=G5Z#*,>"EF!S2-ARD,R9DG!:G&7+'D#R<'(>@NF?%CI]7D?9]^:4@FX\O
M [C\'!4;L7>[@PMPV5(D%6TM+CQ"E:M^KXBG&HKPXKQ%;U3@%X!V?78!9) I
MP$4UC0193F%A. ?TRYXSY(R18'@?['(<XSUZ<?9V0/*";_B._84C8>^'#4W#
M94MU%O\ DEQ\X&A;^CY@\".=>'->0+;JDP28 +-KT8UG_(P F<<$)5T-&1GT
MP<.6<G]#BQ ^#U^$'./JXSQ]GWXK6";AS\#N'P\%#MB[V:'N=A\J&Q_.)M+C
MP\ ?%]7PX$'C3@0>2]6+BJ/(0CQ:=<9",?E@%B<1G(1&= Y\L.<.G00^@L9Z
M8]OMQQ]G9#_F)O\ B._85SL'?8):<+EM0%2/)W'+O_1\O:O:*W*H!ZCQV=7H
M/1F8)5^*:1L/I3<C&7@I1U<L>09DPL0?"+IGQ!SCZN.!C[\TI!-QY>!W'Y%0
M;%WN[1IPV5/4%6_O2X\0H#5OU?$4(-1V$%;JW.3<[H4KFTKT3HVKB0*$3@W*
MB%J%8G,QU+/2JTPS4Z@D>/J" +(<_K\XKV/C<62 M>.8(H1\(*Z[=VEW87+[
M.^BDAO(W%KV2-+'L<.;7-< YI':" 5]O*KCIPB<(G")PB<(G")PB<(HGOB#N
MMF4G;5>L1J8A\FM<S*,,QBTP9*'#L\L"] VA7'%@,&4A&M. $X00BR$K(LXQ
MG/LYL,3=1V63M[R6O2BF8YU.=&N!-/;3E[5WCTSW)9;/]1,%NK)->[&X[+6M
MQ*& %_2BG8^30"0"\,!+ 2 74XCFJ#2*L=@'B96)>J*DG(MWM.,V)5Q55N$Q
MKP+[%4THJ:IHJQS>0N:>4*(HI8OCM7RPA:!"N5N &4]*I F,-P<E+[9#?8B.
MVAQ3KH=.WDCEZH9)I=IFE<YC1I#@[1("W4 W6'-J!1Q^GL5O+TNL-OXKTUN-
MQPFPPMY8Y$Y)EK?=&Y=;Y/)W,UG!&ZW;<MF\G?1/A,T,4!NV30NE8PQSOU=[
MU5O Z+ J%LB:=6W56^V=9T5L);(H^F9K.<I(Q-8XI!DR+#B=(V1R5O*UQ2.9
M[@C(0IB$1!H#C\*,!+SQ9_%BX^T'R$/G9%&Z,-<3$&N.MY--+@&AI:&DDEQ%
M!3CN,=ZV>G#,T=^7E\]EWF[7'X^YL603NEQ\<$T@N;QS^F()HVQ,@EMV02OF
MD?-*QS(S%J?FY12U]/CO=,^05*N+6;/Q&XZR%$G&4P4MQJ1+,V&HH9$)C.SD
M\E4LRQL4-<&<G)U(8U+NN3BRC3EE'C&;DG%;Y/$Q1VMH^X&FQDAEUAKZ2ECI
MGO8SPU!!>UK2\-:?$20*5U^%]0O3+&V&WML7.=C,&S;_ !60\U';7ACR;K2;
M*7=U:V8=;ME9(V2\MX+9]Y':PO'F)7/C:U@D.VO5X&CBS.@KX]2FUTE]ESN,
M/"J4Q(I/=V)9M#7%XQY@CH<O(UK&Y?$V)+4SB-\*;4I3Z)-@LPY-DQ27,>8Q
M8ZDCY@'7D<3' -?]1HM9('.=PHX:WM+=!<3'JJ ZC2L?53TX8V]O[G*-9-NR
MPQ]E<1-MKDNQ'EMNW^'GGG^J#)H_-W44D LW3R.LQ,7,CF#8G^LZ@;S5*K)5
M K9045M(J.)>@'R6&A/HU&3?D@FJ17,"BW\XIV/5UO)1JQA8!NWEOZ7*7.<E
M&@5X#+XMK8&F;C8CAX7_ %Q\NUA#/#P D;I\>FL9U<P6JT?JAZ;0PXB%V78Y
M^RV Q%MO=:<PXX6"T<VU)@!B#;^W$0-Z+;592"8 /8Z!3!1-;V_!)A&%<AK9
M42V4]73_ $HV.">21 X5BD3RZ(V]'3]C+"^"4((]%X+%TSDM(<@HW(Y6J/2)
MDYYA.!FZ[*WN.N[>1L,PUW$S9B"U_P!7TX7#IGP\7.>\M!;5H #G$ \.A>I6
M[MA[EP-[!BLNQUYG\M#EY&.M[H>0-EB9XA93'HZ7SW-Y<26\3[<RV[8HHIYI
M8VR%K(99:#O=I.J1X4UDH.'JHVQ&+-K8CD\-&LN]$WV4:L?'Z%B.D)"-L)20
M-&E<4A#^<TG'.R@Q&+!>"O4#V4N7Q4C;B-LW^7N>XDM?2$F(!K7^&IK(2TE@
M< T!W&M%Z#D?4_TTOH\[80YAK6[VFNKF21]O=AF(>_'AL,-W2 ND+KU\D$K[
M)MRQMLQDX+B_I-]C'K?=Z=.]0YQ@N4R*^9=5-E2N4HI-%CVZF3XC?\ZN:5Q)
MT)][E.SVZDLKNW(6LYG3+D:AT.5",-((*"<<ES6++FW+):NM(Y8V-+75FUV\
M<+'CA1HU!SG!Y:0T-H"305R7JYZ<2RV^?M,EKN-LV&2Q]M;/M[D/RK;K"6>*
MMKJ,](Q0QF:*>:Y9=20RLMVPM8R25YC9]<2J*^V"04S:CA3CF8OUWA5-5.?
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MK^BM_N?T^EW_  W\$-M%;YJ;HNC>7D86+$R2-U Z:SC*L##^087ZJZFJU0P
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M6G(4J0OK?W++.ZO?61T-I/D;>;['NCKLL?D\G-0/@X>6Q-U9W08:^*3K=)I
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MU)W%M2\QUU/<V6X,PUSVR,:UQFW7ALT*-<TD:8L1+ :\Y)F/'A:X&MURM"Z
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MJAI64<L4*3,XZ'@<"L!Z" /(NOXO-Q3Y>WQ+(W"1MQ"S544^IENGF@Y\1.T
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MJOU>51JEK0GF*<KT!#6NRH&:0(1WK6Q*4F-\6<^806$L74 <8QD;-,T ->X
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MT3)R9EP;.@=^)K'?A2=,FB[H!GC/Q;*SY"PLQ488I^QY)#CX?)1CPT"O8:J
M]L>S/N#;LXVQG\;:Z)GT=GUY]M2X(Y0UBSR2-D V*BVI="N]96K4MPJ6J-C'
M'69RDKJ6J;<]%I"PI/XC,$#\'2**6O:*#V%:'5/9][B%&5+K5+*SKW4-CNR@
M.Z)?&X3)12&R9JCH=AJ>[:H8:^:(U'Y.5$"Y&4AK-0B, 2VY(P>>@(*\)^1Y
MR#,H7M)/.E**7;Q[.VYMSE]W"CS5] -]*;B7E%]Q*$LARD4M52M;>,85U:J:
MJOL.&(V?"2.UH:WPYU1.3@0>N6B,6D&)P#  P&"![1I/&H%%CZR[/&P"2O\
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M&BG%)N_J*OLJ/U BV(JQ58LKAS?8,<CA$H1&">82[0M?8S3)4+H$664YJ=H
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MJ_LZT8C"IK<KW\7JPC+XY@3N\Q=O6M;9@AK2!"8,) G9]0HL*#O*3Y7+DR;
M_/4$EC* ">(Y*'7?N&:4L#5,7IYV,KMN00"PFBJ9;ZE8O M:;"D*>0*X]%\-
M?N_+HX+I"1$W3+>-*2>2N$W*0D#,$29@)3I=W+W5CO#1UT;.3W6&J9"BGDBJ
M^NSYO/I3'7%(NCD==TT_5UZI@AXP9\U5(D+JVJLJ1D^-,G,3F)Q#]06:660M
M(%2KB\*J<(G")PB<(N=7= D=?Q?6<ISLERC[5',V/$TV%4E;6]U;?>!J1]$E
M*]*Y4)L>F]0,!8\A%\7<"QC&>BLGKD)G<-CPW<^:T637NFZ+N#20:5;VB>W_
M '3_ ,$\Q]7^YKB=T9KU@=9[1ANILM]D7+M-O(^.30'0ZCJCS6!=I!(J//4/
M"L$G-GYW_EHU#^[:G?\ ]R(A_P#BD.>Q?9NX?^:N?^.__P!K+]6?]7GKO_Z.
MS_\ Y9=?_E-71WM<V)0DJV3<VVM)'7[K(@U=*%1B6,1M@:7'#84]Q0"DT2IL
MT0UM493 .-*P('QA,#D60YRC.Z8,)Z9OJSRT&&:^]9,V'KM'C<XBM'=AOKGC
M_P#LQ_?#D?DKWSMJ>IN$](H;S=]IE(,4<U;M#KBXFECZAAN2T:9-Y9]NH@.H
M?(M( -+B.I9)^ACGD"_*Q.$3A$X1.$7*;:&M+H?K(V!!"H[/G&,W/540K]>L
M837(M&W9K5CEEDH5[5DA27DE7)#,N49,&EQ@TU8[(RQY]@.G?L%?8R*RL_-/
MB;/;7#Y '4J>HYD9!X<F^&7CPHQQ7VWZ,[P]/<9M':SMQ7>+AS.WLW=7S&3"
M,OD^T)K:P>R74TU;;CH9!HDJUL5M<.;^57;-?*HL.#7>CG<NB^&QEDIVTII+
MG$X4\M4F4KW.[E[VR(KR>#WYX!*D#E#DQ*R(*2$2 HKPFD"QXC$N#N/E\A9W
M6+-K;OU2L%KP>]I: ( UQ@&D:2'DB4$N/(]CJ:3U3WOM3<GIQ)MK!7O6R%FW
M;@,=S=Q26[61XAD,S\/$V&(VSX[ISXLI&^69SJLD'!LQC^BJ&"]4,<V*16/"
M)FC3WQ7DCN)D*@TG6+Y:QRZ3%/S&]P1(KD[4PM4!L)NAI\83M;9@]2A N;E9
MWJ<]#<XKD)L4^:S=92Q%UI,V%VMH#',;I<V0AI<9(R\2E[J!VES13DL.]\GZ
M:W.6VG<;2R6/DEVSE8,5,;RW:RUFM;<PS0WCFV\DTE[8ONVY!]S<:(YC#/!'
MTAX 86(@=ZN]<IX/4%:@9R(G8+U<C)(%48LC6Z/2EYK>#PD4(1 K%^3R]3%'
MIRLESSE:T$EH&21&,:M:')&%)@C-GYO%1WANLC/J=)"(7-#H[AS6R/?K/4;H
MU@1C@\ZGQZVMXZ13T.3<WIK8[L?N/?F8-Q)?8J+%30-N+#/3VT5_>7?G'G(0
MNM6W,,=A']5=.=-=V+;R"W(D,+ S"/%>7T_D2-.@@EL-\9=KEM?91G(6$O*9
MU(<K*36?7;; 52/*KU:4+(W8$^91^'TY1CLE&''7P>'-%>8F(L<^6W,[;:*V
M-*$4C,4AD!I0ZCX*\Z,<.];&PW5Z98R6TENLG@Y<Q!M_&X"5S3$Z-T>/=CKZ
M2]:_3I=UI*68EKK<VVG:3356;*DJN2ZW3"I93(F5T4LTLBK\A?8M253V(IA\
M'D(HU7+>@5OD8:U\[<DTCDYR)6)S=C<)$HQ(2@"+ , S3M5D+^#,VMQ;PN:)
M8Y&EKII8];VZI"0UQ#!I;4:6\3XCQI0#SK?6]</ZN8'.X7%7$#,A8WT+X;G+
MY*Q;=7D'F+][VPW$C+.-UO;A\0M[9IED F>X.<US61[_ *11$V)D2HE\B@F"
M8J@JQ/:I7KU.ZR>U PRI_.$!\M22.C@PVTI-PJ+,+/0%I@^#J=@.0&8\'#W/
M<"<L,4FNW%--+ADC?FCYL30'1<C4.KW+JWO&9UF<ELI,;?"ZP#"T0M;G+/(0
MM'EH16'&V\<<V,:-+FN9.9#6D=0YAU7^YU-?+Z<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+
M@4?VC;?:X)6==1"S:=;H\OA%A4Q>@E<5D99S56$LW04[;-LBI%*W>2C(L(LE
M8>RJB73!"'U)A#@ T0D04ZDLFL5K]W)6ET_TBNJ@-CYQ9,\FM7/]:(X;=\!J
ME!$D<M(G:EFN+;&;[/9=+$R\AQ'TSFR9FXF?!+:(THWTF%.1X\[R22AS@1[?
M[B@2!]JJX(>W5,G)NB$-KM7$9TM9@R)H8'E0N1.^KL*VVC+M(61*XA]*:H7.
M>P[8M:BE/V,/NH\"CI@P'"DO!^7Y:*K3KVG=AF6'PZ/6%*4E@32W=Q]=S++E
M$$D-O6<H!0;=KZOI[:A19$]NMY<96D;KJB#"J.,) :)N;W5>@0)2\@P$8H4A
MXK][_@76_;G3!XV0N[4&TF.8L\39J*L4;C;K O:U*Q1:-5I)+ +=8H.@.3""
M0D4M]YTK#W3Q*<"(]$F5EXQXS0]95 Z@(5#(=VL-EX7\27--:E&.CSKV]ZS1
M2ADXV:=M#=,JAH/8&Q+E7NMUJDP5JQ%9TB;+"]$26TEJFPA8@,49,R%R,+2%
M;6/C5K](]!'C5BY+9G<E5Q67I%ZJVVVI9T38-Y/4Y3P.Z[R>KYE$0D==3*3N
M-,P AKD:U$3YD40DB=ST65RCR35!Q.2ASJA5JJ'M579"+&IF12FUJI7QG6N7
MU3'JI)C<?E*&02VE:\M6YK56N=F#6C,0E6NYJK+0MY12$1K65Z%8LR=D;AZ=
M,4ZQ0^U:O&NS];K'5Z"!G6[6QRU'6.(():2RR8",2W';6L;2'UH"A!P;A'\=
MIH2]^']G[J(&5_Q^0\)K'W?#59:U>T98,ZL!QG!LPKV9-$MD$KC$\KB03:_:
MNCLAI>Q]>=0*>F25P?Z2DT8DK^_)7O5XX\+&O&9'WAL=BBU0B3TI9G"!X^[[
M_P"RK.[R:'67LI.6-YK"=5_%(S,**>M7+G33UHD#R]LU3/MI5Q9JB85(:U'8
M3&6.CS!CT!:=U$4A,&K3K!G>-!@A24-< .*EULU*EB+3'9K6,V7, Y'>:K>
MYBDP4KF-D8"MJ+$N*9Q<+JF,P%>J'%D=EIRG#)73!YR<T17P1!X4:O$'=U/D
M7-UU[<5XK;EU<EUH+(P\S.;;8HYIL8;3K')U=/-VNE.:Z4>BBT%?7F8B(?!J
M9O<FFU=.1N5!/0U:O5)2PC(3Y4&%?6*&G=^/^ZK#[D:H7WL;NE%$\,1QF/4:
M[:_58QV]9,H*>#5Z$-<[?PJ]"(Q6)#5D2158+JD@GE>)P\I&A3J@J\&"-*"G
M/*K2 WVJ-VGM@;"U\JIBQ:]LREG2V-?XG22:$L\V:9L57,HD]=SC=I7*"96I
M92S)$UL:^$;>!RUJ$A)ZI*\,^<F%"(.ZX*=8//D?[G["PB'LVR\JN6:I5MTQ
MPR,IFFDH\ZOZ..N:9^$WU]H]L5JM+G%G:QJ3FY$I<95>!3LU(Q'B(3M:(20T
MW(\A'DIZG&OW<U8.K>WO.(SHOM/KL_K*\8[LV4KF50)]L)CL*_K6CKRN%2;3
M2L(E\E<;QDDEFB(Y"RLB<)C4VC+;VYO)(1IO-\CSS2@O\0/8%'<][8=AR1RF
MCJ:Y4I8C?(I#N(]@@-@F65'&%U(V1E&J<ABJ57+8"<EF<1>H49KXL4E/+09A
M<W.Q[>L28$-,+&8HH#Q^!::X=L3;&10.:L$ZV%AE@3*5UEI(['6&[/=LQV8N
M%]:97+(+&9FY\F405M$Q^(,KB[P4U&RM$M2S EP3!=/)&IR+&94ZV]@[_E6'
M7]I6ZG2>4%D%D0F-4U7RJ,R]_KMOM/965IZ_G*U9?+K=9E7MDVD[JQ6&KMR3
M7.4]'RB: 42!&M;1$D>6G-+"G)K%/:I?H'MOW4QZZ;>TA>UDU:%QV,UKJS5^
M-2&GVB5C01R,5-KVZ4(TS-\:Y<)$-2]OI*HMT4MJ8S"0CJ)($XP(?4#*"X:@
M1V%;[2.CU\LEV5_L5<TWJ#,_*OR>W%9,4JALF*>"E-SAIQ#M180R0<^49P[J
M'$*"")7MV4KRR@Y-5C2D!R!.4880N%*#E_=JM<V#[;UC7%8=W3%IL:$-*&TI
MQ>\J:T+HUOIZAK36UVWFW29K2KQIL9*-4-DS0Y>E(B_@C:LX*!]GX0.I]WMJ
MJ_'=IS9)\L28R287A Y(@/A:Z$P^0N\BNE]?S&!;L/JK=+%'%,#?7A;5]:QZ
MM8OK^LC;<7%4B4;SA2E7.61'X,""%;6/N^^I?@7;%LV(V@R3Q79T$5H&N^JS
MMLU F:I !6:T0?9C>N\5S068;CR<.*YCVP:4)0\_8@JVE6(7V,PGDJ"\4I[/
MV/V% %$Z(;)ZQ[)Z4U6C#&[*J"-R& 7O;=C,T7F+0&!S"E-$9KIP:S$R5S&7
M$'*/S=Q<V=8T-@?,D)0CU@S"0(B!*!%)<"">W^ZKOS72.W)5L=85DDS2NDU:
MRG;C4?:MF1')I..<)5M$56SU3.X:XE!*S'O2/*")(%K2L),\SSE2@I2 ("2A
MF%4.%*>PA4R2=I38R'TP@A=?VG4"*UV<O6_X@7(!PMJ%RBC932U"/=-N=H5J
MNAIA9SR[K3'P\)T<> &,$C85"AL<\!*.$+!6UBO'DNE%G:^7D;M?4VR-12VJ
MS"R*B.H&YVNT622'KP04RQXU8V9I5F(N>4BQ.!J6I:D$A<A$MN1*$BD1@O19
M2J2H"*4*H=KKVO-BZ\M>-VI;=S0F;R!CN'6^>R&1BE%U3R56411,!VWALAF#
M\X6B\/.(E+K*<-BD+CEA91$1=C]$I(1E^$8#!E8O%*#EQ4BZRZ*;9:U7 HF+
M-/==I##XZRJ*@@Q;FU62"4.=)S';::;"SYYF!20U*UH[621*<G-+3A(<H:S'
M1*%8JSDH\2<DH+FD=M?[B[*\*B<(G")PB<(J,=PL45#0!>9A85RUFT?'R-=)
M)15H5E44XRK],\>0W"EELR2+143*JQXLJ$N%7JCA +R6 6 #Z=HVAU_M;][0
MVTTG2=X9XI)64JWCIB:YU>XTI0D5XA?27NKC-'U0(P&*V_F+_P"S+C][YG'9
M#)V>G5%63RV,@N;GJMX!DG3Z; YP<X%S:\.O-H/\L/N6_GW:-?AJYZG_ -;?
M^CL)_P"0WW_T*_1_1ZG?^X/H_P#_ &-WA_[)5[>W>.KA7VX8AU_[B6<[?)W(
MLCCE[[.:U6_"2D?O:-^<YD12I+%E4I)?DQG@ 0L&EPD)*-- 8,(C"\"ZGO'S
MWV4WS-ICH(^LWQ06US"^M'<"Z:-C=/>*U) H.!7S3[UC=YCTQB.?VOL'#V/V
MK!2?#;>W!B[LOZ5Q2,W.3L+:V,+A4OB$G5<YK'-:6L<1V_YY@OSD3A$X1.$3
MA%3B?7C:$6M&9I6U- U%9UR\4&S2)I6M$AS.WO%U28474.3%)4\D+84)L;4K
M$QY2(YH497! 85Z@D1@!@[):8JQGL8G/,HO9VSEI!;H;T6ZJ.;IU'4 07!XT
M\#0T*]_VQZ;[,S6S,?->/R;-X9:WS4L$K)8/)P_9-OYAL<UNZW,SQ.UDC'3-
MNF"$EC^E(&N:Z*H[LI?LAJ9EGA30B,<)$X0\Q6!#K1<GCAT=>XW)'QR>&"*+
MK'*D.P"$EQ1-R,1\8&G&D1J3''*=05@)..=-A<3#D'VI<=# ^E;F'QN:YK0'
M.$>F T+C22NH@,J#Q7=<MZ0^F&*WS<;9?/(+6TBN@TOW!BJ74\-Q;PQQ37++
M P81YC?/*&9 /$LL;;42Q/)><DAVHL6:&*V:(J:O:E;>R.DV638N-V)9D74Q
M&.5-0$M7DQR*QU5&)G)7)YF=W8))$$"90C:$6<F(S%8L Y1^!L[4"6X$[FEP
M9HU1QN#W2W#!J<X.8T!D''F"]W!P:N)<^BFT]O-9D,ZS,SP2W$=FRS-Q8X^X
M;=3Y/-VK#<7,[;BTMXXK3$:G@F1DMU+1EPV!NI?)#MW7-WE!#1)6B$M4?>)D
MQ9BDM:W)\5LLHK0BC$EBV0[M@W5(SK\/L$E2@G PGI2/,8G-$<), [U&"KW.
MUV1P&2!TKI6Q.U,(:'-DZYCC!H2-,C0>1-'M<-1%*Y\_[N=G889U]B)\C/E(
M,?-YFUDCA;+;Y!V8=86$4@C=*SHWELUU"R1^F\M[B,3.CZ1?_*KVAMJZVRJ7
M:(/%+M'QFM9]K6=MHHY*)MAJR77<DNJ-JV5Z:[&CB<I<JKI,UHEI!Z<["=X/
M4B"+(",)\K_!8_&/N&7#;EP9;MD8=365^L;"X$&-W 2%Y:015@;VFJ;V]&=C
M>G=YF['.V^X9_)X2'(64G7M[3JUOK?$W#98I+"=Q8V_=<2PO8]A?:LA:6ATG
M5'TL&T]K2.(*[23-5>H(; ":O!8,9/0ORB3R938!S6L=C8:\8D*=#'2HY'Y$
MB$A+5HG(3PX 4)\B2!\L[E9<#80W(L"Z8W,QEZ;JMTM$=0-8TU=J<UVH@MT-
MH?%Q"Q93T5V1B,ZS9<T^5EW!E'9$V-P'PMM[=MB)&1"[BZ#GSF>>"83.BFMQ
M:P&*4-G.IBS-(;?/L[0#^4&,L4:?HG23_:=C,C&>X*C$@T2AD=8LYQTQ<=XE
M$2FT#>RG%(,T(C0*?-2B,R8E.QS'E-NPVC_WF][XI+IL4;G4%:Z@X.I^6R1I
M::<*4=2C@M?ZC>@^,VU=#]5;RYO,9?;C@QMA-,&-#@]LT=S'.&#PW-I>PN@E
M#2&F/1,&ADT:UQ9M-<)\UBD$2M<::'%X<%2=T7M=26=< DGD5-KK/O3#883+
M&1<SH"GBZ%J<YX5&Y1$)T2?Q@P,T6<Y1@L<+9]V7/<QH% 98HJUEN(ZZGL<"
M:0M(8!4EQH:!;:#T6V#%MZ]W+-/>3VL$371LDR>/Q8=7)YVRU":[MIF2O,6)
MAD9:QM$KWS2Z7%K %)=T;5DU==D7J8@</'AU@,@?'7+PYG%/Q4I<V>7N=8(V
MEK3J2Q*V=S/K5X3.><X\TLY8VX+$#S1>+AXW F^QDF0/4\,S6B@\.D%@E)-.
M! D86]E ^O)=0]/?1.3>GIW>[XE%^.AE((8^E&#";:.6UCR+Y9'-.F6-N0M9
M+<#PN9%=EP=H%(J8=V)PIB(9D]U\UX%74/J1ROV"Q[+@YR]ADEAJK"8' B%#
M-7$I'%G)=VJ-NS;E27XUL;>!J/'@T( 8Y\NV+47'EHIG?722B![J!CFQB-PU
M\*@T,C'4^;(P#E5=UR?N[;<ASIV_CLK-3+7^3CPMY/HCM9K>Q;8SL-V PNCE
M,4E_;7 C=2&_M6Q:2PN<K;U/.IF_N,KAUCM[ W3J'H8.ZNI<6]:)B]+-8YA?
MZ9*:O5*U"D33(VQT18.Z@PH(3%'>67DS( ]>R%K;0LCN;)SW6LA>!JIJJQU*
MF@%*M+74["2*FE5X7OC;>W\9:6.?VE+=2[:OY+R.,W.CK:K2?1J<&-:UHE@D
MMIM%#TWR/CU/# XS5S6+SQ.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7.
M3NCV,KJ_6,J3(IG!8*?FR8DV^_+"E=X0V/Y K1OPQ(L/&OP13[*]1Z?J63G'
MH1A +)WP@E\[CL:S;>YOHOCEE'1<=,;87NYMXTG^KIQY\^5.%5]9^YAM.#>?
MK&[#W&/R62C&(N9.C8VV'NIZM?"-?2S?[RT-U4<[],"0(^!>OSH_CG2+\I;5
M/\X#NG?P?GLOZMP_^)7_ /\ (8O]E?K#_P##YBO_ '0WM_ZD].?V5TE[6.P[
MM:6RSI&EMQ4?.R2JLE+IADKNU-V9F_ ,2OD3)"O,:-A2@00#<1A5D)AQ?_E
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M1J#1%:M7$@4B1>L<F"M6,D_("PASE $0<!R(?BFZR5S=!T9.FV<ZN@<AXGO
M';0.D>1_?*^Y?4'<.XV7%A)*8<!/<=46C:&**EQ>73&,):'Z8YLA>.94DCK.
M!) ;3)2*H:WEJ67(Y%%$#H1.W&-N\LP<:N :[N,0PUXC*H:@A44H2"9<LR<1
M&"!E!",&19QD1AF14AR-[;NC=#(6F)K@SEP#ZZA2E#JJ:UK\@7$Q._-W8.:P
MGQ-]+#)C(;B*VH&$11W74\PT-<TM<)>K('EX<2"!6C6AN.%151"S)A?$-C .
M91V"Q25&% 4D&OT?K,U<= VYR-)4 ,4!C(G(["<S.?-\ L $(0 @"&_VKD?!
M]:[ZI[WLY>%TM.H1W:J"O9VKEM]2]]M%F/M.Y+<?=WES; EI$,^0#!>R1@M(
M:;CIL,C?FU&H-#BXG9H["T3!))U*L*C5KM.W1H6+332PEA0-S"Q(61H94F B
M%D21+DA0JR(7PA*%IV?8'(0XP37+IH8K>@$<32![2YQ<7'VG@/@:%I\KN&XR
MF(QN$+&QV.,AE8P DZY)IGS2RNK^4ZK(Z#@&1,'$U)W/G&77DX1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M14BL_N1Z,4Y.I!6=B;+UPR3V)*2D,KBZ-6YR5SBSD<G*6 :)("+-CT4PO7HU
M!9PD2L1*L!)H!B+P$8,Y(M"^EO[<_P"5+"__ -ASS[T^$3Z6_MS_ )4L+_\
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M?ALZVK:\'>1JVOZ:.M'\5/EDE_Y14Q_.0E?_ .-EYZ=]FV__ (G'_P"3,_\
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M32"QV&3*GN.D,X,&%%QCJH-Z> D?4..=LGF+7OMI&W+!.XD@.BT$O)/!Q:0
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MPE;AL7$XQ!;T6OT1:'-3:L1A1*Q/#V&:'*DY@WE#%RUYN4&#,Y$D'G RLA&
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M]K&JHW2.PW=JK"(ND\>H]&-RJCPWN=FV--[:G"K+KHSJV\JLO=@V.^R6:/\
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MDLFJB?))HFG1^N;5*5>RCAAC9&-BCJ29I'UE*5GN @*RRAPC=-!6G,?A5?\
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M,+>:OFBF40<DA;@W2N-KT!K2:_E+43XUJDAC$0<-.>]%J2%1A(VDE06(L:G
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MB08CQB\(?:4AI<:!6$?I5&(L24HD\C88XG/R/!![\\-[02=DO)03,%&N"A.
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M@^3PBZH\(L<\"* T.@SVTYY( W+A'-"8@A4H=2@IC<F-J=,J-(3*#EP,9*
MP8"QB%C A8QG.>$7X8/E"N"'4UNI0NG^N&U$J[=RRMZU<ISKMO'J_8,O+T6L
MZ9;,L#5<$#JF&@-2/]]5_#*_5N4O#%VIQ<T*(:, \*!EY/"?"Y%!4%Q&KV=J
MK"Q:K;'$ZPUT.A:RLMP1;'[6;T=LV2.!%!3ND24.J>V4\I:>0RT$U+N+:<X4
M[6")3$7U<G0GB"V,_O8PC)V!8%XBM45X]@!716@]4+)C_?!?%$F<YM4LZKS<
M*4S>K')KU N"8 LC2A!0B"$P2OU^W['+$M0PVA2H6A+94\85MAAC=+$01YZF
MG?8RH36/V4[^VO<M3[N<)BUB]U78R$1^J)Q8&W4BH/MI@TOET"@$MDSI4UD-
M&U<F?)W,5DVCB4YJJMK+KIO5#5N+L:F2J424\H!GB"(.7:C#1GLJ:_$N?^Y[
M+:DBV#W]M>44H?3\X<:1[L\5NIBAFJ=@5A&6F.IF)J14C);"V?=SUT6V+6W,
MS,B>0(<EF$)6@_/[G+QZD( E9O(#VCM_$I+E=&/LFH6RIYK11,^KKMK+=Y-'
MY7*Z]F6J]PSB%+$T/T_<XA>MHNVJ"55&+$LVHDE_K6DQ[)0F (='(H"X CP)
M<YX0'C0_/H?P]ZMEJI3=-ZCVQ$=K=Q8/:.P5.Z.]J6N+MIBV)SK?/:TFL$=4
M6X5U/<,BL+KZS'X:N.6- X=(4;>VM2]X&L+:/2CQX"#09R57'4*#@2?Q+JSW
MR*ZK&XJF[=-U6GKS+[8K:";MTM([9C"2K))94XC5$V-#)2"?QU\@<'(D#PH1
M/3XDCZ-T3IP*"_6D)P>9X<=12JQU!('.BXHWEJ2[W!:]M,D\UKG4O@Z?;?\
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MB209$+/ZF,<(N0E9=Z&B+I@5D6/5>N^Z$JBT);H1)X<\**'%&&&]X!.;63U
MBL"E)7)Y.U1.1L#=(A'J5!"]<V.N6U(<>4D,\L80E<QD'B0NI)]I5DED3C$%
M5BP1-+&=(8O=XNHET?)D34A*;#'HU:Y,AC@%R0I"F<H:L1AI00!3!R;G/@QD
M7"I0K[XG/8-/4Z]7!9I$YHD:UONUS51.1,\C3MSCY)2GT"\YG6+"T:WTYX#/
M*,R$?@&$73IG&>$HH;:(]J]%[8G&QK8X5HW6M9\'98E,[(',V\:U_K^FW=Y(
M;VGS53V8UI6&#R"5+0JA)BR@E+%F<*19,\& E/'DM@G\6H7:ZE9Y7LR-AMO4
M;8;,\PZ?(&V3DN$5?F0L?DR)A<GR,.Q62B0>2(I8 "DL8 X$ ><>W'"<056+
M3/N%:^;35=*K"@C.^4_2L$M1QH>O)G;3A7T/C%I+(FK51HI96I:&;/*W#.:X
MLYR5$E<RFUR/ 6$PM+DH8!Y*7-(-#S5N)DZ4C.52VD; <JLEZZ2D8)<:CF"V
M)ORQ_3)"2'\)2V!/)JH]T(3IR2EOA&D,"   G>S&,"X4<>:VU5-H<CDA4,4R
MN.$S,]F42%-#QO;8&5*F%*8(I0\I8Z)5AW4-9)P,@$H 3DH(\>'(NOLX44*K
MMK+N=26TM&T]?L0>A0V*7ROEC?5K%9:U@BLTE!\3F,AAZA.@8,O2W*QQ6GQT
M:HM(F-4* )CB_," ?B"$I+2TT/8MUNW9JF:!KVZ;$GDS9Q):"K"06[8\48W=
MC<9ZVP^/LZEYR<3%#75&NRL?"T^"&T!^2 +59Q10!^(8>$ )-.]>JK=GJ5M6
MOJ=G[7/X>R O"'PR7PB,/TQB::4K,39O3JVU@ VIWI4%?($RTTQ <0D&HZ+D
MYI0<B$#/"$$*02[9JPUK>WPJRZ_,98T]"C<C=RYE'!M;!(@&@(&PO;@%RRD:
MGH!YH092GC+/P,6,>'KG'"4*B\_9J'FW'3U41J/R>=,MRP&R[ 9KJA1L3?J8
M84-:*H\D6-,AE)$H"X8=I <_9P@PB0K4XLI#L&FE9#PE.%5-L5F,1G30!_A,
MICDQ83%"I&6]Q5[;)"T&*T1HDZU*!R:%2M&)0D/#D!H,#\18\9P+&,\*%6"'
M[R4%.]D+BUIC$E)<9%1%0Q"Y+*G93G&S*P9&*9R27QI$S"E2=]/P&1,JF#KC
M74D\D@IO)\KQF9$/(0%-#2JT78?N*4S0$HAT*3QNP+ID]A:^WSLE!D-+I(K*
M$<L@>O[='%DD0,+VY2MC9G"2R-3+$1#00 _TZC.31FGDA+QD92&D_&K;1>U8
M/*8Y&Y !^:F;,E4-+.4R/3VPIWULE[LTIWC$!=$R-U6IRIR@3*.BAN*... (
M LA\0,8%DHH5$E&LFINM-1#@E*/]906HH7,Y@G<0D6,D=VQIL*7RAXFDU322
M4R.2.[@.7N\H?EBQ44O6#5X,.SCPA $(0D.HGCS4QMUK5<\-87QHLF NC(-R
M:V8#PW3&.KFL3N]@(,96H+@F<34@G)W J*$E(P/S5&# Y+"+Q8ZDH5DI'/(-
M#E;&@ETSB<572=P+:(TCD<B9V-7(74T00%-C&G<UB4YV<#1C#@)*?!A@LYQC
M&/;PHH5 .N&X=/;2RG8J)U@N6'.>L]WR&A9R!T.9"CG.519ECCJ\/D<0M[PX
MN"J&852+"%.X*"DV%*Q&I" '0OQ9*Q:6TKVA6JX54X1.$3A$X1.$3A$X1.$3
MA%ITSL."UVC3.,[EL?B*%8%\$D5R%T2-:=2&,Q5^G$A$2:K,+"9AEAT7<7-3
MT_XE$A..%T 6+." $\EDR)1'U3DT-"9U2J'!^8ELG9R"!"-PX,#<>RIUCHG.
M  1 DQ)TB18ZY%C(O4!R'&<=<X(L]U__ "?5_P '"*-YI<%75RO&USN>1F*.
M)<"G=I&(WQT3H3RZZK +&*PIF,!PL9!'H>&2H,KU&>@",*R^N?A<*:$K:@2B
M.CCN);AY;\1G+.&09>QJ0%-X&43:%XPY&'F9 $I+[J%A1D0NG0KX6?9PH6KH
M+<K5T;:Q>6V8LR]IN<I(?5SDC.,4(9H0OAB^PT1[0J**$3DA7"FL]Q+&9DL(
MTX.N,^(00Y*:'XEFV&=0Z4O4RCD=DC2\OM>O:*-S=K;U9:A9&']RC$?FB%H=
MR@9SE*O4Q25MK@$O/PO2KB1Y]A@>I10K:^$3A$ZX^I^K]7I_@QTZ_6Z\(L''
M9-'I<VB>(N]-K^U!<WUE$XM*LE<CP[1A\<HS(6_U! AEY5,TA9U2)0#KU*4I
MS "Z"#G'"+.<(G7&>O3/U,],_P"#/3&>F?UL],\(L$9*(X5)4L-,?&L$L6L3
MA)TD=$M(P\*(ZTN#:U.3V4@R/U VQ"Y/"4@T[ ?  U0 .<]18QPBSO"+0I+:
M5=0US"S2R9,$;<AI"5I29[7E-OG)CVN8O@!D&JLE$'BPRU\]K!@ (0RTK8H-
M%C!9>1<*:%;:U.K:^-;:]LZY,Y-#P@1.C4Y(S@'HW!N<4Y2I M2'@SD!R=6F
M. ,L6,YP((L9Q]7A0M0L>U*WI^/DRRTYQ&:^BY[PV, )%+G9(QL@'EZ/RE:6
M\]T7F$HDQ[BJQY17F#!@9F< QGQ"QC)2 3R6RQN1L<OCS!+(RZ)'N.2EE:Y'
M'GA"9YJ)W8WI"G<FIT1&=,>:D7(%19I8NF.H!XS^KPH7A)I/'H9'GF62QZ;8
MY&8\W*G=]?GA62@:VEK0DB4+%Z]8H$ E,E3$@R(8Q9QC&,<)S6=X1?P0L "(
M8L] AQD0L_K8#CKG/_P8QPBU84XB)<)'9!\A;$D#)BYDU42I>HP@9DD3):Q/
M9[^M5+<$!1-B=H!E088;X,%E!R(73IGA/9VKX6ZRX"\&DDM$L9G4P^7*X$ +
M8K"OP"9(&%3)UL</$DP<!*Z)&!&8J,+-R#("P^WIG.,9)0K>.O\ ^7ZG^']7
M_P"+A$Z_J?J_5Z?X^O3Z_3A%@9-*(Y#&57(Y8^-<<84 T9:UX>5A"!O3&."Y
M,V("SE2@8"@#6.*TD@K&<]1FFA!CJ(6,<(L]UZ_4]OU<?6]F?K9X1<:]RH;-
M+V[D&JFN)>Q6S-'5D^ZE;16I($.N%QO=0N,BF,&LS7:/1E8_KFA.KPZ)FQJF
MSD !8P8S@1_7 L8QG BR-H&$T%:A1K;&GD0IZZ-:ZGE&[G=C"S[+R&?P*.6.
M#>F4$QR.6;$X8;/XO WU.>R@4Y<+)C#$_#:S2Q>#*IFRGR')B@GA :@F@X>Q
M8"W]1VV(VU ==:DW1[I%M7W-"V^5OL7'OK.F.+U#3 '?W<_7!;4D219V.CK2
M>-.H0QIM G,<92]EY3)@ 2IG)<@A >%2!3X%Y;-:QRW3B7Z26)76[?<"F:B:
M=P#5RGY;$;@VGEE@P&2P&P)0XI92R/D56($:5Q(<$J$ ,X&/(<!SGKC.,].2
M@-:@@<EW[X6-.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%RE[/QA)&
MO>P<>59#\<(GW&NX^SV$$73*K$I7[CVY*TARW/[,1BZ&21I4E"%^S2G%"QU#
MD.<D42Q*-M#ANEWPJHF-08O9LM:H-0+1^0L:B,(3KL@TRUPGE%.4)2J9J\1Z
M*$E21ZI%<U9/7KDB(@T[&33RL?"P15#UB[B5S:'41+M-=LZ M-/LO6ZV'1OM
MV4_;%BUH\VEN)1%I6LU4W1<(<;0K9[L:!/%H48]R!"Q3U:F&I4I(R2AD*M+G
M"E1G!%>C2QB3ZM]PC<_1RORBV[7EYJ2E=ZJBKQOQTCM$2F]I[<E=WE6\,3X"
M$ICK^73RK"Y<V-) $Z-O<'EUPE*+),"661;CHT8G=-[>\<_L8?'&L[-ZV10U
M81_R%3/8EH_009N47D.?+$N;T[LV)U6<?"P87@(O;CA%U(=1A+:W(P;:<\@
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M75K8J#(6B9QBS+HD%OE5P\TI9L(5+V&1@C[H[*5*,\I6C)&M2(Q (L'JKNO
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MK(,M75G&W<J01VNX*POQ&'W!+VRQ)@:W<G$H7D.DFP2Y(6\A85B1.:8M2O\
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MRTAM4UL:E)3N20E,9!8N-.4E>9>CL%X3%DB:\EEIW6>MR=\4@QC 3W<@M8/
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MCTGPX'X<$2/R4RW!YGG 'XQ=25*],+U>UGK=X89#7>NU%P)_BP78$8?(74D
MBSQ' /X<@?0,+FQQ]"M: O0,YPKPG&7A3C/0SQ<(23S*RZ_7ZA72P#+9<Z2J
M)QM0XQG-.LM?6T-5V :;'E+6L8##)DH93)&,QC6,:(U'G*G.4QB,@1?A$47D
M)*FE.Q94=-U"8V*60RJZW&S+8T^0M8T#@\8$V*X=)W(;U)8FI0":\I#XU(7@
MP2M<@&#*56I%DTT QY\7"5*CQOT^U):<EY:M6]=&S),;>X:3EOI*M$62HA)@
M.!<DBI>4T9+R"-R MV5!7(<=$JO"DW!H!X,'U)4]Y4EME3U8R-*QA9JTK]H8
MG&&--<N#*V0V.(&E=7K"E=4+' UC<E;2D:J&,R)\6DI&L8!(4Q2P\!900FF8
M$2I6(K:AZ.IH2T=/TS5%4C<D:=O<1UM7<0@PEZ!&M7N*1"M%%V=KRJ1I7!U5
M'EE&>( #E)HPXP(P><D))YJ40IR 'FJ@D$A4GEDDG* E@P><2F$<-.4:;@.#
M#"R!J3,@#G.<!R8+..GBSU*%[N$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$59FK6]R;(%*8,+9+9ET/D[BSN!4Z=9S$U$]C 6DXLX;?
M%G8F )FU W.V"_ L <B4", +. B!G/7&[DS+'W;+KR5DT,!'3#']-U12KAU*
MDCF*.''O7L-[ZMV=YN>RW(W:.SH8K.*5ALX[.Y;97'5! ?<Q&]=(^2*M8BR6
M,-(%0[DL\?1:\YQJQPQ>M]DAK%(UI%3>1+HX!NL_+8K(5"5VF2*&C-?U;G@G
MRE0D8VX)A0Q8"$&<X%C",HT-G;Y6T^O)(.AU8ZBGU7C\(',5U4/>M9'ZDVT=
MKFK8[:VPXYF21S7FUGUX[J-+0W''S8$+8ZZHQ*)RUP!)<!0B*,7DN=I.6;UO
MLX-FH79$E;3Y='!ME8B=5)JD"VK2 PT!K N:L&^6D&L,<0EE!#@01YQUR.4:
M60-\K:#H%I)T.K)04I+X_$#S=334]RB3U)MI+/"VGZM;8:</)$]T@M9^ID.F
MT-+,B[S9$S)*:I1$V N<206C@L*NUS<EL&BD*#L=LJB/BSPYNQLV0SB*%3F4
M@<CS#@M$K=3($<WN#.VX'X$Q9*-,,L <8$,>?;S*W,,;=/NO)V1#V@:"QVAM
M.UHZE03VU)6RMO5FTM]R7VXCM+:$D=[;QQ"S?9W)L[8QM ZMM$+T2,EDI61S
MY9 7$D-;R6ZYJ57FTE]F_*W<&$JYH$TAK'$D9/DM0C$TD-?O9 P?%CWN2[A&
M3ZK!@G$8/5C$/P>'. 8XOGV^1%EY>WU!U>II/5/&M"[52G9\WEP]JZX-\P#9
MD6S_ +"P/6CGZOVAY>;[1>.J9.D^;S'2,5#T](@!Z0#=51J.C)-;W))7;O7^
M=DMF5:AVD220 L%7.8F98C26D3DI\Q]H>2X 4UIHZKR3YAQ(T)IHC!BS@T.,
MXQCE/S+'WC;OR5D UA;TPQ_3/&NHCJ5U=@.H<.Q=EN/5NSGW7!N@;1V='%!:
M.@-BRSN18RESB[KRQ&],CIVUTM>)FM#0 6'F=G44HM/D];R7%V7DG*KMB9F1
M3&D\KCX(Q8HV?!V!OED(!1$:M[?7CSOW::E4("S? 'PE@Z9ZX1DFB&:'RUK6
M9[G:M+M4>K\F,ZZ-:W\D$.IVDK31>HEM%ALOB#MW;;GY6YEF;<.MIS<6(EI2
M&P?YH-AABI]4V1DSFU.I[J\,:CH-P2%6B5F_MA%>;,R;E*:LF,9,-K+S7)8X
MXQ5P@0DK##@H*S"8'K,./1,26'VB#D8KORK'=#]Z6@Z/.C'?6< /K?'XN5>&
MGB2N7<>IUK._"O&U]JQ_8]-09:W &0I&R/\ ZQK=GK5T]0]+H?6/>>1#1\Z_
M7MQ71BO(V'878Q ; %SDM425!-(N3)[ "XN13B%%8:XR#')'E"W!*],F E3H
M1 3#$$0A"S@6);EV-FFF\G9D2@#26.TQT%*QC74$\S4NX]RS6WJG:6V8RN7.
MU=IRLRD<;&V[[2X-O8].,QZ[%@O Z)\E>I(9'S R $!H\*V,%.+06'+)_P#+
M)=(T\I8UK*57XY.PYKR*C6($"'#U$V;$4PYM[XC$AR>2:<N4EA//-%DL6!8"
M'$<BTV<=IY:VK&X'J:7=1]"31YUT+36A :. '%:EV_[=VU+':_ZO[>$ME<LE
M-\+>;SUR&O>_HW,OF>F^%VO0]K(8W%C& .!!)U .N#EBM1UU^,CLQE2.5AE/
MRC"G,4S90"L-V&_XK ?/B#AJQ%,BQZC*?T&3O4?"\[P_!YG^V&><\WY.RIT]
M'3T.Z?.NO3KKK[*ZJ4[%O3ZM6AW<-U_JCL\1"Q\MY#R=SY GJ:_,F'SO4\S^
M1KZVCI\.G7Q+;3*;6F3Z&SOY9KK+(B#"WL9T#+E# & S Q D<$@GR9-&8F)R
M<WY?E?@U0<0M2EC.3E9"6' <A%@&2;Y22U\M;5D>7:]+NHRI!TL.N@:*4 +3
MP)XK1L]0+=NU\AMK]7]NF6_N7S"]-O-YVU#W,=T;27S/3CA9HTL:^*1P:]X+
MR2", @U]<$,>LA@%L)L4N,L16WJD[^OFD8.D-=X0.:AR$EK=87!R4S(D7A4>
MF4!5$+Q#2E@"'(18R/.5V68Z6&7REF!"#X0QVF2HI]8-=74YBA;Q[UM+KU2M
M;G*8C)C:NTXFXICVNA9:7 @OM<;8]5^PWA=,YFGJ,,;X0)'.)!!TCV+:!<%B
M.KT8=@-AD>:T,$-2L13*,%++,\3FB<O!:!ID(- _%A"CRFQA(%O_ '*<8']D
M+ PPS+,89SY2S/6Y58[ZO@1]7X_#SKQU<0%2W]4+6WN,S.=K;4D&8 #6OM+@
MLQ](WQUQP%X#"3JZAZIG^L:QW(%IRY%+K29;8<KS=5WG%3]@=V)/%#Y3'QQ*
MOS'8M*6!]KQN#$0+69_:?39$C.4J5Q98C1Y$6/KC&,9R33;PP>6M:Q/:[5I=
MKDI^3(=="T_E  $]X7!D]0K>3!8K"?J[MQK\7=13.N1;3BZOA$7$PWTGFBR6
M"7525L<<+G!K:/;0UU13K>Y*:Z;*^QLELTF4-LE4R,5A)IS$R[%<BU*0Y)B.
M.;T. &-9\:39.\TH@"$LT)P YR;G&/#G.W,L;=NN_)61#F:>F6.Z8XUU =2N
MKLKJI3L6ZA]6[.'=<VZ3M'9SXIK-L'D76=R;&,M<'=>.(7HD;<.II<\S.:6D
MC0#Q6\8J-9BSV>ROE=N+*9I:"VD=9YDK'\F#L,MI5->79X8?BO[W4NY@U6%0
MC .!0,JR@#\& XR#/&^T&^2=9^7MZN=7J:7=0<:T:[50#L^:>'#VKKAWU!^I
MMQM#[!P'6GG,HR'EYOM&(&5LG2BF\QTFQ -Z8:8''I.<W54APTY#KJXH85,H
M:+8S9-<=+W5K="9FNF\5.FL/"V+ *Q-<-="X&2@;&ISP#R519Z14,PG.<!&#
M/PN<EV88ZYCN?)V0$;2- 8[0^HI5XUU)',4(X]Z[!<^K%I<;BQ^X!M+:$<=A
M!)&;1EG<BTNC(TM$EW&;TODDC^=&YDL8:ZA+7#@LLHHI>H6U:LQ>]^IPUDE;
M4RI&GE\; BL[+<L3JQ*;2*%#!F/ZIRP1Y*D2,;=@9)@\!P#.<"QC;E&!L[?*
MVAZQ-"6.K'44^J\?AIS%=5#WK@1>I5M%;YJW.V=KN.9?(YKW6LY?CNHUS=..
M/FP(&QUU1B43D.:TDN H?811JXEWM%US>=\G LQN=V],TGRV.#:*R$['C/ X
M5<F##0',+BTX'Y:,:LUP"66'&!!'GV\@Y1I9 SRMK]26DG0ZLFGLE\?B#ORJ
M::^Q5D]2+:2QPUD-M;9:[#RQ/=*+6?JY#I-#2S(N\V1-'+35*(FP%SB2"T<%
M@EVN3DM@D7@X=C]ED1\:>G%X-G*&<10J=R8#@8:8%GE#L9 CFY>RMWF>%,42
MC3C $(<"&+IUSE9F&-NWW7D[(A[0-!8[IMIVM'4J">VI*V5MZLVEON:\W&=I
M;/DCO+>.(6;[.Y-E;E@ ZMO$+T2,E?2LCG2O:231H6[9J57FTU5G?*Y<&$JI
MIRUXK#$D8_DL2CRT%-7O5*P?%CWN6[8&7ZO!@G$0/5B$/P>'/@QQOM!OD19>
M7M]0=7J:7=4\:T+M5*=GS>7#VKKHWS -ELV=]A8'K,GZGVCY>;[1<.J9>FZ;
MS'2,5#TM(@!Z0#=5?$M&1:X.2.O'J BV2V96*'F0(GX$_6SF)FV&S%HR22LL
M+*\EP IL2Q];DGQGDF(331C&+.# XSC&.2_,L?=MN_)60#6EO3#'=,U/SB.I
M4N'8=0X=B[)<>K=I<;JM]T#:.SXXK>U?";%EG<BQE+R3UIHC>F1T[*T8YLS6
M@ 58>W9CZ37'R2M9#B[KS(+KED9F93'2)7'@1NQQM&3,C>;*1"B U3X]O'F?
MNPU(>@+-\./"6#I[<(R;1%-%Y:UK,]SM6AVJ/5^3&==&M;^2"'4[25IX_42V
MCQ.7Q1VYMMS\M<RRMG-M.9[ 2TI%CW^:#888J?5-D9,YM3J<Y? DH5P2AM(.
M;\V"5?*;@_"42N8QHP58^>XK'#'R6Y!"BO<&2 J\)R_6>\>B8DL.>H@Y$*S\
MJQW0_>EH.CSHQWUG #ZWQ^+E7AIXDKDS^IMK.<*1MC:S/L?3JTVMP/M"D;6?
M]8UNSUJZ=;NET*R.<> ( ^-?KRXKHK7\8#L1L<A-@:]S7'RA!-8L3*IZ%R<2
MW *&P' R"G(WA VA+].E F3(A%IQ9"(0Q?"Q=N78V>6?R=F1* -)8[2R@I5@
MUU!/,U)X]RY%MZJVEMF\IF3M3:4C,G%&QMN^TN3;673C+-=DP7@?$^2NN0R2
M2AT@! :."V<-/+ V-*+"^6.YQ)Y*R*F8JO!2=AS7,9&J;D#?AYB[+B*X=$#V
ME$ARH*-.7*"PJ#S19+R$6 AP?:+?)QVGEK:K' ]32[J.XDT<[50CC0@-' #B
MM.[?UN=IV6U?L#;PEL[ALIOA;S>?N V1[^E<3>9Z;X7:]#FMA8XQL8 X$$G3
M@:X.0*V.KK\9'9@:DV5@E&+&'.8IFR2B@MP6_P"*Q+WB X:@Q00@^HRGR@R=
MZC.1>=X?@\Y!S##>"[\G94$>GIZ'=/G773777V5U4IV+?.]6K1V[F[K_ %1V
M>(6V/EO("SN?($]37YDP^=ZGF?R-?6T=/ATZ\5MAM,K3)W"9QBY[L+(AK"VL
M1T&*E# &"3,QN2KTPGV;-.8F)Q='YQRNP:I.3K$A8S2"LA+#@.<"P?:3?*RV
MOEK6LCR[7I=K94@Z6'70-%. ()H3Q*TC/4"W9MG([<_5[;IER%U),+PVT_G;
M02.8[HVDOF>G'#'HTQM?%*X->\%[B01@4.OS@B8[*91;![%+AV*I1*4STNFD
M8-?*YPC<U+D)-6JHN#DIV-,L"IPF."J)7Y$E+ '&0BQD><KLLQTD,GE+,=$'
M@&.I)44^L&OQ4YBA;Q6RN?5*UN<CB,@-K;3C;B6/:Z%EI<"&_P!<;8]60:;P
MNF<S3U&&-T($CG.(((:/-;0+@L;ZQ0!V V'1BK4TTU2O13*,E.%EX,<T;E@J
MSCC(0:4^E%!293!PD WYPE.,#G.1"P,,-RS&NF=Y2S/6 X%CJ1T!'U?C\-:U
M-=7$!5M_5"UM[K,W)VMM209=H#6/M+@LQ](W1UQP%X#"3JZAZIG^L:UU* M.
M8(I=:3,; EV;JN\XF>,+LQ)XB?*8^*'0(QU*2% ?:_;0Q("YG?FK*7(DARE4
MM++&:9D18^N,8QG)--O%;^6M:Q/#M>EVM]*^%YUT+3V@ $\.(7 D]0K>3 8O
M!?J]MQLF,NHIG70MI_-7HC+B8;V3S19+!)JI*V..%S@UM'MH:ZJHUO<CZY05
M[C9+9DA0ADY\D%8:><Q,%C+BCT1J+$:7O0H -K.C! C?.+("A =@\(19-SC'
MASG;F6-NS=^3LB#'IZ98[ICC74!U*ZNRNJE.Q;N+U;LXMV2[J.T=GNBDLQ;^
M1=9W)L&$/#_,,A\Z)!<&F@O,Q:6$C0#Q6[?)$L^4UCLCY7KC],R,Q30.MOC*
MQ_)D]C*:UC9EX?&+XK>]E;R:)7A4,TMP)+RJ)+'@& XR 7&^T&^2?9^7MJN=
M7J:7=1O$&C7:J <*4+3P)X]JZ[^O<'ZG7.T?L' =:YN#*+_R\WVA"#(V3I0S
M>9Z38@&],-= YW3<YNJI#AIZ#75Q0PR:Q 6QFR:XZ9.;6Y$S!?-XJ=,X8%L6
MX6";84YEP,E UMCH''DJBU"56,PCX(1@S\+G(=F&.N8[CR=D!&"- 8[0^HI5
MXUU)',4(H>];ZY]5[2XW!CL\-I[1CCQ\,D9M66=R+2[ZC- DNXS>E\DD?SXW
M,DB#7\2UPX+*J:)7J%-6J,7Q?R;%9$-Y"I,FE\; FL[*!:F6B/M( X68)_/7
MA39)491B;L#(,&'& YS@6,;<HUHG'E;0]:M*L=]744^J\?AIS%=7%<*'U+MH
M8<U$=L[7><PYY:YUK<%V.UL<RF.(NP(0S5K8)1/1[6DD@$'WD4>N(>K/>,WE
M>YX+*;'AM3,Y\MCHV6M!.QHC0.=8)0PX!["YM&!>%&8K-< %@QC @#^KP<FT
MQP1^5M?J7-).AU9-/9)X_$'?E4TU[*+%)ZCVTF/PUA^K>V6NQ$T4CI1;3B7(
M"(4,>1=YHMFCEYRB)L!<>3FK7UVN+DM@4:@P=D-ET1\=>G%Y,G2&<10J>R,#
M@(T06:2NYD!.;5S*W^;T3E%(B# 8"'Q&"Z>W*S,,9=ONO)V1#V@:"QW3;3M:
M-=03VFI6UMO5JTMMSWFY3M'9\D5W;LB%F^SN390%E/K;>(7HD9,^GC<Z5[34
MT:%N_P DJOY4S;.^5NX/2F-66O%8?&1D^2PL7N@+5[T*8/BQ[X"Z^,/J_,RX
MY!ZO.1^#P_ YQ?/M\CY+R]OJK7J:7=7YU::M5*=GS?F\/:NN?KS!^I8V=]A8
M'K"?J?:/EYOM$CJ]7IF;S'2Z=/JM/0KTO#JKXEHZ'7!R15\_0(6R.S"U0^/J
M!\+GRZ<Q,VP6("$!(!,;"\%P$EM2,2[RNIY)B(XP8ABZ&!Z^SE/S+'7;;OR=
MD UI'3#'=,U[7#J5+AV&H^!=DN?5NTN-TVVYQM'9\<5M;/A-DRSN18S%Y)ZT
MT1O3(Z9E:,<V9C0 *L*V-12*X^0UF_XN^]2"ZX9F9H4L">61X$>L@;.(8AN]
MF(Q0\:E\>7CQ=%IJ0]  W&,>$ .81DVB*:+RMK69SCJT.U1ZNR,Z_"&_D@AU
M.TE:B+U%MH\7F,8=N;:<[+7$LK9G6TYGL!* !%CW^:#88HJ5B;*R<M-=3G+X
MTE#+THK2%F^]@57RF@5@2A5S"-&!K'U3@K7X'5N 0HO+ -*%5A.5E9[Q\*<H
ML.>HL9%FS\JQ_0_>MH.C2M&.^LH /K/'XJTJ::>-5R)_4VUG&% VQM9GV.6E
MVFUN!]H:6-93(UNSU@[3K=TNA5[G$4! 'P+]>'%=$X'%0[$[((38,XN;@?*D
M$VBQ,LG07)P"O"WSQQ,@AR-W;FT(?(2@3)D8BT^<A$(8OA<NW+L;<2S^3LR)
M0!I+':&4%*L&NH)YFI/'N7)MO56TM\YD\V=J;2D9DHHV-MGVER;:SZ;"S791
MB\#XI)/GR&224.?0@-'!;5BGUF+(DEB?+#<V4TB9%+,7769,Q?)O'1J&U"W8
M>8VR?%7WJB>TXD65)9IJ\\L*D\T62\A%@ <'VBWR;+/R]M5CJ]32[J.XDT<[
M50CC2@:. ''M6E._;<[1M-J?8&W^K:7#93?^7F\_.&R/DZ5Q-YGIOA=KZ;FM
MA8XQL8 X$%QTPK7!R+K=37>=D=F35"F5%R?%BFSF)BLA,46WEH/BNF>\0$+6
M"*F"+]0)/E ([*@61>=@.?#CD',L-X+OR=D (]'3T.Z9XUUENNNOLKJI3L6_
M?ZM6C]W,W7^J.SVQ,LC;^1%G<^0<2\O\PZ'SO4-R*Z \3!F@ =.O%;6;3"TV
M;P6:8NB[BB(2P-;$?"BI2P!A$W,;$ZY.)]G35F)"<'5_<\K<&*CDZM&48805
MD)8,!S@6#[2;Y:6V\M:UE>7:]+M;*T\+#KH&BG $$BIXE:5GJ#;LVYDMO?J]
MMPR9&ZDF%V;:?SEF)',=T;.3S.B*"/1IC:^*5S6O>"]U01A46O[@C9[,:!;!
M;$+1V.I2J$SNMF<8->*WPE=%3GE/6:DN#E$,:94%3A,:%64OR)*4 .,X%C(\
MY'99CI(7^4LQT0> 8ZDE13ZSQ^*G,4T\5L;GU1M;B_P]\-K;4C;B6.:Z)EI<
M"*_U1MCU9!IO"9G-T]1IB= !(YSB""&@MH!P6-=9-@=@MB$0JW/4'*7-%,XP
M4Z63@]T2.6";-4&0<TI](("ERF+PD+;\X2FF!SG(LX'@W+,:^9_E+,]8#@6.
MI'0$?5^/PUK4UU<0%%OZHVMO>9B\.UMJ2#+M:&QOM+@QV&F-T=<>T7@,)=JZ
MCC*Z>LC6NH "TYHJF%I4TGDQS=-W&DSA@=6(B&FRE@%"X,8Z$(B0OL#:PQ(*
M]I?VO*/(TARE6L++&<9D18\"Q@./[2;Y:*W\M:UB>':]+M;Z5\+SKH6FO$
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MKKJ[*UI3L789/5NSDW;'NH;1V>V*.R-OY$6=R+!Y+R_S#X?.F0W KH#Q,&Z
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MQ5YFFGBLDWJ7;30X6(;9VNPX=S"YS;6X#LCH8UE,B3=D3!^G6\1""KW.((!
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M \%YBCI@S(<BP#*HCQY"'KXA8#Y/7H'PYZY_4Z<:2FI?S%YIA%^=B*NF2?\
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MI? (?Q5<_ #.<#'ZLCPAR'.,"P(7D],9#G.,9_6SGC24U+PQ>Z+(1#Q&''(
M9Q@0\+4^0AR+KX<"%Y73&1=/9^OQI*:EY8O1*+ <ABSGG \#$#.%9&<"P7CJ
M9D.<$_"P7C]ET^I^KQI*:EYXO D60X#$W861A\0<84DYR(./#G(@XP3[<=!8
M]O\ AQ^OQI*:D%>!  B&.)NP0 ST&(2DD(0YQGIG A9)Q@.<9_7XTE-2_F+R
M3B!@T,4=1%YSTP9A43D&<^+P],#P3X>OB]G^/C24U+RQ=Y(A9 &).PAXQ@60
M84DY%@.<YQ@60X(ZXQG..G7C24U+P!>:8P0@%Q5T,&'KX@ 5D#$'IGIGQ!"3
MG..F?9QI*:E_<WDF#G.!11T#G 1"SC*HC&<!"+P"%G&2?8$(_9G/ZF?9QI*:
ME_#+S3$Y#@V*NA61]?!@Q40#(NG3KX<")QXNG7'U.-)34O(=XD%XSDR)NP,8
M#D><C4DAQ@.,XQD6?$3CH'&18QU_P\:2FI?S%XD9 $S$3=<ECR' !X4D^ >1
M9Z!P$7D^$619]F.GU<\:2FI>6+O*SXND2=\^'VBZ*"L^''3Q=<]"/9CP^W_%
MQI*:EXXO)/GQ=(HZ9\&,"'^ZB/@!$'(PB%]A]F! QUQ^OCV\:2FI>.;T2!QD
M0HLYX#@(!YSE61C& &>PL><Y)Z8"//U,_4S^IQI*:DQ>B7(/,Q%G/)?7IYF%
M:?(.O7 >GB\KIUZBQC_'GC24U+R'>2<H00F11U+$//0 1JB0"'GKC'0.!$XR
M+/7./J<:2FI?T5XD!'@L43=@F""(00"4DX&((>N1"P')/BR$/3VY_4XTE-2\
M<7HE$#S Q9S$7UP'QX5D9#XLYP'&/%@GIU\0L8_QYQQI*:EXBO9&#'4<7<@8
M\0@=1+$X<>,'3Q@ZY*Q\('7VX^KCC24U+R^7--C/AS%73 O&$OP^J(Z^8,/B
M"7T\GKXQ!]N,?5SCC24U(*]$H?%XHLYAP#(,#SE61C <F8Z@P+.2?9D>/J?K
M_J<:2FI?WY<D_7./BHZ]0Y%C./5$]<9 ' QXSCR?9D ,]<_K8]O&DIJ7]#>!
M \9R")NP\8"$6<A4DBQ@(P^((LYP3GH$0?;C/ZN.-)34O$=YIBP!,,BKH L7
M3PC&J(" 77'7'A%DG <]<>W'^#C24U+^"O1*'&<BBSF' < SG(E9&,8P;_Q>
M<YR3[,&?_)_7_4XTE-2"O1*'Q^*+.8?*\/F>)61CR_'^P\?4GX'BZ^SK]7C2
M4U+SQ>!.?'TB3MGR_P#C.BDGX'P<#^']A^#\'/7V_J<:2FI>)EYI2?#YL5="
MO'C.0>8K(!XL8Z=<A\1./%C'7]3C24U+R^7 GH#/Q2=NAN<8+SZDGH9G(?%C
M /L/P\Y#[?9^IQI*:EXCO-,5UR9%70OPY"'/C5D Z9%C(@XSXB<=,B#CKC]?
M'&DIJ7]S>2</3K%'7'4.1XZJB,? #TZB_P")_8X\6.N?\..-)34O =ZI"^GF
M1=R!UR(./&L3AZB!GH/&/$5CVAS[,_K<:2FI>6;T2X\76+.>/"7@T7561CPE
M"Z=#!?8?87GK[,_4XTE-2\LWB1@(QYB;M@)?L,%E23X0>S&?AY\GH'V"QGV_
MK\:2FI>)=YICL"$5%70T(?V62U1 \!]G7X60DYQCV8XTE-2\L7BGSD&,11US
MDW&<EXPJ)SDS& X%G(,8)^%C <]?9^IGKQI*:EXYO--@WR<Q5TP=UQCRLJR,
M&]<XZXQY?D^+KG'M^I]3C24U+SQ=Y61"#B(N^1 Z9&'"@K(@8%CJ'(L>1U#X
ML8ZXZ_5XTE-2\,7FER#!F(JYY (6 A'A61D(A9%X<!P+R>F<Y%[.GZ_&DIJ7
MEF\" CP6*)NV#,AR/!>5).!Y!C/3(L!R3XLAQGV=?J<:2FI>/RYI< $9F*N>
M  R+ QY5D>$.0YP$6!"\GIC(19QC/ZV<\:2FI?S-ZI,9SC,6<\9"7@T6,JR,
M9"5GIG!F<>3["\XSCV_4]O&DIJ3-Z),%X-S%G/!6?J&96)_!GVYQ[!^5X?;D
M.<?X\<:2FI>OY>F_[FU_V\E_:^-)34GR]-_W-K_MY+^U\:2FI;'%+822I\3,
MA3*K1#4E*3<*#59!H 83$B.R'(  P+.1X#T^K[."V@JI!JI;Y52G")PB<(G"
M)PB<(G")PB<(OQ_?VPS^:MIY_23D?\DTIY!6>#F?@7X",F%X'@K(P8-$#(PE
MY%CQY '. Y'@'7Q9!@6<8SGZG7A<A?H\_LQ'\^ZW/Z+$M_E*K'EF<U@N?T?W
MPNL%Q5E?DR[E6Y]STRM21/\ %3=->[1DMNN-P3-$JC\)8M2)')WVC6>@D1:B
M$6(SW*Y)4IC@M=<DDMWI/'C QCY;C7@L0+1& >VOX>:P[OW =UZRB6KKY+=B
MZNDC]/M8]?-O3XR^4C#(NX;++MA+SK*JUFK=;$-+R6>W**PB\E5N0'5H <]*
MU*U,8I+ E*%CBI30PUX&@)'/E3M4?QGNA;@.$B:8*Z;*TTD;[IG;7%WBW%M5
MU^6AT/;Q;D6G0 3YZD(>4L>D*B80.%(5: 4IRCP6M5X.\.2,A$.-14])O.AX
M?+PJMECO=NOYBS5UG7K:\+CE6RS4N?R9HCU-5C6ME2.:7- XK<+H;+9Q#G6>
M,]H54TSAIA;5+HB8 @R(.C0,](H5)_-"H+G44,3>0'&JAB-[O[C6/*8_-SK0
MJG.P-.P3N#UO7LKG4@I>)UZZ'HG#256Q&R9=%96IUT<)\G16"X-C*KPO$SFN
M)Z1.H-Z"49%%2IT, I0T-/Q_?7=^@;ZO2]-%J=NR@#X#>-MRPC*=T7W^E5:^
ML+H)BELDB\X,=VNIDEG-S1(H\O9?1DA:1JV=S,)&J)/ 2: .+ U%0L+FAKR'
M<![./X5))43MZZM>+C@NZ=<5!'C)"TOZ$$;HBTK*D+$Z1- R)GI"N<):Y,=<
M2QC?RI*A%U*19P7Z<DO.3<^887B>-.*CPAP+*_?7Y9GA-95:ZA5RNH,3,(NR
MNQ;;US7\XS^V;1)=,&22WH>EF-HU^80HDF%5GX,;D1*)*:-M:RR,F^$TG.<A
M'3LX=RY' OH[Z?#XEU:[:S; WC>+<^82QUJ=79K/=$ZB]:&K;\FJF_S6P==5
M8IDS$'7Y:]A@^*J0,R@]4E?$Z4]PPN&H +!99>#.2WF5CEKH;SI3N_&N9ECV
M7;5=[C[S2NGYB%%8JR:=UV/LZ.O+=F4GN)P.@VO#5+(6585$*W,R(PNIJ\7E
M*7**R1O2C<3I+G";/@ $/6O:?OK* "UH/+P_A[UJ=[62X1RH;?U<T)F]H6G7
M4YG^I-OUHHK::2&VWQMEU4:DNVQ^S06&0.,I4N0FE3-F.&N<P3%KLEMASFKR
M(CS,Y3"'N" "H<\"M#^&@5@)':;S>G<H@EW0IW%$8E<5DZ .#/?B.U)^C#!B
MISIH\W$YZ_DU6SK2J^D#%LBF9E3,)>Z!SZ5S( $ /&/ ^3S-54#3'I/,5_#3
MY%9OL;/S;\=8Y'JLG;Q.(C)>W_3-I;%,JFPGZPX]$MLG6Z9\PMV#\O3T^)X5
M-Y=62'(W5I3C2]4Z-.<8G!G(19EOXE68<*GZ7#X%S@?)TN-UWN=^A]IR^07!
M<.D&Q\UWY9U=FRMR412_8KO] (75ILI:QO*@52R-*T.+K'F].B);C#8^GQY9
M0RPX'F.SVJ]/%Q^:"*?$NT6Y=0-&O?:1>X OBT:IC"JRM>U]G1R V]9TNA;&
MHF.S57(IN!CM:Q7-!8 XZXQP70\Y08BP0 PW  E@QXLR>#5B:=4M>?/\"X^W
M;-',FLKECU>V7+)%1D-J[NP0O6"4J;&DSV0]T;$=E-1FR$'-,Z4.RQUD\9C#
MRYO#4SO(E"HT+<7D))X@?5C\'%912H)^=5M?B*^N-,"1XF&N%?W.LJF$5MC=
MK?"&3#6F[-L;KA]4:X,M8UQ13*_1!/>BA\;YY)'1U,*4S.*)5)I#6K4/9)./
M)*,-\)#R)%:T'$ 5/WOPJ\5)PO4N\'/<8RW+;FKWMS()+W!HHOIIONJQ$J)V
MH>CG>/.](GOD/CSP)&PQ2M8:R1=SB;D6I:P.&7!0(!KA@TX&)%/OJCB\4H/#
MP[.]479"([7E=TFZH)[-(A<T6TQ[9E]Z2L.+9GGK;%V(V"V!1H-E9#'(\XRA
M258SU.<E(VA\;Q%+$J%E,S@!"<D61<C]A7XDFHX:B#\%."]E&,LCE,JV^CS_
M 'X@TRCTUH3?%Y'>4@N2SWJ/7:2HWA<*M87F7,*QU(CU7)=?G=B^+ZH<?$%T
M.8Y(2: S&3!  0\*4%:$?>X?C5\Y+.(Q(>QALJUUA$L5BJKFRW.G9 PQN]YA
M;-;YG[%L76K;*E-,7DY/3M(5](R8YYQ[H&0H%EL2'FIL8&84,1D_DJ@!ZPKV
M^SV?A5'8 Q,\DLO4R#WJYU3$JL'LUW&&*8Z\7AM?<\(KK6!BK&3T!$7JKF>Y
MU4@;IM-Y='\H5TDBJ1R/(;%WO\(.I)(A9Q"OV$CG0<:<UOTHF-.@I38^S''8
MBR&/=">[!V[6>SL-8[=FP?<VG#1O96=>RA\DD31J5K77C%7%#KFE)'G<DYG'
MAF>5IR<2K C3"GX5 !J!3P4%/AHHZLZ^;7UVF5+2S4AX?[1IZB=N>Y?!->FA
M/.GN7LLLU\<T= U@RM3%(U[F\#G4-K>W+6/PT*CCU@224.<%&] =>.7+DI #
M@=?!Q _&J:.%T[95;2K1%8"_2N4KK=[:+KKU9[X*8/9YL0E2_8O;":N%GA6&
MJS3$[@EAE*RM$%P!D"@)9P<8'C  XQ''Y%>C2:GL=7Y KUOF84Z?253>;2:M
M2IE"='JT%3[L^[%3^-; -LI>>W75RQ8BK*F$TA0Q"7PUP9G!U7.3N8 YS2.6
M,"*!^R.!/?\  J<?#2M-7=PYE1O"I"]3";(*SW^G:Z,1Z$;C:E4S=DK<;4DE
M>L,@A$&T V"-BMEAE2*0L"IB*GC(VL+[D9:D&53ID(Q>:8+PYCX5)'"L8XT/
MX59_4*?X1[#=NNXM@+,S?-E7!6M TXSQ4R\YO&-CM:I4YQ"UQUA.)=2J5]1,
MEN4CL76)"1[E"E:B,6(78"=8I$,H0 F2.8JJ/'A<&B@!K[#_ ,"M3MGLI-HK
MWF-5SVD<VQ1M"HZTU_NEW:B31U@SS?>H$Y2QU)8#B%R)2-\E!EBBAK.4:F/$
M;@P_.!DY"'!LD^)58T&$]YX_$LKN;%+1!W/:;HZ)&24VO]W"J'N66%I'AS(;
M6IV[>[O/YG,V8"<I66!(FL1J61!&O*)P M6$/A/P+Q>T?G4[T81TBX\V_C7)
M$PB)6!JU=,E;K$F\[F[CVRY/M;MH,RWY^M6UYOI&MGW6&Q>42-$DE108)/01
MM]DK1[B$!,D-:&].,:,0223,1V?>67DX"G#50?!1=2M8:JI2$=UNWH6=BJFA
MCIN&:P-U#M$YV1LY%<S%*)!KLG<0LE450\2I2P6O''XUQ<%#VK=1K5Z-1Y/D
M%CQG.02*56)Q<8P>/&M>'#FH>VTAMA*K_P"\Y?D.CZ96^:XTY6RFO;1;+6M=
MJM6GI5(]9XN6Y_)U5T>4@KEZ9U4(<GMR6.+AU7H%Z<DQ,2/.<F 'M*LPBC&G
MM/L[U1[854P,RI^K[6="Y;+ZHUA?=MRJF8.5L+9Z*/O)K9VVF*VKH00VV(L_
M.LN>3J_F)(9.G;"5IA/O_)J7(B/-,P&#[.2NVO-W!Q'X^"[ ;IU\T2CLK52_
MSFR'2Z9;754ZJ2F-WDURN71Q9+7Z72&K8<\3@2UF?&Q<[!DD0EZQ*(+D-0(7
MG^<,.%6,##)^:L3#]<:"@J>"I[.$]E59M?/ZFKLJ.LNKD"[L&L,#;!*;+L=?
M:4>>&[2)+\7H"TM3KES:76ME+& 2I:H7.HEYCD$(A$F]<F\CM]E5?@6@GY^D
M_A5O.S*UP))V]WV6M+G4JFVYA29#W8JFM[[FMOS1:VIZ]D(XG(KFCTO>EV*D
MLY8ZJ'4*EK;""$& D@$ TT818+EO)4FKU*<:5[O;V>Q4.TUD=25?KWVIK*<[
M&H^&2*5[?5.\7Q)8KM!*IQA3&A:KW>**O.Q15ARCW55,Z=GI0X>O9"0$-&#R
M2LEC-,!CRH'8KOJ2X<>7#A[>Q?%;DKC?QA[RMU1B?U>&?-5DR5DJ>?Q+9&:F
M[!M]32YGH)/;CC *=;)!\1#ZA;*2D+\ZI)2W$J'!,HR>87DHHG!X1[4 /@%#
M2G=P^ZJM4Y:UZ#2"\^W8SZWS666]4KCO->-4/II5\VU*(FU)8E2$RN0-2PY]
M*DR!*ZP>)S]*A>$XDZERQZDXXD2TTK)B<,T%13O50Y^EQ<*'37D.]<ZI+/SU
M=?S!UGUM3.-3FIJAV.M71$E+9,FCRN3;6#[J-EQ!W^*[8A>DA5C3),P)&)A]
MT'%K@IV)>:$"<!0A"Q'W?*KTH>'(D5^#2K*Z7SO8%/W/JR@T]=7ASI^<;@=T
MJQZW6B?'0Y(RR:+L\JKFU*I6I#5)B4U"R.K,T/C<FSU*1A<#,E #G(LX"M?8
MJO#>F2/G4"D'8V8FD;X7%)?E&DZ':B,;Q4Y256UTGGK^C]5HM+--GN3V+E#6
M1+L4R.=?KW$UX?')ZRA,RF>4!6<J0&  '(\_;5&_, IX=-?OU5B^W[5)];=G
M>?6DOB;%#YU<FFTHG"V6Q*U[1L9SGS&BH)^6Q*?R@=@J\IX/8JU8ZKC%K<PA
M"VD"P4(LXW/3RY'S55YK,!V _C7,ZR9&KB_:BUUJ76$V-.NRFPLYAMMV&UZF
MW9.MA):)GUQHS-WCDL[^-DI"]P64N"]F:!S!H3>F;FXL:GR *L%X ..SAS60
M<9"7?-'?PY\%9YFN7738BTML-CK3O681+8UVBJ3\3R#1ZT)4SER.C[![;QEE
MIXTFKEK,5L;U6SL^.TD>'%S,2)BBWYK)\:\HTLLH:H/'M5=+F@- \/;\:L5V
MC9-=;[<TM)ND<1(6D]LCMS.$-10B9R^7MBZ$+VZV/BW+9+F6H&PQNLJ1HR<C
M>P)2STWFE@P!2>''7$BM>/<J2:=/AK\XKAM4EM[)LE9BAMC3B:HZ_(TQ129F
MLYLELB(7F:EW[W#J1;;:4G.Y:[UB!SJ]""6,BEU+-]0A:%'0)A100\J*_(L[
M@VO#GJ^4!3G9-ZW!K]<4)<=-WI_LZF*LNSN/TMKJW)IZ^3)A=Z4L9SUYIR(?
M%Z1N#F\9FD1JC8.VR\M*TT]7@@I&(!1WA#GCX.2@ $>+YQH3\OXEK!*BYI!K
M51$*@MJR1FM=[U'[;#!$I8HESX<%-9CMW';GC35(5RGWCYJS"UZ3IRE9P\B$
MJ2@P69XR\>#A.%22.%3^!2-KK,$>PU\:I/FT(:UC#+*[0[ALRM:&7WL//Z58
MH-(F[:^IR7Y!!W*-OC,&36/"'!6L1L,><#26PU-DX!F0!+QC,CCS4.&D$-[A
MR%>PKJQV?VR!.%R;;3=W<ZE77$NV3V=C;,<W7U,Y9>KA7S9L9*"WI-8E&/;R
M9$H'$8^I0LY+"XM:09BI*/.#S"O$$!DMYK'+72!QI0=GL7):G-GKOUSOF73&
MQ']V>*EB3%WG+_H5Z6R!U4IC7U)+G6K'&J5Y*I2<2L.C-IPIL<&TK/CPD+D?
MA) #Q].16A^-9"T.;PY^$%:+'-G=IM>*IT6:T*"SWB_M';LW0AEFUM82AQ9I
M[)H38$"IZ0Q/X[Q\QT>/5&I";Z)5HPJ#5."TZ()A8@].F%2/A"DM:XGEI<!]
MWR*8M)VIHDUK]NN.[+RVL7I'%M7K.=9BXWAL=/ZM7%6)&.X#<#'B0U86S2!L
M;[4M#$B0E(R6=Y-PB-;,F_5R665D.RJA_)Q;7GV#V=JN)V3I WXM^#LM;S]\
MF+9--*7^R=L6 ^PGZ>,D2V)2;:2^*5HY.3>[O+TCK^?2:L"5I2AL3X1"4-R(
M@\:?I@(\RW\2K-RX]CN'P47**U)M)&%VWF]WSMO;PS<KN'('])#KWG;U+'4V
M!;I5&GBJO8>OE3V%FI"*1)H7J44.=V4H*ET)4G@-&'&/!RO>L@ \/WOP=G>N
MS=03BG=?=G-?FR&V/KU!FY?VZ]IC6]CKS9=TM6C'38Y=?E?*$49@U@VE)SW:
M:2!4M"F+(2*?"O+\TPHL@!>>@K<C]Y82"YIJ#\X=GL7*($X>X?KRJNK7JT)K
M/)-7&INF>Z>T9"NS)5*\MVYRG9.5UE8">7%.+TXXALVDT+F3RG=F+ 4I?I&A
M*,:8."BQ\KV<%EI5U'#@20/@HNMO99D5A5IJSMG=^RSJZ8>:-D)5)2(V0OC@
MYDHHYHM329BD:K)[H>8$H]S?%+@8K-Z8&>=CQ&9$+'+-Y<5BFH7 -[?QKDE5
M5V;?N%(4] 6E98[)M9$NXG%-QH!%+&-<V5YGD)OO5JU]C4L* WX=UQKM7$Z?
M(*_M#-@S.4YZ9<2/R"19R6"O&GMJLI:P$G\C33XC1?)5UC$.,1I&U4%D2YBV
M4;M;M()'J?'BK1E":4R:?V3W%;XC\]AI$,*?BR+)1/%8J#D#\2K0K2T[:GP8
M/R0EASQ^%"*$BGAJ:_$N[&[M1J+S[I6H-=&0F,V/$&W6*YI[)(K*K4L^MD30
MWQR\*U2%SB*DUHK3"F$[91N!:= VNAA+6I)4FX..#X08S8_.6%II$3[5PG=I
M2O?:-3!KVQ9/8-DW[0-83+>Z+O=P3/"=-M2I[G5>U]%F>=J27=<MIF0R%D=7
MR-&)T!*(X$=2 &!,,!8,BKV+-R=QY \/@HND*)QE*?L*[ANZI[<V=T^42\VY
MIK JP)M(7#6M,R;*QZ%#UL)LJ6+S9PY$P18T*  7J#L#],YAR5CRO#C-OR53
MAUQ]W9S5%-V:.O\ UM98,QSN/IRT?R8[UWG ZE8=I;PD#5IA62I^UHC$>FL<
MM=O&V36UG:B'MT62[W8>$#<!.M5$@'D!7A'!JKM+37[PY<^?X5*]G2QT9K6M
MA_.O>53';Y'>VS]!S8":?/Y9DET9BG;8=)5')V&LB7KW(V5\Y/R-%+T#X4C!
MG+ZO$(*H1HNG'X5 %0.%&T'QU7C7E%RBO*KTV*VWEP:6T0VXG%:/<MKQ#LU9
M,ECB-QA^D4ZDS%8,]MAZ<8ZLK\V_K4,2/ID80K<-B9T:$Q>1F&9P'+X>2@FI
M.GB\>SVK[-:;[CE.V=IOM3LU:B>\95(]=:X8?=AU[S2.W]J\[PVA[7EL4>+#
MI0M^2QVTJ'V&J5A(D+TXK$1BMO?3$ZM5D81%X&![2CFU!:W@*_']_O"U_3K8
MN>L%:Z\1'9>5RZLY+$NZ_KSL-)'"YGKXBFDU#M]0]J6JC6.BQX?AH@U<.9H'
M?W6:J4 2'I/)'DHD6?* ![^]2YO$Z>/A(^^"NC5$S*H&GNY3=S:[2ANRCELV
M*TUM6635>P4CD+W12>$5=7[S*]?+EI!NDBN K:O2,J<EUA,J2)<DEKG(XD8A
M*!^,N?REB()BY4 ]GRKO3RRPIPBDNH?\_6S_ ,4=/^9&<AWS59O-7&YC5TX1
M.$3A$X1.$3A$X1.$3A%^/[^V&?S5M//Z2<C_ ))I3R"L\',_ N*U4:@5T]?V
M>RX)$K2P$>R\LE,QWPA*(YQ9OEC-H+7NS8'K\_+&2/B2BDRBL<-*Z3K5RXHX
M*$E:(@(RQ#.",!7+CU1W<EC?[,/_ #[K<_HL2W^4JL>69S5;G]']\+]QH8M%
MP*9*M!&8\!;,R4R:9+ ,C6%7+DZ-N&SHT\I4A2X.D1"1H-$D* L$<$M*+)0<
M8+SD/,BX:Q!E:5HH4P%6KK:O5JBJ3DZBKS5T)C*L=;FI4Q*).* C/:QCAOD(
MDY9(/=N4W@*+"$/3 0XP2I^-0M3VFVMU)58_4]%JJA[U#YDY/SO86)S%XK+'
M2S7"0RMZF:HZQEJYB "9%-[R_GX;REQ9I;>F"621@(2P\4"L7N)K7BI8S3M/
MB>R)-FI*MS)$L3,@*60YKN'Y?$T$-1>[3(00[>YO7DP\QMSZ;+8$S"+*;/E>
M5Y>?#PJU-*5-%A$>N^O;>QBC""A*111D:)V;!1Q)4T 3,(FU_ UEOS>)G)CP
M&_*)[ QH<+"LE^!5Z)/YF!>27X5 IU.YU-5);$PL4696N-Q=C9HS'&-$0VLD
M>CK4@8V)F;DP? G;VEG:TZ5N;41 ?8 HDL!8?U,<*%K=FV)"*DKV8V993L%B
M@,*85CY+7836Z/>$C,3@)*CPLS(@='=V,4"/"4%.G3'&G",P' ,]>$ )-!S4
M+41+-4]FJO(FU-Q>!2>O4[=)*05-3I4Q,271AJ8G(@<IIF20*7Q9E?(JU(7+
MR3E4>5HB$@A"*.R2+ @#X%"K.U--#S6C0&WM&GS;"85+ V&NF[:^+II28]NY
M-&J8C)GCXOI6=+/D$:MY?!FEOG+A&4#ZA+>DS8[+#$R=27@[&2^O2.%?:A#P
MVI^;\*DJVI7JWJ7'YELE9S76%3)7)R9F*9V@D@303+Y4\S1]1L[.R.#E&V$^
M82]QD#TJ+QE/G*D9F B-,QX"AC#/ <5 U.\(J5\<]=]2]4FZM5LNC-35 W3"
MT$=.UD8R5LQ-91ME7DH$C41]I+B\=_\ (HK ,:^CLJS@A*H+(#E:9D 0]' (
M-3N53P_ HO47OH'%9/**J]/4S3):]O&!4C)H:WU 04*.W,SUH^V;6#8-&AA^
M$@!L-=L;B>R.Y7B1(,)SDJ906=@17(J%.EYX\>2V+3+8?2V^XO*S=,U<#3,;
M(M8W>91V)5:MIIP)'+6PQ?%Y6ZQ%VB,,<7%KE+6D,&WN^$YZ5862,)1PO (.
M (/)'M>WY]5B==;PTFVP4VUBBXE'Y45(P-;[;3R[ZXR.#,%HX+=UK2UNCO)I
MQ7D>8[?,1.S,;@)H%#H).,K!F<AZA%D""C@]M*_A5PY/%(K-V-=%YK&(Y,HP
MYX("YQN6,;7)(^Y!2GE*DP5[*])5K:LPG5$ -+\PH7@, $0>@L8SB54$CDM?
M55152YL;65;5U;K&9FCRN(,S.J@<4/:6B)."A"L<(JU-IK2)$W1I>L;$QQZ
MDL"0XU,4,9>1%@S@E3WE8B34/14V,6&S2DJ>F)KBZG/S@;*ZP@\C,7OJE A:
ME+XM&\,2T2MY4M36E2F*C,B/&F3%%"%D!8 A4":G#D2L^@K*M&I]>Y2UUS &
MR3R9A116225NA<:0R&0Q=M2@0MT:?7M*V%.;O'T"(L))*)0:8F+) $ 08"'&
M,$J>78O'-7UB)7!%XJUKT2ZK2LD5@M%"8P)96I&4Q:/R*^5":\GPHC"0D!6
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MZ,#&LC13<U*B5S4B#'<MI;"!(U*TY1B8H"4!:<9)8@!"( <X**FM>U>U37T
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M",J!*G;#5Z]1"BT0<$X:AF"08)Q@ORO!C >$J>78OL?ZZKR61$NOI7 (/*(
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M=[OEFP=?[W"W&7:H[(N4$H6O[*IIR:GZQ:ZF-76&V6G+JL@%./VH[.VKUK[
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M07'TE/D0EW[Z8_MM7_ .-0324^1"7?OIC^VU?\ XU!-)3Y$)=^^F/[;5_P
MXU!-)3Y$)=^^F/[;5_P#C4$TE/D0EW[Z8_MM7_ .-0324^1"7?OIC^VU?\ X
MU!-)7E\B4P\.0>L9/#G.!9#ZU9X<BQC.,9SCT'3.<8SGI_CXU!-)0-)3 &?$
M%8R!%[<=0K5F,],XSC..N$&,^W&>G^+C4$TE>/R(2[]],?VVK_@'&H)I*?(A
M+OWTQ_;:O^ <:@FDI\B$N_?3']MJ_P" <:@FDI\B$N_?3']MJ_X!QJ":2GR(
M2[]],?VVK_@'&H)I*?(A+OWTQ_;:O^ <:@FDI\B$N_?3']MJ_P" <:@FDI\B
M$N_?3']MJ_X!QJ":2GR(2[]],?VVK_@'&H)I*?(A+OWTQ_;:O^ <:@FDI\B$
MN_?3']MJ_P" <:@FDI\B$N_?3']MJ_X!QJ":2GR(2[]],?VVK_@'&H)I*?(A
M+OWTQ_;:O^ <:@FDI\B$N_?3']MJ_P" <:@FDI\B$N_?3']MJ_X!QJ":2GR(
M2[]],?VVK_@'&H)I*?(A+OWTQ_;:O^ <:@FDI\B$N_?3']MJ_P" <:@FDI\B
M$N_?3']MJ_X!QJ":2GR(2[]],?VVK_@'&H)I*?(A+OWTQ_;:O^ <:@FDI\B$
MN_?3']MJ_P" <:@FDI\B$N_?3']MJ_X!QJ":2GR(2[]],?VVK_@'&H)I*?(A
M+OWTQ_;:O^ <:@FDI\B$N_?3']MJ_P" <:@FDI\B$N_?3']MJ_X!QJ":2GR(
M2[]],?VVK_@'&H)I*?(A+OWTQ_;:O^ <:@FDI\B$N_?3']MJ_P" <:@FDI\B
M$N_?3']MJ_X!QJ":2GR(2[]],?VVK_@'&H)I*?(A+OWTQ_;:O^ <:@FDI\B$
MN_?3']MJ_P" <:@FDI\B$N_?3']MJ_X!QJ":2GR(2[]],?VVK_@'&H)I*?(A
M+OWTQ_;:O^ <:@FDI\B$N_?3']MJ_P" <:@FDI\B$N_?3']MJ_X!QJ":2GR(
M2[]],?VVK_@'&H)I*?(A+OWTQ_;:O^ <:@FDI\B$N_?3']MJ_P" <:@FDI\B
M$N_?3']MJ_X!QJ":2GR(2[]],?VVK_@'&H)I*?(A+OWTQ_;:O^ <:@FDI\B$
MN_?3']MJ_P" <:@FDI\B$N_?3']MJ_X!QJ":2GR(2[]],?VVK_@'&H)I*?(A
M+OWTQ_;:O^ <:@FDI\B$N_?3']MJ_P" <:@FDI\B$N_?3']MJ_X!QJ":2GR(
M2[]],?VVK_@'&H)I*?(A+OWTQ_;:O^ <:@FDI\B$N_?3']MJ_P" <:@FDI\B
M$N_?3']MJ_X!QJ":2GR(2[]],?VVK_@'&H)I*?(A+OWTQ_;:O^ <:@FDI\B$
MN_?3']MJ_P" <:@FDI\B$N_?3']MJ_X!QJ":2GR(2[]],?VVK_@'&H)I*?(A
M+OWTQ_;:O^ <:@FDI\B$N_?3']MJ_P" <:@FDI\B$N_?3']MJ_X!QJ":2MQ@
M=7R&,R=&\N"AK,2IR%I0PI5"@P[(E"<90/" Q(4'.,"%[?A?4X+@112 05/W
M**RB&_XA9-@4?;D&IRP_DDM>75W+HY7%H9;PNWR?35W9%B&-S'W8+J%P^+SJ
M<4J\G/L,\OP_J\*10'CR7X9.]CI!W5]?]#Y38FX?<\#MG2B2PZU:G.G,5H1%
M,NC^Z/F2(^]^^"@X$7[A6XR?Y><XP9TZ?5Z<A9XW,+N H5V,U*[=W>ECLFUJ
MLF;]X0$VI%D=*EF<KIW%1IT?QJK%"-C>'6NO?.0!-3Y=8T 3?ZG.,"#X_'GV
M\*CG,-0&\5^FWDK$G")PB<(G")PBK]M+>AVM5$SR[BH.X6(7!$[0N6Q=M?&J
M.*E#<X/[4S.#A[U>,#2E$,J1Q&L,+ 6<H/ 1DLDLPT00Y*0*FBP.UMYV!0$)
MADJK^JX_;"^5V]5E3J6>0V<;5J9I/MN:L]>1U]"[EP&P,N"='*I$BPK(],2(
MM$(XX QC*"280 'FM3B^^^M,JJ>T[H1RU[10:G2FE7+U;S")HQN"QIE"1(M@
M4DAK*\L+>\S6*6<0O)S&7%O3G)WK)F D9R/ @A*=)!IVJ%$_=?U6*=AF/S\X
ML<'=2ZU^)LQ$TOS@H>#YF7,L3 <FBR1D][5^UU"XQ 2.0JW'."D2H[ #/+SC
M'C*=#OOJ1VS?VM)5:M(UQ X1:TK9[IL6W:Y;;(S7<V8X2F4U%%CG]QE3*[NT
M;);IC WE>G-0)GI$H]W9-(-'@T00AP,HT\*E:PD[FNO+(X3YON 4FI?$1V$G
M&OK"XS"-R43-.G>%3NKZY,D#"[D,($.6Q?)+::NN/&8!,D\]28;Y*90,HF@]
MG'@IBI3=S7K8&1/,9K61R)<M9X;B> 6/<#FD78WZ.) L8).HBK[(&-O:Y,J@
M3A)VU"_IT9IIS0O7$ISPA,%TP4%I'-0!".X>[+XU6$]M#7Q[K: 7-"+ N&MW
MMJGK38KN]4O%*YB-C,4E719C8&]S:)F^(I<6E6L0\C+;3RLB*7+BLY, 5BWN
M*V1M[HVHSY&'.8QR16!)(^V I)-A<Q5-8+AASDNPA#(LK""LY9;"$QPG#P@D
M:,\QN!CS20'9QG.1@,  HT.4@7)N&WU%=<!IPV .3Z=.TU0*27_#V4T!:PVU
M=[/2Z<"EG5-*A488Q'N^'$T.3"Q&@+R1T+%GQX(&U%5&<O[CL!A6LM#7ZZ0&
M7+I-L-$XU+(74D<(<I&YH6UV70Y!(7>2RIJCY[3'(?"3YTV@<'E<2F2!.6)R
M_8,X.,$#:FB^,ONEZT,T5?Y!.E\I:C8D:S(9(HB=?V;+XIA^DI[TL8HG&Y.;
M!6#,HE@X<PJGU:WITN%"!K2*#S,>46$PPIT'L6S.G<7ID^9UE%J[CUE6>RV%
M>L>HXVRXU7TVQ5K6O?*UG5CK)$TS\R-CBLO;(FGA7IGL*)7CW3@\P]0,!:4[
M'"C2>U?$B[HNHKBVA=T4@LA0@*C]AS=T-#2UJ ,CU9UI"8?9#S;$C3'10M4R
MUB\P2PF)S9GDX 4KP0ZD!2Y,-\PL!-#E)5C[T4/4M35;<]@"LAAA]NEJU483
M9JJ>.4H0M;5$7R?R%^E,6:61<\1F.QB#QM<[+UZHL"4E GR;@8@B+\9 TDT"
MCJQ>Y]J75<EL*'R]^L,N35A+/BK+V5CJ.Q)4O1 !&Y3+5,K((C,?=AJX4B8(
M0['G.0/L184(NN/LA'FD#"5Z_I2M,R5*="Z6!(F%R,@\HFJUJ?JYG;6ZL:B'
MFSLIZKY^;E##A6UVQC-82'*>-F!]Z*L-)ODE#R,C!Q-#E@WON5P2)T75&PDO
MJJSV&#V/?-X4V]M.(W(76P:X9Z0!L*H?IY*J_;8X?*"PD(-?U*EU;/3EGL:=
M88,\TS"(SS84Z.-.U;K])1J@JF;Q7L?E<NF4T:K&C]7)8]"ZVG,G7R:2OZJ:
MMV541"ULAQ<BC$?=ZW?T;N[)Q";VM0TGX4&@#Y8S)4:7+1\=U/5AS]&[Q&2N
M,KB93M(6!Y,:HA8RJ;JW8H^MDM?C@,$;H,XK)RRV<=9S<)J6@4I"U11H1)L*
M,A/"G*=#EOTS[@=-Q-KU@FI*"5N]3;*M-F2<-EE1N1I6RKXA5M5OMI2.06&T
M#8SG=B"C1,)R520J F-2&$GY%@62!%Y*-)XCM"QE@]Q*IX?2,/OEBB%G2^+O
M=X-U'RN*%0&9LEL0!]R!Z/D67JJ'"-CG)[Q'$3/A2-L"C <H1J"U(!^1G \D
MTFM%\[QW*=>!OC1'H(O=9JK<IM5$;]\*&61Q*%K8]8DF@L?DDMB<V?H^7'9I
MBIRK'9C9$@0G"4-QS@0G49),$/RR:"LO67<&J&QZPNBZ0QZQ(_6]669"*UC9
MSC!9@.>VNMLJ!TY+J[60RKL1TF:GG6*ZW2V-L>2!3'G.H32%0,@*4X"60M((
M':JHSOO ,K=-W!IK6DY!-*V*+BJEMN!_#9T6BAC>OULLW9R9.KT2UTU+EC"G
MA\4@93::F%@UQ Y&K<J4Z8I#U/*PCX5/-6FF7<KU5KEM?WB<R68LC)&IL;7B
MZ4 J^QUD-=I.R,\A>[%Q#I27%RVV8LE0H(@[#E2Y#DPIE]WF!4>$P10!E72>
MQ2C<&Z.O-%/3JP63,EC2XLL68)FO"AC,C?4X8[)HS=DP9EY"ME;%R=5ZM@UZ
ME1W@+$(P.4)8,XP)2GP80-)XA5P*[G]7/\M-CD+A$Z,:T\$9I:X2V?Q2P*^:
MF!^5;)MVM[U74J;E4!=GV.3-M?%N5:8@]/X5N!%!ZE$#&J**=!IQ4J-^_5--
MU1Z[VE91,@@P]BF1/(&*.MK%(9[F(LF%L>;'J3S9ZB[$<AC<%BCK,&=(YOJX
M*1O2'NB; QX"9XL%&DU-.Q?;%^X'K9.);74&A;S-Y9*+17,"6,-C#64[79)2
M2"-AEQ#_ "%2!CPDC4:;8\/"A<O6C)3H_%@!@L&""')-)"CZ^-Z9=25X.E*E
M48U3E8[1N#J*P<V.WT92URE]C6E5M.PAKN-BQ!5N:2ATPFUDJ2FAZ&I>U+B1
M%WDPEN%Z8(#"!M16JTR-=Q:83)U@+;'=?H]D=@4O:UAE%O5^-#0L@<NI)U=(
MK8[=;!0*^7H()3+=/&-6QHIV8J4!<5Q8?*:?!DP113I6S3;N+,M<Z+P?=285
M,_) 31XA[4EK%OD)"I8I1R"?BC;K+HY)US&U8D$)00!O<)LWK1MR(YUC:4!O
MD)C#O 64::NTA;C,>Y'K!!Y39$*=7&S%TGK20-L37-4>INRY";+Y.X2"*1<U
MBK0YIC:E-83@S/L[92' +6-0%%ES($:((<C$ FDE>!G<NU''!9#8K3-Y!(XQ
M&88\V"X*6&!R]6I,B,?D4*B[L[HDAS2E-5%I'2P&OJ#'0P11PC,!R$L?A)H=
M6G:M9GO<>KZ"45:6Q!L/<GJMJSV(IBEAN;<\!+,>XA<)]"FE6\20J9RSV]HC
M<?O$#FH;C@>H&E:S,"-*$9]B(&\:=M%KM4]VC5>P44>5R9]4UT"<6I>L!@RI
MT(<7ED=8M3=L2>IV:SG^0MS06TPN-6R[1K)K %>,/JLGA* 8;G&1\*2PA8AO
M[LE'S>0JFFJ6&2R9C15D"P7&<2EAG4*C3"XCM2OJ]30R3@S WUY8WIX9;%;W
MQN$-,,*Q&L28\( 'C.))H/:M^)[J.GY["&0%2"RA)12<I@$B^1:TL/)#,>WL
M#D39BAHS%L+D]1&D2EN"&2C!AKR8L+!YG7.>A1H<MGVD[@],ZQ$6LR.*&7S6
MRZTJ*3V:1#8[$Y8>ROKRSP:86&PUD?8*"/.T78YY+8E G=V3-QHS%V&9M5+<
M)QEE@"80-)^!8>X]X7ZEY11$6D--A&?:U-S2UI X.DT<8B!&[P.+MTC?*CJQ
MJ>X -SM*X,)E2A87'%08XZ&,Z%0J)).-(/2E$#:@FJ^&&=S[6E]B#)(98;/:
M^>%E)QRXGR//E;S\TMG6/L)A<_-JEO? 1<AOE%MI(Q8;(O*CR+ G98WNR-24
MGR [H$F@_*M+?^ZE6#,ZVS'TU7VHZRNIYSK>PN]?D1*6$6:&';&+J09V25/5
M?'Q4,BC,F3OUOJT+;%U)8G9^/C2[*;PE!&824Z#S[%M[_P!SW7$3 X.%:*I!
M8SL5#Z_FS*E%')5#HQ(FV<KJ@&J:&Z>/\<Q'1S.%1.\XT]O+)@0G) A<R?-*
M +SO))H/;P6N,G=FU>62F3-<C42R&Q1+/85!X!-'V(RU.GL=!+8PSR4ZSD3.
MHCB1>PTZVE21L 7)E6<MBLIP(/ 8$L>.$T.[%.E4;X4'=,_B-:P+-E+)-.&F
M=R2/X=:GGL?:CX?7KX*+N\X4.[TR(D*6&N<G).;FQQ&+"=P6$Y 4+/F$Y-*"
MTCBKE\*J<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G"*CO<-T+J[N1:V/&L%PRF>0Z%/4KB4N4O=<+&)!
M)RU\/<!.3>G(42-AD;9A(H.%X3L"2B'D/[$0<^WA6:XM-0KA1*.(X=%8S$6\
MY2H01:/LL<0J%@BQ*ST;(VIFQ,<J$2622)2:2E"(>0  '(LYZ8QCV<*JV#A$
MX1.$3A$X1.$49W)4T2O6LI?4L[ Y&1&;MQ;4^@:%V6UQ&D*6I5^ I5V"CLIQ
MY/1@ZY\.>H>N/U>%(-#5:V]T)%Y5 XS7\RD<ZF+?%;1B5MH'N1R I9)54D@M
MKH[?BJ!R<R6Y*4KCK0_MR9$6D\D/5H3@39'G.,F9)7C55_CO;HUVC],7#1)O
MQ_DD*N=OC+ ]'2N7C?'V+Q"O$*-OJ6$PEP/;P)VJ+5"0WDY84ZDA:/ PY$M,
M69&9XBG4:U6"7=LO7!P>Z_E2D<P'+J[4P(YJD72O\Y<4\&:7AF.;G2,#K\4#
M)135,\C&\>@:4)PE!11J(Q$8#Q9)K*D""Z.5=73U7#O&YG;P"*AL^>6/63 X
M31*X1^&-MC1YYCTDJAH0J&(1OR4B ]F*DZ$XTUP3JBB?"M\DO!/"%Q*T&V^V
M/K!>+;,&:RTL]D#/+K2MJWPMF9@8C(B\NNVG7JF9_P#%0U(WDK6]K6M;\<])
M2#S5.4,C+(6D"!@@DH! \CDI:I_3&FZ0LV4V?"13#*R0L#K&FJ(O4D&Z0* M
M4J7QMZL$J!QP20GW.*R9%#VQR>?/.58-6(P93X3EB,+&0N)%%!:CM::\+8*R
MUXY2^]WJ/0Q<H.K(F0V>9) 54RD"@PHE"X(VR!E<V!+"8#FNVS#:W+D2\I2$
M!F'/WA@P6.%.LK!&]I;7$R(O$)Q-+N Q.]$1W6O)695#E!R.GV-T;WE;%BQ+
M:^5%.0)$YMP3S37$"X;6>:>:S>ZS3SAC)K//VJT,PU#J";S: SYY!*\/M;--
M8,L9PFDRO*4*"HK&:K1B 7/"TM:L=% 9.S$^K...$:J3^( Q=19'PJU-**-Y
MEV]J,F=:T)5AKS:4>CFO$?*AD04QB: ;GF00,2F&KW2#3E:H:%Q3_') Z5XQ
MJEF %)E0CVTK)9Y01&A,*0XCBM;=>V/K2Z0.0P'_ -.TB1]L2%VJG>_?K,\O
M$=F\$97.-,[JR)I3&G^,&E'QQ\7(E*9P;5R<TE68+  FX+,+)K-:K<TNAM1M
M\DP^-4LMEJ:DMULU^,4"02] 57T6GA##+(U-0QR-F1XT*&/6VS3IV*DB$1II
M9N%QF4.4&< \)-1I18&I^W/1=+GJW.$2.W"I.; 9Q5[=,'B<$O4C8(++XW4\
M-9H^S'KF,QO EK*)4JPM\=$H3*!D$DG&+!+E"D\X9"XE?<;V\=?5%$UGKPH'
M.S8'5+-;C+&S@25,B>S2KNA5AP.>GKCFYG1M!/GL]H.HD"5"B1-S49D@M(F)
M3)RDX2:C6JBU)VDM44CK.W4)]I&BGQLP]:C%,D)*5H0S=';"5Y;&DQ''4K@H
M)".Z7XXE2Y'N#@$PXD(U(RDY)82G65L;CVN-77%^L"0"3S9.JM")V%%IJ AY
M8C#7(^P)K/I[\;$#VMC"N4QN60Y[LAQ"SGM:]$F+3A3 5D*\IBA!*-94A+M#
M*9>J5B]&R5\LZ41^,2>\IKF3/4N3CG,AE>Q4:NZ+V@^2-Z0LR!&L5NJ38&1'
MD!)2)R4JDQ.(L& D8!DFHUJO@K_MZ:^5E- S:*$RI(I2W*FO5G:1+8\!N9)W
MB.V*P._IG!'&$<K=&&2'6F[N"M"YN2\DI>85E)Z8@D!&"%Q*U"*]K[6.'L4.
MC3.7."F2O9JHF<)1%O# W"80YE58R]KBXUK'%FIPD,=C[E4K46C&[FN#IZ82
M@!RT[)WB"365(;]H71$CK"I*@<13GXD4\CL9F94*:5F)U4BBULP::UW8$1F*
MX*+)[HQ2"-SM8$7D>D6$'%$&$GEY+SXR:C6O:O:V:+TZDJ]EJ]V>[,EI+=;C
MA>;Q-Y5, N%@S6S7-M>&97(9@^IFM"B7Y$SO'I0D)TB0@LA*G"$&/+SD1-1K
M51U&^V#K+&75N7$&68Z-C"9#3XO$WJ<FKHI%5,9<*^>)$I86L+<08G.M=YJQ
MB5RG)IIV%QZ+JGPD"<>$PFLK9X5V^J=@M&S.B&N9W*N:)?-:\L)/.GJ<I%]F
M0V64\RU9'Z?=(;),1\A$@%6392\; V@5(E@#<M_5;A7YQ^#":B358Q+VUM:D
M41.A*8J?ELJEE6LBD0ID>:X*@.FN\XUE=W)0N.1&''/#O +$=5:D\77)CV?A
M9TQX?+X365\DG[:E"2H\T2^16H%N26X?=4/CALBC3[%JZF3\DE"6Q0PJ.2V&
MR-I2M%K#F;FH?"%I2X>%2G!S>8@&21DHFLK:=A= *0V6L$BPY^[V6VJ_B 97
M3M&H=+D[!$9(SDQ:Y(='W!\:A,RY0:]Q!DOV5 ;3DZA.6 ;EXCBS\D$>60.(
M% OA-[=U!C?GE^+7V4F%(SG93(FM/, 8:'M4XW?%=@4:E:F-:33P&QZP8J'*
M'R#2< 0KE1!N#L#*$2345DY3H'14M@]&5XM66(@C5"LY\18D[-,C4"B9UTY.
MD0?)'65D'X0&_&6$2MYK]D4N!)6$BHP;84$M046,X!I X@U6,HSMX45K_8;?
M9D/>;2>9$R+GXR-E3&9E/;5&V-ZC1$02PYH1$LS>(,7C4>3@3MI9XSU)73(S
M3SAYR+A"XD47OF.@M:S6>7;/5UGWNUJKV=X-+I$PL<W8T,?B]CU<37(:OLR!
MX-AZI\89?7JNK6I4V!-7*FH"CU.3D1P%1X!D#B!3@HQ5]JNB36>PHPV6AL='
MHA:U4QNI+#B;/9+/EHE3-&"'7*-^=#W:&.KV;)E[S(G9T7#PLPA6N3RO-.2B
MPJ- (IUGV*=;+TDI^\ZJKRGM@%TRON)UZZ25\!FU7%A?ELQ>I'#9W!2G:<DH
M8TTLCTOB[)82P;.84C2Y;UI"14#J>G /A0'$&HX+0D';;UW0N\:?C%EFN;S&
M) GE*1R=9N-6J7OA#U4;^)<[F>[2_7F*G.E689V<^')G53_]MU"365#(^S7J
M?EG6Q\B17@G9LLC"RQUK%/6=R;83[I+C8'9SC+:]P]T;ANDS,C)1SJ)R*<2<
MJ#C#DI:4P) B2GJ.]BLN#0[7_--R*A5C=)G2MY9-J^GD@:7.0C5GN3I6T<K2
M*,3>H5B2A&)C6,E4M92Y/TZJ<B49\0<F_!*-1K7M4<,7:YU-C#Q"7-AC3VA0
MPENL6/$QHU6QNL??(99*]6ZN,(=2GJ.N3FW,#"YKSCFHQG5-;DF\T18U9I0L
ME\)K<O&+=L77>)1Z.QAO>+-&TQZ"KZX$3A\BS3[_ (H98<$LI@324N-0MB3.
MCE#7RO$)+>X>6!>:D,/"N.6&&8-"345%ML]IFJI+%8XQU/.IU6CVB<:VC[_*
M%+\I?CG2GHB".HI57QK3Y*-"X FC1$F\)@S\AP2N2DJL9S@L:<\I#SVJQUSZ
M"43>]A2NPYRIL("F;0=RA\FB[%,#&J&.;HNKN=5(BL@QEPA/-!9$?K*RGIE0
MK0GX2@2+,",3&GD)SBB@.(%%O=\:GU[L8\U\LL>266.,P%R1/ JU8ID:T5U,
MW9E<4;W%G69L0$1RI4Z1-\0EJT*E J;U&18R2H&>E$(C)0'$<E7M-VM]= H1
MMSG)KLD"0-9-E>HBGFQ0B"TO[-"(#6K5=#4!O8VXM'="& U7&VHMTP'*,*=G
M)%Z+SC%)IY6UGV+/HNVQK\18BJW'%YM:16@]NM5O4XG;Y-$QS_9+A3#O2<@K
MLR>'(F) E>28Z^T2V*DY191!28;DZ@("44O&6$HUFE.Q8*/=K'6",X E;C[1
M&Q)H9%XBWQ=9.A*8\UJXZEIYK7S= C$U!/*G$S8:&B[<\*A&C3GI&\?D)TYJ
MM8:>365\D<[56M,9?(K(TKM:3J]0>=LDLB*R52*,R\,?C$=CS-$FFGV]')H8
MZH 5>CC4;;4998BA/90$)0RW,!V33#"G65NKIV\*?6)*10M4]NV(D:\-,Z15
M29$YLTM;I&WFP$<J;7F8$2 V*K)$&1%MLR6IP@+5EMBDO"?*U&J&D2B)*-1X
M^U7UQCIC&.N<],8QUS[<YZ?JYS^OPJK^\(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(N<EV[Y/M57H_54P4H"=1R,%L\2=I2*Q4<6>5%SS2FK5O" PM
MKCB^,+FP<2<8O50D;B^J'5.-"XO2/!:%024J-+*P;455D*IV6@5B1?7-6[+$
MT2GNR-/,5O0^O335KJK]VK8<QR^0(B'DEK3-ZD,:(? %C--PF$?T\0"\=?#@
MH((KW!0ZNW[JN%4E&+QMMM=X3')3?UAT"D+:\E2C*%XA=V3ZG$$@<,A"TK!-
M;P;"/7FE)4ZI2E"J\L(#_+R9D@:2:!>+!W&-<Y=)H%#XA\I,JD%B&M F9$RU
MT_' ;VEUBZN9#DLC5J )DC%'&>/HAG+51X\8(%D)?01@PAR4Z3S47V9W/*S;
M-4T>TE0-+=+6%3>K10K@DLU]>JX9HM)3Y4*-/JZ3OD2AEM..6YF\(3@#:6QV
MPI"<7@.<9\?@*0SQ4/<OE+[N&LC- X_-[':K.K\AQ8JG6O@E4,6O<=89#9M(
ML6Q#A%$DP;!>YY.OK:HWXI[?C$/C"G1Y#@ 3%)I:81-#JT6=EW=ET[@Q,X62
M603QN;83($K(!V-KU^"U35O$XV^VO,RKMP, 6FE\*BIM!3$;@O3BQ@(&(SR
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M3!DI8A. D$62H-/\D@913K/RK,*.UOJB\QUPCTR:Y_/\2$))TV>9C83\XO\
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M'%Y!"[;:6MYKQU+=4J0R2IWAC+DB5&C;EQB9R+>RF4WSU+>84!<CP$83RBQ
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MP8 )XRQB\/"4-*]A6SJ+0K1'@O*NQ(*EP<S(I&5E1+6 C!L><CD:=N?B\FN
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MRB5-;:08]0&/A  PQP5X=;2F#7 :^(&@;"UBXHF53!Y3(4IXRPI\F#R(0P@
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M1K_LUJ5L3KY%7=G8)'<E23.O&9ZD&7 +(UKY.T*&TA:Z":2%+F!&0([J,2<
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MAM%-=)+&>GBJ8G\B[A7]B6M!!K'#!C%93;+JYEDU*@$O00Q[D<C8W5DC[K'
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MA1R.C=J8BYP5)*0U[#!JJJ36W># [(VY.S-B)*@80>2@)-2(2L0G4';]W)7
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MMVW8BZM2Y(YM;GL+N6X-KDWJ"5B%P0+=L;B5(ER)6G&80J2*TQH3"C "$ P
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MBH7*N2G 40=E4KE^&1&[*TK<]*'9T6D)EX_LY)3XQ4+.QAK[56MM+'T3('*
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M%:7(2FCN_A13!3-NZ)WK:D4K*$ZQM'Q4EC$D=JWM5TKZ I8/)YE'ZKK^X'2
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M+%A<OG)D2A,?])7]1NHXZIB</F"^K:VI:2V"F>2&)-,'1ZD5<5.TI!IE:\U
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MVXIU#B<G$-*,W*47DX)J)6()[:NH93,7&1P.4+(GF<L<\7Q!RM>TW.)OBF(
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M5#X]5Y8#(L(5)I,<X0^&6%!7QM>%YRDM<0K+=C1A5I0X-"8$P0@E&KQ:ELU
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M<YA5REYKE]AR[)[W,T*M.ACBE+@:D6?.\."R%Q#Z=E5L/]F(_GW6Y_18EO\
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MG#?3RPA&'H+$<%;6[@!R IQ7VD]EW7%NEE<2F.PV]8FFK&-P".M$*CMBO::
MOZBL(K-H5"Y?-HZM0.&9/.FN.6*\DB<S3P&&C7&&"#XQ"%EX4ZC^/M]BM:#2
MF,8U:*TY40B9KJ0+I,G7_+<N5*%$C-KQ/%00X@!T@]* 8G\EI* ,"W!.,A5
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M'X@DT'4&GM6BN'>_[?[?X"ASF?J7$=3([7"R(ZLEZA^SZLQ/D59X9\(@KA7
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M*9LXR42Q+5[=;R->8P.S7%GV(JF"!2ATPQO[BG3IUKS$V*T8\>[HQ!+-1>]
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MRTK+N8AY6S!$5+GJPK;C5KQ6;.[NK:X^W,!"5>@N5Y,*1-S<@1)U.23 %8R
M6#":S6O:H$;^Q5I"V/$B=DJR[L%R!K?6<+0*QD66QE12B%V?"I'AI'B+!=3#
MG@FX'Q<,Q<J6C)7'E8(R4E(*3 *>H[V*=*X[5VKE4WO&-BH9BP$5AQUVESPM
MROD#(\L\M.E3P_2!*1(TKK%U:XHB'O,H<#VD38I;3BQ*?"I,5 *("44%Y(IV
M*OUU]E2E[!L.6V?7%M7'4<OM*]HW;ECN['(V]4K:6Q),978TR::D4"9"ED/D
M$TF\H.4"<7$YY"@).-)3$@("0244B0TH5A(KV*M9BD]N(9Y*[#>FN2S@EWHE
MECKV2V,^L\39E-2JV%+7;7(F^5-KG-G-333+E_='@AQ3.Q"8"?*0!?G9/BBG
MJ'L4S1OLXZAQ6]&C8!H4VP5+V*80>?-++\<FDJ'HY="5M?.@7@+4DBJ9<=F2
MN=9-1[BG,5C2^(!H4A20LT0.311K=2BE:-=MF@8]!+]@BE^MJ4D[*W5!;YM.
M32F;IULK<YK6TD@LEAQ2->A8FQ F;&U1738G/,,2G.3BF /UBM0:+!H8HHUF
MH/<H61]EG3-M42(UMQ::%/+X8VQ"4(2I:R' >CF:;%35HEQKDLB2E_02U ,@
MMLP8B6)D1K6#!9R8P[[/R:*>HY;++^T5JS+'6Z'PAZN2%O5T6NHNM2]0&<ML
M8?Z[L-]Q-"Y^ZUI)$T6-D32DL])8S\G?$;BK=$HT[H:!(6DP CR2=1W#V+;J
MN[7^N5(SB.SVGGVY*U<8TYJCT37$['/;V)7&U]@,UC.5=NR,36<I=*^<W=@2
M)E+>:<+*AO*\H9@A9R9PH+R10KU65VO: M6P[2M.3SK8?$TL,YC<8JYHKC>1
M!U^D;)/(#:'QHUY3N:-S*KMV=;"K!B=510\+V_)R#RRDQ2<Y02:0/(%."T&.
M]FC2^)N;8Y1Y#9[=AH)KLE&@#8*A0BQ\FC]K1)F4X_*MM4+52IR?-4XRH<33
M#A&*S#W'.<ARKQY2BGJ.4FO_ &SZ&D6KM<ZG*9E>B"#5%(W=_K.9L]FG-EKP
MM*]M4WB3A%&>:)VC& Q(ZM;&>(IZ4U*:/W"KR#S,J@ 5!*-9K7@HD<>R;H.L
ML*3V>@@4HCDLE7K2U:J/2H:$AO1*VJA&4MM:2CF]6-*A;T&N[.%,$8S1%C<'
M4>1"$N%D!3U'4HO$WLLZ9"63%4G#:2(NP8.^0B:HT\M93 2 +U.)%.2I.:X+
M8DK?&R4LJB4*F](:@5I$N6S!9:A.>:4 ["B=1RM*P:1UE'+HV0O]%,[>,M#9
MF"(*UDT@.FY)1L%AS3E]/:&RLLH&5$H9361PD2E2WJ7 QT5-P_"4E,)3!P1P
MHU&@'8%4EF[(6D#9%_BBN36Q)&A22;A[ ]V  H4@6JFC95I7.:PE@8F)"TJE
M>=K92IP4TDMR-,J"A&F(("E\!A3U'+T./9(U%>%J!T=YEL>Z/)S3-$U@/+A;
M@%;E<THG":Z$BZR;6..C(P/U@-"?8"4 ;E:0+>F2EK@ ].,!!(0$UGV*;ZA[
M7NL=-++ZPQ&6;(HOL-6+[3<MK^:3L][A4<K25R&>R^6Q2 (2&]N=(RWR:6V@
M_N:K/K#S JG,SR1%%A++ 0O)4+M_9(TR3KZB7NBJW))FHV55&RTCS*HN0AL&
M.B62]2U,UB)X_!F/#BFCZ>=NB5.8VY:U*E,H#A::K&20864]1RE:M^UKK_74
MPK"?FSO8*Q)E4:VL%,0D-HVH9+W M%3:2[VVNV%:8:QHP'1^/M-_/B4"8L)0
M1E%I1"SDTLTPXJEY/#L6#L'M'ZL6I8]PVM8KA;DVEUTKWM3)L/L_P2TI&MVJ
MFXZ@2Q5H3,K(U*BF"/1>\WO+:8H.5.B$P*,LM7A&B3I0112'D<J*#Z0[+%=Q
M*OFX5PWQ=TSV$4RE?/I'>E?3-1 '\J:FS?8&:LK[&E!Z1\<DCU'CMC'DKWD<
M:-0M.3IU(@%9#DKDJ3(:\ **Z&RW;PUHVXD-5RN\H^_2J0T\P&1V'NN'W*97
MA&=8]/6DH4NIOI#1.#BHDM)-0!G9\&<I%2XKI^ZLB 50XMY* YWV:=/+ FF+
M%=!VHAG!$QE,V:Y$WR]G4',KE.K;N>XYJB;FU_BCVQY:9,_7R_HCRSTIYA+;
ME*%,80J2E*L%/4=2G8IYJ_M\T932VWG2N':S8R\7-!957\@>$$R 4XQ]IEEN
M73=JM?"CBVD (\]-DXOE[$A/P$T*=*6D)\ L$>(907$\U1"X.Q11;Q0#S5-"
M6-8]63]U2L# EME_D)\B6-$=5&WFS6AY<98"(DQJA6%!MF)FA5-10$3)D2A&
M E.E(2A!DK"0UX\ON_84SO797TTD!ZE4Y&V^(]9%;;B"D2>P2TX!M5U*MA5D
MU& L+"()2K)^S<FRC'CV)L81XZ"]/]D*.H[V+'G=HVNH[M50NPE4V),(4PP"
MV9]=MQPQR=%\B#<LT=%]L/\ 6R<PD9J!E84-?R:^I6H)5>G/5X1*@(P]0YR<
M64Z^!![E[Y_V5=2+$E5\RATE%]M)6R#^I>[0C$?L1G0QAR3.T_=[2DD>2)E,
M-7.A+/(I\^JG,9AJL]Q;5(BA-:I!Z9+Y!1U#PY<%+U[]KG6'8J]%5_V"*R 2
MQSJMXJ-\9&"8E-L4?8\[5A;M/ <5Z4]G7/I+\U0.[Y F3&)7!,ER<>4H.(./
M) /!0'D"BCUZ[/6LLF../DU@[*OYSD\1YTDYJ^XSRQS)(DJJ TU8,<E.6]A1
M>OC5YP>K(X3,4Q?DY7FLR8:0:' 1!&4ZR.Y;+(^TGJ)+89 *^D3?83G$:ZB[
M[#&AG-FF2R'*,R38J%[.O+4^C3M91JTA98D$1$9R6(D86@9R8.<"'@T).H[[
MOB41+NSK63$5K4R5-8\HA;;K0GVA=(#-WE(TOMKQ6;7M2R6EX,^Q=]8T$/9\
M)JC0@ Z(\KDBIQ4.34WFF*\G /.,)KYU[5:&WNWG3=US:E+1EDLM5OM>CZW6
MU>QV3'9,SAE<CCRPE >4KE*^41N5"/D33)VX#VB<T?HG$ETR,0CS"3#"1E <
M0*=BK_$^R;H_"E4; R--DCC$<A$_K$,%>IJ1(XNZ5K8A4D/=H,M,?F)QDZ%E
M;)+-W]\0&-KD@7$.SXK,&H,*\@D@IZCEFG+M :WR-XK1^G%F[/V(YUQ"CZ_/
M43BYC7L5AQLA+;3=%$UBB^+R<QU,KUHN^2HV+*$3<%&G7]!A.&6 82:S[%ZF
M;LXZHMD@C<F<9+?DM<XF.JG9D#+K5.=F]+.:K<:04E6;AL R)$.)[.F;7.'L
M\A4A %,L:6GRDZ=*,\\TPG4=[%N5N=L.I]C*=U[K'8>TKLLN34 %V-36Y\;4
MK=.IXKE 4>9D&7&.S7*$8VV1'MJ7. $!+6("4I9*5445YH32!Y!)':HS5]E'
M3M>Y3E>N>;V6)IJ*:)4S(JL\)[-!8W.&&[&!QA4!3F1X2EEB385L%)E"!,<<
MK,3*E18O-$ H)?"=1WL64?>S)IQ(G28O#B9;N5DY2VBC?/(L$LDKR;=/O-1+
M?1 ]Q"]./!FPL@]+G.1>1C"7]EY&?&360O7(.S1JE)53BI<Y7?\ X1P^THE%
MTZ6S4B4NNS;@N(N]IC)X,>5%\+T#Z.Q4Q"Q,2K.6M! TX#/0B49,/&36?8ML
MD?:6U;E$PJN=.;I;PI'5%S3F\F]8"<HC?C3++"O.&['2%!,/6QQ68K8#+:@;
M<X  A$WK,E &G,4F$&#+R360HY5=D;3AR8D<7>'[8)YC"* +J]+CCG;JH]E-
M1$M%EQ.!2%2@"REDGRRGZ_MU^CD75BQX4;0LP%26K4E%*011.H[V*V3[I@QS
MRKV>NK1MZXYDXQC98W9N(V"GE8F691.1M=KO%CP*&L*HTEX2(H)!V)Q*C)"'
MR\@-:"<Y#Y)P\#+E1JH:^Q0*M[1.KYRZ@G!GE%\Q$_72.(XQ#,1*T,M 7M"Q
M326V%#%<RS[B4&NKK )A.G5<SJ4PD9B<U7GS/-P O "G6?9Q6BA[(^GP(9B%
M@D5[A2#8BD*UP^/[$(]RE;?>TBV*CUF+6,R%#A.9I%;&F3T) 26U%L($#NJ3
M&MIH1AR IZCO8K/T5V]M?-=[=GER5TGDQ+Y9,.98E*X^[*8VLBBM2UQJ'Q)P
MEZ5(GBR)Y02>5,<$;2W,)2\+6:8 TTE$2:H4#-*I>2*%:?K;VP-:=6K&C5JU
MRMM9UF</895#(XXSVPE<N"UUX_1VN(=':W3@6("1AA=71"K6MMC2;Q><B39/
MR>:J..$;A1"\N%"JR3'LMUG9FPVQ-J3.WK19*\M8YJD%9P>N9.N89-4%A/LR
M>K&NB;1N7/ 'U(WEVA+9$OP<TE-XD92=>K'C/FG%^G*PD( H.*DJL>S'IY4=
MC-=E1!5;Y;FQ26K):Q,CA/$:R/-#U4\HCLU:#R"OBV4\+"G^41DA4YEJUJD(
M_&82F]*GR H$44&1Q%%KJ;L?:9$M$F8U#S?3HVOJ1T:FE.[VB!QQ!8Z?&@Q2
M,1:&9/C@O2QNNVDDG#(D7>O 7D@ 5?JRLF%CE.H[V+ZV'LSZ_5RPI 4Q:VP%
M8V$U.*IV8;603I(KEK,Y/4<<X5*7)%[O9X^F2.3Y#Y"YI0FIL)PHSU>#R@8P
M6$K,436>VBW&]^UG6.SVS%IWE=,^GR^&SBEH55+%4T/>AQAD:WU@B>PD&<;/
MD"KR5XY!,6V*[!N::.9\)*9H,,4'&EJS#2?32@>0 !WK0)EV.-)YG&YA$3S;
M<8H_++%D5CD(8Y+8TB'$U4V8; C\^C,97*X0X.&8I-4EGO)BHIR-<5B,Y0#+
M>I1 3D +)U'+:?H;M3CI]FUG)]NA]LXRXBK@5SJ0S./OCRXF%L+)&3H Y)7.
M%*6)=!US+&V\A0:8C%(C0HR>KK]C#T)K-*=E%\&T':?@VTFUZ:\Y/8LJC%82
M&LI-&K@JV,N+@2?9$^5P)^J2&3I(O5*#VF'N42K66."(:E.D/4+L!3%BP !0
MA#('Z6T[5MCKV@].U[^HE:%IFT>DJS:>R-N%CRTOS,H.4S^W44806-%!HY!&
M7QJ!6LE3P]!U;@)P*D8RA#2*TXS!B$36[Y**3=E>W+0NTCM84BG3U:T9E-BI
M:93+917,W!%WN/9HX%P(XHJBIQK.Z)FY2ZLE[21N=<G%*0*T2P. A*,* ;@H
M#BWDOFH_MJ:T:_O<Y?(,1/5!UB5@]5%)44BEXW-O-AC^!A+<DR0HAO0GHUQA
M,<3@">$SQ QD?3'477!"\D4*BEM[/NK[:CB9 )CL"J<(G#&:NBI LL].:^/D
M$9:+F&NI,5D2DN,E)G!J5UI,1D'X 248)0@2&!& )9@#BG6?8I+I3MCZPT(A
MOEB@R.:"B>Q,'5U_.XH[O[>>W(V1[8#6&8'1EX;F)KF+8X3?SQK' 1KHI* M
M%XT9:0& EX*"\FGL4<4]V@M8Z6>J->(_,+V?0:_VK);LAC-*)VPG,:^S9)%4
MD)S)GY$PPN/C\UJC",",DAN,;DRHC& +BU@ @"$I+R>Y?!=G9RU>OZ9W#8L^
MG&Q&)W=+\D<G^51^T$;(ZL4<(AEH5ZLKF,B(B@TX(,[0JXGYK.+<2W%Q*;U)
M25.L(3I4Q11 \CAP7WOG9^U8D2-^8G:37XJA+FMMU9'JZ.M=2? ZV!>R-U+M
M-#7#"I9SPQQ%*WE]7.IP1&'C"X*A9"+"<LE.40/([ET5K.!!K2(IHB&8SV>8
M3.TF=OC+9DE-ETN49DTF=Y+EN4OAR=*,YI8,N_H&PCP8PD;$R<C&18*\62J3
M5;[PH3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X15(WEL6
M8U5K1,9C YP76LF#+J6BZ:?F-\7=/B@VV#>%<5_(GXI%-D#I$C%+?').K&4)
MQ3G)"C<!,,!D(>G"EHJ5R'E/=ANQBJQP@D7'7T[M-+K]MR]$7L:F6Q]EQ,*1
M:=CY+35GCC2>.O$$>X_;]7T'B1A3-BD]'@YQ"+ "D6  ,+)H'/LJ%T%UMWAL
M6YKJOJJ'RE2"(]1<><$Q]EPZ1.+TRR>PH<W0DR2,+>G=8ZRA4-<V/F UD64I
M#%(CFMO&:M F,4)RLE0M %52=/W6M@8HP5NK<*PJFPD#M2]671/9,YS][@KZ
M1FSJ@>]E)!%HA$F6O9"S'-\)@#:?'V@]:Y@4KUQ1!ZT0,>>8,K:15;&V=W2S
MRG*9KIA258M$%;XQ:3G$7&.VE)'^9.3XP0N\9;6K,Y1IPKQB:,*I6?0RYN4E
M)G(X8'!Y0EI_." \>2%@[U!Y?<8VFJ8,DJU:_P!42.106IG6HV1_L:P@X69O
MJK)1;D2M*YKU=RX6K4Q4$I=Z4=!Q&/I?6HW ES;0FF%9,'D,*=(/'L4]QO?F
MY(X[1NRG1J^4^.V\Y:WZ<5NV#?1Q>-"VI>*BB]L2"0JT+6Q."!,BG4FMEQ8W
M564' 6K,$\DHH6#!])4:1R6Z1;NI3F4/T#8RM?VY .QKV.U%83U,U=QX3[20
ME=6P[IB+D67#>I4.@,<=YHN(<09$>M^(RLO)!7GA$630._LJM[H3?>P;ZL2C
MU),,00F'RRZ[8U<G<*4K,O+R&TJOH!7:EER5M<36AI6)&JG[9@;M!1>T:=T]
M8-28 DTI.7PH+0![5>^#V;:TDGTCB\JUPG%<1!H ]B9K/?)W3[['Y3EN="43
M9A!'H?.WZ;-WO] 8):3ZUN3^247D!_EG9"7DJD"G-<*:P[@^[-84Y7%]WQ[S
MGL$G]2SBV(8R26.5)&I;8*MKKFM!*S"3*;2O*6.TNS6#-PJF52H2E2PUFPJ&
MYI1Y+2X&60M:30<U/3]W;;80/$3AC+K.UNEEO5+3*32&!N,W=HZNC=KQU#()
M-'V-.YO,62MLAC$ZKJ/XD#8F3C"^F$+DR,Q.4O'Z?,54:!W\%9+4_N%O6TE^
M.]:QNK$CA5#56<9DF+QB[O(SF!9+7:M:9LS)9+1+8C$W(N&R=NN'TS*:,(74
M!K&>)P1I?5IP@E06T%>U51BW=?N6T8T<@9ZGJR./2^J[/N)PD4<N!S?@16MH
MQ1C):B!"T&+ZJ6MI]Y-2I^PF7-3BD]SH?"0>8:H+-\@13H /WU_&_N7;$3F4
M5C"XQ%JHAB1UOZGHKF626=K7=PE]9'W#8U(V.CE:0NMFUGBTR?I+"TZIL$UY
M-3B*59*\:<WP@X30./P*7]I^XE.*6VGS7#<&OF"KJQ12%--B7UU<G*P;)F[[
MKW(;(KA"WQ-HBKJYLM9?&I4TMQCNA/-6GO 3$XB0I@&#R0-JVO:JQQ[N[;%B
M9I;8Q],P66%RPZ@8G5U+-$O=BY#&IJ^P[8Z264-]=D4$5KE+-*%NOZQO9CS<
M&%)7%8D H$626K,Y"G0.2MEN!OW9FKUT5*Z!BC0\U0\:\&V'8U//#LC9;>,?
MI!<E1UPS_)L4D9WO$NF,3,GH\.#1E6D1"0EJ#@FC- 5TE0UH</;50=&^Z+?<
MC+@<P7U=#()\H$"1M<7ATVEBICJM?*9W>U-02$7 ]V>?#1S=BKIHCU@JD:PH
M;2$:AV2B 46(!Z51Q[4T!;%5G>6!8UVU14#G1R>"I;,9X%)E4UD5A%$1R(L,
MVI]@V$\QW<5,=0(,C0TV-Z<P'#-)3G":PAR(&#^H(0LH*KN1C.,XQG&<9QG'
M7&<>W&<9^IG&?U<9Y*QK^\(G")PB<(G")PB<(G")PBXX;E[6VS0&P,_;U-L"
M;JY6:URQUJ*"0#Y'5SB5;L2@=E6')PVYF4QR5V="'A?%HF6Y1!W)1+(>J(;7
M!&XIL+!HQ*2NUH(]M5$$E[P5I-Q<R51^C*D>4S&HE,M:DBBZ'Y.[D5A XWMM
M*)0U3-,CK9>5&[F$@U/5@): B.;B37Q/YZL 2#,CBJMTQWK*/W=&M.:6TKBM
M0QZM4L(@6R;'&E<FD+Y(VP%NU(Y5/N<X*&1N1N\(,<H_,2K%U;4$)SB,>0N4
MX*3$F"(&8<;*C0*<>=%])7=^ECNQS"91:E(,_1.LZ)GUZ3<2*T7-R=UC=$J=
MU>FZ*.10MEA#DWJ5^9OLN2WN9ZHXD#>VLQZC #5!F$Q9-'?S5DW?:6]9%3&F
M=IX94=)OUG[=P.H+6@[@TDRLF3PAUF$VA*DV*/#X6T.<<:I@!D1OJ ]0WA=D
MZ(X*0XH@_P PP!1I%2.?!7*;K,M97;BJ!K=<)PU5V0H7E$7BHG=/*8FL)2M.
M5R145$$,\4V846Y.&/1 "8S@&6;GS#,!)^R<*M!2M>*XR,FZVZD#62BZ;%5O
M<GUR*V,V'AS*WN,7IIM?):GH3\>UW<:]J 4&PIDN8.*)T7%B5#K*TR>0BD)"
ML*<1R PSA9-+>7;3]A;P1W=K."EHAN5:WL>9_:1LR*=X8HG[I&$0V]2SS]12
M$QB\TED3:H^EBEG2&O'!L,P\^A6H34:HT904Y9)R@HT>W@I<UI[F4QV!O6I*
M>;J70N+3)*W1OUM3N+NTN)15M-EV;D(4M(6>9PN-JU#-$9+3*B-/&%!A+B&0
M.&,)25")$>J,*"R@JJYL?=UMQHE,_J\-)'VS/HSN3>%*LJ3*X^(O$HKB"SRT
MU[<\QAM;(JL9SD)L4CR:+1YQ5*0)W-^CCZ:Y'I0I,"/A6T#G7L6:?N\59R.+
MRR9-^M4<:8TT61;;;&WFP[+>(8AE$&I:%7E,I='THAP1>>&[E)5&C2I&PLLU
MG&JD",K"\9B56'DJ- [U:'<C=^9498*ZLDK @C+"_4*;8T'GX9*G+F\CL%OD
M9N7VOV)@6P:;Q6.JHW"T'O-09(0D>]$J@[W8!0:W*\%E#6@_&JN+.\+9X2G)
M>UT94CHWHU"F;X()NE]$YHZ?;HM+9DYM+X416ZA,U7H@:XH),>SC'[K3+3\8
M,6X"#/6*JW3'>O&1=UNUI'/7+Y+XG6WR>5E>,[;'%<\/TC;#;NJ-!JYM+:L2
M3L)+O"!.\9E:J64$=D.0 "!88 @HL0DXSQ"54:!3CSI^PMG<^[M+S&^S)1$Z
M8@<BAU35M+Y])%J.SW9S='<2)?5T3B:..$,$(=&]0AQ,K/ )\4F*,"0-;><,
M@I0H%@H$IH^-3+=/<@L"C-4J&V+ENN2T<AMR4/=?.E;%RH]*O:YBA2S)='SV
M=6;'C5"N.S-G@"]S296)TBQ,B.3@4%!/R86 H# 7$55/)EW+=C9(<_S*LUT.
MA,*<]9]@+O;6B6N;*]N2 35I;6FP5**H0FS7R(Q<J+Q,R79Q;798I]0-0IQY
M@4R<I/R%8,';SJMJ5=U&]HXCGXE-8U^_61 1)8-)(HJM!8WU-[\K]KWDFTZE
M\5?D=09G^5LKB>KJ<@E,X%B2@6*RPA+2@3GGJY30/N^]^RIEVZW%V6B%F5TV
M48Z5@QQBP]?:+L%E9)\H%AZ.G5G;CZ_U*8F4&IHL^C,C&819!K>O4)1#4(0K
M#%9! U!2;K"@-%./.OXEN6H/<DFVT]V,-:%Z^J(]$S*GCTEF4[;Y,L>$L5L!
MS@<2GAR((5L=9D+I7[F&4C:VQ<4?ES,7(A#4(R23@B!*AS*"M54: ]WNX8U6
MF<6%":DL*9LN)A8:^7);/S$V1\J:,8N-_70<:-# U"-IV?/:ZK,0LT6+P8C<
M,*B%!BT'A-P*%8L%>"Z9ZI;GI]B9UL7!WYJ@\(6T9?<@U^8RT=@)WMTM!_C"
M1\?W*41MH4MC2?B-*(VD  G!0E1V'5H?DX^@&S)IDJCFT ]H5[>%5.$3A$X1
M.$7Y\85W%+DKQTD<9LBP6VY+5C+O99#\D3O5/Q_71*.53.@(I2,@BUBUM"GM
M]<*1+06J)T5'N:@J6QT"9Q2NQ3CG"!3DLA8#Q');&W]XB=XPW*)%3]6M+4^,
MR:',CDT65,I6<X7^^LCJ[0Y@;VIMK4DUSKB4K6G#>E<0G%+LJ5Q!AI!*8)IP
M(!30%KT8[M]L(FN57--X;5I=8R2JJ>F4)@)M@Y:)%!']^TZV3V,DB5X>U$1(
M(>6:33&B<,:%08;D8<K >67DT R1JIH'+C6OXU,Y_<_N8M[JY&W:VL$M2VY>
MURU[%VN(3R0N4G*@-!63!ZJGSRZ%K(,@84<Z<'F=@=6QO$LPW9:FQ0 Y:!4:
M46&5&D=_8K1.5MV"Z]PU@IZ!7(E702(5C\8K\J-[;:T0M$>Q*V23CJ[XE.WH
MP7!([3D3TQ&.:XDM09'&F+H1Y4E 6+T QE%/#4JQ\*LRUI%8L@B4GUPG%?0Q
MJR]X9[5>9W3SW'I/AM<B4;7E!'(G/'N<M_QA0F"5D>M;4_D%EY H\HW(09*"
M!3FN#, [B&[U65%5-[W9A?/H):; ]2:#M,JC54QN1SAS.B,;;%1Y Z81/F6*
MBXW.Y>WKVA2J1ES)2W%KL+TX\82>.%E+6DT"LNL[L=J"D+?"&76A NL53KC+
M;"=8$YS=?'G6.W5&&6/3!+ #G5XCB5E?&"4P"3HGMN$D-PYF$+4J8PDI<=E,
M65= YUX54^:I=Q![VAOU364:JM(YU8BJV+2=3=\6=9.-A,F#U651V=D!+-,8
M?$70J$OZ.U\M[48:$#P6L93\KD28*DGP2H<V@JJ4ZT]X6WI\Q4/%G2BW*RYY
M)YI,X[9*I">;'9=\4(0^TQ'U\_:(@@BQ<:3YD)=TER1D3&+2$CA$FPH8%&7!
MQ*3$0K%@%35;S"N\!:<JC].2QRUKB\2C]F.^7T)DAL]V0.,EK!RE^J44:,5.
MW*((4JF%FM:S:,!+@VJ@-Z,\V-J#$:@TA60,N5'3'?\ =Q5A]F=]);3=X3FH
MG*+HV!GB>==I7!7%ADQ#C/KB8)1<]2PZV4K<TK(-)8>PML53V*F;5K8L6HI*
MHPN2JD6"DZXI<E* T$55?87W>+'?'&">_J@I<F.+9##%=BR&*71(Y,E8ZYL5
MQTE;6!PB @5HF*D4QC1^ZJ+WVB4"1)@"CBLM.>88H)""*J>F/N^_^PM)3=W&
MY)()-9['":O;ZP@<>VQ=Y9&'&6/S2OM-EKFL]4;=J.51)8]P4#W'SSH;L#YR
MQ"J 1D28)ZHT(<%%D@E3H'+M4CS3NUV4@#8CG Z,K^61R'3!@K-I7EV3)G)8
M^S6=;+;'T9"73":+U\])00D]CUO6N"E02><I&Y.Z1&06,L)BG)1H':5+>X/=
M$<]08EKU-)A0#P<BO&JE%EN\?4RDDF1UF*+(X6]V<R/X6]G<VYP,@4>FA9IA
MQ!N *3DIH08P'H+A0UFKA55CL/>_<9',71AA3I6L>. ND;!F.SMV;G)P1V.@
MWUUZH)0Q(%S-6B7)\ :HQ8RQI&=Y2IV1I5(U@Q*UI2<62G2WM^[@LTR=V>S#
M'AC=B:MCCJU25+6\IG#$]66!,D@$<5)-:HK-$%5FL]6E.,I<#I=>^5J7#^K*
M >2B%GS4GG 3%$T*0MK-R=KZIV#N.%5JXU"KCD,G&GZ.#165+5+<O=6NQX9>
M,HLMLEK@DAKZYLS1(C*\ 6D<485IZ<U*666 O!R@0(KQ1K01Q]JE_5_N(2_:
M66W6U--(.,'@,#JW,MC5AJG@QU,!+"(E!Y JC,A;%3*V-QHW8,[PK9C6]0L*
M/;VLXQ7A.)0G+S*@MI\*JC0O=RM5YB5 QZPJ_JN539W2TQBTIU'+.4IVB9-%
MHM&GB%"MJAH3P)*E?;>1/FW:%7((QC*-"V%,BLM.J,PI2^"%8L KW?\ #^PN
MB^B^YR7<&#2F2NC5"(1(6"RK"KQ!#F&P4LR<GU%51T<8)/8"# FUD5FPB22)
MY"X1]6!.,M;%G-G<#!%B<0D E4<W2KU\*J<(G")PB<(G")PB<(N9G<BVX<=>
M$NNU/,.HZ'<^3;A6@_4W'Z?>9Y!H%'5ZN.P)_LU4:_+;&CLAB2]#[NB9V<$J
MPD@P8 (L"R+PAR5VMK4UI15@4WAOHL<F]Y5_V?\ ABIW:8@97K4ZJ=Q]/SW)
ML@)R%6V'0=O7&Q$2I'$#6U>>G$V%B"B$0>87DOPC%C)31GTOD*R4:V)[AD,=
MUC_#^PK'XH^N+(P1EP>XUNMJ2Q.Z^-Q1&%OB\?6.37%DJQ4R1M #!"!(,8B$
M9., )  ..G"49]+Y"L,T71OBPMON=I[ L82-?F.@\(OQUM3#R X>3G<]Q3@"
MIC)V0(CO?RPL)&,X)*3J!DE@"3GP<)1GTOD*]3]<6]LG0$-;[V HNX($KU'9
M$G3F;K:FE8(>XF^8DD=<2QIXT28!0U/?B4%YP+ID1IH18R TP(RFC?I_(4>;
M?WDD1\P52#^SXP%]4V&:TGS]0\[?:<.9\X.8#DRAB.F!RV''F28UE/1$C2"6
MY/RF&2#)?AR$.<$HSZ7R%8D5F[X 20)M0=A\QF9ZUMEWO"*LC'W =;&AF3V<
M^%3/#A)UK<B:BD[D>-=/G%: H[ B2EHBC@ "(@GP$HSZ7R+X66P=^6!9"%S?
MV.I+ZFO[<M.]H^-3W'->E0<VK<9<_(F\N= '-P@NZY0EL]Z)2!/P,M 2JP @
M(,%%>"$HSZ7R+-02WNX#72IN<XWV+E^'QI=[;?6^0NG<)UO=WY,ZWI/!V3:B
MLIT7M1R@!LNEN0''YQG&0DDE$ R$DL)>"$,/Y7R%3#^.QW5OT+#S_P!X'K/_
M .9N2HTQ_2^1:>HV6[C"MI0L*KL0-"EC:V-SC#8RJ-W=33FENC3T@ UO$>0M
MQD9$C2,;LV%!3*4A8 ISR X+& 0,8QPE&?2^0K255E;H+B$J5=_9X*Q6)D4-
M!72).JVRTP4$)*^+\[RX*E).A0RT\-+]29X6P&,(L>8+H5\+/4IHWZ?R%;@R
M[&]P^-O_ ,:X[V&&%AE.(NU0C$E9=V-2FM_Q"V+(1,D1]\(8N0X_%=GR#&4K
M?YGI$^<8\LL/3A11GTOD*T*J[ W;I6",E;UMV 6&.Q)A;W=N2H@;Q:JK%:P$
MC0HFV4*WIT71Y0Y/KG+$3:G+=52LTX]R 2#"@1F !Q@I(:>;OD*W$^_-_P!4
M1A,J[!454IL*D"["<_<[4,XC"UJD89@V+,%&101>%3=+0!="#.GC)<<84@S@
M['CX449]+Y"O"1WSOY,'Q5)Y=V!XG*9(NC"V$K9#(]S-0GM\60QR K+<(BJ=
MG.)JEZB,+P.!X3D S,I#<'F8$7GQBZDHP<G?(5AC[6W;5- V!3_9ZJZ4L)C.
MP1XQD/VYTU.:#&"*O*N1Q=C&VF0P2,3/&Y"X'KT";(/)1K3S#R0@-&(684T;
M]/Y"MM>-E.XK(I'&)A(.P\S/DMA.5>89*7C=S4USD<1RO)RG79C#VMC![FP9
M6I\^6;Z0TKS ?!%UQ[.2HHSZ7R%:P7;V\9,6508G^SX5^5"5S>YM"Z'E[>Z<
M BRQJ>W@J1/+8JCX8=AI4-[O(" +E1(R<EJ%@ G#P(S&!<*:-^G\A6:=-@>X
M(]DJT[UV#HR[IUZ,+>N(=-T=15Y*UO"QG1@*%64KBIH%",,:4F-V"AXR#"$P
M1'3RA9!DHHSZ7R%;]C=?NJAQ@(>RN\8QC&,8QCN!:SXQC&/9C&,89NF,8QPF
MF/Z7R+^_CL]U;]"P\_\ >!ZS_P#F;A-,?TOD3\=GNK?H6'G_ +P/6?\ \S<)
MIC^E\B?CL]U;]"P\_P#>!ZS_ /F;A-,?TOD3\=GNK?H6'G_O ]9__,W":8_I
M?(GX[/=6_0L//_>!ZS_^9N$TQ_2^1/QV>ZM^A8>?^\#UG_\ ,W":8_I?(GX[
M/=6_0L//_>!ZS_\ F;A-,?TOD7WT?W'-D)/N/5NGFSF@3QJM(;AJJU[6A$L/
MV6K&Z43@UU&JB2-_0FM5?,!64)QJF8I0@&>J*STZY" >.OA*"T:=335==^%1
M<$3]Z;XNR\-EQ4-V<FS95+KY<-HZ<22]7/8G7&#/<GQ!5+:JDL8 @L:,$RY/
M$'0A[2JC&\1RA ,1W3.1C"+H632 !5WM6NQ68[FQ":V]839V!Q*I9>;\FD-C
MN#QO%JB[$NZM+&G.)A(3MJQM,;&U(I9G]T KP22 Q>-V6"5#.RH'U)X?I?(M
MY(O+>=*L='!-_9^(TG7ODL:YZ]+B-N=-"5CQ.F-2J6LDT=%); $YPEC.L6G'
M)7$T0UB<TX8BS B&+.2>'Z7X5[(W>^]D-;E31$/[/['HHTK4+VV+6N-[>:;,
M3<K;9,)$.2-ZI$UL*5,H0R ;:FRN*&'):O*<O)N!^ /0E&_2^19IIV;[AS!'
MHW$6+L-D,L3AJA"KB$8:=T=1&Z/154V&&'-JF-LJ-H);6-0WFG#$0-*44(D0
MLY!G&<YX44;]+Y%N/X[_ '3OT*LJ_/WU?_@W":6?2^1:Z#;#N1%)T"0OL6J"
MTC6\.,A;$H-W=30)VY_>!.XG=\0$A;,%HWAU$_K\J5)> G'Y6J/&(7G&>(E&
M_2^11Z3:NYB=+'4)']G@@I"*'HWYNB2,G:G2DM+%V^4F'G2=#'4X(T$ID1R,
MY4:->4FP4!8(P63<#R+/4IX?2_"LXQ7YOA%E\5=8SV 6&..D%CJN(0AR8MO]
M.&A?#HFO.]2NC$56-[$G41Z.K5'V0U$D$2F,'\(0,Y]O"BC?I?(O%UOC>Y]$
M6-\_L_T?>1DO*&1E#==O=-W$14A:WQZD[8_%B6,)V0/+=))(XN!"K'0\E<O4
MG@%@T\T8BFC?I?(M&E$RW!F<IC4RD?\ 9[V9P?8M8;C;:([.YVHY*5RL]RC:
MV)F3^3MY#46AEDN2,C@:6E<'(M4I2&>$TD8#2P#"3A]+Y%)#QL=W I#(Q3%_
M["#<^2X<?,B0Y2\;DZ?N<C%%3EH'(V,B?%K,>YBCYKB6$\2+)OIA'!P/(/%C
MKPHHWZ7R*,83+]S8#);9ES'V!Q'2&[IBKG-B+GC>+5%X [O:UF+85 4R)<VF
M-[6@/; C"<2G*+PJ,4'FJ,FFG&#$4\#^5\BWE+>&\R%0M5HO[/O&4:IRF!5A
M.*E+MSIHG4+Y\1AP"1.%IQ+  Q5,"0NZO 7,S(EH<*C>AGV0?B)1OTOD7DP7
MGO1$V17&8M_9^8W&HVO9W2/+H^P;=::LS(L8'PS!KVQJVEN8$R!0SO!N/$J3
M#+R2H%[3 BSPHHWZ7R+.I=F^X<ACD?AZ+L-D(XC$PI0Q:+)=T=1$\<C04*4]
M"B#'V0IH V,P4:)4:25A,47Y91@@!Z!%G&24;]+Y%BU>P&^C@!&6O[ C(M W
M!R!O KW!TZ4@0@%%#(&(",)S&/"4(H.<-FS@'AQEI%E)_P GSDOA*-^E\B^@
MS8O?\TQ:<;V#6PPUQ./4.!IFY&GPS%ZA4F?T:D]:,3+D2HY0DE;H48(>1"&6
MY*@YSD*@[ R4;]+Y%];GLSW#7M>P.KSV&D[NZ15)E!%W)SW0U$7KXVARN9W/
M*)@6*V@U0SI,N4=;U'EIQ%@\]"G,Z>,DO(24;]+Y%Z&C9#N!L$@2RUA["*!D
ME2*- AB.3-&Y6H#;($D/*7#<RXHE>4;,2XD1HMR,$H"A 9A+@\63, \>>O"4
M;]+Y%@D]S[NI$0FU)_9[XFE;ASA)9PT"?;/3 E$.R4 @B0V$)*7'@D"G",0,
M9*=LA]>7G&/";CA3X?I?A6<1[']P-N<VMZ;^PBWH'ED.$H979'N5J E<V@\1
M<C)$>UKR&8"I <(F8NX,B*& 60NJS'7HI.\911OTOD6]?CO]T[]"K*OS]]7_
M .#<)I9]+Y$_'?[IWZ%65?G[ZO\ \&X32SZ7R)^._P!T[]"K*OS]]7_X-PFE
MGTOD5A- -W)9N<U[#);"U[=M:K'ULOARH*?5X[61&K3,!)&R%0V:GK4\HB38
MW,1R?*29$E8"0)0'Q%Y%YF>OA"4.;IIQJ"IJW-V20Z>:J7WM$YQ)7.V^BJVD
M-C+(<@=B&%;(R(^F]28UIGE2A<R&XU2'V8-$G.P'_P#1SPH:-1HN3S7?.Z4F
M@3JGC'8(9VR)VJR21U<36';S3MA,?$UKM2 <H>EA 8V3DQWEB(A(8O-4E#.5
M#3D^HP/)0<8*]&_2^0KX8--=Q:\K"-TXP?V?1L45[%HTEB3<QR/=34N5^I9$
MK8:SY(>ELD;'-:^&JVY0:4>8K&:,X!HPBSD(LXX3PDUU<?@6QN5N[IO+;AG>
M/[/-"W5H"TQM@"U.6UVEBYM"Q0U6N7Q!EPA51PU+AIBBYT4G-J;P^2A-4&C(
M" 1@\Y)X?I?A6P+]BM_G4IB(=.P8UN1,7E0IU&25^X^GRPJ.S<9ZE4.8L1:A
ME, T2H2E8<9EP3X+5Y,-&+S.HA9R44;]+Y%_#-B-_#9^1;!O8+:C;22HA-J:
MRC-QM/1S].W"1FMPD!$R$R9D1*(3>>,C)05. 9)&('3PYSCA*-I35P^!;_\
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M_9[F-'*JX4SUTA*E!N7J(@01^26:[0]ZFTU0LZ-I):@3U[<(*W"&^9)RZ@"
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M0[6L+HPR2-/R$YM>61X;E54&)ES:YH%!A)Q0PY 86/(<XSC.>$ZG<&_$NO\
M7<(:*SK^#5O'S5Q[#7\.C,(9#W,XI0Y'-$4943"VFN"@@A*0>N,1H 9-& HL
M C,YS@(<9Z8+&>)JMQX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1?G()[BVU0]3&>V!3&.YFJSNA UA/7_$B.X2BI\20XS+(%N]+Z0+EYP,9
M]?@/JO#[/%^KSUW]4<)]MNL>F[RXP_F*:W?I>IIK6M::>%.5>-.Q?K+)[J'H
MHWUPN-D"PN_U>C]&CN%K/-SZOM36!UNIJU&/2:=&O3KQT]BF/O7;S;%Z5MVN
MZF@).R1PRPUEGDRG+Q$V.4>L!&2(*8S^G]])5047D"?%/C\O&,F>/'7]CCG"
M]-]KXC<IO!E&.?T1&6T<YM-74K\TBOS1SY??70?^SP]VWTG]X:ZW9%ZH6=Q=
MMQ4>.-MTKF:WTFX-X)=71<W7JZ,=-7S:&G,JIN]O<]W!HJPM,H]7,VC#8V7-
MK%15F3PI; HRZC<)C.79T221<D-7HSC6U(J)3%X+3D9 63TSD/MSSL&V-C[?
MREID9KN-Y?;7\\3/&X48S3I' BI%3Q-:KW'W:O<W]!?4K:OJ#E=V8Z\FO-O[
MRS./LBR]N(PRULXHG6['!CP)'-+G:I'@N=PKR5E]L-\ME:IGW=#885*F% V:
MP5?K)**?*51!A<3&1WLQQ@*>7G.9RM,8-^ M*?56"@*O&!/D8<@QCP8ZZ#";
M7P][9X::X8XR7K[D2^)PKTQ,64H>%-#:TI6AJ>*\?]$?=F](=[;7]&<GN&RN
M9;S>69W#;Y0MNIF":+'QWKK41AK@(2PPQZC'I+Z'43J5C:DVNNJ6=P"MZ ?'
MYJ45I(] 87?SLU$QYJ3+CK+>7YK0.#J4[E$8<"$!J=4/ 481^G!G/7 >N.O-
M7D,!C;?:D^6B:1>,RSX =1/U8#B!2M*\!QI7VKR??7HCZ>8/W7<OZH8VVG9N
M^T]4;O"12&>1S!CXH9'LC,1.ASPYHK*1K/::*E\A[BNT[?WCT^G267Q\%$F6
ME&(N./"A<=&[99G.L6J3K",202/WS@T;LJ&/!GF^((<X#CX..G.R1[.PCO3O
M]8S&[[3Z#G:M3J5#W-'AKIY =B^@\5[J'HM=>X&[U]FL+H^I0PMQ<"?S<XBZ
ML>0EMV.Z&OI4$30"W30GCSXK!Z>]R/;"X.X??6O,YF,=<*O@0=E<QMI20B-M
MR]-FMGUP01/SGA&B*<5?HDZ<&#/,&+S^G4?7.>O,FX=F8+';2M,O;1N%Y-Y?
M4=;B/K TNX$D<:GD.'8MGZ]>Z/Z(;"]U7;/JIMO'W<6\LG]@=>5UY<2,=Y^&
M-]S2)[S&W6YQTZ6C1^30+=Z'[@^T,[AW:?>9)+8^J7;6V_?\1NDPB&1](%^8
MH#*RFN,)VLLA,$$>.2(19"8:DP6,X700L^SIGB9;:6%M+G.10QN#;&"W=%XW
M&ADB<YU>/&K@"*UH."ZWZF>ZSZ-;9S_K=C\18W3+;9.!PEUB0;N=W1FO;8R7
M#I"YQ,X<\ M;+J#!P:KLZ'[.V_>\1W9=K'>FQT74IM%=M7U^8A86QI VQ"$M
MJ!1'T2PI 24!T4IC5 LC//\ $:;C/06<\ZYNC"8_%W&,CM&D-NK&&62I)JY[
MB'$5)IP'(4'L7SM[R_HYL/TTSOIU8[2MYH;;<6S<1D;X/FDE,EU=R/;.]A>2
M8VN#11C*-;^2 N2.DO=1W+NRE]])I8$YC#D_4-K@KL:MU". 15K):Y648\!
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M=F-+950+50,J8HXBG\=L%PDH'B(,$G&J51]QBJ9L&08](U0D@2BG4[ @E^'
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MDSW=>SU>&S%<%5<PMJ:MJ?B<PH]D=I,AP\66^/;];L?*>90[MQJYNAD9D[S
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M,+PL1A:7M5[MQ@A"8$9>"3RE/'MLUB?/NR=Y;R><;=]>,QEK :&HB>VE&MU
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MCF&1'F -:9>F'&6%E]_32.=! 3.SU[T6J"<A+6C5A*)P7R&;EOH@QL+(FM8
M"*%VIO:PZG.TL=VL9I:#Q:&U-=[9^\+O/&0VEOB[;&P06T;(GM,<LPF@:");
M5PN)INC:3\#);6GEXHW:G6[8"^35]41TMH^(OK2_8:G&3&LAV%+8VS ;._LZ
M1624K*0*4R!0S  F,: +3?1^7D.$_CSX<8ZYY6XW-E+B)T.IK [F65:2.%>.
MKC6@K7FL.=]X7U'SN,GQG6BLV7#=,DEJ)8)7-):7M<]LI+A*6-ZNH$OH-2RT
M6U?8HM+X=,BYU+7MP@[2&-L)4A8:J<O2Q<A8O6HV),Z_)P3(&P*8QS/ )6B6
M)EZDH> GG&X 'IBGSDL]O);&*-K)7:G:72BKB "2.II/(<""T4X 5*X&:]9<
MEF\%?X!^-L;:UR4_F)C!-DH]5P6L8^9T?GS!(7"-A$4L4D,;@3%&S4ZNM.&D
M%+.*)[0FGS<H$B;#BGA05)QB7*)2K=$[NNL5.L4HU)S;-G!2D+ >:FR4A,3A
M\G*7RQ""+D,W1DV.:\"*K'</#PT@4$= >+ #P!JZO'55;BU]X[U"M+FWN8VX
MXNM)@8FFW&AMLV-T3+!S6O:)+1C7.+&R:IFO/4$VL-(V<G5>#F05Y@;W)IS(
MD3RDA+5EW<5[ D>FQ@K<9ID'86D;'&VEM2I& ]0:<$X:8Q:<H.&8:>,7@\&
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M\+WE0[O4A>#'!O6FC=9$4M4(5X21$I5* \162<9\(L9F;JR<;=($-!\WP?-
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M&4U(-[P>6ZIXXC-7F)\AP:!&6([(<%XR+A*'N4E1&8Q&P(XU3&!RF.S6)/I
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CPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g664711dsp002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g664711dsp002.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_[0 L4&AO=&]S:&]P(#,N,  X0DE-!"4      !
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M%4)B%O$S)'*")4/_V@ , P$  A$#$0 _ /W\8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MR0PY,K3'EBT(!A8A %K?QUO>L#WX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MUS1:U4RI,O>&@M+-4*O>G!L]PM8:89:+&Y'Y_P#UVUY"Y-O#G)F\L\>AW/\
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MK7'G2BK943_8_0W-O2#(\'=.=;T["HG5]0?3SFN@7+YTNDDEERY$[3\"D\^
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MO>4FE#1@-2JP$%\.>&C#*/.QR.CM!;6:NK^KTZ=OLEQKE59VZ81'U0 EDO\
M3\O/UAAEB2:*#S*V9;R<D+">X!2;/VJ<"?;3F!T=LHOAS3L]-7:;#F8# 8#
M8# 8&DV5"4EEUS/ZX<%RIL06!"95"5KDA 28M;TDK8E[$I7(RU(#$XU20E>(
MPO1@1 V,.O5K>OC@C2:J/&>.2 FNE>.1EBS,?W>Q?AF*I4PD,?V2[(^&)A8$
MPB1R_?R7K ;/S[!4)W?1>PA)*(+VF]L6Q;V:R_7VMMX=X4A'#<:E<0A+VRR%
MD=#F5LC"LNH:EKZ7L\'C '$J-QR:S:NXM'Y#;[TW%.8PC>G\U0L.WKW/2$XU
M28>+KLG\BG!T$B- <L\_MLPD.F7ENRZGL]ED06R/IGF;O54+%:Q 3*24J$I
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MTB>'R6!T,![E;^V<K,/)ZU6Z6ZE=A6 C@:B*1E(\(8CHP]F:G<Q281K>S]C
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M5RK_ !SS?_9Q@I9SGU?$^]GR<?N5<J_QSS?_ &<8*6<Y]7Q/O9\G'[E7*O\
M'/-_]G&"EG.?5\3[V?)Q^Y5RK_'/-_\ 9Q@I9SGU?$^]GR<?N5<J_P <\W_V
M<8*6<Y]7Q/O9\G'[E7*O\<\W_P!G&"EG.?5\3[V?)Q^Y5RK_ !SS?_9Q@I9S
MGU?$^]GR<?N5<J_QSS?_ &<8*6<Y]7Q/O9\G'[E7*O\ '/-_]G&"EG.?5\3[
MV?)Q^Y5RK_'/-_\ 9Q@I9SGU?$^]GR<?N5<J_P <\W_V<8*6<Y]7Q/O9\G'[
ME7*O\<\W_P!G&"EG.?5\3[V?)Q^Y5RK_ !SS?_9Q@I9SGU?$^]GR<?N5<J_Q
MSS?_ &<8*6<Y]7Q/O9\G'[E7*O\ '/-_]G&"EG.?5\3[V?)Q^Y5RK_'/-_\
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M-CB<SJUA:90H*T+?P,UO!-LQ%94_;_-ER7!TVVGH:5F16=K+$N6,-3/4%;=
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M0= ."'>P;WK6\(QZJ9P]"8Z%+I7&D9K(!,:]%JGUK3F-!:Q2%$D,= '*@"0
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M?(%33FB,E4=\<%=3U?"*4KJ':(VYHR^P+(C"YDDG1MBHFTLLY\;3EZ*O6M2
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M//77D=J99M)S+.E]AM%J/=-U57EN,2QF+:R3;ED1;4O3+&51Z6HIPVA-+//
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M[[\2,A9*#?6SF>W+'>;U016+P.#/4Y<X*<0X,9G*#;Q;+4U@/4FCKN2J97R
MDER!Q5IT9[LF7(0@;BQ?$) S47ZZ\/C5="H?'U%ZPL"L;0,L*1.<DKZ;N%AF
M-12!J(CS@^O/(-3<BN+:7LQ.-U)92&"J"'A/L1NU'SRLP QB*" .C,W5BBKW
M7GBID]L*>F)]5MV2#3];C+<CS!Z=D33#D$$CENWA3E<4A,)FKG06!?,SVT$;
MK)M6I6\WWDJ97\Q_D. < LHU;?2E>Q: SQ],CQR?>W-DSMV7RR2='3F36I:5
MQJ(W#T#B]6,_O\=?$R[5?)VTR#BAR!/#6EK/CYQ!R)R:$QJ94(S2DX6S.7S1
M/)AN:O'0V\S3>HYS%;F?5ZJOVWJ-GE["57=<Q>*V U=06RSW<Z-B!@B[0W-]
M;-T$L!C3C:B68!8!( :2G:%KXCV6;JQ1CK$\6E+V/U0KZR=9?-T4W57ES?>F
MF5!]#A82';G*&2B(H(T3HQ")9J.6 :]-SB^@V/9AZU@0""(.BQ:V(OF(HQM<
M>)N@:YZ 'T$ED,Q>7M3->NI@XQET^B/JVXE=:_5M,Y1M420A+4B8:N9FQT0Q
MTOU^HE/(5^C=CV,/P$WS,48SF3Q30GD1V9)+25XV:RRI)6_/]4R60/+1!Y(I
MF42J"R9+/; VZ)W=A4I43_T"VO:-ED+DF"6L2HF9&8A&2>7Z]B;YNTG@S<"\
M75=0$<"$@M*>KOJ#(.8Y A"K01L&EYO,-F=!V;'DJS9" &PD2APZ%7)5^P?
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MJ!21JG"6=[J[G_GBF54U?EZ*#$U%.70N 0%M3@FM+NT%*<DZS01:?%:HTMQ
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M:T'6M?#6M:U^#6M:PYO[@,!@,!@,!@,!@,"IEV\%\1=)O&Y'T!R+S;<LFV$
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M)NK%(BB\F&3 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M*:4Y[<>!M4 2F","4(I2,Q22>$-<[HI.G!PXXVF_G'E'EZM3D:_>FEKMR[S
MH3V?.YP51-(L)5O5-+S' RBH\TOK17:8UO>[&$E- \;1*"SD 6-V*+&6< D6
MXZ7>'AE$?-+]6^5Q,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,#Z?ET^U&E>R"=J@DB3A4^T#Y@*<8PFB(T=Z?<T2(
MP&A;#\?3L6M;^'QU@:JY5[ 7F1(I>\0>'NLL;1- VZ4.4:95TB0"CXGT;")$
M]JD1KDE$R#E#GM)LLT/RVW%5LOT_,&^LM9X=C++XU'75T:GQT8&5R>F).[)&
M1X7M2%8Z,R5^)3IWQ,U."@@Q6WIWE.D* K 2, 5 "@!,T+0=:T1HK#15(Q5D
M9(S&*<JN.1N-:E&HY'V&O8BSLC!J;DJD\TTR-3>T)T#5J7IUIP'3V"R_I !P
MPG^YH8M;+67]%1E)"0*&H5.U8)K6(7QK5MHJ^B6T"ILDT>9XC)&Y0CVT?+GH
M9!$X\WM:XD0=EJVY"G3&Z&226 (K+S.U 4._PV(UT^TG4;U7U?J&U9 H*[5O
M#7&&PE6S$F)F=5$8PL9CF2-J&E.<,M,-$02(@ ]A!L.M[U@K-:]K>/J;$/\
MWK_]U8W_ ._>P[G'_L-L_P#?+861)&@[E?\ RO\ [P[#'$!#?KYSWO@B)+(_
M^J $.B-/)HJD4RPIP3TY59"\AM4LQ"XFO8D6L)9UC>]-"MI*5 :-'EMBEIDC
MBE,3A%HH:9>H*V'8#S0B+66A3'CKD^P&04>E_-M(/+;IDE,=1^NL8>D<65HF
MS6>S2Q/&GIO:4CU%SGYL4C*4'MRA*H%K>M^O0M:WH971VRD!PH^F'=WBLA>*
MDK5YD,%C#C"H7(7F#1EV?XG#W=MVS/$6CCVXMBET9H^[M(MIE:-.:6G4D;V
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M:LWE0?(ULP./=8'%G$XZ6N2-L;G"4FFK&HX9DC7M[*C(.7;WM2:2D) (>PE
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M*31AUH1@][$S,\4HA3D /-5!()"I/+)).4!+!H\XE,(X:<HTW0=&&%D#4F;
M'>]Z#LP6]?#U;^)'W8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# K,U<WN39 I
M3!A=)=,NA\G<6=P*G3K.8FHGL8"TG%G#;XL[$P!,VH&YVT7Z%@#D2@1@!;T$
M0-[^.OM[GG-E_5V=5]%T5L61,>'%E_AW5BE;H\2LS'&*71KS?V'K?Y;Z/K/N
M?HON2W[1^SMG:Z/:W;)Z/;Z/J;>BZCQ8F(OZG:GK;MR_<VJUVILW=N+9B*Q=
MP9X^BUYSC5CAJ];[)#6*1K2*F\B71P#=9^VQ60J$KM,D4-&:_JW/1/M*A(QM
MP3"ABT$(-[T+7&/-+8MW[?I>D_SS,Q.%U=NL4_Q?/\L1QBN5)YOF;?\ )/3;
M?2^==-/VU]L73YSN;EUM\]+OY^7>);-L6^73]7$;-NW7+;C=C?FVZ(F9NB*2
M(HQ>2YVDY;O6^S@V:A=D25M/ET<&V5B)U4FJ0+:M(##0&L"YJT;[:0:PQQ"6
M4$.A!'O7QVGS2V;-BWZ7I(\";9F<+J[E(I3=^?YHGC=3&L\DW/Y)Z;<Z/R7I
M/_-?;%L^3[FU?=N1TN_XGF'AVQ;-GF-WU<QO6;E,MV-JW8FZZ9F)MC1A5W.;
MDM@T4A0>CNE41\6>'-V-FR&<10J<RD#D>8<%HE;J9 CF]P9VW0_0F+)1IAE@
M#K0ACW^'.MOG%EO57]5]'T4Q?;$839=A;3MMCQ*Q,]M9E]+IOY9Z3I_N3KON
M*?M+[0W-OK>GV]J.COZ/J9Z/IIV[8CQ>FVHZV-RS=W*5W+K]W<B;IF8MMX-U
MW4JO=I+[-^]NX-)5S0)I#6.I(R?=:A&)I(:_I9 P?5CZ7)=PC)^:T8)Q&#YL
M8A^CT[T#7E^OM^ACHOI^GRBZOB8SXLZUI-V5*=G]O#3O?G(^^=B/LS:^S_\
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MV.#:*R$['C/ X5<F##0',+BTZ'[:,:LUP"66'6A!'O\ #DGS2V;-BSZ7I?\
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MV;6U=-MED1?;,3,ZD/G!R'6Q-=_M(],@4%2L<HW8H)S%-62:4-O$@^JQSWN
M[:A10 A?,:3Z0:.THUH7O>G_ "YWCSBR.LGJ_H^BI.WCX>%WA\:YX^)7/LK6
ME.Q]RW^6^DM^[KONO_R/V?.U=T,=-]!/1]3]!$YY_4QL_6^)]3_PF_QL,-/#
MKJW(=/+!V-%["^^*YP)XRR)68VO 29BU7,F&E;UZ#;U*&7<5VZ+WM4)=I0::
M2N3EB4$%"T7H(=A%YX\QMCH]SI/INFKN75\3&[Q+=8FEDY4B-*4FV=)G5^?M
M^_>GM^T^M^UO]!]O3N]9U-V['73T^]]?T\77V7^%TV[]3X=FS;AA;;=L[ET6
M7WQ-TS,3&L(.>G%#%; BXNA^CEYL\7MBXB4+YK%CI5 @MKB-P$AK]P+@I*-G
M0.01_+J0*4RT0TX=!"( O\V^UWF]EV_M;_T?1Q&U$QC%EV-]8I7<C.LS'&*3
M%)YOL]3_ "ITG4^=^5^<Q]J?:6U9Y9M;EEW3V=)U,=-UOB;<69];9/63?NW[
M=,]N=O<VHC<F9F+HT>.5\WN4H8(0Q%=)=-18R%M"II/?HI.8FWO\U&I.).T[
M3=8L@#BF=7=-HGT%&)R4@ @&+6P;WOXZUT_G-FQN;NY/1]%N1NS6E]ETQ9IP
MLB-R*1^,SJ[^2?RWT?DWFGF/F5_VC]G=;;YAOV[D;/4]'U-^QTD6Q,>%T=MG
M6[=VWM75K=;??NS,Q'S1P6:SXK^/& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P.7GE&>_)(QUY59WC8>:-
M99Z?/'$JS#;S((/9SX3J-+AMY3#H].I"%UU(=$;'O6M;]G0OPY8B9X-6S9$_
M/6CBY]?_ .Z?^W7CY_%S?^2\8W=S>6QWGU__ +I_[=>/G\7-_P"2\8W=QEL=
MY]?_ .Z?^W7CY_%S?^2\8W=QEL=Y]?\ ^Z?^W7CY_%S?^2\8W=QEL=Y]?_[I
M_P"W7CY_%S?^2\8W=QEL=Y]?_P"Z?^W7CY_%S?\ DO&-W<9;'>?7_P#NG_MU
MX^?Q<W_DO&-W<9;'>?7_ /NG_MUX^?Q<W_DO&-W<9;'>?7_^Z?\ MUX^?Q<W
M_DO&-W<9;'>?7_\ NG_MUX^?Q<W_ )+QC=W&6QWGU_\ [I_[=>/G\7-_Y+QC
M=W&6QWGU_P#[I_[=>/G\7-_Y+QC=W&6QWGU__NG_ +=>/G\7-_Y+QC=W&6QW
MGU__ +I_[=>/G\7-_P"2\8W=QEL=Y]?_ .Z?^W7CY_%S?^2\8W=QEL=Y]?\
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M_%S?^2\8W=QEL=Y]?_[I_P"W7CY_%S?^2\8W=QEL=Y]?_P"Z?^W7CY_%S?\
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M.MMKIL8UUC321ODT.>U];P"QXTHT';DW 1:4IC3# 'B"FT(K.M.YTC&;J_\
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MW43]0+CQ:CKF -3K8L8F,;,KU\Z9;5#>KMA\F4G>4SZPG.9"\]686(DDTO\
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M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@;1"/\ ]\8O_P#=QO\
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M1][^F"@Z$7] K=;/]O>]:,^'P_Q^&1WV[K)NTBDNQG)7CN\TL=DW-5DS?S"
MFU(LCI4LSE=.ZJ-.C^M58H1L;PZUU],[ $U/MUC0!-_S.]:$'U^O?X<,7763
M6(MU?IMRN1@,!@,!@1A9])4Q=S>UM%T5'6%NM3&O,=&1LL^ Q2?-[.YG)C$9
MKBUHI6TNR9O7FHS1%".)" P18MAWOT[WK"Q,QP0S^P)PG^Y7R5_#C3OYFX7.
M_G/K/V!.$_W*^2OX<:=_,W!G?SGUG[ G"?[E?)7\.-._F;@SOYSZS]@3A/\
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M33^X8I.:WE#':[NV/KNY(&*1M$@G;K&RC$924L"('RWH]01[$6_6)B>R='[
MLK@8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# ACH3GRHNIZ>FU"W
MM#TTZJRPF],WR>.*%SFU#4:0.*-X:ER!W9%K<\L[LSO+>G6)%:4\D].I( ,
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MTK;SI -"X)HK&90M3JRCRQEO'O>I=I0((=Z&=WO]K[>4?%MQGQ3:#_;_ #S
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M^U#7\0E]B\W=V127S-9:2UNH9YYJ7H+Z05E2C&P2&T;W?( ?)PZ::6BC?(R
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MY@AK$Q2:+#X0P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M<W95;IT[18R,\YR7["B+^65%^O9A PZCK6VZZL3&EU?R1AV[XP>JGZ:=2W+
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MB;K=G3G'4L4G(G=?(!R\!,)5GC1(FQ6SJ1A6A"IV3".>OPJR2:ZNHU'C 8[
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M&G#7/9)$*<Z!FW,LY?8*A?%.FR9&U=/VERC<AD416EE'J&Y.]M#XS-:I4A5
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M;5#G&G7=D>HBCBX -;0-9$Z1>^=H5IY0!+-TYIX/4<@4-32#8@:2%^@6OCL
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MYDZX%>*."S.%77*GQCZ1W&V>""\G,8<U4:YN=XZB :6PF\4IP+R4]5'#=1M
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M>7X8W2:2VU;]6U7"$5D(:[A,OD-D1M0@G9ZZH('<^EH4J,W:V**TT1G):PY
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M?P]DM[LSQ37Q/'F[&,BS*>0US(T'5$NJQS,;Y?NPSK0ZSKZNH/*6.RA%H!-
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MZ'V@?NFA=B0>?,YFW-VAD7J:YH!!8I0QT+C@VU >;.Z^=Z'K]6_Z5+0H7 E
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M^U2X!WS%)L]?PJTZ,><2)3:GI!:\7H89R5NG=&,R1P>;EC;35D?K[H5JG[I
MYW=-PD15SCM*NC8JKPYID#2O3JR&)Y=V@E2X:3+1+"!X>M*MB\L_:-V<P&<]
MJ:HL=]K-'-ZMZ.G+I]5:,:>AP22=P(BCD511"4Z,$21#:T?Y791C>ZR,M:VI
MDXE2;8UJ8(PFA%EL3Q2<U>3]8RS5WAEM4JB@C-&&VQ8(^V^MM:+ME=_M,TAS
MW'N@+DK-:G=$OSL1KID9W)>A02Y6I4IU*UH4A&F 5M,>I)AR53L[S+SZ;<Z.
M[_SY3*=GME!NTE,V?E4^99'!ZLB%1W94-0O$YCA\@AC$MM8R3+K82B;VPYJ9
M5!11"L9_I,((*52K4;<5UX.LG;-LS>E*+33FO5R-ND9MY\K08:E>VIG9/N.6
MIU!4%83-+I&KULG2A=#I>O()._[Z<XP)H/\ . .5BV*SKRE&=F]\1:M>V:6X
MX.CL?D2^WCBV=1(&.R$*F8P.3+X+9%A,A$JJ\$<,$BC;JPUN=H"XYZ3K!F+2
M!DH#T^CCRQ%M;<GC[/ZU>>5K-I9X7FF'U &GNR+:MUA;6AO7R20-] 59')TP
M(8VL6FI]H7,:E2I+ #1I1:DPT 31! 'XZ%MM8[ZPH9T7Y,^C&=CER%A@:/GF
MV*FK/L#5J5V\N,4N-"@L&N*7YON2F7Q@FR%O;VU]8#XA>Q*E23I(GW](:-2G
M!&6GT,^-Q9'Y5A?ZF>]HS;_9UQ<>ML;83EE7PV13)!8,2L=#-T#J7"YK&Z_E
M\=EC*EC;05"Y8TR.3DEZ1D.#SZ=IU)2H:-23M/NL3;2W)@[FGG44Z[49>?*!
MMB$5!'*JHVM>B)\7*ZW26%]\1,_NR4P(^O%IZAU:G2',+7#*N>C KV@PM?\
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M8'377$&;?(=&W_I^7LKOR<@JJQ8$_./+]7PR?V.LL$=L1M-7-<PJ2:D<;E-
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MG%]&$JRG#0D;GI5L8#$@B3"Q9';.GPJW:;^427TBZ6DE<Z:E]O@AMG]&.,]
MJL"M8>&H:MYX:.5-3M+"?D(:WFV84WK>APFM*9<(MV<#$JC1RT!0T^B1A7AR
M_JG=W\F,39U4\1N$!1QX$+:NV%@7V;V4RQ*)+'#CGH*N.>]-SB_GLB_;,&U9
M%9*50WC"0K/2[+TET0J4'%!V3#2OX>U1UT\J]W62ADME0B"G0*D$?C\Z9NU[
M6QJ70.23N&V]15_S"EECW"]S:NU#9,F@USA.BVK3H@1)3TSJ%4M0@,($FPUA
M$<>-5E[!\LQ5?+;?$/G25/L2AI%Z-=.S#5B11M,O*;<RVC6].W-'5#$)K-/K
M%,CF=C%_0R]:-42[(VU6<,M'K2<!YF+*]OI+:H3Y-G&46;SM4K[0((!*+BL7
MH&JIFOE]QQYNA\/L'G:W%=32N"UQ*S8N4VW5/G42(Q_;V,KZ"<54>*-4$EFG
M$FIP##29JV'I;R8Q'F_H]NY_6PMDG)ZNN)],7!9&K0;=S6-/T+I.UKV21^3U
MWN,*0,;/)(E5)Y29P4.X%>SW!,8!O-2;,4 $65BJGUQ>7NXC.>[B#6O,I\*Z
M9B=67+8IC.\VM"I-$:VKN"<V4IT WW -_,CQ+;/G1,T='1<H,3 C(,4KREI.
MU>B22SCW958LBNLZ+U=D]_QWC!KHH^0Q]@G:ZU7E@;G9BU8K?$IZB87*202(
M+9;$889''HR: ;G>=)Q*"S5#,A*UH)6UH5!Z8@TS%N55+W+R4V].;T>$;-'7
MBK: ]FLVBMG9J<*]D\ULMQ6>2J#<<R:;NJ*119S)@<8<BMN*8;49\TN&RK-+
M$RA*Y>V%(:QBG.?@FJO/+&US>30YD<>?95%6RW)K215(O:N=1USW/J<N^XYK
M2K-:SLVH6WWH6[,T@AH5JF.'F*3Q-KHC&%7[_P R0F)-C72_+8]NE=36VHUR
MP[.\ K?E*"=,31>KN.,M#TE7VC)[4B4 K)E8S8NIV\+W1TJE4)8[#/2HD!*D
ML6P&"UL.0P[*]K"2+R\SEE/;&)'QLZN\T:I+*(3;$>+OJ&H$,#EK-UG$^/&1
M$P2!;$RTT\:I%8T]:%NUFBFSY)H-4&&%[/("0?5PCGZ<659_,G"E=A\\5D\T
MNY,4KMI5&F:R&?=DQUR>:SD4NZ.L'E=I1PMF2LP5MU-#5:%8NJQZ7HM-06F,
M:)<A%FB&)(63"=914Y>5SH*S2*635-S:C@CY-;]Y4^"&3V[#WU)/.=[[FG0\
M""K YD0]3J$RU7*N>W D]&).I/2H5"<\M1[I@RB2X1'&>R71'F'L=SZ;UTP0
MUU:BA3Y0%BRZMT4)?[*:C;&<W:-N4I:VXRS8/]7D;M2^I@7'TSHSB5?2J-R8
MG5,N3*3M:.*+,S;2G>Y@4+Y0.K4Z?CJ67I6#'(89;O+%"S>YQ1:71%$MB$DO
M?J*,T!$+D;228LC/D*!U.F#>:IBJ/:3Z(2;4"$I5*"R@&FYLMUIS2_!/-*UV
MZPOBBH.=5<XE:VS:/@]61S[XXTV-DO9K^F5BPJ'.LXE@(NY(*KF;,LK<]:]1
MDXET6(&UQ0&@./,.&243"DZRSC=YG(.[2J\(8TTH[OLAKAS7P^O6V/V/&G-3
M85E-'1T-Y-60R9:,:D1-+A=KHGB 3*L<C%OTK%P*7;V21)Q(MCPYT;73G9E^
M=#]JT- VZ'J*KJ9LI;K-PZ!@>Y7!)$X(KYH6^&SGIVCREZ-A*UXE$(C+\+2M
MH6L:UA$[ =R%*L&@)#4!A)MB+:]J5^M/)977'EQQ6J+)@S\I2RP-/N:28MSN
M@+;D,3L&56?%Y[+G% H2Z.(9J9W!&U2ZBT8+WB9&ET'9>P"]9(MK%57XOW_T
M5870'.K# H"O+B=N]"P:-6= 9Y)Z_;%%<0N9^.&/=3EQF(O#5 ]/;P./N,@-
M>G U<:8N4N30:V$'D(EI.DYK&*37E^J>/&GW#8G2U2'$=!0Y%";'@E'47<[]
M.P2F+JHE8D$NQIGRMBGGR;.@:$E;J-+*S=MK693[^FY-H@>U1NS!Z+)?;C.G
M"JD\\\OUAV5 I7)*.;HC E];_M:-CXN;']INJ&3$V >/N?=1T[)HO*U$9B83
MD)$E2-XW).!%L@\2019"M8B/">8:BR(G7N]Z_/3W?4@Y;9:A4[I1SN4M_P"?
M[%Z+M=[:IU'8.H@]6TJ.G2++DC4RNS4J+F<@+3VR!8C:$YJ'WPHC2_>+]0=Z
M,1;$]M$:R/RS1^'S1Z3RBBY&STZ*P)W#(-<YL\C9R*4M%'='UES/T7-GV($H
M!N\&8ZUEUGIW)OTI.4#?V= J.^*(82RS"X5_%"YWG1K\^G6*T6NB'E&YR)YB
M$/116>V=&X"D;K"7P2X[/L"!2*5+V)Q1,S_!H55:3Y<OY<T3PZR=M2!"F+V<
MJ++X<UHOGRUV7(>KWRW%\*I!?'JDKU+#D,7G\LG;>WR>;S694[55U)HLOK$$
M>,=8,0UQFV4294M5KC]A7ISBPD#"'UX9FW'\7+VO/*-UK&*KXZN2X*E9I@Q3
MOG*^K;OZ.Q&9PYL<D\>A]^<X5K&K9C:LR+)"G!:RM=J+RM0]+I,-7L83#5VS
M"@?$W-EM9B)[4J7EY7K!<)3<E0\UUW!9/8%/WQRK&DLF;+DC[[$YQ7MJ=>(N
M=IDRN+DL@1C;!9PK<T!C4803].%-('42H2K2MN/1:B19VSP6@ZIZ:Z*JSI>"
MUQ XS&]5L[</]?7E,'Q>_-)CC&Y_41E6%1-V3LBEA/<)*VQI=*@)#$!"M&!S
M"^"4#V'39[9]2VV)BO;6%)V[S?JZQHF K;UHD_5\DMT>,F4>(M6&MS++(PEY
M=J?I)ZL&'OJ>.%-JV<RYBM1 C9X02C*,/?3A) K2TQ?SF&O#UTX.C'3/>\9Y
MT;&YYU7C_-VYVY6NKJ= 8G=4T;4C8:==:3;1150B<T"A0C=I*7=)!H#3-:"C
M^0, 8 0C ^DQ%M?71760>5URCU@V3 E',3XI&AGMC5-0SHFMF*;!=5EUOT]3
M_*3DR/B(UD+.J-E7V!>3$J)<E@G(.FLM<;LKUIRBU)<-*U].*&:I\P+M'%%#
M5G?-?D.MMVG9-C-]A@8IA&T)M:QQX[IM;D^JV6#QQO91JKL51%3#/5(%*+Z.
MVF86PYW'LXTX*419LXS'#X)OA?E%E\F>^;$S_P QI*]BO45Q636]<SN87Y&D
M$9-9JTF;7!E)RASW"=-)=N31R4."R,P<Q62M?&YF6;3K-K0 0C)-E*Z\&E4S
MY2GQW4<^PH=432SD$Z?J;B5GW)*9C7<0>H1(^C;*NJ*5<DW XI#VQJF!:-NJ
M!4:XF-X&T*0A0BU\%)PU9A)9LXM=2>:Y&14B:>3'F[Z@2Z7*^=%55164WS#$
MD.E,1Z6KJT[/A<EF%H!C0D%<J6V-TM(0+4!K<X&A6Z0DEC'M8(2<>'K2K>JZ
M\ELUZ/Z(Y)C].UB[0WGFQ[ .B5DSB<N+ 5,'>8.O"C[U>AJM/79B$Y]CA<33
MR./&K7X"S0%"](J0@)V1O2@T39$6S7C\6R6-Y;H/7'03]S4Y4W+%ED-4U?8"
MA)(DC66W.DD.FU%L%5MXE(FTPU"IMN(W X2) #99@DZ*)N!8O=%L(@DBR9BO
M8^58>5M!8$GKE@=>?)1#DUURRA55,.BN>1MY^N%&=$O]P1J"VX[HFUNT.)O:
M5PIY08X1@T:A0G2NB(85A@]J"B!-G?P0NP>4^U9<K=WN!5-J8.%S57RX_<Z4
MTOE,9B.XE(;,I'J>]K1=)U9JUJ5I5Z%BA=#B,(+TD'I2L*(2D@*TI./++A$:
M3WNJ?(-A2FV^3>8;6G"XASFMF\]TS8,O<4R!,UIE\HF=<QR1OZQ,V(M!1MR=
M0ZN1HP$%:]LH.]!#^#6L,712Z8CFL3A# 8# UJ9Q-EGL/E<%DA!RF.S2-/L3
M?TR=2<C/4,LC:U3.ZD$+$PRU"0XU"L,"$PL01EBWH0=ZWK6!2%3XR.3U<C#(
M3F">[(U6I=;BB8;3G88(::11:CF5-99T.T]?0AMQ)* 5F10J2[*^D -0OAH7
MNA";HUG*9'+CN@7M++&]^AZA\:ISS;&N2Y4TN;\]GM[M2$3-F!K/'#"@+BAI
MW(L4Z<?6YDB+<!;,!OW="*+V$F4^U#$DX'C+R^<9?-36:3Y@Y.ON3W]I]O"<
M3.V[6D,B5UC.X5%&E'.9,[*5"5E99!,$KH80:$PGXLZ8)183?4;HUEQYS"VX
M*?@Q=T*;^"@6ZLI76"*GSW/Z47;;A09OE;A-$J#3+[WT8%:!_<SC-JM%^_L
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M;-I&]%3P9+'5(;]=Z B<RK:J)!MG Y%I2V]G8YXX)ADZ*TE6J=DC."8:03L
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MD!"8K6A-]>Q'D(\/5!UW6[34L0G=C,D!86^=$LL?;R82D0M;Q:/'X>0+(D"
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M9[?-8U?-TLIF_,T\;*TNID(;W9&.&S)XC3?+$#4-4X(4B-V"<SN(=[/1&*"
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MI/8/._O)E$<*,*;9[&%'N?."UI*WG@&0L,3G@$7H8W>G<U&K?+KP+<L1?)K
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M<EQVQ"))&468,!<+M.]X7SS*^.V.)ZD<'B]%Z9DNB#@L:+20JJ;>71IBB&K
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M'BPG:\V1>PM<A;V*EK??8)%W&3P@-BL**5VVT0E95T84N<1, I* N=TXA",
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MJAAJ"*0E]23SEJS^]^OU]\V<]M$[=>U.EPV]!2N5I0Q.&K%:5<-L^Q*9CI8
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M[E5[1-+#DLSJ:(**Q:I.M=6A.?(R3)3:ZAGDS<RD+']NKVMXW(70A9I"G+5
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MOC5I(2FI% UC0>O>VI4UGL6A*MEJ%!BD"D:8!98APFR(K69T_59OQP^5Z/\
MD&L9MA,0(J]P1MW$7.G1%EKZ^F"Z3*:]O2V7Z:-%@42]$GHTY20ZO2HZD'ZC
M=Z6"$K^!H ZT'XU+[,([>+LAAS,!@,!@52[:Y@*[-YJL#FA?.%E?1RT5,,;I
ML]MS/]-+W&!LTZC<GFD-3$?2[)M%]?HZR*&4U8$[8T9"\9P2S! T#9;9QFKE
M5)/!BM'74@YMKGKU]KSC:3]!OMTJN=U%)1&>JXHVN\Q@%BHFNLK>F4G<+#A=
M@1V80]=M!*/?5C)0OJ@'R.U(?FC#?B=LQ\RS'<WB[7]JWBUV09TC(*EKN0T
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MEEC*(NBZ(TA6I9X58CN](ITFPW])(A=<'Z)Z?O&)S^/UW%S'IF9>E**;JE'
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MK6L63M9NC]&=?(R#IY CN78F\RUMDJ&HZMJQN=V^TCK)2/IK0E%4Z!QVU;3
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M%K?H  &Q;W_AK6M[_P"S ^6SR B"#9Q6AC+&< &S :$,DOT:,-"'>_B(LOW
M^H6OP:]6OC_CK BDN]*L.NM1SP1*DYUN(ZN2W,MBY:-P$%'73A,%<";GU0\_
M*?081KY6WJ4A272G:O>TXQ;*T#TB$6DTKV-TETSB\#B,IG<M>DC+$84QO4DE
M+V?[IR9G98\A4.3RM4%I"U"DSY%&E,&(LL S1;#Z0A$+>M;)Q>.N+ BML5[
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M_H[[,%_C87Y/QB92??T=]F"_QL+\GXQ,I/OZ.^S!?XV%^3\8F4GW]'?9@O\
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M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P+9TG_\
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MM*E_%9O^NQD8GW"K?M*E_%9O^NQD8GW"K?M*E_%9O^NQD8GW"K?M*E_%9O\
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M>GD%?@K*S:%KVWI"V6BV3(XB<6+VA-^75\-A+6Y5DA1RN"K?NH=UATA-/9W
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M,F P&!QH\E?_ (V_"?\ _&W:G_E,N?':Z6?VW?@[+X<S 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'&GRG?\ B-\,_P#ZE31_
MY<+[PW9PN_!V6PPXT>#;_P *=Y_^H9Y ?_,]/LD-W\?RCW.R^5@P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!QN\+'_X)^WO_
M %4N_/\ \;X\.FYQC\(=D<.9@,!@<:/)7_XV_"?_ /&W:G_E,N?':Z6?VW?@
M[+X<S 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8'&GRG?^(WPS_P#J5-'_ )<+[PW9PN_!V6PPXT>#;_PIWG_ZAGD!_P#,]/LD
M-W\?RCW.R^5@P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P&!QN\+'_X)^WO_52[\_\ QOCPZ;G&/PAV1PYF P&!QH\E?_C;\)__
M ,;=J?\ E,N?':Z6?VW?@[+X<S 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8'&GRG?^(WPS_\ J5-'_EPOO#=G"[\'9;##C1X-
MO_"G>?\ ZAGD!_\ ,]/LD-W\?RCW.R^5@P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P&!QN\+'_ ."?M[_U4N_/_P ;X\.FYQC\
M(=D<.9@,!@<:/)7_ .-OPG__ !MVI_Y3+GQVNEG]MWX.R^',P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!QI\IW_B-\,__J5-
M'_EPOO#=G"[\'9;##C1X-O\ PIWG_P"H9Y ?_,]/LD-W\?RCW.R^5@P& P&
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MRS25_FULNR=\E*A4@B*!K8B@'.A0SM>R07KU&BUH.M:UK59NNRFJ[F&3 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M@?XX5A<A];J+$L50GY3Z9/3J+"G2A.>30-M&D'ISY6[FD'D&EQ 19I)Q0]"
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) 8# 8# 8'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g664711g16y78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g664711g16y78.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1@24&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "T=@ .$))300E       05%68-C-/P(#9'0W1
MJ*EJ&SA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M#@             _@   .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]       $@ U     0 M    !@       3A"24T#]P      '
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         6<   .?          $                          0
M       #GP   6<                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   6<     4F=H=&QO;F<   .?    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   %G
M %)G:'1L;VYG   #GP    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $     3A"24T$#      .=@    $   "@    /@   >   '1
M   .6@ 8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M2S<YK+=C';+['^RS_1*?1/\ &-TGJ.0,3-K=TV]YVUNL<'4O<?S&Y#=NQ_\
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MFAV<U[*+&7@LL%A^UX]&S&?BW5.VV_9'^O2S])^C_FZ;$E/_V3A"24T$(0
M    50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $
M.$))300B      $N34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  6XV    G$ !;C8   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-#HS," Q,3HT.#HQ,P   Z !
M  ,    !__\  * "  0    !   #GZ #  0    !   !9P         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
M @$ !     $   $N @( !     $              $@    !    2     $X
M0DE- _T       @          /_A 3!-30 J    "  ' 1(  P    $
M 1H !0    $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X
M  !R 3(  @   !0   "0AVD !     $   "D    T    \     !   #P
M  %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C T.C,P(#$Q
M.C0X.C$S   #H $  P    '__P  H ( !     $   .?H , !     $   %G
M          8! P #     0 &   !&@ %     0   1X!&P %     0   28!
M*  #     0 "   " 0 $     0   2X" @ $     0             #P
M  $   /      ?_A06)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_
M>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK
M8SED(C\^/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX
M;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R
M+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR
M9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN
M<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q.2TP-"TR.50R,3HS
M,CHR-EH\+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A
M=&4^,C Q.2TP-"TS,%0Q,3HT.#HQ,RLP-3HS,#PO>&UP.DUO9&EF>41A=&4^
M"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,3DM,#0M,S!4,3$Z-#@Z
M,3,K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C
M.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H
M;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^
M"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C$\+W!H;W1O<VAO<#I#
M;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX
M;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @
M(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12
M968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.D0X
M134T-S9&,#,V0D4Y,3%"1C!#0C4V-T,W-C(W-#4R/"]X;7!-33I);G-T86YC
M94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.D0V134T
M-S9&,#,V0D4Y,3%"1C!#0C4V-T,W-C(W-#4R/"]X;7!-33I$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z
M1#5%-30W-D8P,S9"13DQ,4)&,$-"-38W0S<V,C<T-3(\+WAM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D0U134T-S9&,#,V0D4Y,3%"
M1C!#0C4V-T,W-C(W-#4R/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 T+3,P5#$Q.C0X.C X*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W!D9B!T;R!A<'!L:6-A=&EO;B]V
M;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A
M=&EO;B]P9&8@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<#PO
M<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z1#9%-30W-D8P,S9"13DQ,4)&,$-"-38W0S<V,C<T-3(\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,3DM,#0M,S!4,3$Z-#@Z,#@K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I$-T4U-#<V
M1C S-D)%.3$Q0D8P0T(U-C=#-S8R-S0U,CPO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q.2TP-"TS,%0Q,3HT
M.#HQ,RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N
M<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P
M<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO
M<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z1#A%-30W-D8P,S9"13DQ,4)&,$-"-38W0S<V,C<T-3(\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,3DM,#0M,S!4,3$Z-#@Z,3,K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-
M33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z1#=%-30W-D8P,S9"
M13DQ,4)&,$-"-38W0S<V,C<T-3(\+W-T4F5F.FEN<W1A;F-E240^"B @(" @
M(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z1#9%-30W-D8P,S9"
M13DQ,4)&,$-"-38W0S<V,C<T-3(\+W-T4F5F.F1O8W5M96YT240^"B @(" @
M(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#I$-44U
M-#<V1C S-D)%.3$Q0D8P0T(U-C=#-S8R-S0U,CPO<W12968Z;W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T
M(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_  !$( #D E ,!$0 "$0$#$0'_Q  >   " @,  P$
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4 /P3N!A?4O\ X#H'_;,?^\<#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
